GLOBAL CARDIOVASCULAR RISK REDUCTION
Vancouver Canada • September 26-30 • 2010
www.vancouverhypertension2010.com
SPONSORS AND SUPPORTERS

Platinum

Boehringer Ingelheim

Gold

MERCK
Daiichi-Sankyo

Silver

BORYUNG pharm
NOVARTIS

microlife WatchBP
SERVIER
Takeda

Corporate Supporters

Abbott
AstraZeneca
Bayer HealthCare Pharmaceuticals
OMRON
Pfizer
Institutional Sponsors

- Public Health Agency of Canada
- Agence de la santé publique du Canada
- Société québécoise d'hypertension artérielle
- International Society of Nephrology
- Canadian Cardiovascular Society

Media Sponsors

- BMJ Journals
- Nature Publishing Group

Supporting Societies

- Asian Pacific Society of Hypertension
- Canadian Council of Cardiovascular Nurses
- Inter-American Society of Hypertension
- World Hypertension League

This program is also supported in part by

The American Heart Association’s Council for High Blood Pressure Research

Meeting Hosts

- International Society of Hypertension
- Hypertension Canada

www.vancouverhypertension2010.com
# TABLE OF CONTENTS

Sponsors and Supporters ........................................... Inside Front Cover, 1

Programs at a Glance .................................................. 4

WELCOME ..................................................................... 7
  Welcome Letters ....................................................... 8

MEETING HOSTS ............................................................ 15
  Hypertension Canada ............................................... 16
  The International Society of Hypertension ...................... 19
  ISH 2010 Committees ............................................. 24

MEETING INFORMATION ............................................... 31
  Meeting Information ................................................ 32

PROGRAM ..................................................................... 41
  Program Overview .................................................... 42
  Thursday, September 23 to Saturday, September 25 ........ 43
  Sunday, September 26 ............................................... 47
  Monday, September 27 ............................................. 51
  Tuesday, September 28 ............................................ 87
  Wednesday, September 29 ....................................... 147
  Thursday, September 30 .......................................... 223

INDEX ......................................................................... 283
  Index ......................................................................... 284

OPTIONAL TOURS & SOCIAL EVENTS ................................. 299
  Optional Daily Tours .............................................. 301
  Optional Social Events .......................................... 307

EXHIBITION ................................................................... 311
  Exhibition Hall Floor Plan .................................. 313
  Exhibitor Profiles ................................................ 318
TABLE OF CONTENTS

AWARDS .................................................................325
   Hypertension Canada Awards ..............................326
   ISH Awards ........................................................328
   Other Awards ....................................................332
   Vancouver Hypertension 2010 Award .....................333

Vancouver Convention Centre Map .......................Inside Back Cover Fold-out

Downtown Vancouver Map .................................Back Cover Fold-out

Meeting Venue
West Building, Vancouver Convention Centre (VCC)
1055 Canada Place
Vancouver, BC, V6C 0C3
T: +1.604.689.8232
E: info@vancouverconventioncentre.com
W: www.vancouverconventioncentre.com

Go to the back cover for maps of downtown Vancouver and the VCC.

Meeting Secretariat
Contact the Meeting Secretariat (Sea to Sky Meeting Management) at the VCC by visiting the Registration Desk located in the Foyer, West Level 1.
Alternatively, you can contact the Secretariat via email at info@vancouverhypertension2010.com.

Photos courtesy of Tourism Vancouver
## PROGRAMS AT A GLANCE

### ISH 2010 at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Thursday, Sept. 23 to Saturday, Sept. 25</th>
<th>Sunday, September 26</th>
<th>Monday, September 27</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>The Endocrine Heart – 30 Years Later</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>Ottawa, Ontario</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>The Heart and Kidney Interface and the CardioRenal Syndrome</td>
<td>08:00-11:45</td>
<td>Room 213, West Level 2</td>
</tr>
<tr>
<td>08:30</td>
<td>Room 213, West Level 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>The Pathogenesis of Essential Hypertension: Focus on Salt, Stress and Obesity (continued)</td>
<td>09:00-13:00</td>
<td>Westin Resort &amp; Spa, Whistler</td>
</tr>
<tr>
<td>09:30</td>
<td>Westin Resort &amp; Spa, Whistler</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Room 213, West Level 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Room 109-110, West Level 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Scientific Program Concurrent Sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>See Page 55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td><strong>Behavioral Cardiology and Hypertension: Current Developments in Assessment and Intervention</strong></td>
<td><strong>12:00-14:15</strong></td>
<td>Exhibition Hall</td>
</tr>
<tr>
<td>12:30</td>
<td><strong>13:00-16:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Westin Resort &amp; Spa, Whistler</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Retinal Vessel Analysis – From Risk Assessment to Therapy</td>
<td><strong>14:00-16:30</strong></td>
<td>Room 212, West Level 2</td>
</tr>
<tr>
<td>13:30</td>
<td>Room 212, West Level 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>Scientific Program Concurrent Sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>See Page 62</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td><strong>The Pathogenesis of Essential Hypertension: Focus on Salt, Stress and Obesity</strong></td>
<td><strong>15:00-20:15</strong></td>
<td>Westin Resort &amp; Spa, Whistler</td>
</tr>
<tr>
<td>15:30</td>
<td><strong>16:00-21:00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Westin Resort &amp; Spa, Whistler</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Scientific Program Concurrent Sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td><strong>17:00-17:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Opening Ceremony and Welcome Reception</td>
<td><strong>17:30-19:00</strong></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Opening Ceremony – 17:30-19:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Welcome Reception – 19:00-20:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>Ballroom C/D, West Level 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td><strong>19:00-21:00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td><strong>20:00-21:00</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All sessions take place at the Vancouver Convention Centre unless otherwise stated. Full details on each session (e.g. room location, session titles) are located in the Program section.
# PROGRAMS AT A GLANCE

## ISH 2010 at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Tuesday, September 28</th>
<th>Wednesday, September 29</th>
<th>Thursday, September 30</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>How to Sessions</td>
<td>How to Sessions</td>
<td>How to Sessions</td>
</tr>
<tr>
<td></td>
<td>Rooms 203-207, West Level 2</td>
<td>Rooms 203-207, West Level 2</td>
<td>Rooms 203-206, West Level 2</td>
</tr>
<tr>
<td></td>
<td>See Page 90</td>
<td>See Page 150</td>
<td>See Page 225</td>
</tr>
<tr>
<td></td>
<td>07:00-08:30</td>
<td>07:00-08:00</td>
<td>07:00-08:30</td>
</tr>
<tr>
<td>08:00</td>
<td>ISH Past Presidents’ Meeting</td>
<td>Scientific Program Concurrent Sessions</td>
<td>Scientific Program Concurrent Sessions</td>
</tr>
<tr>
<td></td>
<td>08:00-09:00</td>
<td>See Page 91</td>
<td>See Page 226</td>
</tr>
<tr>
<td></td>
<td>Pacific Room 2, Pan Pacific Hotel</td>
<td>08:15-09:45</td>
<td>08:15-09:45</td>
</tr>
<tr>
<td>08:30</td>
<td>Scientific Program Concurrent Sessions</td>
<td>See Page 154</td>
<td>See Page 231</td>
</tr>
<tr>
<td></td>
<td>10:30-12:00</td>
<td>10:30-12:00</td>
<td>10:30-12:00</td>
</tr>
<tr>
<td>09:00</td>
<td>Break</td>
<td>ISH General Meeting</td>
<td>Scientific Program Concurrent Sessions</td>
</tr>
<tr>
<td></td>
<td>09:45-10:30</td>
<td>13:00-14:00</td>
<td>See Page 158</td>
</tr>
<tr>
<td></td>
<td>Exhibition Hall</td>
<td>Room 220-222, West Level 2</td>
<td>14:15-15:45</td>
</tr>
<tr>
<td>09:45</td>
<td>Break</td>
<td>ISH General Meeting</td>
<td>Scientific Program Concurrent Sessions &amp; Late Breaking Studies</td>
</tr>
<tr>
<td></td>
<td>09:45-10:30</td>
<td>13:00-14:00</td>
<td>See Page 237</td>
</tr>
<tr>
<td></td>
<td>Exhibition Hall</td>
<td>ISH General Meeting</td>
<td>14:30-16:30</td>
</tr>
<tr>
<td>10:00</td>
<td>ISH International Forum</td>
<td>ISH General Meeting</td>
<td>Scientific Program Concurrent Sessions</td>
</tr>
<tr>
<td></td>
<td>12:15-13:45</td>
<td>13:00-14:00</td>
<td>See Page 231</td>
</tr>
<tr>
<td></td>
<td>Rooms 220-222, West Level 2</td>
<td>ISH General Meeting</td>
<td>14:15-15:45</td>
</tr>
<tr>
<td>10:30</td>
<td>Scientific Program Concurrent Sessions</td>
<td>Scientific Program Concurrent Sessions &amp; Late Breaking Studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:30-12:00</td>
<td>14:30-16:30</td>
<td>See Page 237</td>
</tr>
<tr>
<td>11:00</td>
<td>Poster Session B</td>
<td>Collation Ceremony</td>
<td>Closing Announcement and Handover to Hypertension Sydney 2012</td>
</tr>
<tr>
<td></td>
<td>12:00-14:15</td>
<td>13:00-14:00</td>
<td>16:30-17:00</td>
</tr>
<tr>
<td></td>
<td>Exhibition Hall</td>
<td>ISH General Meeting</td>
<td>Ballroom A, West Level 1</td>
</tr>
<tr>
<td>12:00</td>
<td>Scientific Program Concurrent Sessions</td>
<td>Scientific Program Concurrent Sessions &amp; Late Breaking Studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:00-14:15</td>
<td>14:30-16:30</td>
<td>See Page 231</td>
</tr>
<tr>
<td>12:30</td>
<td>ISH General Meeting</td>
<td>Scientific Program Concurrent Sessions &amp; Late Breaking Studies</td>
<td>15:00-16:30</td>
</tr>
<tr>
<td></td>
<td>13:00-14:00</td>
<td>14:30-16:30</td>
<td>15:00-16:30</td>
</tr>
<tr>
<td>13:30</td>
<td>ISH International Forum</td>
<td>ISH General Meeting</td>
<td>Scientific Program Concurrent Sessions &amp; Late Breaking Studies</td>
</tr>
<tr>
<td></td>
<td>12:15-13:45</td>
<td>13:00-14:00</td>
<td>See Page 237</td>
</tr>
<tr>
<td>14:00</td>
<td>Hypertension Research at the US NHLBI</td>
<td>Scientific Program Concurrent Sessions &amp; Late Breaking Studies</td>
<td>15:00-16:30</td>
</tr>
<tr>
<td></td>
<td>14:15-15:45</td>
<td>14:30-16:30</td>
<td>15:00-16:30</td>
</tr>
<tr>
<td>14:30</td>
<td>CHEP/Hypertension Canada Symposium and Presidential Lecture</td>
<td>Scientific Program Concurrent Sessions</td>
<td>16:00-17:00</td>
</tr>
<tr>
<td></td>
<td>14:15-15:45</td>
<td>14:15-15:45</td>
<td>16:00-17:00</td>
</tr>
<tr>
<td>15:00</td>
<td>Scientific Program Concurrent Sessions</td>
<td>Scientific Program Concurrent Sessions &amp; Late Breaking Studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14:15-15:45</td>
<td>14:30-16:30</td>
<td>16:00-17:00</td>
</tr>
<tr>
<td>15:30</td>
<td>Scientific Program Concurrent Sessions</td>
<td>Scientific Program Concurrent Sessions &amp; Late Breaking Studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14:15-15:45</td>
<td>14:30-16:30</td>
<td>16:00-17:00</td>
</tr>
<tr>
<td>16:00</td>
<td>ISH Awards Ceremony, Presidential Lecture and Franz Volhard Lecture</td>
<td>Closing Announcement and Handover to Hypertension Sydney 2012</td>
<td>17:00-18:00</td>
</tr>
<tr>
<td></td>
<td>16:30-18:00</td>
<td>16:30-17:00</td>
<td>17:00-18:00</td>
</tr>
<tr>
<td>16:30</td>
<td>Scientific Program Concurrent Sessions</td>
<td>Scientific Program Concurrent Sessions &amp; Late Breaking Studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16:30-18:00</td>
<td>16:30-17:00</td>
<td>17:00-18:00</td>
</tr>
<tr>
<td>17:00</td>
<td>Hypertension Canada Annual General Meeting</td>
<td>Hypertension Canada Annual General Meeting</td>
<td>18:00-19:00</td>
</tr>
<tr>
<td></td>
<td>18:00-21:30</td>
<td>18:00-19:00</td>
<td>18:00-19:00</td>
</tr>
<tr>
<td>17:30</td>
<td>Exhibit Hall</td>
<td>Exhibit Hall</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>16:30-17:00</td>
<td>Exhibition Hall C, West Exhibition Level</td>
<td>Exhibition Hall C, West Exhibition Level</td>
</tr>
<tr>
<td></td>
<td>17:00-18:00</td>
<td>16:30-17:00</td>
<td>16:30-17:00</td>
</tr>
<tr>
<td>18:00</td>
<td>Business Centres &amp; Internet Cafés:</td>
<td>Exhibit Hall</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>18:00-19:00</td>
<td>Exhibition Hall C, West Exhibition Level</td>
<td>Exhibition Hall C, West Exhibition Level</td>
</tr>
<tr>
<td></td>
<td>18:00-19:00</td>
<td>16:30-17:00</td>
<td>16:30-17:00</td>
</tr>
<tr>
<td>19:00</td>
<td>Speaker Centre &amp; Speaker Lounge:</td>
<td>Business Centres &amp; Internet Cafés:</td>
<td>19:00-20:00</td>
</tr>
<tr>
<td></td>
<td>16:00-17:00</td>
<td>Speaker Centre: Rooms 116-117, West Level 1</td>
<td>Speaker Centre: Rooms 116-117, West Level 1</td>
</tr>
<tr>
<td></td>
<td>17:00-18:00</td>
<td>Speaker Lounge: Room 115, West Level 1</td>
<td>Speaker Lounge: Room 115, West Level 1</td>
</tr>
<tr>
<td>19:30</td>
<td>Exhibit Hall</td>
<td>Business Centres &amp; Internet Cafés:</td>
<td>19:30-20:00</td>
</tr>
<tr>
<td></td>
<td>16:00-17:00</td>
<td>Exhibit Hall C, West Exhibition Level</td>
<td>Exhibit Hall C, West Exhibition Level</td>
</tr>
<tr>
<td>20:00</td>
<td>Business Centres &amp; Internet Cafés:</td>
<td>Exhibit Hall</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>16:00-17:00</td>
<td>Business Centres &amp; Internet Cafés:</td>
<td>Exhibit Hall C, West Exhibition Level</td>
</tr>
</tbody>
</table>

*www.vancouverhypertension2010.com*
### Optional Tours & Social Events Program at a Glance

#### TOURS

<table>
<thead>
<tr>
<th>Tour</th>
<th>Vancouver City Tour</th>
<th>Forests &amp; Mountains Tour (North Shore)</th>
<th>Fjords &amp; Glaciers – Whistler Day Tour</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Schedule</strong></td>
<td>DAILY</td>
<td>DAILY</td>
<td>DAILY</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>Four Hours</td>
<td>Six Hours</td>
<td>Ten Hours</td>
</tr>
<tr>
<td><strong>Departure Time</strong></td>
<td>08:00 (Sunday, Sept 26) 10:30 (Daily) 13:00 (Monday, Sept 27) 14:00 (Daily)</td>
<td>10:30 14:00</td>
<td>08:30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tour</th>
<th>Victoria &amp; Butchart Gardens Day Tour</th>
<th>Bowen Island Excursion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Schedule</strong></td>
<td>DAILY</td>
<td>SUNDAY, SEPT 26</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>Twelve to Thirteen Hours</td>
<td>Six Hours</td>
</tr>
<tr>
<td><strong>Departure Time</strong></td>
<td>07:30 09:30</td>
<td>09:00</td>
</tr>
</tbody>
</table>

The meeting place for all tours is in front of the West Facility, street level (between Burrard St. and Thurlow St.), unless otherwise stated.

#### SOCIAL EVENTS

<table>
<thead>
<tr>
<th>Event</th>
<th>Sunset Dinner Cruise</th>
<th>Fun Run Through Stanley Park</th>
<th>Gala Evening</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Schedule</strong></td>
<td>MONDAY, SEPT 27 Three Hours 19:00 Harbour Cruises Marina (foot of Denman Street)</td>
<td>TUESDAY, SEPT 28 Two Hours 17:00 (rain or shine) Thurlow St. Entrance</td>
<td>WEDNESDAY, SEPT 29 Four Hours 19:00 Ballroom C&amp;D, West Level 1</td>
</tr>
</tbody>
</table>

Full details on tours and social events and how to purchase tickets are located in the Optional Tours & Social Events section.
WELCOME
WELCOME FROM THE PRIME MINISTER OF CANADA

It is with great pleasure that I extend my warmest greetings to everyone attending the 23rd Scientific Meeting of the International Society of Hypertension.

This event offers a chance to gather with fellow scientists, clinicians and health specialists from around the world to discuss the latest developments in cardiovascular biology and medicine. It will no doubt provide you with unsurpassed opportunities to network with colleagues and other professionals, and to expand your knowledge in a setting that promotes education, dialogue and debate.

I am certain that you will make the most of the planned workshops, scientific programs and presentations from renowned experts, and that you leave this event eager to put what you have learned into practice.

On behalf of the Government of Canada, I offer you my best wishes for an enjoyable and productive meeting in Vancouver.

OTTAWA
2010

WELCOME FROM THE PREMIER OF BRITISH COLUMBIA

June 2010

As Premier of the province of British Columbia, I am pleased to join in welcoming everyone to the 23rd Scientific Meeting of the International Society of Hypertension in Vancouver.

I understand that workshops, meetings, scientific programs and exhibitions have been planned in relation to this year’s theme *Cardiovascular Risk and Cardiovascular Diseases*. This gathering is a valuable opportunity for everyone to meet and share findings, renew friendships and gain new knowledge.

I would like to recognize the organizers, staff and volunteers for the hard work and dedication that has gone into planning this year’s meeting. I wish everyone an enjoyable and successful meeting.

I hope you will also have time to enjoy the beauty and diversity of Vancouver and perhaps some other areas of our beautiful province.

Sincerely,

Gordon Campbell
Premier
WELCOME FROM THE MAYOR OF VANCOUVER

June, 2010

On behalf of the citizens of Vancouver, and my colleagues on City Council, I want to extend my warmest welcome to the Canadian Hypertension Society as well as the International Hypertension Society. As Mayor, I am very pleased you chose Vancouver to host your conference.

We are very proud of the reputation Vancouver enjoys as one of the world’s most beautiful and unique meeting destinations. I hope that in addition to attending the conference you are able to experience the many cultural and recreational activities the City has to offer. I know everyone involved in organizing the conference will ensure your time with us is special.

This conference is a wonderful tool to connect people, ideas and resources in order to provide public and professional understanding of our cardiovascular health issues focusing on hypertension. Once again, welcome to Vancouver, and I hope you enjoy the conference.

Yours truly,

Gregor Robertson
MAYOR
Dear Colleagues,

ISH 2010 consists of four days packed full of outstanding Science and Medicine. Focusing on Cardiovascular Risk and Cardiovascular Diseases, the meeting deals with hypertension at all levels of research including pathobiology, clinical medicine, management and prevention investigation, and therapy. We cannot lose sight of the fact that hypertension is a key factor leading to arterial disease with its consequences on the brain, heart, kidney, and other organs. The fight against hypertension and its consequences is not won. There is much more to learn and while focusing on hypertension, ISH 2010 is inclusive of diabetes mellitus, obesity, dyslipidemia, and other factors that contribute to the development of the leading cause of death and disability in many countries and a growing cause of morbidity and mortality in many other countries.

The ISH 2010 scientific program has the highest level science encompassing the spectrum of molecular and cellular science, clinical medicine, and population and health policy. It permits basic scientists, clinicians, and population health specialists to attend different streams and learn the latest information on cardiovascular biology and medicine through a cutting edge program. Regardless of your specific interest in the field, all health professionals interested in understanding, managing, and preventing cardiovascular disease will find the program enriching and educational.

An international meeting serves the function of bringing together people from around the world to permit an exchange of ideas to the lasting benefit of our countries.

Vancouver is a beautiful city surrounded by spectacular scenery. It was the site of the 2010 Winter Olympic Games. Before and after ISH 2010, there are opportunities to cruise the ocean, visit the mountains, and enjoy the events around our city and country.

I know that you will enjoy the meeting in Vancouver from September 26 to 30, 2010. It will be a memorable event.

Yours sincerely,

[Signature]

Dr. Simon Rabkin
The ISH 2010 Executive Organizing Committee
Dear Colleagues and Friends,

Hypertension Canada extends a hearty welcome to all the delegates and participants attending the 23rd Scientific Meeting of the International Society of Hypertension (ISH) being hosted here in Vancouver, British Columbia, Canada between September 26 and 30, 2010.

Exactly 20 years after the last ISH meeting in Canada (Montreal 1990), Hypertension Canada is proud to welcome the ISH meeting to Vancouver, another one of our most beautiful cities and earlier this year host to the 2010 Winter Olympic Games. The program planning committee has put together an exciting scientific program rich in educational updates and current research developments. We congratulate the organizers and extend sincere thanks to the many volunteers who helped make this event come to reality.

It is with great pride that we welcome all the delegates and accompanying family members to Canada as we showcase advances in hypertension to the world!

Yours sincerely,
Welcome from the International Society of Hypertension President

Professor Anthony Heagerty
International Society of Hypertension

Dear Colleagues,

I write on behalf of the Executive Committee of the International Society of Hypertension to welcome you to its Biennial Meeting being held in Vancouver, Canada. ISH 2010 will be truly international and will extend beyond the boundaries of hypertension to look at global cardiovascular disease management. It promises to bring together the world’s cardiovascular research community to argue, exchange data, and address controversy.

At its core is a variety of sessions embracing the clinical, basic, and public health aspects of circulatory disease management. In addition, the Local Organising Committee has assembled a glittering faculty of internationally reputed speakers who are on the cutting edge of both research and treatment to present state-of-the-art sessions on the modern management of risk reduction.

All of us will be able to reacquaint ourselves with old friends while engaging in lively debate in the areas that are still controversial in the management of all our patients. At the same time, we will be able to sample the stunning and unique Canadian countryside and the unsurpassed hospitality of our local hosts. I look forward very much to welcoming your active contribution to what we know will be a lively and outstanding meeting.

Sincerely,

[Signature]

Anthony Heagerty

www.vancouverhypertension2010.com
MEETING HOSTS
MEETING HOSTS

Hypertension Canada

Mission

Advancing health by the prevention and control of high blood pressure through research, advocacy, education and knowledge development and translation.

Organizational Overview

Hypertension Canada is a newly integrated, volunteer-based, not-for-profit organization representing over 50 years of expertise in the field of hypertension. The leadership of three organizations is aggressively moving forward to achieve a common vision – a vision that will bring about positive benefits for the millions of people in Canada who, on a daily basis, deal with the dangers and harmful effects of hypertension.

The positive outcomes of joining the resources and expertise of three already strong organizations (Blood Pressure Canada (BPC), Canadian Hypertension Society (CHS) and Canadian Hypertension Education Program (CHEP)) will be ONE authoritative voice on hypertension with more synergistic interactions across all pillars of education, scholarship and research.

CHEP is an innovative knowledge translation program designed to reduce the disease burden of the leading risk for death in Canada. This program provides practical, trustworthy, up-to-date knowledge to healthcare professionals. CHEP is serving as a model that is being adopted in Canada and around the world. 2010 marks the eleventh consecutive year that CHEP has updated recommendations for the diagnosis, management and treatment of hypertension.

Hypertension Canada fosters effective approaches to the management of hypertension in Canada through the dissemination of information about hypertension to health professionals and to the public.
MEETING HOSTS

In the area of research, Hypertension Canada encourages and coordinates research on hypertension in Canada. Annual scientific meetings provide a forum for the presentation of hypertension research and encourage trainees in their studies in the field of hypertension.

Hypertension Canada believes strongly in partnerships at all levels; cooperating with other Canadian, American and international societies and organizations with interests in hypertension.

Leadership of Hypertension Canada

Norm Campbell, MD, FRCPC
Professor of Medicine, Community Health Sciences and Physiology and Pharmacology, University of Calgary
Member of the Libin Cardiovascular Institute of Alberta

Ross Feldman, MD
RW Gunton Professor of Therapeutics, Departments of Medicine and of Physiology & Pharmacology, University of Western Ontario
Robarts Research Institute

Michael A. Adams, PhD
Professor, Department of Pharmacology and Toxicology, Queen's University

Mansoor Husain, MD
Director, Heart & Stroke Richard Lewar Centre of Excellence
Associate Professor, Department of Medicine, University of Toronto

Janusz Kaczorowski, MA, PhD
Senior Scholar, Michael Smith Foundation for Health Research
Professor & Research Director, Department of Family Practice, University of British Columbia
Director, Primary Care and Community Research, Child & Family Research Institute, Vancouver

Sheldon Tobe, MD, FRCPC
Associate Professor of Medicine, Hypertension & Nephrology, University of Toronto
Director of Home Dialysis, Sunnybrook Health Sciences Centre

Heidi Liepold (Observer, Transition Committee)
Manager, Cardiovascular Health Program, Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada

Judi Farrell
Executive Director
Contact Information

Hypertension Canada  
3780 14th Avenue, Suite 211  
Markham, Ontario, Canada  L3R 9Y5  
T: +1.905.943.9400  
F: +1.905.943.9401  
E: judi.farrell@hypertension.ca  
W: www.hypertension.ca

Visit us at Exhibit  
Booth #204 for further information on our activities and the benefits of joining the association.

Membership in Hypertension Canada

Through membership in Hypertension Canada, we invite health care professionals, trainees, other health care associations and corporations to join us in making an important contribution to hypertension research, education, prevention, treatment and control in Canada. Our members become actively involved and encourage others to join this community of stakeholders in hypertension. Active members and volunteers help support initiatives such as the Canadian Hypertension Chair and in maintaining existing programs and services.

Members of Hypertension Canada can avail themselves of reduced rates to attend meetings and take advantage of educational support for trainees. Other research award offerings are also made available to members.

Hypertension Canada Awards

Hypertension Canada is pleased to announce the awarding of a variety of awards. Winners will be announced during the Hypertension Canada Annual General Meeting. Go to the Awards section to view the listing of awards.

Hypertension Canada Annual General Meeting

Date: Tuesday, September 28  
Time: 18:00-21:30  
Location: Malaspina Room, Fairmont Waterfront Hotel
The International Society of Hypertension

About the International Society of Hypertension

Established in 1966, the International Society of Hypertension (ISH) is a dynamic, fast-growing worldwide group of experts who form a network committed to educating healthcare and allied professionals and the public on hypertension and preventing its consequences. The ISH was awarded charitable status in England and Wales on December 31, 2007. As a not-for-profit organization, all revenue generated is committed to research and teaching projects.

Key ISH activities include the organization of Biennial Scientific Meetings, the new Research Scholar Fellowship Award, and development and publication of recommendations in conjunction with the World Health Organization (WHO). A special focus is additionally given by the ISH to teaching activities in economically disadvantaged countries in Asia, Africa, Eastern Europe, and South America, where knowledge, education, practice, and research related to blood pressure and its consequences have been less well advanced as in some industrialized countries.

One of the goals of the ISH is to represent the interests of its constituents around the world and this is achieved in large part through the ISH International Forum. First established in 1992, this consultative forum embodies and nurtures the global nature of the ISH and provides a unique infrastructure and platform for networking and “cross-talk” between the ISH and national or regional Societies of Hypertension or Councils of High Blood Pressure Research. There are currently in excess of 80 Affiliated Societies of the ISH Forum.

The ISH collaborates on educational activities on an ongoing basis with other societies including the Asian Pacific Society of Hypertension (APSH), the European Society of Hypertension (ESH), the International Forum for Hypertension Control and Prevention in Africa (IFHA), and the
World Hypertension League (WHL). A partnership has been recently formed with the International Society of Nephrology (ISN), a global professional society of nephrologists and renal research scientists. In recognition of the shared goals of the two societies, and the close interrelationship of kidney disease and high blood pressure, joint projects are planned for 2010 and beyond.

Membership of the ISH

Today, the ISH has just over 1,000 members from more than 70 countries. It includes academics, researchers in basic science, and clinicians ranging from senior professors to more junior fellows working in clinical and epidemiological research. We invite you to become a part of this international community of hypertension experts. Joining the ISH will allow you to keep up to date in best practice, share experiences, and learn about recent research developments in the field.

Regular Membership is open to those who have accomplished meritorious original investigation in the field of hypertension. Applications should be accompanied by a list of the nominee’s academic degrees, professional positions, and a list of the five best and the five most recent publications relating to hypertension or allied fields. Reduced membership fees are available for new regular members joining the ISH who permanently reside and work in certain developing countries.

Research Fellowships are designed for graduate students and are entirely free. This is a special opportunity for any young researchers or clinical scientists undertaking a higher degree to enhance their curriculum vitae.

Visit the ISH Exhibit Booth #102 for further information on our activities and the benefits of joining the ISH. Alternatively, visit www.ish-world.com.
MEETING HOSTS

ISH Scientific Council 2008-2010

President: A.M. Heagerty (United Kingdom)
Vice-President: T. Fujita (Japan)
Secretary and President Elect: S. Harrap (Australia)
Treasurer: L. Burrell (Australia)
Immediate Past President: L.H. Lindholm (Sweden)
Officer-at-Large: E. Schiffrin (Canada)
Chair, Low & Middle Income Countries Committee (Ex Officio): R. Fagard (Belgium)
Chair, Research Foundation: J.E. Hall (USA)
Chair, Membership Committee: R. Touyz (Canada)

Members

P. Dominiak (Germany)
T. Forrester (Jamaica)
G. Grassi (Italy)
O.J. Kohlmann (Brazil)
G. London (France)
B. Onwubere (Nigeria)
S. Oparil (USA)
K. Shimamoto (Japan)
N. Stern (Israel)
Z. Wu (China, People’s Republic of)
K. Yusoff (Malaysia)
J. Zicha (Czech Republic)

Ex Officio Council Members

WHO-ISH: G. Mancia (Italy)
Board of Management:
  L. Landsberg (USA)
  A. Zanchetti (Italy)
ISH International Forum: J. Chalmers (Australia)
ESH Representative: S. Laurent (France)
APSH Representative: T. Morgan (Australia)
MEETING HOSTS

ISH Society Meeting Agenda

**ISH Past Presidents’ Meeting**
Date: Tuesday, September 28  
Time: 08:00-09:00  
Location: Pacific Rim 2, Pan Pacific Hotel

**ISH International Forum**
An invitation is extended to all Presidents of National Societies of Hypertension, Councils of High Blood Pressure, and Affiliated International Societies.  
Date: Tuesday, September 28  
Time: 12:15-13:45  
Location: Room 220-222, West Level 2

**ISH General Meeting**
An invitation is extended to all ISH members.  
Date: Wednesday, September 29  
Time: 13:00-14:00  
Location: Room 220-222, West Level 2

**ISH Awards Ceremony, Presidential Lecture and Franz Volhard Lecture**
The ISH, with the collaboration and generous support of corporate sponsors, is pleased to announce the presentation of a variety of awards and prizes. Winners will be announced during the ISH Awards Ceremony. Go to the Awards section to view the listing of awards.

The Presidential Lecture will be given by Professor Gary Owens, Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia, United States. The title of the lecture is 'Epigenetic Control of Smooth Muscle Cell Differentiation and Phenotypic Plasticity in Cardiovascular Disease'.

The Franz Volhard Lecture will be given by Professor Graham MacGregor, Wolfson Institute of Preventive Medicine, London, United Kingdom. The lecture is entitled 'Salt – A Pathophysiological Pursuit'.
ISH Awards Ceremony (continued)
An invitation is extended to all ISH 2010 attendees.
Date: Wednesday, September 29
Time: 16:30-18:00
Location: Ballroom A, West Level 1
Chair: Professor AM Heagerty
Co-Chair: Professor S Harrap

ISH Future Meetings

24th Scientific Meeting
September 29 – October 4, 2012
Sydney, Australia

25th Scientific Meeting
2014
Athens, Greece
(a joint meeting with the European Society of Hypertension (ESH))

26th Scientific Meeting
2016
Seoul, Korea

ISH Corporate Members

The ISH Council would like to acknowledge the assistance of the following Corporate Members who are participating in ISH and therefore helping to promote the advancement of scientific research and knowledge in hypertension and associated cardiovascular diseases.

Astellas
AstraZeneca
Boehringer Ingelheim
Daiichi-Sankyo
Medimark International
Mitsubishi Tanabe Pharma Corporation
Novartis

Omron
Pfizer
Roche
Servier
Shionogi
Takeda
MEETING HOSTS

ISH 2010 Committees

Executive Organizing Committee
Dr. Simon Rabkin, President (Canada)
Dr. Arun Chockalingam, Secretary General (Canada)
Dr. Catherine Pang, Treasurer (Canada)
Dr. Venkat Gopalakrishnan, Hypertension Canada Liaison (Canada)

National Advisory Committee
Dr. Norm Campbell (Canada)
Dr. Jacques De Champlain† (Canada)
Dr. Ross Feldman (Canada)
Dr. George Fodor (Canada)
Dr. Pavel Hamet (Canada)
Dr. Pierre Larochelle (Canada)
Dr. Frans Leenen (Canada)
Dr. Richard Lewanczuk (Canada)
Dr. Martin Myers (Canada)
Dr. Ernesto Schiffrin (Canada)

Industrial Relations Committee
Dr. Martin Myers (Chair) (Canada)
Dr. Kikuo Arakawa (Japan)
Dr. George Bakris (USA)
Dr. Lawrence Leiter (Canada)
Dr. Pierre Moreau (Canada)
Dr. Toshio Ogihara (Japan)
Dr. Arya Sharma (Canada)
Dr. William White (USA)

Hypertension Canada
Dr. Michael Adams (Canada)
Dr. Marcel Lebel (Canada)
Dr. James Van Huysse (Canada)
MEETING HOSTS

Investigator Initiated Symposia Committee
Dr. George Fodor (Co-chair) (Canada)
Dr. Frans Leenen (Co-chair) (Canada)

Program Committee
Dr. Ming-Fong Chen (Taiwan)
Dr. Cheryl Dennison (USA)
Dr. Kim Elmslie (Canada)
Dr. Martha Franco (Mexico)
Dr. Guido Grassi (Italy)
Dr. Rajeev Gupta (India)
Dr. Vladimir Hachinski (Canada)
Dr. Steven Haffner (USA)
Dr. John Hall (USA)
Dr. Stephen Harrap (Australia)
Dr. David Harrison (USA)
Dr. Soon Pyo Hong (Korea)
Jacquelyn Jayasinghe, MN, RN-NP (Canada)
Dr. Darwin Labarthe (USA)
Dr. Daniel Lemogoum (Cameroon)
Dr. Liu Lisheng (China)
Dr. Rhonda Low (Canada)
Dr. Wael Al Mahmeed (United Arab of Emirates)
Dr. Ricky Man (China)
Dr. Shanthi Mendis (Switzerland)
Dr. Carlos J Pirola (Argentina)
Dr. Neil Poulter (United Kingdom)
Dr. Rhian Touyz (Canada)
Dr. Thomas Unger (Germany)
Dr. JR Viskoper (Israel)
Dr. Corliee Watters (Canada)
Dr. Zhaosu Wu (China)
Dr. Dingliang Zhu (China)
MEETING HOSTS

Abstract Reviewers

Edward Carl Abbott (Canada)  Jolanta Gutkowska (Canada)
Michael Adams (Canada)  John Hall (USA)
Andrew Advani (Canada)  Stephen Harrap (Australia)
Enrico Agabiti Rosei (Italy)  Paula Harvey (Canada)
François Alhenc-Gelas (France)  Anthony Heagerty (UK)
Kerstin Amann (Germany)  Robert Hegele (Canada)
Lawrence Appel (USA)  Karl Hilgers (Germany)
Michel Azizi (France)  Berthold Hocher (Germany)
Michael Bader (Germany)  Norman Hollenberg (USA)
Lawrie Beilin (Australia)  Masatsugu Horiuchi (Japan)
Giuseppe Bianchi (Italy)  Norbert Hübner (Germany)
Steffen-Sebastian Bolz (Canada)  Hiroshi Itoh (Japan)
Marie Briet (France)  Garry Jennings (Australia)
Ellen Burgess (Canada)  Xavier Jeunemaitre (France)
Kevin Burns (Canada)  Stevo Julius (USA)
Bo Carlberg (Sweden)  Janusz Kaczorowski (Canada)
Maurizio Castellano (Italy)  Kalina Kawecka-Jaszcz (Poland)
John Chalmers (Australia)  Genjiro Kimura (Japan)
Chern-En Chiang (Taiwan)  Ulrich Kintscher (Germany)
Renata Cifkova (Czech Republic)  Osvaldo Kohlmann (Brazil)
Lyne Cloutier (Canada)  Rainer Kolloch (Germany)
Antonio Coca (Spain)  Jaroslav Kunes (Czech Republic)
Kennedy Cruickshank (UK)  Armin Kurtz (Germany)
William Cupples (Canada)  Yves Lacourciere (Canada)
Cesare Cuspidi (Italy)  Lewis Landsberg (USA)
Björn Dahlöf (Sweden)  Richard Lariviere (Canada)
Sandra Davidge (Canada)  Pierre Larochelle (Canada)
Alejano De La Sierra (Spain)  Stéphane Laurent (France)
Peter De Leeuw (The Netherlands)  Marcel Lebel (Canada)
Ralf Dechend (Germany)  Frans Leenen (Canada)
Debra Diz (USA)  Martine Lelièvre-Pégorier (France)
Anna Dominiczak (UK)  Jacques Lenders (The Netherlands)
Jörg Dötsch (Germany)  Richard Lewanczuk (Canada)
Rainer Düsing (Germany)  Lars Lindholm (Sweden)
Georg Ertl (Germany)  Empar Lurbe (Spain)
Robert Fagard (Belgium)  Fabio Magrini (Italy)
Csaba Farsang (Hungary)  Franco Mantero (Italy)
Ross Feldman (Canada)  Carmel McEniery (UK)
Isabel Ferreira (The Netherlands)  Phil McFarlane (Canada)
Albert Ferro (UK)  Peter Meredith (UK)
George Fodor (Canada)  Anea Mezzetti (Italy)
Toshiro Fujita (Japan)  Martin Middeke (Germany)
Haralambos Gavras (USA)  Harald Mischak (Germany)
Guido Grassi (Italy)  Pierre Moreau (Canada)
Robert Gros (Canada)  Trefor Morgan (Australia)
MEETING HOSTS

Abstract Reviewers

Alberto Morganti (Italy)  
Ryuichi Morishita (Japan)  
Suh Mukaddam-Daher (Canada)  
Michael Mulvany (Denmark)  
Martin Myers (Canada)  
Krzysztof Narkiewicz (Poland)  
Georg Nickenig (Germany)  
Peter Nilsson (Sweden)  
Eoin O’Brien (Ireland)  
Michael O’Rourke (Australia)  
Jake Onrot (Canada)  
Suzanne Oparil (USA)  
Sergei Orlov (Canada)  
Gianfranco Parati (Italy)  
Brian Penner (Canada)  
Harm Peters (Germany)  
Geoff Picking (Canada)  
Luc Poirier (Canada)  
Anna Posaday-Malaczynska (Poland)  
Neil Poulter (UK)  
Karl-Heinz Rahn (Germany)  
Alessano Rappelli (Italy)  
Wolfgang Rascher (Germany)  
John Reid (UK)  
Rainer Rettig (Germany)  
Darren Richard (Canada)  
Eberhard Ritz (Germany)  
Damiano Rizzoni (Italy)  
Talma Rosenthal (Israel)  
Gian Paolo Rossi (Italy)  
Luis Miguel Ruilope (Spain)  
Heikki Ruskoaho (Finland)  
Michel Safar (France)  
Ernesto Schiffrin (Canada)  
Roland Schmieder (Germany)  
Jürgen Scholze (Germany)  
Yackoob Seedat (South Africa)  
William Semchuk (Canada)  
Peter Sever (UK)  

Ayra Sharma (Canada)  
Kazuaki Shimamoto (Japan)  
Ram Singh (Canada)  
Don Smyth (Canada)  
Virend Somers (USA)  
Ashok Srivastava (Canada)  
Madhu Anand Srivastava (Canada)  
Jan Staessen (Belgium)  
Alice Stanton (Ireland)  
Ulrike Muscha Steckelings (Germany)  
Anea Stella (Italy)  
George Stergiou (Greece)  
Monika Stoll (Germany)  
Michael Stowasser (Australia)  
Harry Struijker-Boudier (The Netherlands)  
Reza Tabrizchi (Canada)  
Stefano Taddei (Italy)  
Sheldon Tobe (Canada)  
Rhian Touyz (Canada)  
Johanne Tremblay (Canada)  
Jaakko Tuomilehto (Finland)  
Satoshi Umemura (Japan)  
Luc Van Bortel (Belgium)  
Jim Van Huysse (Canada)  
Bruce Van Vliet (Canada)  
Paolo Verdecchia (Italy)  
Massimo Volpe (Italy)  
Bernard Waeber (Switzerland)  
Hui Di Wang (Canada)  
Jiguang Wang (China)  
Michael Weber (USA)  
Ulrich Wenzel (Germany)  
Judith Whitworth (Australia)  
Jiri Widimsky (Czech Republic)  
Robert Willette (USA)  
Bryan Williams (UK)  
Yoram Yagil (Israel)  
Josef Zicha (Czech Republic)
MEETING HOSTS

Meeting Secretariat

Sea to Sky Meeting Management Inc.
Suite 206, 201 Bewicke Avenue
North Vancouver, BC, Canada, V7M 3M7
T: + 1.604.984.6448
F: +1.604.984.6434
E: success@seatoskymeetings.com
W: www.seatoskymeetings.com

ISH 2010 E: info@vancouverhypertension2010.com
ISH 2010 W: www.vancouverhypertension2010.com

Volunteers

We would like to thank those who have volunteered their time to assist ISH 2010 attendees and organizers. Identifiable by their volunteer t-shirts, volunteers provide assistance and ensure attendees have everything they need to participate effectively in ISH 2010.
The Future of Cardiovascular Protection
29 September – 4 October 2012
Sydney Convention and Exhibition Centre

www.ish2012.org

KEY DATES

Abstract submissions open
26 October 2011

Abstract submissions close
23 March 2012

Registration opens
29 March 2012

To join the mailing list, please visit the website and complete the online form. All enquiries may be forwarded to ish2012@arinex.com.au.

Mark your diary now
and plan to join us in Sydney for excellent science in a relaxed and beautiful setting

www.vancouverhypertension2010.com
MEETING INFORMATION

Registration Information

Registration Desk

Location: Foyer, West Level 1

Opening times:
- Sunday, September 26: 08:00-20:00
- Monday, September 27: 06:45-18:00
- Tuesday, September 28: 06:45-18:00
- Wednesday, September 29: 06:45-18:00
- Thursday, September 30: 06:45-17:00

Name Badges

In addition to being a means of identification to colleagues, you are required to wear your name badge for admission to ISH 2010 sessions and events. Room monitors will verify name badges before allowing admission.

The Standard registration fee includes four lunches (Monday, Tuesday, Wednesday, and Thursday); the Basic registration fee does not include any lunches.

Replacement badges are available at the Registration Desk at a cost of $25 per badge.

Member, Non-Member and Student: Attendees in these categories are entitled to admission to all Scientific Sessions, the Exhibit Hall, daily refreshment breaks, the Opening Ceremony and Welcome Reception, four lunches (not included in the Basic registration), a certificate of attendance, a program book, and a CD-Rom of ISH 2010 Abstracts.

Accompanying Person: Attendees wearing this badge are entitled to admission to the Opening Ceremony and Welcome Reception, and the Vancouver City Tour on Monday, September 27 at 13:00.

Exhibitor: Exhibitors wearing this badge have access to the Exhibit Hall and to daily refreshment breaks. Access to Scientific Sessions, the Opening Ceremony and Welcome Reception, and lunches are available for an additional fee.
Accompanying Persons Program

The Accompanying Persons Program includes:

- Opening Ceremony and Welcome Reception, Sunday, September 26, 17:30-20:00
- The Vancouver City Tour on Monday, September 27 at 13:00

The Accompanying Persons Program costs $180. Visit the Registration Desk for more details and to register.

Dietary Requirements

Attendees who advised the ISH 2010 Secretariat of their special dietary needs will receive tickets listing their dietary requirement, for all plated meals, with their name badge upon registering onsite. Please submit this ticket to your server at each plated meal. If you have not advised the Secretariat of your special dietary needs, please advise the staff at the Registration Desk before 16:00 on Sunday, September 26, and we will do our best to accommodate your request.

Optional Tour and Social Event Tickets

Pre-purchased tickets for optional tours and social events are provided with your name badge upon registering onsite. To purchase tickets onsite, please visit the "Tour and Social Events" Registration Desk located in the Foyer, West Level 1. Tickets may be available for purchase onsite for the Gala Evening at $99. For more information on the tours and social events such as the Gala Evening, go to the Tours & Social Events section.

Gala Evening

This is your chance to unwind, socialize and celebrate in Vancouver’s newest ballroom featuring floor to ceiling windows looking over Burrard Inlet and the North Shore. Featuring fabulous Canadian entertainment and Pacific Northwest cuisine, the Gala Evening will be an opportunity for participants to celebrate another successful ISH Meeting and Canadian hospitality!
Accreditation

The University of British Columbia Division of Continuing Professional Development (UBC CPD) is fully accredited by the Committee on Accreditation of Canadian Medical Schools (CACMS) to provide study credits for continuing medical education for physicians. As well, the Accreditation Council for Continuing Medical Education of the United States (ACCME) maintains a reciprocity relationship with CACMS which the American Medical Association (AMA) recognizes for the purpose of allowing Canadian medical schools the ability to certify activities for AMA PRA Category 1 credits and to award such credits to eligible physicians.

This program has been reviewed and approved by the UBC Division of Continuing Professional Development. UBC CPD designates this educational program as meeting the accreditation criteria of the College of Family Physicians of Canada for up to 33.5 MAINPRO M1 credits.

This program is an Accredited Group Learning Activity eligible for up to 33.5 Section 1 credits as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

This program also meets the accreditation criteria for a maximum of 33.5 Category 1 credits toward the American Medical Association Physician’s Recognition Award.
Meeting Administration & Services

**Banking**
There is a Royal Bank ATM located in the East Building of the VCC. The nearest full service bank is the Bank of Montreal, four blocks from the VCC, located at the corner of Burrard Street and Dunsmuir Street. Its hours of operation are from 08:00 to 17:00 Monday to Friday.

**The Business Centres**
The Business Centres will be available for attendees who need to do a bit more than check their webmail. These seated workstations will afford the opportunity for attendees to use MS Office applications, make Skype to Skype calls, and print documents.

**Location:** Exhibit Hall (Exhibition Hall C, West Exhibition Level)

**Opening times:**
- Monday, September 27: 09:30-18:00
- Tuesday, September 28: 09:30-18:00
- Wednesday, September 29: 09:30-18:00
- Thursday, September 30: 09:30-15:00

**Certificate of Attendance**
All ISH 2010 attendees will receive a certificate of attendance with their name badge upon registering onsite.

**Cell Phones, Pagers and Other Noise-Making Devices**
Please respect your fellow attendees by turning cellular phones, pagers, and other noisemakers off during the sessions.

**Concierge / Information on Vancouver**
The VCC has a Customer Service Centre in the Burrard Street Lobby of the West Facility. A wide range of information is available regarding the facility and downtown Vancouver. The Customer Service Centre will also do light business services for attendees such as photocopying and faxing, at a cost.
MEETING INFORMATION

Disabled Access
The VCC offers the following to accommodate the needs of people with disabilities: wheelchair services, accessible elevators, and accessible restroom stalls.

Evaluation
ISH 2010’s aim is to deliver a meeting that is an enjoyable and educational experience. We rely on your full and honest feedback to improve future meetings. An online survey will be emailed to you following ISH 2010 and we appreciate your time and assistance in completing the survey in order to provide your feedback.

First Aid or Medical Emergency
For first aid assistance or in case of a medical emergency, dial 7500 on one of the VCC house phones and explain the nature of the emergency. The VCC has a fully equipped first aid room located on Level 1 of the West Facility adjacent to West Ballroom A.

Food and Beverage
Lunches on September 27, 28, 29, and 30 (four lunches in total) are included for attendees paying the Standard registration fee, and will take place in amongst the Exhibits (Exhibit Hall C, West Exhibition Level). If you are entitled to lunch, please present your lunch ticket to the server. A ticket for each lunch was provided with your name badge upon registering onsite.

There is a myriad of dining options within walking distance of the VCC, from cafés and sushi bars to specialty restaurants serving West Coast cuisine.

For Dinner:
• Oru (located at the Fairmont Pacific Rim Hotel across the street) serving a fusion of east and west flavours
• Miku Restaurant (located at #2 – 1055 West Hastings Street) serving Japanese cuisine with a West Coast twist
• Water Street Café (located at 300 Water Street in Gastown) serving seafood and creative pastas
• Aqua Riva (located next to Canada Place) serving West Coast cuisine and BC wines
MEETING INFORMATION

For Coffee or Snacks:
• Giovane, a cafe + bakery + deli open from 06:00, is located in the Fairmont Pacific Rim Hotel, across the street from the West Building
• Starbucks (located in the Shaw Tower –150-1067 West Cordova) serving coffees, teas, juices and light snacks
• A Food Court serving many options for quick meals and beverages is located beneath the Fairmont Waterfront Hotel
• Mink Café (located at 863 West Hastings Street, a 5 minute walk from the VCC) serving specialty hot chocolates, coffees and snacks

For more information on dining options, visit the Customer Service Centre in the Burrard Street Lobby of the West Facility or ask the Concierge in your hotel.

Internet Cafés
The Internet Cafés will be available for the convenience of attendees to check their webmail.

Location: Exhibit Hall (Exhibit Hall C, West Exhibition Level)
Opening times:
  Monday, September 27:  09:30-18:00
  Tuesday, September 28: 09:30-18:00
  Wednesday, September 29: 09:30-18:00
  Thursday, September 30: 09:30-15:00

The VCC also offers Wi-Fi service that is accessible in the public areas, meeting rooms and exhibit halls of the VCC. Wi-Fi service may be purchased on site, by credit card, through the VCC’s website (www.vancouverconventioncentre.com).

Language of ISH 2010
ISH 2010 will be presented in English.

Liability
Attendees take part in ISH 2010 at their own risk. Oral agreements shall not be binding if they have not been confirmed in writing by ISH 2010 or its agents.
MEETING INFORMATION

Lost & Found
Should you lose or misplace an item, visit the Registration Desk for assistance.

Meeting Room Protocol
Every effort will be made to ensure that all sessions start and end on time. Speakers and attendees are asked to work together to achieve this. This may mean having to cut short a valuable discussion; however, ISH 2010 organizers request your cooperation for the benefit of all attendees. Please turn your cell phone and other noise making devices off or set to vibrate.

Messages
Hand written messages can be left at the Message Desk located near the Registration Desk.

Public Telephones
There are two pay phones located in the Burrard Street Lobby of the West Building.

Smoking
Smoking is not permitted within the VCC or within 7.5 meters of the outside of the building. Check with the VCC staff for the location of the nearest designated smoking area.

Taxis
The closest taxi stand to the West Facility is across the street next to the main entrance of the Fairmont Pacific Rim Hotel.
MEETING INFORMATION

Information for Presenters

Poster Presenters

Poster Session Location: Exhibit Hall (Exhibition Hall C, West Exhibition Level)

Poster presenters should note the following:

- Each poster must fit into the allocated area of 4 feet x 4 feet (1.4m x 1.4m)
- Push pins and assistance with finding your board and hanging your poster will be available
- Set up your poster on the day of your presentation between the hours of 08:00 and 09:30
- Remove your poster on the day of your presentation at the following times:
  - Monday, September 27: 18:00
  - Tuesday, September 28: 18:00
  - Wednesday, September 29: 18:00
  - Thursday, September 30: 14:30
- Posters left up after that day’s poster removal time will be taken down by ISH 2010 staff and will be stored near the Poster Area until the close of ISH 2010, after which time they will be recycled
- ISH 2010 will not be responsible for any lost or stolen posters
MEETING INFORMATION

Speaker Centre
It is ISH 2010 policy that in order to avoid technical difficulties affecting a presentation and to ensure a smooth transition during sessions, all presentations must be pre-loaded and pre-tested prior to the session. Speakers are required to submit their presentation to the technician in the Speaker Centre 24 hours in advance.

Location: Room 116-117, West Level 1
Opening times:
- Sunday, September 26: 12:00-17:00
- Monday, September 27: 07:00-17:00
- Tuesday, September 28: 07:00-17:00
- Wednesday, September 29: 07:00-17:00
- Thursday, September 30: 07:00-15:00

Speaker Lounge
Next door to the Speaker Centre will be the Speaker Lounge. We invite speakers to take the opportunity to relax before or after their presentation, and network with their fellow speakers.

Location: Room 115, West Level 1
Opening times: The Speaker Lounge will be open at the same times as the Speaker Centre.
PROGRAM
PROGRAM OVERVIEW

Program Theme

The theme for ISH 2010 is Global Cardiovascular Risk Reduction. Presentations and exhibits will focus on risk reduction and will stress new integrative approaches to cardiovascular diseases.

Publication of ISH 2010 Proceedings

A CD of proceedings has been inserted into your attendee bag.

Program Session Descriptions

The following Program Section is organized by day, starting with the day’s overview, the detailed session descriptions in chronological order, and the poster sessions taking place that day, if applicable.

Acronyms and Definitions

Scientific Sessions:
- L = The level of the Vancouver Convention Centre, West Building (e.g. Ballroom C, L1)

Poster Sessions:
- “PS#/THU/#” = Poster Session # / Day of Poster Session / Poster # (to easily locate the poster)
- The presenting author is underlined (e.g. Mimran A)
- The highest scored posters that will be discussed during that session are identified in green (e.g. PS#/THU/2)
THURSDAY, SEPTEMBER 23, FRIDAY, SEPTEMBER 24, & SATURDAY, SEPTEMBER 25
## Program by Day

<table>
<thead>
<tr>
<th>Thursday, September 23</th>
<th>Friday, September 24</th>
<th>Saturday, September 25</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The Endocrine Heart – 30 Years Later</strong>&lt;br&gt;University of Ottawa Heart Institute, Ottawa, Ontario 07:15-17:00</td>
<td><strong>The Endocrine Heart – 30 Years Later</strong>&lt;br&gt;University of Ottawa Heart Institute, Ottawa, Ontario 07:15-12:00</td>
<td><strong>The Pathogenesis of Essential Hypertension: Focus on Salt, Stress and Obesity</strong>&lt;br&gt;Westin Resort &amp; Spa, Whistler 09:00-21:00</td>
</tr>
<tr>
<td></td>
<td><strong>The Pathogenesis of Essential Hypertension: Focus on Salt, Stress and Obesity</strong>&lt;br&gt;Westin Resort &amp; Spa, Whistler 15:00-20:15</td>
<td><strong>Behavioral Cardiology and Hypertension: Current Developments in Assessment and Intervention</strong>&lt;br&gt;Vancouver Convention Centre, Room 212, West Level 2 13:00-16:30</td>
</tr>
</tbody>
</table>

See the Optional Tours & Social Events section for the tours and social events schedule.
Thursday, September 23 & Friday, September 24

Thursday: 07:15-17:00
Friday: 07:15-12:00

**The Endocrine Heart – 30 Years Later**

**Location:** University of Ottawa Heart Institute, Ottawa, Ontario

**Symposium**

30 Years Later is a special scientific symposium commemorating the thirtieth anniversary of the discovery of atrial natriuretic factor (ANF). The discovery established that the heart possesses an endocrine function.

Friday, September 24

15:00-20:15  **The Pathogenesis of Essential Hypertension: Focus on Salt, Stress and Obesity**

**Location:** Westin Resort & Spa, Whistler

**Symposium**

**Chair:** Paul Korner

This symposium will provide the opportunity to discuss the mechanisms by which the elevation of blood pressure is influenced by genes and environmental factors related to lifestyle, including high salt intake, stress and obesity. Some of these factors act on several components of the cardiovascular control system, which will undoubtedly result in vigorous debate as to their relative importance. Lastly, there will be discussion of how the new pathophysiological insights result in better treatment or even prevention.
Saturday, September 25

09:00-21:00  **The Pathogenesis of Essential Hypertension: Focus on Salt, Stress and Obesity**  
Continued from Friday  
**Location:** Westin Resort & Spa, Whistler

13:00-16:30  **Behavioral Cardiology and Hypertension: Current Developments in Assessment and Intervention**  
**Room 212, L2**

**Symposium**

**Chairs:** John S. Floras and Robert P. Nolan

This symposium will present novel initiatives within behavioral cardiology for the assessment and treatment of hypertension, using research methods from cardiovascular neuroscience, neuroimaging, exercise physiology, nutrition sciences, and behavioral psychology.
SUNDAY, SEPTEMBER 26
# Program by Day

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 213, West Level 2</th>
<th>Room 212, West Level 2</th>
<th>Room 109-110, West Level 1</th>
<th>Ballroom C/D, West Level 1</th>
<th>Westin Resort &amp; Spa, Whistler</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>The Heart and Kidney Interface and the CardioRenal Syndrome 08:00-11:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td>WHL and CHL Joint Symposium: Traditional Chinese Medicine in the Control of Hypertension 09:00-11:30</td>
<td>The Pathogenesis of Essential Hypertension: Focus on Salt, Stress and Obesity 09:00-13:00</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>Retinal Vessel Analysis – From Risk Assessment to Therapy 14:00-16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Opening Ceremony and Welcome Reception 17:30-19:00</td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Welcome Reception 19:00-20:00</td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

See the Optional Tours & Social Events section for the tours and social events schedule.
SUNDAY, SEPTEMBER 26

08:00-11:45  **The Heart and Kidney Interface and the CardioRenal Syndrome**  Room 213, L2

**Chair:** Branko Braam

This session will discuss the following:
- **Pathophysiology of the CRS**
  - Arterial and venous pressure regulation in the CRS
  - Non-hemodynamic coupling between heart and kidneys
- **Definition, Classification and Epidemiology of the CRS**
  - Classification of the CRS
  - Operational definitions and epidemiology of CRS
- **Clinical aspects of the CRS**
  - Diagnosis and treatment of anemia in kidney and heart failure
  - Relationships between heart failure and renal failure in acute and chronic settings
  - Heading for a research agenda: Where are the questions in this field?

09:00-11:30  **WHL and CHL Joint Symposium: Traditional Chinese Medicine in the Control of Hypertension**  Room 109-110, L1

**Symposium**

**Session Organizers:** World Hypertension League (WHL) and the Chinese Hypertension League (CHL)

**Chairs:** Arun Chockalingam, Canada and Liu Lisheng, China

This session will discuss the following:
- The anti-hypertensive effect and mechanism of Yang-Xue-Qing-Nao Granules
- The role of berberline therapy in the association of CD31+/CD42-microparticles and endothelial dysfunction – an animal study
- Puerarin attenuates cerebral damage through improving cerebral microcirculation in SHR
- Cardiovascular protective effects of herbal medicine Danshen-Gegen – a novel randomised double blind placebo control trial in high risk hypertensive subjects
SUNDAY, SEPTEMBER 26

09:00-13:00  The Pathogenesis of Essential Hypertension: Focus on Salt, Stress and Obesity
Continued from Saturday
Location: Westin Resort & Spa, Whistler

14:00-16:30  Retinal Vessel Analysis – From Risk Assessment to Therapy  Room 212, L2
Chairs: Leopold Schmetterer and Arno Schmidt-Trucksäss

This session will discuss the following:
- Physiological regulation of retinal vessel diameter and blood flow
- Assessment of retinal structure and function by static and dynamic vessel analysis
- Association of atherosclerotic risk factors and cardiovascular outcome with retinal structure and function
- Lifestyle and retinal microcirculation
- Benefit of pharmacologic treatment on retinal blood flow

Opening Ceremony and Welcome Reception  Ballroom C/D, L1

17:30-19:00  Opening Ceremony
19:00-20:00  Welcome Reception

Price: Included in registration fee
Name badge or ticket is required for admission

The Opening Ceremony and Welcome Reception will be one of the highlights of ISH 2010. Featuring welcoming remarks from ISH and your Canadian hosts, an outstanding lecture and Pacific Northwest entertainment, the Opening Ceremony and Welcome Reception will kick off ISH 2010 in style!
### MONDAY, SEPTEMBER 27

#### Program by Day

<table>
<thead>
<tr>
<th>Time</th>
<th>Ballroom A, West Level 1</th>
<th>Ballroom B, West Level 1</th>
<th>Ballroom C, West Level 1</th>
<th>Rooms 211-214, West Level 2</th>
<th>Rooms 109-110, West Level 1</th>
<th>Exhibition Hall C, West Exhibition Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td>Uncontrolled Hypertension – A Global Health Issue: Problems and Solutions 08:15-09:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td>Hypertension-related Cardiovascular Complications: Predictors of Risk and Responses to Therapy 08:15-09:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td>Determinants of Central Arterial Compliance 08:15-09:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td>The Renin-Angiotensin-Aldosterone Axis: ‘New Targets’ for an ‘Old System’ 08:15-09:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td>Formulating Cardiovascular Public Policy 10:30-12:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td>Blood Pressure Measurement 10:30-12:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td>Metabolic Syndrome/Obesity 10:30-12:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Poster Session A 12:00-14:15</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td>Bridging the Gaps: Reducing Cardiovascular Risk in Low Resource Settings 14:15-15:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td>Heart Failure and Hypertension 14:15-15:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td>Rapid Signalling Pathways Mediating Estrogen and Aldosterone Cardio-Metabolic Effects 14:15-15:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Break 15:45-16:30</td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td>Multiple Risk Factors in Development of Cardiovascular Disease: A Global Perspective 16:30-18:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td>Sleep Disturbances and Blood Pressure Regulation 16:30-18:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

See the Optional Tours & Social Events section for the tours and social events schedule.
08:15-09:45  **Public Health – Population Science**  
**Plenary Symposium**  
**Uncontrolled Hypertension – A Global Health Issue**  
Ballroom A, L1  

**Chair:** Mendis S, Switzerland and Rabkin SW, Canada

08:15  **Incidence and Prevalence of Hypertension in Canada, from 1998/99 to 2006/07**  
Robitaille C, Canada

08:25  **Hypertension Prevalence in Malaysia**  
Yusoff K, Malaysia

08:35  **Prevalence of Uncontrolled Hypertension in South America**  
Juncos L, Argentina

08:45  **The Perspective from China**  
Zhao D, China

09:15  **Hypertension in Developed Countries**  
Poulter NR, United Kingdom

08:15-09:45  **Clinical Science**  
**State of the Art – Oral Presentations**  
**Hypertension-related Cardiovascular Complications: Predictors of Risk and Responses to Therapy**  
Ballroom B, L1

**Chair:** Meredith P, United Kingdom

**Learning Objectives:**
- The blood pressure values at which drug treatment should be started with CVD history
- The blood pressure values to be reached with treatment in patients with CVD history
- Strategies to achieve optimal blood pressure control
Baseline Predictors of the Development of Resistant Hypertension among Hypertensive Patients in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Gupta AK¹, Nasothimiou, E¹, Chang CL¹, Mastorantonakis S¹, Sever PS¹, Wedel H², Dahlof B², Poulter NR¹, on behalf of ASCOT investigators

¹United Kingdom, ²Sweden

Optimal Target Blood Pressure for Elderly Hypertensive Patients

Rakugi H¹, Ogihara T¹, Saruta T¹, Matsuoka H¹, Shimamoto K¹, Shimada K¹, Imai Y¹, Kikuchi K¹, Ito S¹, Eto T¹, Kimura G¹, Imaizumi T¹, Takishita S¹, Ueshima H¹, the VALISH Study Group

¹Japan

Achievement of Blood Pressure Goal in Patients with Resistant Hypertension Treated with Baroreflex Activation Therapy®

Bisognano J¹, Bakris G¹, Nadim M¹, Sanchez L¹, Sica D¹, for the Rheos Pivotal Trial Investigators

¹United States

Long-Term Outcomes in High-Risk Hypertensive Patients: Results from an Extended Follow-Up of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants

Oparil S¹, Cushman WC¹, Davis BR¹, Pressel SL¹, Cutler JA¹, Einhorn PT¹, Ford CE¹, Probstfield JL¹, Whelton PK¹, Wright, Jr. JT¹, ALLHAT Cooperative Research Group

¹United States

Prognostic Value of Blood Pressure in Patients with Coronary Artery Disease: Evidence from the “Action” Database

Meredith PA¹, Lloyd S¹, Ford I¹, Elliott HL¹

¹United Kingdom

Effects of Perindopril-Based Blood Pressure Lowering in Isolated Diastolic Hypertension: The PROGRESS Trial

Arima H¹, Omae T², Anderson C¹, Hata J¹, Woodward M¹, MacMahon S¹, Neal B¹, Chalmers J¹

¹Australia, ²Japan

Best Evidence for Blood Pressure Targets for Patients with Stroke and for Patients with Coronary Artery Disease

Ruilope LM, Spain
08:15-09:45 Translational Oral Presentations

Determinants of Central Arterial Compliance

Chair: Lakatta E, USA and Park JB, Korea, Republic of

Ballroom C, L1

08:15 Pulse Wave Analysis in Responders and Non-Responders to Initial Antihypertensive Therapy
Kotovskaya Y1, Troshina A1, Kolesnikova I1, Karaulova Y1, Kravtsova O1, Kobalava Z1
1Russian Federation

08:25 Relationship between Arterial Stiffness Indexes and Blood Flow of the Middle Cerebral Artery in Untreated Patients
Xu T1, Fan W1, Xu J1, Gao P1, Li Y1
1China

08:35 Combined Effect of Pulse Wave Velocity and Augmentation Index on Mortality in An Elderly Population: The Proteger Study
Protogerou AD1, Safar ME2, Papaioannou TG1, Zhang Y2, Agnoletti D2, Papadogiannis D1, Blacher J2
1Greece, 2France

08:45 The Potential Role of Low 25-Hydroxyvitamin D in Increased Aortic Stiffness
Mayer Jr. O1, Filipovský J1, Seidlerová J1, Dolejšová M1, Cífková R1
1Czech Republic

08:55 Acute Elevation of Serum Triglycerides Modifies Ventricular-Vascular Interaction by Increasing Left Ventricular Contractility
Holland DJ1, Erne D1, Haluska B1, Leano R1, Marwick TH1, Sharman JE1
1Australia

09:05 Increased Arterial Stiffness in Patients with Fabry Disease
van den Bogaard B1, Rombach SM1, Aerts JMFG1, Hollak CEM1, van den Born BJH1
1Netherlands
MONDAY, SEPTEMBER 27

09:15  Gender Difference of Arterial Stiffness in Apparently Healthy Subjects in Korea; The Korean Arterial Aging Study (KAAS)-Gender
Park JB1, Kim DS1, Kim KS1, Jeong JW1, Chae SC1, Park JC1, Oh BH1, Chung N1, The Korean Arterial Aging Study (KAAS)-Gender
1Korea, Republic of

09:25  Peripheral Augmentation Indexes Measured by the Omron HEM-9000AI and Sphygmocor Systems: Correlation and Their Determinants
Fan W-X1, Wang J-G1, LI Y1
1China

09:35  Associations between Eas Index for Tissue Doppler Imaging and Aortic Stiffness as Assessed by Transesophageal Echocardiography and Radial Augmentation Index
Sako H1, Miura S-I1, Kumagai K1, Saku K1
1Japan

08:15-09:45  Basic Science Symposium
Jointly Sponsored by ISH 2010 and the High Blood Pressure Research Council of the AHA  Room 211-214, L2

Chair: Touyz R, Canada

08:15  The Adipose Renin Angiotensin System and the Cardiometabolic Syndrome
Cassis LA, United States

08:45  Disruption of Npr1 Gene Enhances the Expression of RAS Components Leading to the Cardiovascular Events
Pandey KN1, Vellaichamy E1
1United States

09:00  Aldosterone, Inflammation and Target Organ Damage
Brown N, United States
Possible Involvement of ACE2-Angiotensin(1-7)-Mas Axis in Inflammatory Vascular Remodeling after Cuff Placement
Nakaoka H1, Iwai M1, Sone H1, Kanno H1, Senba I1, Inaba S1, Horiuchi M1
1Japan

08:15-09:45 Clinical Science
Core Curriculum
Core Curriculum Part 1
Room 109-110, L1

Chair: Myers M, Canada

08:15 CHEP: Algorithm for the Diagnosis of Hypertension
Bolli P, Canada

08:45 Measuring Office BPS. Avoiding the Pitfalls
Cloutier L, Canada

09:15 What Lab Tests Do You Ask For in the Routine Workup of Hypertensive Patients?
Wilson TW, Canada

10:30-12:00 Public Health – Population Science
Symposium
Formulating Cardiovascular Public Policy
Ballroom A, L1

10:30 Formulating Cardiovascular Public Policy: The view from a WHO perspective
Mendis S, Switzerland

11:00 Formulating Health Policy for Cardiovascular Health – An Australian Perspective
Neal B, Australia

11:30 Formulating Health Policy for Cardiovascular Health – A Canadian Perspective
Butler-Jones D, Canada
10:30-12:00 **Clinical Science**  
State of the Art – Oral Presentations  
**Blood Pressure Measurement**  
Ballroom B, L1

**Chairs:** Kaczorowski J, Canada and Stergiou GS, Greece

**Learning Objectives:**
- To review the rationale for using automated blood pressure recording devices in routine clinical practice
- To show how automated office BP can be used to eliminate the white coat effect.
- To present an algorithm for BP assessment in clinical practice using automated office, home and 24 hour ambulatory BP

10:30 **Central Aortic Pressure Predicts Hypertensive Organ Damage in Japanese General Population**  
Takase H¹, Dohi Y¹, Toriyama T¹, Okado T¹, Sonoda H¹, Hagikura A¹, Kimura G¹  
¹Japan

10:40 **Blood Pressure Measurement during a Campaign against Hypertension: Usefulness of Multiple Blood Pressure Measurements by Using an Automated Oscillometric Monitor (BpTRU)**  
Crippa G¹, Cassi A¹, Fares ML¹, Prati C¹  
¹Italy

10:50 **Strict Thresholds of Clinic BP (130/80mm Hg) and Home BP (125/75mm Hg) Eliminate Risk of White-Coat Hypertension and Masked Hypertension Even in a High-Risk Group: The Japan Morning Surge – Home Blood Pressure (J-HOP) Study 4000**  
Kario K¹, Hoshide S¹, Eguchi K¹, Kabutoya T¹, Ishikawa J¹, Ishikawa S¹, J-HOP study investigator group  
¹Japan

11:00 **Can Masked Hypertension be Diagnosed in the Doctor’s Office? Experience with Multiple In-Office Blood Pressure Measurements with an Automated Oscillometric Device (BpTRU)**  
Crippa G¹, Cassi A¹, Prati C¹, Fares ML¹  
¹Italy
11:10  Difference of Systolic Blood Pressure Measurement by Nurse and Physician may Predict White Coat Effect in Treated Hypertensive Patients: The BP@home study
Park JB¹, Park CG², Youn HJ¹, Choi DJ¹, Ahn YK¹, Shin J-H¹, Kim DW¹, Rim SJ¹, Bae JH¹, on behalf of the Korean Hypertension Research Network
¹Korea, Republic of; ²Kosovo, Republic of

11:20  Prevalence of Masked Hypertension in Subjects with High Normal Blood Pressure
Llisterri JL¹, Alonso J¹, Gorostidi M¹, de la Cruz JJ¹, Segura J¹, de la Sierra A¹, Banegas JR¹, Aranda P¹, Roca-Cusachs A¹, Ruilope LM¹, Spanish Society of Hypertension ABPM Registry
¹Spain

11:30  Automated Office Blood Pressure Measurements
Myers M, Canada

10:30-12:00  Translational – Clinical Science
State of the Art – Oral Presentations
Metabolic Syndrome/Obesity  Ballroom C, L1
Session is a part of the Cardiometabolic Tract of Sessions, sponsored in part by an unrestricted educational grant by Boehringer Ingelheim

Chairs: Forrester T, Jamaica and Pang C, Canada

10:30  What is the Evidence for the Use of Pharmacologic Therapy in the Treatment for Obesity
Sharma A, Canada

11:00  Plasma Copeptin, a Unifying Factor Behind the Metabolic Syndrome
Enhörning S¹, Struck J², Morgenthaler NG², Bergmann A², Melander O¹
¹Sweden, ²Germany

11:10  Using Glycosylated Hemoglobin to Define the Metabolic Syndrome in United States Adults
Cheung BMY¹, Ong KL¹, Tso AWK¹, Lam KSL¹, Cherny SS¹, Sham PC¹
¹China
11:20 Exercise Augments Weight Loss Induced Improvement in Renal Function in Obese Metabolic Syndrome Subjects
Straznicky N1, Lambert E1, Grima M1, Dawood T1, Lambert G1, Nestel P1, Eikelis N1, Schlaich MP1
1Australia

11:30 Visceral Adiposity as Predictor of Left Ventricular Hypertrophy in Hypertensive Men
Jakovljevic B1, Stojanov V1, Lovic D1, Paunovic K1
1Serbia

11:40 Demographic, Behavioral, and Dietary Traits of at Risk and Less at Risk Obese U.S. Adults: The INTERMAP Study
Hankinson A1, Daviglus M1, Brown I2, Chan Q2, Stamler J1
1United States, 2United Kingdom

11:50 Genetic Variations of Girk4 are Associated with MetS in Xinjiang Uygur population: A Case-Control Study
Zhang D1, Li N1, Zhang J1, Guo Y1, Yan Z1, Wang H1, Zhou L1, Hong J1, Wu Z1
1China

10:30-12:00 Basic Science Oral Presentations
Vascular Consequences of Obesity and Insulin Resistance – Pathobiology and Pharmacology
Room 211-214, L2

Chairs: Cassis L, United States and Stern N, Israel

10:30 Effect of Calcium Channel Blocker on Glucose Intolerance and Adipose Tissue Dysfunction in Type 2 Diabetic KK-Ay Mice
Iwai M1, Kanno H1, Inaba S1, Senba I1, Sone H1, Nakaoka H1, Horiuchi M1
1Japan

10:40 Angiotensin II Stimulation in Prepuberty Induces Sustained Insulin Resistance and Hypertension via Continuously Upregulated Rac-1, Oxidative Stress, and Inflammatory Cytokines.
Yamashita T1, Togashi N1, Okazaki Y1, Ohta H1, Ishimura S1, Yokoyama Y1, Tanaka M1, Hyakukoku M1, Yoshida H1, Shimamoto K1
1Japan
Diabetes Accelerated Memory Dysfunction via Cerebrovascular Inflammation and Beta-Amyloid Deposition in Alzheimer Mouse Model: Generation of Novel Transgenic Mouse Models of Alzheimer Disease with Diabetes
Takeda S¹, Sato N¹, Uchio-Yamada K¹, Rakugi H¹, Morishita R¹
¹Japan

Role of Renal Nox4 Based-NADPH Oxidase in Mediating Hyperglycemia-Induced Oxidative Stress and Redox Signaling – Implication in Diabetic Nephropathy
Sedeek M¹, Callera G¹, Montezano A¹, Gutsol A¹, Page P², Syzdralewiez C³, Heitz F³, Kennedy CR¹, Burns KD¹, Hebert RL¹, Touyz RM¹
¹Canada, ²Swaziland, ³Switzerland

Angiotensin 1-7 Is a Novel Means To Prevent the Metabolic Syndrome through Multiple Effects on Adipose Tissue, Liver and Skeletal Muscle: Lessons from the Fructose-Fed Rat Model
Marcus Y¹, Shechter Y¹, Kohen F¹, Limor R¹, Sasson K¹, Biton I¹, Fridkin M¹, Benayahu D¹, Shefer G¹, Stern N¹
¹Israel

Angiotensin II Reduces Muscle Mitochondrial Content and Affects Glycemic Control
Miyashita K¹, Mitsuishi M¹, Muraki A¹, Itoh H¹
¹Japan

MitoQ₁₀ Decreases AMP-activated Protein Kinase (AMPK) Activation in Endothelial Cells from Patients with Coronary Artery Disease and Diabetes
Mackenzie RM¹, Hamilton CA¹, Miller WH¹, Salt IP¹, Murphy MP¹, Delles C¹, Dominiczak AF¹
¹United Kingdom

Spironolactone Improves Cognitive Decline Observed in Female Type 2 Diabetic Mice
Mogi M¹, Sakata A¹, Iwanami J¹, Tsukuda K¹, Min L-J¹, Jing F¹, Ito M¹, Horiuchi M¹
¹Japan

Walking Promotes Metabolic Improvement and Baroreflex Sensitivity in Fructose-Fed Male Rats
Machi JE¹, Bernardes N¹, Irigoyen MC¹, De Angelis K¹, Wichi RB¹
¹Brazil
MONDAY, SEPTEMBER 27

10:30-12:00  Clinical Science
Core Curriculum
Core Curriculum Part 2  Room 109-110, L1

Chair: Milot A, Canada

10:30  Hypertension and Heart Failure; Looking Back and Looking Forward
Arnold M, Canada

11:00  The Challenges and Benefits of Cardiovascular Risk Assessment in Clinical Practice
Grover S, Canada

11:30  Blood Pressure Measurement: Ensuring Quality and Interpreting Results
McKay D, Canada

14:15-15:45  Public Health – Population Science
Symposium
Bridging the Gaps: Reducing Cardiovascular Risk in Low Resource Settings  Ballroom A, L1

Session Organizers: ISH, in collaboration with the World Health Organization (WHO) and the Lancet

Chairs: Harrap S, Australia, Heagerty AM, United Kingdom and Lindholm L, Sweden

The symposium will be attended by high level representation from Ministries of Health from a number of developing countries (in particular sub-Saharan Africa and Asia), who will deliberate on the constraints and the day-to-day challenges faced by the health workforce and the health system in low and middle income countries. It is hoped that the findings of the Symposium, an Accord, will be signed by the Ministers of Health and published. It is the ultimate aim of the organisers to secure the commitment of Ministers to implement these programmes more extensively at the national level.
MONDAY, SEPTEMBER 27

14:15-15:45 **Clinical Science**

**Symposium**

**Heart Failure and Hypertension**
Ballroom B, L1
Jointly Sponsored by the Canadian Cardiovascular Society and ISH 2010

**Chairs:** Hong S-P, Korea, Republic of and Kerr C, Canada

14:15 **Prevalence and Prognosis of Left Ventricular Diastolic Dysfunction in the Elderly: the PROTEGER Study**
Zhang Y¹, Safar ME¹, Agnoletti D¹, Iaria P¹, Protogerou A², Blacher J¹
¹France, ²Greece

14:30 **Diastolic Dysfunction at Rest and Exercise in Persons with Hypertension**
Ha J-W, Korea, Republic of

15:00 **E/e’ is an Independent Predictor of Heart Failure Admission in Patients with Type 2 Diabetes Mellitus**
Wai B¹, Patel SK¹, Ord M¹, Grant S¹, Maclsaac RJ¹, Jerums G¹, Srivastava PM¹, Burrell LM¹
¹Australia

15:15 **Management of Diastolic Heart Failure**
Arnold M, Canada

14:15-15:45 **Basic Science**

**Symposium**

**Rapid Signalling Pathways Mediating Estrogen and Aldosterone Cardio-Metabolic Effects**
Room 211-214, L2

**Chair:** Feldman R, Canada

14:15 **Reconsidering the Roles of the Mineralocorticoid Receptor**
Funder J, Australia

14:45 **Choreographing the Rapid Vascular Effects of Steroids: Sorting out the Partners and the Steps**
Feldman R, Canada
MONDAY, SEPTEMBER 27

15:15  Rapid Steroid Effects in Hypertension: Role of GPR30
       Leeb-Lundberg LMF, Sweden

14:15-15:45  Clinical Science

14:15-15:45  Debates

Clinical Science – Debate 1  Room 109-110, L1

Session is a part of the Cardiovascular Risk Factors Tract of Sessions,
spared in part by unrestricted educational grants from Pfizer Canada,
Servier Canada and Takeda

Chair: Hollenberg N, United States

14:15  Should Masked Hypertension be Treated?
       TBA

15:00  Are the Antihypertensive/CV Risk Reducing Effects of Diuretics
       a Class (or a Chlothalidone-Specific) Effect?
       Poulter NR, United Kingdom

16:30-18:00  Public Health – Population Science

Symposium

Multiple Risk Factors in Development of Cardiovascular Disease: A Global
Perspective  Ballroom A, L1

Session is a part of the Cardiometabolic Tract of Sessions, sponsored in
part by an unrestricted educational grant from Boehringer Ingelheim

Chair: Yusoff K, Malaysia

16:30  Determinants of Cardiovascular Disease: Comparative Risk
       Assessment of Dietary, Lifestyle, and Metabolic Risk Factors
       Ezzati M, United States

17:00  Metabolic Syndrome and Hypertension in Japan – Lessons From
       Tanno – Sobetsu Study
       Shimamoto K, Japan

17:30  Lessons from Cross Cultural Studies of Determinants of
       Cardiovascular Risk
       Lear S, Canada
16:30-18:00 Translational – Clinical Science  
State of the Art – Oral Presentations  
Sleep Disturbances and Blood Pressure Regulation  
Ballroom B, L1  
Chair: Bram B, Canada  
Learning Objectives:  
• To review normal circadian cardiovascular biology  
• To describe the prevalence of sleep related breathing disorders in different populations  
• To illustrate mechanisms by which obstructive or central sleep apnea increase cardiovascular risk  
• To review clinical trial evidence for cardiovascular risk reduction with therapy directed specifically at obstructive or central sleep apnea  

16:30  
Sleep Apnea and Cardiovascular Risk  
Floras J, Canada  

17:00  
Serum Level of Aldosterone Is Related to Obstructive Sleep Apnea Syndrome in Male Patients with Hypertension  
Yang J¹, Yao X¹, Li N¹  
¹China  

17:10  
Systolic Blood Pressure and Body Mass Index are the Mainly Possible Contributors to the Alteration of Left Ventricular Structure in Patients with Obstructive Sleep Apnea Syndrome  
Yang J¹, Yan Z¹, Yao X¹, Song H¹, Wang Y¹, Wu Z¹, Li N¹  
¹China  

17:20  
Dietary Sodium and Aldosterone Levels are Related to Severity of Obstructive Sleep Apnea in Patients with Hyperaldosteronism and Resistant Hypertension  
Pimenta E¹, Gaddam KK², Gordon RD¹, Oparil S², Stowasser M¹, Calhoun DA²  
¹Australia, ²United States  

17:30  
Impact of Impaired Fall in Night-time Systolic Blood Pressure on Stroke Mortality  
Callaly EL¹, Dolan E¹, Staessen JA², Stanton AV¹, McCormack P¹, O’Brien E¹  
¹Ireland, ²Belgium
MONDAY, SEPTEMBER 27

17:40  Effect of CPAP on 24-Hour Blood Pressure in Patients with OSA and Resistant Hypertension. A Randomised Controlled Study
Tovar JL¹, Lozano L¹, Espinell E¹, Segarra A¹, Sampol G¹, Romero O¹, Jurado MJ¹, Untoria MD¹, Lloberes P¹
¹Spain

17:50  Impact of Impaired Fall in Nighttime Heart Rate on Cardiovascular Mortality: Dublin Outcome Study
Van der Poel L¹, Dolan E¹, O’Brien E¹
¹Ireland

16:30-18:00  Basic Science
State of the Art – Oral Presentations
Vascular Signaling  Room 211-214, L2

Chairs: Davidge S, Canada and Zicha J, Czech Republic

Learning Objectives:
- To highlight molecular mechanisms and cellular processes underlying vascular changes in hypertension
- To provide insights on the role of reactive oxygen species in vascular signaling and implications in hypertension
- To introduce the concept of cross-talk between angiotensin II and aldosterone signaling in vascular pathobiology of hypertension

16:30  in vivo Imaging in Ca/calmodulin Biosensor Mouse Arteries Reveals Mechanisms of Arterial Tone
Zhang J¹, Chen L¹, Blaustein MP¹, Wier WG¹
¹United States

16:40  Major Role of Renal Dopamine D5 Receptors in the Regulation of Blood Pressure
Asico LD¹, Zhang X¹, Jiang J², Cabrera D¹, Escano C¹, Sibley D¹, Armando I¹, Jose PA¹
¹United States, ²Canada

16:50  Vascular Smooth Muscle Cell Differentiation to an Osteogenic Phenotype Involves TRPM7 dysregulation and Oxidative Stress – Modulation by Magnesium
Montezano AC¹, Zimmerman D¹, Yusuf H¹, Burger D¹, Chignalia AZ¹, Touyz RM¹
¹Canada
17:00  Estrogen Receptors Regulate Paracrine Cardioprotection of the c-kit+ Precursor Cells
Slavic S¹, Curato C¹, Altarche-Xifro W¹, Kaschina E¹, Unger T¹, Li J¹
¹Germany

17:10  Endothelin-1 Overexpression Exacerbates High Fat Diet-Induced Atherosclerosis in Apolipoprotein E Knockout Mice
Li MW¹, Kasal D¹, Paradis P¹, Schiffrin EL¹
¹Canada

17:20  Uncoupling Protein 2 Ablation Exacerbates High Salt Intake-Induced Vascular Dysfunction
Ma S¹, Ma L¹, Yang D¹, Hao X¹, Liu D¹, Zhu Z¹
¹China

17:30  Integrating Newer Concepts in Vascular Signalling for Understanding the Mechanisms of Hypertension
Touyz R, Canada

16:30-18:00 Clinical Science
Debates

Clinical Science – Debate 2  Room 109-110, L1

Session is a part of the Cardiovascular Risk Factors Tract of Sessions, sponsored in part by unrestricted educational grants from Pfizer Canada, Servier Canada and Takeda

Chair: Hollenberg N, United States

16:30  IMT is a Useful Test in the Clinical Assessment of Atherosclerotic Risk Treatment
Schmidt-Trucksaess A¹, Spence D²
¹Switzerland, ²Canada

17:15  Should Diastolic Blood Pressure be Lowered to Less than 70 mmHg to Control Systolic Hypertension?
Heagerty AM¹, Larochelle P²
¹United Kingdom, ²Canada
The following highest scored posters will be discussed during this session between 12:00 to 13:00: PS1/MON/1 through to PS1/MON/33 (all posters identified in green).

Chair: Pang C, Canada

**PS1/MON/1**
GW9662, a PPARγ-antagonist, Inhibits Telmisartan-Induced Rise of Adiponectin and Ameliorates Hypoglycemia and Insulin Resistance
Younis F1, Oron Y1, Limor R1, Stern N1, Rosenthal T1
1Israel

**PS1/MON/2**
The Adipokine CTRP-1 Is Expressed in the Human Adrenal Gland and Could Be the Link between Hyperaldosteronism and Hypertension in Overweight-Obese Patients
Seccia TM1, Skander G1, Belloni AS1, Lenzini L1, Pessina AC1, Rossi GP1
1Italy

**PS1/MON/3**
Expression of the Novel Adipokines CTRP (Complement-C1q TNFα-related protein)-5, CTRP-6, and CTRP-7 in the Adrenal Gland and Periadrenal Fat Tissue
Seccia TM1, Ferraro S1, Belloni A1, Skander G1, Lenzini L1, Pessina AC1, Rossi GP1
1Italy

**PS1/MON/4**
Effects of Hypolipemic Drugs on Modulation of MCP-1, PAI-1 and Adiponectin in 3T3-L1 Adipocytes
Lobo S1, Quinto BMR1, Oyama L1, Ribeiro AB1, Zanella MT1, Batista MC1
1Brazil

**PS1/MON/5**
Comparative Effectiveness of Renin Angiotensin System Blockades Plus CCBs or Diuretics for Essential Hypertension: A Systematic Review
Ma R1, Yu J1, Yang L1, Xu D1, Liu P1, Bai F1
1China

**PS1/MON/6**
Protection of Retinal Vasculature by Losartan against Apoptosis and Vasculopathy in Rats with Spontaneous Hypertension
Yang D1, Zhang M1, Huang X1, Fang F1, Chen B1, Wang S1, Cai J1, Shi X1, Qu J1, Geng Y-J2
1China, 2United States
PS1/MON/7
Regulation of Lipoprotein Lipase Expression via PPARalpha by Angiotensin Type 1 Receptor Blocker Telmisartan in Hepatic cells
Liu M¹, Jing DQ¹, Yin SN¹, Mu YM¹
¹China

PS1/MON/8
Cilnidipine Ameliorates Osteoporosis of Ovariectomised Hypertensive Rats through Inhibition of N-Type Calcium Channel
Shimizu H¹, Nakagami H¹, Rakugi H¹, Morishita R¹
¹Japan

PS1/MON/9
Combination Therapy with Angiotensin Receptor Blocker and T- And L-Type Calcium Channel Blocker for Attenuation of Proteinuria in Dahl Salt-Sensitive Rats
Takai S¹, Jin D¹, Sakonjo H¹, Miyazaki M¹
¹Japan

PS1/MON/10
Sustainability of Blood Pressure Following an Evidence-Informed Chronic Disease Management (CDM) Program on Hypertension
Moy Lum-Kwong M¹, Tobe S¹, Von Sychowski S¹, Kandukur K¹, Kiss A¹
¹Canada

PS1/MON/11
EUROASPIRE III Primary Care: Lifestyle, Risk Factor and Therapeutic Management in People at High Risk of Developing Cardiovascular Disease in Europe
Kotseva K¹, Jennings C¹, De Backer G², De Bacquier D², Amouyel P³, Gaita D⁴, Keil U⁵, Pajak A⁶, Reiner Z⁷, Wood D¹, EUROASPIRE Study Group
¹United Kingdom, ²Belgium, ³France, ⁴Romania, ⁵Germany, ⁶Poland, ⁷Croatia

PS1/MON/12
Therapeutic Resistance as the Key Barrier to Blood Pressure Control: A STITCH Substudy
Nelson SA¹, Feldman RD¹, Dresser GK¹
¹Canada

PS1/MON/13
Hypertension Control in Communities (HCC): Baseline Characteristics and Preliminary Result of Blood Pressure Management among Hypertensive
Wang Z¹, Wang X¹, Zhang L¹, Wang W¹, Chen W¹, Zhu M¹, Hu S¹, Lei Z¹, Kong L¹, Liu L¹
¹China
MONDAY, SEPTEMBER 27

PS1/MON/14
Reducing Lost Therapeutic Benefit (LTB) In Hypertensive Patients Impacts on Cardiac Events in Australian General Practice
Reid CM1, Huq M1, Ademi Z1, Magliano D1, Liew D1, Owen A1, Bhaat D2, Steg G3, REACH Registry Investigators
1Australia, 2United States, 3France

PS1/MON/15
Identification of a Locus on Chromosome 5p that Confers Risk of Coronary Artery Disease by Genome Wide Association Study
Aoki A1, Ozaki K1, Sato H1, Takahashi A1, Kubo M1, Sakata Y1, Mizuno H1, Kamatani N1, Tsunoda T1, Takano H1, Yasutake M1, Mizuno K1, Hori M1, Nakamura Y1, Tanaka T1
1Japan

PS1/MON/16
Urinary Proteomics: A Novel Tool to Diagnose Coronary Artery Disease and to Monitor Treatment Effects
Delles C1, Schiffer E2, von zur Muhlen C2, Peter K3, Rossing P4, Parving HH4, Dymott JA1, Neisius U1, Zimmerli LU1, Snell-Bergeon JK5, Maahs DM6, Schmieder RE2, Mischak H2, Dominiczak AF1
1United Kingdom, 2Germany, 3Australia, 4Denmark, 5United States

PS1/MON/17
EUROASPIRE III: Blood Pressure Management in Patients with Coronary Heart Disease in Europe
Kotseva K1, Jennings C1, De Backer G2, De Bacquer D2, Amouyel P3, Gaita D4, Keil U5, Pajak A6, Reiner Z7, Wood D1, EUROASPIRE Study Group
1United Kingdom, 2Belgium, 3France, 4Romania, 5Germany, 6Poland, 7Croatia

PS1/MON/18
Usefulness of the Combination of Abdominal Obesity and High-Sensitivity C-reactive Protein for Prediction of Future Occurrence of Hypertension – The Tanno and Sobetsu Study
Ohnishi H1, Saitoh S1, Akasaka H1, Mitsumata K1, Chiba M1, Furugen M1, Furukawa T1, Mori M1, Shimamoto K1
1Japan

PS1/MON/19
Incidence and Prevalence of Hypertension in Canada, from 1998/99 to 2006/07
Robitaille C1, Dai S1, Bancej C1, Stewart P1, Waters C1, Loukine L1, Baclic O1, Blais C1, Campbell N1, Quan H1, Reimer K1, Smith M1, Tu K1, Walker R1
1Canada
PS1/MON/20
H-type Hypertension and Risk of Stroke: A Prospective, Nested Case-Control Study
Li J¹, Sun N¹, Huo Y¹, Qin X¹, Jiang S¹, Xing H¹, Chen G¹, Wang B¹², Liu L¹, Xu X²
¹China, ²United States

PS1/MON/22
Investigation on Left Ventricular Myocardial Multi-Dimensional Deformation in Hypertension Using 2-Dimensional Strain Echocardiography
Ruan Q¹, Lin M¹
¹China

PS1/MON/23
Is Left Ventricular Mass in Treatment Resistant Hypertension Determined by Sodium Intake Independent of Blood Pressure?
Raff UG¹, Schwab J¹, Schmidt BM¹, Bär L¹, Schmieder RE¹
¹Germany

PS1/MON/24
Overexpression of Arginase II, Not Arginase I Enhances Endothelial Dysfunction and Atherosclerosis
Khong SML¹, Andrews KL¹, Vaisman BL², Remaley AT², Chin-Dusting J¹
¹Australia, ²United States

PS1/MON/25
Effect of Aldehyde Dehydrogenase-2 Gene Polymorphism on Vasodilatory Response of Brachial Artery Induced by Nitroglycerin
Sakata S¹, Matsumura K¹, Miwa Y¹, Oniki H¹, Ichishima K¹, Arima H¹, Takahashi-Yanaga F¹, Yoshihara T¹, Shiraishi F¹, Iida M¹, Sasaguri T¹
¹Japan

PS1/MON/26
Effects of Exercise Training on Nitric Oxide Synthases in Rats with Chronic Heart Failure
Ito D¹, Ito O¹, Mori N¹, Suda C¹, Hao K¹, Peng-yu C¹, Muroya Y¹, Takashima K¹, Shimokawa H¹, Kohzuki M¹
¹Japan

PS1/MON/27
Poor Sleep Quality during Preceding Night Increases Self-Measured Home Blood Pressure on Day-To-Day Basis in Japanese Perimenopausal Women: The Japan Hot Flash (J-HOT) Home BP Study
Kagitani H¹, Ishihara N¹, Asou Y¹, Kabutoya T¹, Hoshide S¹, Kario K¹
¹Japan
Regulated Expression and Role of C-Myb during Cardiovascular-Directed Differentiation of Mouse Embryonic Stem Cells
Ishida M1, El-Mounayri O1, Kattman S1, Sakamoto H2, Ogawa M2, Keller G1, Husain M1
1Canada, 2Japan

Prehypertension and Risk of Stroke Subtypes: 11 Years of Follow-up in Korean Men and Women
Ahn SV1, Kim HC1, Suh I1
1Korea, Republic of

Dietary Protein, but not Carbohydrate, is a Primary Determinant of the Onset of Stroke in Stroke-Prone Spontaneous Hypertensive Rats
Chiba T1, Itoh T1, Tabuchi M1, Satou T1, Ezaki O1
1Japan

Systemic Treatment with Pioglitazone Early After Ischemic Stroke and Neuroprotection
Nguyen-Ngoc M1, Gohlke P1, Culman J1, Zhao Y1
1Germany

Cerebral Microbleeds Are Negatively Associated with HDL-C In New-Onset Stroke Patients
Igase M1, Kohara K1, Tabara Y1, Katagi R1, Miki T1
1Japan

Role of Calcitonin Gene-Related Peptide (CGRP) in Lipid Metabolism and Intracellular Signaling Mechanism in Cultured Adipocytes: Comparison with Adrenomedullin (AM)
Nishikimi T1, Takeda Y1, Akimoto K1, Iemura C1, Ishimitsu T1
1Japan

Concordance of BP Control Assessed by Office BP and by ABPM in a Large Cohort of Treated Hypertensives
de la Sierra A1, Banegas JR1, Segura J1, Gorostidi M1, de la Cruz JJ1, Listerri JL1, Alonso J1, Aranda P1, Roca-Cusachs A1, Ruilope LM1, Spanish Society of Hypertension ABPM Registry
1Spain
PS1/MON/35
Two Hour Post Glucose Load: A Biomarker of Cardiovascular Risk in Patients with Isolated Clinic Hypertension
Martin CA1, Cameron JD1, Chen SSH1, McGrath BP1
1Australia

PS1/MON/36
The Difference of Effects on BP and AI between Morning or Bedtime Cilnidipine in Patients with Morning Hypertension – A Randomized Study Using ABPM
Narita S1, Yoshioka Y1, Ide A1, Yoshida M1, Momii H1, Kadokami T1, Ando S-I1
1Japan

PS1/MON/37
Hypertensive Patients with Morning Surge in Blood Pressure Show an Exaggerated Circulatory Response to an Unloaded Pedaling
Wakamatsu Y1, Takeda Y1, Yamamoto K1, Sugiura T1, Yamashita S1, Dohi Y1, Kimura G1
1Japan

PS1/MON/38
Comparison of Ambulatory and Clinic Blood Pressure Targets in Obese and Non Obese Subjects: A High Blood Pressure Research Council of Australia Initiative
Head GA1, Mihailidou AS1, Duggan KA1, Beilin LJ1, Berry N1, Brown MA1, Bune AJ1, Cowley D1, Chalmers JP1, Howe PRC1, Hodgson J1, Ludbrook J1, Mangoni AA1, McGrath BP1, Nelson MR1, Sharman JE1, Stowasser M1, Ambulatory Blood Pressure Working Group of the High Blood Pressure Council of Australia
1Australia

PS1/MON/39
A Study of 24 hrs Circadian Rhythm of Ambulatory Blood Pressure in Night Shift Workers
Anjum B1, Verma NS1, Tiwari S1, Jain V1, Mishra S1, Singh R1, Singh RK1, Singh RB1, Schwrtzkopff O2, Cornelissen G2, Halberg F2
1India, 2United States

PS1/MON/40
Arterial Rigidity Estimated by 24-Hours Monitoring of the Blood Pressure and ECG in Elderly
Oleynikov V1, Gusakovskaya L1, Sergatskaya N1
1Russian Federation
PS1/MON/41
Beneficial Effects of Long-Term Atorvastatin Treatment on Blood Pressure Profile and Endothelial Function in Hypertensive Hypercholesterolemic Patients
Chumburidze S\textsuperscript{1}, Rogava M\textsuperscript{1}, Shelia G\textsuperscript{1}, Shavdatuashvili T\textsuperscript{1}
\textsuperscript{1}Georgia

PS1/MON/42
Relationship between Ambulatory Pulse Pressure Coherent Index and Early Renal Injury in Patients with Primary Hypertension
Kou H\textsuperscript{1}, Mu J\textsuperscript{1}
\textsuperscript{1}China

PS1/MON/43
Decreased Blood Pressure Rhythmicity Correlates with Increased Arterial Stiffness in Children with Primary and White Coat Hypertension
Feber J\textsuperscript{1}, Niemirska A\textsuperscript{2}, Litwin M\textsuperscript{2}, Ahmed M\textsuperscript{1}
\textsuperscript{1}Canada, \textsuperscript{2}Poland

PS1/MON/44
Predictors of Mean Arterial Pressure Morning Rate of Rise and Power Function in Subjects Undergoing Ambulatory Blood Pressure Recording
Head GA\textsuperscript{1}, Andrianopoulos N\textsuperscript{1}, Reid C\textsuperscript{1}, McGrath B\textsuperscript{1}, Martin C\textsuperscript{1}, La Greca L\textsuperscript{1}, Chatzivlastou K\textsuperscript{1}
\textsuperscript{1}Australia
PS1/MON/45
24h Ambulatory Blood Pressure Monitoring Is Superior to Predict Arterial Stiffness and Early Vascular Ageing (EVA) Than Clinic and Home Blood Pressure Measurements
Kotsis V1, Stabouli S1, Papakatsika S1, Karafilis I1, Sion M1
1Greece

PS1/MON/46
Relationship between 24-h Ambulatory Blood Pressure Monitoring, Conventional Blood Pressure and Brachium-Ankle Pulse Wave Velocity in Prehypertensive Patients
Zhao Y1, Lu F1, Liu Z1, Wang S1, Sun S1, Yao G1
1China

PS1/MON/47
Effects of Telmisartan or Losartan/Hydrochlorothiazide (HCTZ) Therapy on Various Metabolic Parameters in Male Hypertensive Subjects
Hirose H1, Kawabe H1, Saito I1
1Japan

PS1/MON/48
Increased Lipocalin-2, but A-FABP Level in Essential Hypertension
Na JO1, Choi KM1, Kim EJ1, Choi CW1, Lim HE1, Rha SW1, Seo HS1, Oh DJ1, Park CG1
1Korea, Republic of

PS1/MON/49
The Lowering of Blood Pressure in Non-Diabetic Dislipidaemic Patients with the Metabolic Syndrome Treated with Atorvastatin Correlates with the Reduction of C-Reactive Protein but not with Changes in the Lipid Profile
Martinez-Martin FJ1, Comi Diaz C1
1Spain

PS1/MON/50
Relationship between Adipose Asymmetric Dimethylarginine-Related Enzymes and Circulating Lipids Biomarkers
Iwasaki H, Japan

PS1/MON/51
Beneficial Effect of Combination Therapy Comprising Angiotensin II Receptor Blocker plus Calcium Channel Blocker on Plasma Adiponectin Levels
Matsumoto K1, Sumi Y1, Kakuma T1, Nonaka Y1, Sumi S1, Ando C1, Miyoshi K1, Yamanouchi Y1, Urata H1
1Japan
PS1/MON/52
Eplerenone, an Aldosterone Blocker, is More Effective in Reduction of Blood Pressure in Patients with Metabolic Syndrome (MS) Compared with those without MS
Suzuki H¹, Eplerenone in Saitama
¹Japan

PS1/MON/53
The Effect of Eprosartan on Reflex Activation of the Sympathetic Nervous System in Sodium Restricted Patients with Essential Hypertension
Vase H¹, Lauridsen TG¹, Pedersen EB¹
¹Denmark

PS1/MON/54
Effect of Lisinopril on Heart Rate Variability in Patients with Essential Hypertension
Gahramanova S¹, Bakhshaliyev A¹, Nasrullayev N¹, Zulfiqarova A¹
¹Azerbaijan

PS1/MON/55
Influence of ACE Inhibitors on Catecholamine Secretion in the Perfused Rat Adrenal Gland
Koh Y-Y¹, Lim D-Y¹
¹Korea, Republic of

PS1/MON/56
Indapamide, Central Blood Pressure, and Treatment of Hypertension
Agnoletti D¹, Zhang Y¹, Blacher J¹, Safar ME¹
¹France

PS1/MON/57
Factors Associated with Diuretics-Induced Serum Uric Acid Elevation in Hypertension Treated with Angiotensin Receptor Blockers/Diuretics
Nakamoto M¹, Sakima A¹, Ohya Y¹
¹Japan

PS1/MON/58
Lack of Effects of Chronic Sildenafil administration on the Aortic Remodeling in SHR
Huot-Marchand J-É¹, deBlois D¹
¹Canada
PS1/MON/59
Effects of Telmisartan on C-reactive Protein, TNFα, Modified Risk Factors and Quality of Life in Patients with Essential Hypertension and Abdominal Obesity
Bazhenova EA1, Belyaeva OD1, Berezina AV1, Karonova TL1, Karavani AV1, Lukina AE1, Nikolaychuk EI1, Bolshakova OO1, Berkovich OA1, Baranova El1, Shlyakhto EV1
1Russian Federation

PS1/MON/60
Comparison of the Effect of Angiotensin II Receptor Blocker and Calcium Channel Blocker on Arterial Stiffness in Middle Aged Subjects with Essential Hypertension: Using the Changes in Central Aortic Pressure, Carotid Stiffness, Pulse Wave Velocity, and Biomarkers
Jung HO1, Seo SM1, Youn HJ1, Baek SH1, Seung KB1, Kim JH1
1Korea, Republic of

PS1/MON/61
Effects of Olmesartan on Renin-Angiotensin System in Hypertensive Patients with Type 2 Diabetes Mellitus
Hiroi N1, Sue M1, Yoshihara A1, Ichijo T1, Ando Y1, Higa M1, Yoshino G1
1Japan

PS1/MON/62
Amlodipine / Valsartan / Hydrochlorothiazide Combination and Ambulatory Blood Pressure
Lopez Paz JE1, Hermida Ameijeiras A1, Pena Seijo M1, Romero Miguez ML1, Coca Payeras A1, Calvo Gomez C1
1Spain

PS1/MON/63
The Addition of a Low Dose Diuretic to an Angiotensin II Receptor Blocker Enhances Blood Pressure Lowering Across All Levels of Systolic Blood Pressure
Zappe DH1, Curt V1, Cheng J1, Teshima R2, Sugimoto T2
1United States, 2Japan

PS1/MON/64
Education Program Increases Control of Hypertensive Patients Attended In Primary Care
Silva SSBE1, Colósimo FC1, Pierin AMG1
1Brazil

PS1/MON/65
Factors Contributing to Success or Failure of Antihypertensive Treatment – One-year Observation in Workplace
Kawabe H1, Saito I1
1Japan
PS1/MON/66
Reproducible Changes in Blood Pressure in Three Patients Following Repeated Switches between Once Daily Nifedipine Delivery Technologies
Pollak PT¹, Herman RJ¹
¹Canada

PS1/MON/67
Hypertension Screening of Non-Treated Subjects by the Use of HBPM
Postel-Vinay NG¹, Pannier B¹, Mourad JJ¹, Girerd X¹, Hanon O¹, CFLHTA. French League against Hypertension
¹France

PS1/MON/68
Resistant Hypertension In Out-Ward Patients with Hypertension – Myth or Reality
Kosmalova V¹, Lietava J¹
¹Slovakia

PS1/MON/69
The Effect of Intracoronary Bolus Dose of Abciximab Administration in Patients with Acute ST-Segment Elevation Myocardial Infarction
Lim SY¹, Kim SW¹, Ahn JC¹, Song WH¹, Ahn YK¹, Jeong MH¹
¹Korea, Republic of

PS1/MON/70
Matrix Metalloproteinases in Patients with Arterial Hypertension
Kuliczkowski W¹, Urbaniak J¹, Kaczmarski J¹, Greif M¹, Wozniak M¹², Polonski L¹, Gasior M¹, Zembala M¹
¹Poland, ²Canada

PS1/MON/71
Risk Factors of Anxiety-Depressive Disorders of Coronary Artery Disease Patients
Shlyakhto E¹, Kozlova S¹, Golubev A¹, Krilova U¹, Neznanov N¹
¹Russian Federation

PS1/MON/72
The Relationship between Angiographic Severity of Coronary Artery Disease and an Epidemiological Risk Score Developed by a Japanese Population Study
Fujishima S¹, Murakami N¹, Ishihara S¹, Haga Y¹, Kaseda S¹, Koga T¹, Kawazoe N¹, Sadoshima S¹
¹Japan
PS1/MON/73
Efficacy of Influenza Vaccine in Reducing Major Adverse Cardiac Events (Cardiac Mortality, Death and MI) Among Patients with Coronary Artery Disease: A Meta-Analysis
Fama RP, Philippines

PS1/MON/74
Timely Rhythm Assessment for Chest pain at the Emergency Room of the Philippine General Hospital (TRACER)
Magno JDA¹, Santella C¹, Reyes E¹
¹Philippines

PS1/MON/75
The Effects of Pioglitazone on the Expression of NF-kB in Atherosclerotic Rats
Wang Huimin CH, China

PS1/MON/76
Relationship Between 24-hour Blood Pressure Parameters and the Extent of Coronary Lesions and Structural Carotid Alterations in Coronary Artery Disease
Yuan SH¹, Sun N¹
¹China

PS1/MON/77
Clinical Outcome of Percutaneous Coronary Interventions in the Elderly and Very Elderly at Cardinal Santos Medical Center
Fama RP¹, Cheng FC¹, Encabo RR¹, Miranda AA¹
¹Philippines

PS1/MON/78
Evaluation of the Longitudinal and Circumferential Strain and Strain Rate in a Normal Adult
Oleynikov V¹, Budanova V¹, Donchenko I¹
¹Russian Federation

PS1/MON/79
Prevalence, Awareness, and Control of Hypertension in Mongolia: Results from Nationwide Survey
Davaalkham D, Mongolia

PS1/MON/80
Blood Glucose Profile of Patients with Essential Hypertension in China
Wang H¹, Sun N¹, Xi Y¹
¹China
MONDAY, SEPTEMBER 27

PS1/MON/81
Vegetables Consumption and Cardiovascular Risk Factors in Central African Adult Populations: Results of the VITARAA Study
M’Buyamba-Kabangu J-R1, Lemogoum D2, M’Buyamba-Kayamba J-R1, Bayauli P1, Fagard R2, Staessen JA2, Degaute JP2
1Congo, the Democratic Republic of the, 2Belgium

PS1/MON/82
Trends in Systolic Blood Pressure in the Untreated and in the Treated Population in 25 Years of Follow-Up. Copenhagen City Heart Study
Andersen UO1, Jensen GB1
1Denmark

PS1/MON/83
Association of Left Ventricular Geometry with Left Ventricular Function in Middle-Aged Hypertensive Individuals
Kim SH1, Cho G-Y1, Lim SY1, Lim HE1, Kim EJ1, Park CG1, Lee SK1, Shin C1
1Korea, Republic of

PS1/MON/84
Left Ventricular Hypertrophy (LVH) is Related to Beta1 (ADRB1, Arg389Gly, Ser49Gly)- and Beta2 (ADRB2, Arg16Gly)-adrenoceptor Polymorphisms in Normotensive Men
Masuo K, Australia
PS1/MON/85
Predictive Value of Left Ventricular Mass and Geometry in Type 2 Diabetes Mellitus for Adverse Cardiovascular Events
Wai B1, Patel SK1, Ord M1, Grant S1, Srivastava PM1, Burrell LM1
1Australia

PS1/MON/86
Regression of Left Ventricular Mass by Percutaneous Transluminal Angioplasty for Peripheral Artery Disease
Eguchi K1, Murakami A1, Kawasaki A1, Horaguchi T1, Ogata K1, Kato M1, Kario K1
1Japan

PS1/MON/87
Role of Fibroblast Growth Factor-23 and Vascular Calcification in Left Ventricular Hypertrophy in a Rodent Model of Chronic Kidney Disease
Shobeiri N1, Beseau D1, Phelan R1, Holden RM1, Adams MA1
1Canada

PS1/MON/88
Among Patients Affected by Chronic Kidney Disease Abdominal Adiposity Is an Independent Predictor of Subclinical Cardiac Damage
Vettoretti S1, Alfieri C1, Floreani R1, Bonanomi C1, Danzi GB1, Messa P1
1Italy

PS1/MON/89
Relation of Central and Brachial Blood Pressure to Left Ventricular Hypertrophy. The Czech Post-MONICA Study
Wohlfahrt P1, Wichterle D1, Seidlerová J1, Filipovský J1, Adámková V1, Cífková R1
1Czech Republic

PS1/MON/90
Abnormal Cardiac microRNA Expression in Heritable Polygenic Cardiac Hypertrophy
Charchar FJ1, Porrello E2, Delbridge LM1, Harrap SB1
1Australia, 2United States

PS1/MON/91
Dynamic Change of Thioredoxin System and Peroxiredoxin Is Closely Related With Progression and Regression of Pressure Overload-Induced Left Ventricular Hypertrophy
Cho M-C1, Bae J-W1, Park K-J1, Hwang K-K1
1Korea, Republic of
PS1/MON/92
RAS Independent Manner: COX-2 Induction by ACE-ACE Inhibitor Signaling Prevents Development of Diastolic Dysfunction
Aizaki Y1, Yoshikawa A1, Iida S1, Katoh M1, Sun X1, Maruyama K1, Muramatsu T1, Matsumura M1, Nishimura S1, Inagami T2, Senbonmatsu T1
1Japan, 2United States

PS1/MON/93
Decrease in L-NAME-Induced Inflammation of Left Ventricle in SHR Previously Treated with Enalapril
Hale TM1, Abidali A1, deBlois D2
1United States, 2Canada

PS1/MON/94
Left Ventricular Mass of Normotensive Adolescent Progeny of Patients with Hypertension
Mbakwem AC1, Amadi CE1, Oke AD1
1Nigeria

PS1/MON/95
Tanshinone IIA Inhibits Cyclic Strain-Induced Endothelin-1 Expression via Akt/Endothelial Nitric Oxide Synthase Pathway in Human Umbilical Vein Endothelial Cells
Chan P1, Liu J-C1, Chen J-J1, Cheng T-H1
1Taiwan, Republic of China

PS1/MON/96
Telmisartan Enhances Endothelial Progenitor Cells via Peroxisome Proliferator-Activated Receptor-Gamma in Rat Hindlimb Ischemia
Ishikawa M1, Kobayashi N1, Takeshima H1, Koguchi W1, Fukushima H1, Ohno T1, Fukuda N1, Ishimitsu T1
1Japan

PS1/MON/97
The Preventive and Therapeutic Effect of Melatonin in the Spontaneous Hypertension
Pechanova O1, Paulis L1,2, Kunes J3, Vrankova S1, Dovinova I1, Dobesova Z1, Simko F1, Zicha J3
1Slovakia, 2Germany, 3Czech Republic

PS1/MON/98
Prevalence of Resistant Hypertension among Hypertensives in Heilongjiang Province, China
Li Y-F1, Hui R-T1, Jia L1, Li S-H1, Xiao C-S1
1China
PS1/MON/99
Overlap Syndrome; Additive Effects of Chronic Obstructive Pulmonary Disease on Cardiovascular Damages in Patients with Obstructive Sleep Apnea
Shiina K1, Tomiyama H1, Takata Y1, Yoshida M1, Saruhara H1, Matsumoto C1, Odaira M1, Kato K1, Hashimura Y1, Usui Y1, Asano K1, Yamashina A1
1Japan

PS1/MON/100
Berlin Questionnaire for Screening of Obstructive Sleep Apnea Syndrome in Patients with Resistant Hypertension
Margallo V1, Muxfeldt E1, Salles G1, Fiszman R1, de Souza F1, Pereira VDS1, Dias VB1, Nascimento AC1
1Brazil

PS1/MON/101
The Impact of Obstructive Sleep Apnea on Macro and Microvasculature Assessed by Pulse Wave Velocity and Augmentation Index
Shiina K1, Tomiyama H1, Takata Y1, Kato K1, Saruhara H1, Hashimura Y1, Yoshida M1, Matsumoto C1, Odaira M1, Asano K1, Usui Y1, Yamashina A1
1Japan

PS1/MON/102
Serum Neuropeptide Y Level in Hypertensive Patients with Obstructive Sleep Apnea Syndrome
Yao X1, Li N1, Wang Y1, Li T1, Zhu J1
1China

PS1/MON/103
Cognitive Function is Not Related to Severity of Sleep Breathing Disorders in Hypertensive Patients
Konradi AO1, Korostovtseva LS1, Sviryaev YV1, Zvartau NE1, Kalinkin AL1
1Russian Federation

PS1/MON/104
Impact of Insomnia on Quality of Life among Patients with Arterial Hypertension
Khachatryan AH1, Ohanyan DV1, Melqonyan AA1, Khachatryan SG1, Zelveian PH1
1Armenia

PS1/MON/105
Influence of Excessive Daytime Sleepiness on Quality of Life in Patients with Arterial Hypertension
Ohanyan DV1, Khachatryan AH1, Melqonyan AA1, Khachatryan SG1, Zelveian PH1
1Armenia
PS1/MON/106
Increased Circulating CD31+/Annexin V+ Apoptotic Microparticles and Decreased Circulating Endothelial Progenitor Cells Levels in Hypertensive Patients with Microalbuminuria
Huang P-H1, Chen J-W1, Lin S-J1, Division of Cardiology, Taipei Veterans General Hospital
1Taiwan, Republic of China

PS1/MON/107
Skin-Derived Precursors (SKPs) Can Generate Functional Vascular Smooth Muscle Cells in Vivo
Steinbach SK1, El-Mounayri O1, Frontini MJ1, Nong Z1, Miller FD1, Gros R1, Pickering JG1, Husain M1
1Canada

PS1/MON/108
Constructing the Prediction Model for the Risk of Stroke in Chinese: Report from a Cohort Study in Taiwan
Chien K-L1, Su T-C1, Hsu H-C1, Chang W-T1, Sung F-C1, Chen M-F1, Lee Y-T1, the Chin-Shan Community Cardiovascular Cohort Study
1Taiwan, Republic of China

PS1/MON/109
Beat-to-Beat Blood Pressure Variability in Clinical Stroke Subtypes
Clarke BJ1, Deegan B1, Carew S1, Cooke J1, Costelloe A1, Sheehy C1, O’Laighin G1, O’Connor M1, Clinch D1, Lyons D1
1Ireland

PS1/MON/110
What Does Determine the Blood Pressure Variability in Subacute Stage of Ischemic Stroke?
Kang J1, Bae H-J1, Han M-K1, Lee J1, Lee J1, Park J-M1, Yu K-H1, Cho Y-J1
1Korea, Republic of

PS1/MON/111
Difference in Vascular Risk Factors between Isolated Intracranial and Isolated Extracranial Atherosclerosis in Chinese Ischemic Stroke Patients
Ng NC1, Soo YOY1, Leung TWH1, Yu S1, Wong KS1, Zhang XH1
1Hong Kong

PS1/MON/112
Cardiovascular Risk Factors, Blood Pressure Control, Co-Morbidities in Patients with Symptoms of “Ocular Stroke”
Dános P1, Somlai J1, Gubucz I1, Császár A1, Szilágyi G1, Fazekas F1, Róna Tas Á1, Récsány Z1, Kristóf V1
1Hungary
MONDAY, SEPTEMBER 27

**PS1/MON/113**
Beneficial Effect of Angiotensin II Receptor Antagonist Olmesartan in the Prevention of Arterial Stiffness Development in Elderly Patients with Hypertension and Cerebral Infarction
Matsumoto S, Japan

**PS1/MON/114**
A Genetic Variant on Chromosome 9p21 is Associated with Ischemic Stroke in a Chinese Population
Wang Y1, Wu L1, Shen Y1, Liu X1, Zhang H1, Liu L1, Wang X1
1China

**PS1/MON/115**
Significant Correlation of Right Ventricular Dilation with Stroke, Complicated by Hypertension
Wang X1, Li S1, Liu X1, Jia L1, Chen J1, Hui R1
1China

**PS1/MON/116**
Screening for Atrial Fibrillation with Handheld ECG in Primary Care
Hendrikx T1, Rosenqvist M1, Sandström H1
1Sweden

**PS1/MON/117**
Efficacy of Nighttime Treatment in Resistant Hypertension
Lopez Paz JE1, Hermida Ameijeiras A1, Pena Seijjo M1, Calvo Gonzalez G1, Romero Miguez ML1, Coca Payeras A1, Calvo Gomez C1
1Spain

**PS1/MON/118**
Late Morning Hypotension is Highly Prevalent in Effectively Treated Hypertensive Subjects
Stern N1, Grafi-Cohen M1, Stern Y1, Osher E1, Marcus Y1, Tordjman K1
1Israel

**PS1/MON/119**
Ambulatory Arterial Stiffness Index is Higher in Hypertensive Patients with Chronic Kidney Disease
Gismondi R1, Bregman R1, Oigman W1, Neves MF1
1Brazil
# TUESDAY, SEPTEMBER 28

## Program by Day

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 203, West Level 2</th>
<th>Room 204, West Level 2</th>
<th>Room 205,  West Level 2</th>
<th>Room 206, West Level 2</th>
<th>Room 207, West Level 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>How to Session</td>
<td>How to Session</td>
<td>How to Session</td>
<td>How to Session</td>
<td>How to Session</td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>How to Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>How to Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:15</td>
<td>Optimal Guidelines for Management of Hypertension 08:15-09:45</td>
<td>The Genetic vs. Environmental Basis of Atherosclerotic Risk Factors; Focus on Asian and North American Aboriginal Cardio-Metabolic Risk Profiles 08:15-09:45</td>
<td>Resistant Hypertension 08:15-09:45</td>
<td>CNS Regulation of Blood Pressure 08:15-09:45</td>
<td>Clinical Science Core Curriculum Part 3 08:15-09:45</td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>The Genetics and Pharmacogenetics of Atherosclerosis 16:30-18:00</td>
<td>Hypertension in the Elderly 16:30-18:00</td>
<td>Molecular Mechanism of Cardiovascular Senescence 14:15-15:45</td>
<td>Hypertension Research at the US National Heart, Lung, and Blood Institute (NHLBI): From Basic Science to Implementation 14:15-15:45</td>
<td>Clinical Science Debate 3</td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Optimal Guidelines for Management of Hypertension**
- **The Genetic vs. Environmental Basis of Atherosclerotic Risk Factors; Focus on Asian and North American Aboriginal Cardio-Metabolic Risk Profiles**
- **Resistant Hypertension**
- **CNS Regulation of Blood Pressure**
- **Clinical Science Core Curriculum Part 3**
- **Dietary Sodium and Population Health**
- **Determinants of Atherosclerosis**
- **Smoking and Associated Cardiovascular Risk Factors**
- **Lipid Signalling in the Vasculature (Focus on Sphingolipids)**
- **Clinical Science Core Curriculum Part 4**
- **Dietary Approaches in Management of Cardiovascular Risk**
- **Kidney Disease**
- **Molecular Mechanism of Cardiovascular Senescence**
- **Hypertension Research at the US National Heart, Lung, and Blood Institute (NHLBI): From Basic Science to Implementation**
- **The Genetics and Pharmacogenetics of Atherosclerosis**
- **Hypertension in the Elderly**
- **Molecular Mechanisms of Vascular Disease**
- **Clinical Science Debate 3**
### TUESDAY, SEPTEMBER 28

<table>
<thead>
<tr>
<th>Rooms 220-222, West Level 2</th>
<th>Pacific Room 2, Pan Pacific Hotel</th>
<th>Malaspina Room, Fairmont Waterfront</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISH Past Presidents’ Meeting</td>
<td>08:00-09:00</td>
<td></td>
</tr>
</tbody>
</table>

| ISH International Forum      | 12:15-13:45                      |

| Hypertension Canada Annual General Meeting | 18:00-21:30 |

See the Optional Tours & Social Events section for the tours and social events schedule.
07:00-08:00  Clinical Science  
How to Session  
Room 203, L2  
Session is a part of the Cardiovascular Risk Factors Tract of Sessions, sponsored in part by unrestricted educational grants from Pfizer Canada, Servier Canada and Takeda

Smoking Cessation: Practical Tips for Achieving Success!  
Pipe A, Canada  

07:00-08:00  Clinical Science  
How to Session  
Room 204, L2  
Strategies to Prevent the Development of Chronic Renal Disease in Patients with Diabetes Mellitus and Hypertension  
Chan JCN, China  

07:00-08:00  Clinical Science  
How to Session  
Room 205, L2  
How to Effectively Manage Hypertension in Pregnancy  
Magee L  
1Canada  

07:00-08:00  Basic Science  
How to Session  
Room 206, L2  
Single Cell Assessment in Hypertension: From “Form to Function”  
Gros R, Canada
07:00-08:00  **Population Science**

**How to Session**

**How To Set Up a National ABPM Registry for Global Cardiovascular Risk Reduction**

Room 207, L2

**Chairs:** Myers M, Canada and Parati G, Italy

07:00  

About the Existing Spanish ABPM Registry. “How to set up 100,000 scale ABPM national registry – The Spanish Experience”

Ruilope LM, Spain

07:15  

About the Existing Italian ABPM Registry. “How to set up a national ABPM registry by a Simple & Economic Approach – The Italian Experience”

Omboni S, Italy

07:30  

From National to Global ABPM Registry for HTN Control – An Action Plan

Parati G, Italy

08:00-09:00  **ISH Past Presidents’ Meeting**

Pacific Room 2, Pan Pacific Hotel

08:15-09:45  **Clinical – Population Science Symposium**

**Optimal Guidelines for Management of Hypertension**

Ballroom A, L1

**Chair:** Ortiz E, USA

08:15  

European Guidelines in the Management of Hypertension: The 2009 Reappraisal – Where are the Gaps

Fagard R, Belgium

08:35  

Canadian Guidelines in the Management of Hypertension – Impacting on the Bottom Line

Toke S, Canada
TUESDAY, SEPTEMBER 28

08:55  United States Guidelines (JNC Guidelines): What’s Fallen Short Before, What’s Being Fixed in JNC8?  
       Oparil S, United States

09:15  ISH/WHO Guidelines Why is it Different and Why is There a Need for it  
       Lindholm L, Sweden

09:30  Panel Discussion: Can We Have the Same Guidelines Across the World?  
       All Panelists

08:15-09:45  
            Translational – Clinical Science
            Symposium  
            Ballroom B, L1
            Chair: Hegele R, Canada

08:15  The Genetic Basis of Cardiometabolic Risk in North American Aboriginals  
       Hegele R, Canada

08:45  Ethnicity and Cardiometabolic Risk: Definitions and Risk in Chinese  
       Zhao D, China

09:15  Diabetes in Asia: Is there an Asian Phenotype for Diabetes Mellitus?  
       Chan JCN, China

08:15-09:45  
            Clinical Science
            Oral Presentations  
            Resistant Hypertension  
            Ballroom C, L1
            Chair: Rosenthal T, Israel and Weber M, United States

08:15  The Prevalence and Predictors of Resistant Hypertension in Type 2 Diabetes Mellitus  
       Wai B¹, Patel SK¹, Ord M¹, Grant S¹, Srivastava PM¹, Burrell LM¹  
       ¹Australia
08:25  Clinical Profile of Hypertensive Subjects not Controlled with a Combination of 2 Antihypertensive Drugs  
        de la Sierra A¹, Redon J¹, Orellana M¹, Aristegui R¹, The COMBIKAR Study Investigators  
        ¹Spain  

08:35  Risk Factor of Resistant Hypertension in Hospitalized Primary Hypertensives  
        Wang Y¹, Gao LL¹, Wang JG¹, Chu SL¹, Zhu DL¹, Gao PJ¹  
        ¹China  

08:45  Association Between Renalase Plasma Levels and Systolic Blood Pressure in Patients with Resistant Hypertension  
        Socratous F¹, Hennebry S¹, Eikelis N¹, Chopra R¹, Lambert G¹, Schlaich M¹  
        ¹Australia  

08:55  Baroreflex Activation Therapy Preserves eGFR in Hypertensive Patients with Stage 2 and 3 Chronic Kidney Disease: Results from European and United States Trials of the Rheos® System  
        Sica D¹, Rothstein M¹, Bisognano J¹, Nadim M¹, Lovett E¹, Kaufman C¹, de Leeuw P², for the DEBuT-HT and Rheos Feasibility Investigators  
        ¹United States, ²Netherlands  

09:05  Empiric Spironolactone For Difficult to Control Hypertension in Chronic Kidney Disease  
        Ruzicka M¹, Heshka J¹, Hiremath S¹, McCormick B¹  
        ¹Canada  

09:15  Retinal Arteriolar Structure is Determined by Sodium Intake in Treatment Resistant Hypertension Independent of Blood Pressure  
        Raff U¹, Harazny J¹, Schmidt BM¹, Schmieder RE¹  
        ¹Germany  

09:25  A Great White-Coat Effect is Associated with a Better Autonomic Balance in Patients with Resistant Hypertension  
        Salles G¹, Ribeiro F¹, de Souza F¹, Cardoso C¹, Fiszman R¹, Muxfeldt E¹  
        ¹Brazil  

09:35  Urinary Albumin Excretion Independently Correlates with True Resistant Hypertension  
        Oliveras A¹, de la Sierra Á¹, Hernández del Rey R¹, Segura J¹, Cotilla EM¹, Prieto LÁ¹, Labrador PJ¹, Roca-Cusachs Á¹, Ruilope LM¹, Armario P¹, Spanish Resistant Hypertension Registry  
        ¹Spain
08:15-09:45 Basic – Translational Science
State of the Art – Oral Presentations
CNS Regulation of Blood Pressure
Room 211-214, L2

Learning Objectives:
• Roles of AT1 and AT2 receptor activation in cerebral ischemia especially focusing on cerebral blood flow, oxidative stress, inflammation and other factors
• Roles of exaggerated angiotensin II production in cognitive function in human renin/angiotensinogen transgenic mice.
• Roles of AT2 receptor stimulation in improvement of cognitive impairment and its possible molecular mechanism and possible neurogenesis by AT2 receptor stimulation

Chairs: Adams M, Canada and Korner PI, Australia

08:15 PPARα Regulates Systemic Blood Pressure by Modulating the Central Renin-angiotensin system (RAS) Predominantly through Renin Expression
Tordjman KM1, Vechoropoulos M1, Litvak A1, Sack J1, Stern N1
1Israel

08:25 Chronic Exercise Training Reduces Blood Pressure by Modulating Central RAS and Improving Balance Between Pro-And Anti-Inflammatory Cytokines in SHR Rats
Agarwal D1, Francis J1
1United States

08:35 Direct Angiotensin AT2-Receptor Stimulation Improves Survival and Neurological Outcome in Experimental Stroke (MCAO) in Mice
Schwengel K1, Thoene-Reineke C1, Namsolleck P1, Horiuchi M2, Iwai M2, Hallberg A3, Altermann M3, Unger T1, Steckelings UM1
1Germany, 2Japan, 3Sweden

08:45 Sympathoexcitation by Oxidative Stress in the Brain Mediates Arterial Pressure Elevation in Metabolic Syndrome
Fujita M1, Ando K1, Kawarazaki H1, Fujita T1
1Japan

08:55 Role of Brain Salt-Inducible Kinase 1 (SIK1) in Responses to Central Na⁺ in Dahl Salt-Sensitive (S) and –Resistant (R) Rats
Huang BS1, Leenen FH1
1Canada
TUESDAY, SEPTEMBER 28

09:05  Brain Immunoneutralization of Ang-(1-12) or Renin Inhibition Improve Autonomic Function in Transgenic (mRen2)27 Hypertensive Rats
Isa K1, Shaltout HA1, Garcia-Espinosa MA1, Arnold AC1, Chappell MC1, Ferrario CM1, Diz DI1
1United States

09:15  The Renin Angiotensin System in the Brain: New Insights into its Role in Cerebral Ischemia and Cognitive Function
Horiuchi M, Japan

08:15-09:45  Clinical Science
Core Curriculum
Core Curriculum Part 3  Room 109-110, L1

Chair: Touyz R, Canada

08:15  Optimizing Patient “Buy-in” to Their Management Plan: Adherence Strategies
Campbell T, Canada

08:45  Lifestyle Modification as a Prescription for Hypertension: Physical exercise, stress management
Bacon S, Canada

09:15  Lifestyle Modification as a Prescription for Hypertension: Dietary counselling, weight reduction
Trudeau L, Canada

10:30-12:00  Public Health – Population Science
Symposium
Dietary Sodium and Population Health  Ballroom A, L1

Chair: Mimran A, France

10:30  An Overview of Salt and Cardiovascular Disease
MacGregor G, United Kingdom

11:00  Salt and Hypertension: Its Relevance for Blood Pressure in Children and Adolescents
Neal B, Australia
11:30 Strategies for Sodium Reduction in the Food Supply for the Population
Labarthe D, United States

10:30-12:00 Translational – Clinical Science
State of the Art – Oral Presentations
Determinants of Atherosclerosis
Ballroom B, L1

Chair: Shimamoto K, Japan

Learning Objectives:
• To understand the effects of atherosclerosis on cognitive function
• To appreciate the importance of vascular dementia in patients with atherosclerotic disease
• To understand the interrelationship between behaviour barriers in reducing CV risk and atherosclerosis-mediated cognitive impairment

10:30 Klotho Gene Single Nucleotide Polymorphism Is Associated With Stroke and Hypertensive Organ Damage
Oguro R¹, Kamide K¹, Kato N¹, Shimaoka I¹, Congrains A¹, Sugimoto K¹, Tatara Y¹, Katsuya T¹, Ohishi M¹, Rakugi H¹
¹Japan

10:40 Multiplexed MRM Analysis and Absolute Quantitation of 25 Proteins Implicated in Coronary Artery Disease
Domanski D¹, Yang J¹, Kuzyk M¹, Freue GC¹, Hill J¹, McManus B¹, Borchers CH¹
¹Canada

10:50 Effects of Individual Risk Factors on the Residual Risk of Cardiovascular Events in a Population of Treated Chinese Patients with Hypertension. Data From The Fever Study
Zhang Y¹, Zhang X¹, Liu L¹, Zanchetti A²
¹China, ²Italy

11:00 Multimodality Imaging of Aortic Atherosclerotic Plaque Using CT and MRI
Cecelja M¹, Hussain M¹, Greil G¹, Botnar R¹, Spector TD¹, Chowienczyk P¹
¹United Kingdom
11:10 Antihypertensive Drugs in Very Old People: An Updated Meta-
Analysis of Randomised Controlled Trials
Bejan-Angoulvant T1, Saadatian-Elahi M1, Wright JM2, Schron EB3,
Lindholm LH4, Fagard R5, Staessen JA5, Gueyffier F1
1France, 2Canada, 3United States, 4Sweden, 5Belgium

11:20 Pre-Existing Diabetes and Cardiovascular Risks in High-Risk
Hypertensive Patients: A Subanalysis of the CASE-J Extension
(CASE-J Ex)
Kenji U1, Yasuno S1, Ogihara T1, Fukiyama K1, Saruta T1, Nakao K1,
CASE-J Trial Group
1Japan

11:30 Subclinical Atherothrombosis: Scientific Challenges at the Basic,
Clinical, and Population Levels
Fuster V, United States

10:30-12:00 Clinical Science
State of the Art – Oral Presentations
Smoking and Associated Cardiovascular Risk Factors
Ballroom C, L1
Session is a part of the Cardiovascular Risk Factors Tract of Sessions,
sponsored in part by unrestricted educational grants from Pfizer Canada,
Servier Canada and Takeda

Learning Objectives:
• Be familiar with contemporary understandings of the mechanisms underlying tobacco addiction
• Appreciate the need for systematic approaches to the identification and treatment of all smokers
• Be familiar with the use of contemporary pharmacotherapies for the treatment of tobacco addiction

Chair: Carlberg B, Sweden

10:30 Contemporary Approaches to Smoking Cessation
Pipe A, Canada

11:00 Prevalence of Arterial Hypertension and Associated Cardiovascular Risk Factors In France: The FLAHS 2009 Survey
Postel-Vinay NG1, Mourad JJ1, Girerd X1, Pannier B1
1France
11:10  Smoking and Overweight Are Major Contributors to the Risk of Incident Hypertension in Chinese Population  
Guan TR¹, Zhang XH¹, Zheng RP¹, Wang SY¹, Liu LS¹  
¹China

11:20  Third-hand Smoke Exposure May Contribute to Increased Risk of Hypertension: The Guangzhou Biobank Cohort Study  
Chan Y-H¹, Jiang C-Q², Schooling C-M¹, Thomas G-N³, Xu L¹, Chim D¹, Cheng K-K³, Hedley A-J¹, Leung G-M¹, Lam T-H¹, Guangzhou Biobank Cohort Study (GBCS)  
¹Hong Kong, ²China, ³United Kingdom

11:30  Uncontrolled Hypertension is Associated with Poor Outcome after Stroke Especially in Older Patients  
Park J-M¹, Yu K-H¹, Lee J¹, Bae H-J¹  
¹Korea, Republic of

11:40  Evaluating the Worksite Intervention Programme for Cardiovascular Diseases in Shougang  
Zheng RP¹, Guan TR¹, Zhang XH¹, Wang SY¹, Liu LS¹  
¹China

11:50  Prevention of CVD Prevalence by Local Community Action: Chandigarh’s Smoke-Free Initiative  
Goswami H, India

10:30-12:00  **Basic Science Symposium**  
**Lipid Signalling in the Vasculature (Focus on Sphingolipids)**  
Room 211-214, L2

Chair: Spiegel S, United States

10:30  Complex Actions of Sphingosine-1-Phosphate  
Spiegel S, United States

11:00  Role of Sphingosine-1-Phosphate Phosphohydrolase 1 in the Regulation of Resistance Artery Tone  
Bolz S-S, Canada

11:30  Relevance and Potential of Sphingosine-1-Phosphate for the Vascular System  
von der Giet M, Germany
TUESDAY, SEPTEMBER 28

10:30-12:00  **Clinical Science**

**Core Curriculum**

**Core Curriculum Part 4** Room 109-110, L1

Chair: Larochelle P, Canada

10:30  **Global Vascular Protection in Hypertensive Patients**

McFarlane P, Canada

11:00  **Recommendations for the Management of Hypertensive Patients with Cerebrovascular Disease**

Hill M, Canada

11:30  **Maximizing the Use of Single Pill Combination Therapy for Better Adherence and Achieving Targets**

Feldman R, Canada


An invitation is extended to all Presidents of National Societies of Hypertension, Councils of High Blood Pressure, and Affiliated International Societies.

14:15-15:45  **Clinical – Population Science Symposium**

**Dietary Approaches in Management of Cardiovascular Risk** Ballroom A, L1

Chair: Beilin L, Australia

14:15  **Dietary Approaches to Prevent and Treat Hypertension**

Appel LJ, United States

14:45  **Diet and Cardiovascular Disease**

TBA

15:15  **Value, Utility and Limitations of Food Guides in Attaining Cardiovascular Health**

Barr S, Canada
Clinical Science

State of the Art – Oral Presentations

Kidney Disease

Ballroom B, L1

Chairs: Fujita T, Japan and McFarlane P, Canada

Learning Objectives:
- To become familiar with past approaches and guidelines proposed to achieve BP goals in patients with kidney disease
- To become familiar with the most recent literature on worldwide achievement of BP goals and what new approaches seem responsible for this improvement
- To become familiar with an integrated method incorporating these new approaches in a cost effective way that can be used by most physicians to aid in BP goal achievement

14:15

Effect of Homocysteine on Cellular Arginine Uptake

Nel MJ1, Woodiwiss AJ1, Candy GP1

1South Africa

14:25

Assessment of Potential Risk Factors for Cardiovascular Disease in Patients with Chronic Kidney Disease (CKD) By Metabolome Analysis

Hayashi K1, Sasamura H1, Hishiki T1, Suematsu M1, Ikeda S1, Soga T1, Itoh H1

1Japan

14:35

Association between Prehypertension and Urine Albumin Excretion in Middle-To-Old-Aged Chinese Population

Chen Z1, Wang Z1, Wang F1, Zheng R1, Zhu M1, Wang S1, Wang Y1, Lu J1, Wang H1, Liu L1

1China

14:45

Role of Aldosterone in the Initiation of Renal Insulin Resistance

Minakuchi H1, Wakino S1, Hosoya K1, Sueyasu K1, Hasegawa K1, Hara Y1, Yoshioka K1, Washida N1, Tokuyama H1, Hayashi K1, Itoh H1

1Japan

14:55

High Prevalence and Unsatisfactory Treatment of Hypertension in Heart and Kidney Transplant Recipient

Małyszko J1, Przybyłowski P1, Małyszko J1, Sadowski J1, Mysliwiec M1

1Poland
TUESDAY, SEPTEMBER 28

15:05 Aliskiren as an Antiproteinuric Add-On Therapy in Various Kidney Diseases
Heidenreich SN¹, Xie WH¹
¹Germany

15:15 Current Approaches to Optimal Management of Patients with Hypertension and Kidney Disease
Bakris G, United States

14:15-15:45 Basic Science Symposium
Molecular Mechanism of Cardiovascular Senescence
Room 211-214, L2

Chair: Horiuchi M, Japan

14:15 Arterial Aging: A Journey into Subclinical Arterial Disease
Lakatta E, United States

14:45 Cellular Enzymes Regulating Lifespan: Implications for Prevention of Vascular Disease
Pickering G, Canada

15:15 Teleomere Length and Hypertension and Vascular Disease
Aviv A, United States

14:15-15:45 Translational Symposium
Hypertension Research at the US National Heart, Lung, and Blood Institute (NHLBI): From Basic Science to Implementation
Room 109-110, L1

Session Organizers: US National Heart, Lung, and Blood Institute (NHLBI)

Chair: Simons-Morton D, United States

14:15 Overview of NHLBI activities in Hypertension Research
Simons-Morton D, United States
TUESDAY, SEPTEMBER 28

14:33  Genetics of Hypertension  
       Levy D, United States

14:51  Blood Pressure Trial Results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study  
       Cushman W, United States

15:09  Research Tested Strategies for Improving Hypertension Control in Primary Care  
       Green B, United States

15:27  Cardiovascular Guidelines Supported by the NHLBI  
       Ortiz E, United States

16:30-18:00  Basic – Translational Science  
Plenary State of the Art  
The Genetics and Pharmacogenetics of Atherosclerosis

Ballroom A, L1

Chair: Tomaszewski M, UK

Learning Objectives:
• Realities of personalized medicine
• Where it can be applied
• Where it cannot be applied

16:30  Plenary State of the Art: The Nature vs. Nurture (Genetics vs Environment) Basis of Atherosclerotic Risk Factors  
       Hegele R, Canada

17:15  Plenary State of the Art Pharmacogenomics: Personalized Medicine - Hope or Hype?  
       Hayden M, Canada
Tuesday, September 28

16:30-18:00 **Clinical Science**
Symposium
**Hypertension in the Elderly**
Ballroom B, L1

**Chair:** Jennings G, Australia

16:30
**What is the Threshold and Target?**
Bulpitt C, United Kingdom

17:00
**Considerations of Arterial Compliance and Consequences on the Kidney**
Townsend R, United States

17:30
**Hypertension in the Elderly: Overview**
Liu L, China

16:30-18:00 **Basic Science**
State of the Art – Oral Presentations
**Molecular Mechanisms of Vascular Disease**
Room 211-214, L2

**Chair:** Leeb-Lundberg LMF, Sweden

**Learning Objectives:**
• Review the mediators of innate and adaptive immunity
• The role of T lymphocytes and cytokines in the cardiovascular system
• Understand how immune mechanisms participate in the development of hypertension

16:30
**Toll-Like Receptor 4 Modulates Vascular Constriction in Mesenteric Arteries**
Sollinger D¹, Eißler R¹, Liskova S², Zicha J², Heemann U¹, Baumann M¹
¹Germany, ²Czech Republic

16:40
**Characterization of Signaling Cascades Leading to Activation of Nuclear Factor kB Transcription Factors by Angiotensin II in Vascular Smooth Muscle Cells**
Doyon P¹, Servant M¹
¹Canada
Adoptive Transfer of T-Regulatory Lymphocytes Attenuates Angiotensin II-Induced Hypertension and Vascular Injury
Barhoumi T\textsuperscript{1,2}, Kasal DAB\textsuperscript{1,3}, Shbat L\textsuperscript{1}, Laurant P\textsuperscript{2}, Neves MF\textsuperscript{3}, Paradis P\textsuperscript{1}, Schiffrin EL\textsuperscript{1}
\textsuperscript{1}Canada, \textsuperscript{2}France, \textsuperscript{3}Brazil

Pro-Oxidative Microparticles are Increased in Hyperlipidemia: Role of Lipid Rafts/Caveolae
Burger D\textsuperscript{1}, Montezano AC\textsuperscript{1}, Nishigaki N\textsuperscript{1}, Touyz RM\textsuperscript{1}
\textsuperscript{1}Canada

A Novel Mitochondrial-Antioxidant MitoQ10 Improves Cardiovascular Function
Mclachlan J\textsuperscript{1}, Hamilton CA\textsuperscript{1}, Beattie E\textsuperscript{1}, Murphy MP\textsuperscript{1}, Dominiczak AF\textsuperscript{1}, Nicklin SA\textsuperscript{1}, Graham D\textsuperscript{1}
\textsuperscript{1}United Kingdom

Activation of Macrophages is Crucial for the Loss of Anticontractile Capacity of Perivascular Fat Following Inflammation and Can Be Rescued by Eplerenone
Withers SB\textsuperscript{1}, Livingstone DM\textsuperscript{1}, Little MC\textsuperscript{1}, Heagerty AM\textsuperscript{1}
\textsuperscript{1}United Kingdom

Immune Mechanisms in Hypertension
Schiffrin EL, Canada
Speaker sponsored by the Société québécoise d’hypertension artérielle

16:30-18:00 Clinical Science Debates
Clinical Science – Debate 3 Room 109-110, L1
Session is a part of the Cardiovascular Risk Factors Tract of Sessions, sponsored in part by unrestricted educational grants from Pfizer Canada, Servier Canada and Takeda
Chair: Hollenberg N, United States

Is Heart Rate Control Important in the Management of Blood Pressure?
Julius S\textsuperscript{1}, Floras J\textsuperscript{2}
\textsuperscript{1}United States, \textsuperscript{2}Canada

Is Salt Restriction a Public Health or a Patient Health Prescription?
MacGregor G\textsuperscript{1}, Rabkin SW\textsuperscript{2}
\textsuperscript{1}United Kingdom, \textsuperscript{2}Canada
TUESDAY, SEPTEMBER 28

18:00-21:30 Hypertension Canada Annual General Meeting Malaspina Room, Fairmont Waterfront

An invitation is extended to all Hypertension Canada members. Awards will be presented.
The following highest scored posters will be discussed during this session between 12:00 to 13:00: **PS2/TUE/1** through to **PS2/TUE/51** (all posters identified in green).

**Chair:** Orlov S, United States

**PS2/TUE/1**
**Aldosterone-Induced Hypertension and Renal Damage in a Model of Inherited Hypomagnesemia**
Yogi A¹, Callera GE¹, O’Connor SE¹, He Y¹, Correa JW², Tostes RC², Mazur A³, Touyz RM¹
¹Canada, ²Brazil, ³France

**PS2/TUE/2**
**Local, Ligand-Independent Mineralocorticoid Receptor Activation by High Glucose Stimulation via Rac1**
Yoshida S¹, Nagase M¹, Kawarazaki W¹, Takeuchi M¹, Ishizawa K¹, Ayuzawa N¹, Fujita T¹
¹Japan

**PS2/TUE/3**
**The Endothelial Mineralocorticoid Receptor Regulates Vasoconstrictor Tone and Blood Pressure**
Nguyen Dinh Cat A¹,², Griol-Charhbili V², Messaoudi S², Loufrani L², Labat C², Benjamin L³, Farman N², Lacolley P², Henrion D², Jaisser F²
¹Canada, ²France, ³United States

**PS2/TUE/4**
**Epigenetic Regulation of the Aldosterone Synthase CYP11B2 Gene**
Demura M¹, Wang F¹, Yoneda T¹, Karashima S¹, Mori S¹, Kometani M¹, Oe M¹, Cheng Y¹, Uchiyama K¹, Nakanishi C¹, Tsubokawa T¹, Ino H¹, Fujino N¹, Yamagishi M¹, Maeda Y¹, Namiki M¹, Takeda Y¹
¹Japan

**PS2/TUE/5**
**A Chromosome 2 QTL Restores Aldosterone Regulation and Reduces Salt-Sensitivity**
Sampson AK¹, Graham D¹, Miller WH¹, Schneider MP¹, Hamilton CA¹, Mc Bride MW¹, Dominiczak AF¹
¹United Kingdom
PS2/TUE/6
L- and D-Tryptophan Esters Dilate Rat Mesenteric Arterioles by Inhibiting L-Type Calcium Channels
Jadhav AB1, Liang W1, Guillaume B1, Kroetsch J1, Balsevich J1, Backx PH1, Heximer S1, Akhtar J1, Gopalakrishnan V1
1Canada

PS2/TUE/7
Efficacy and Reversion of Left Ventricular Hypertrophy of Combination Therapy with Amlodipine plus Amiloride/Hydrochlorothiazide versus Amlodipine plus Telmisartan in Hypertensive Subjects
Sun S-W1, Lu F-H1, Zhao Y-X1, Wang S-J1, Pan H1, Jin S-K1
1China

PS2/TUE/8
The Role of AT2-Receptor in Catecholamine Release from the Rat Adrenal Medulla
Lim D-Y, Korea, Republic of

PS2/TUE/9
Aliskiren/Amlodipine/Hydrochlorothiazide Triple Combination Provides Superior Blood Pressure Reductions Compared to Component Dual Combinations in Patients with Moderate-To-Severe Hypertension
Lacourciere Y1, Taddei S2, Konis G3, Salko T3, Fang H3, Zhang J3
1Canada, 2Italy, 3United States

PS2/TUE/10
Aliskiren-Based Regimen Provides Greater Rates of Blood Pressure Control Than Ramipril-Based Regimen with Fewer Patients Requiring Add-On Therapies Over 54 Weeks
Pool JL1, Keefe D1, Ibram G1, Xiang Z1
1United States

PS2/TUE/11
In Vivo Evaluation of Aortic Stiffening in Rat Models Via Echotracking: Pulsatile Distension Waveform Analysis
Vayssettes-Courchay C1, Ragonnet C1, Isabelle M1, Verbeuren TJ1
1France

PS2/TUE/12
Effect of High Sodium Diet on Arterial Stiffness in Subjects with Sodium Sensitivity
Lee MM1, Rhee MY1, Kim YS1, Kim YK1, Shin SJ1, Oh SW1, Bae JH1, Nah DY1
1Korea, Republic of
PS2/TUE/13
Carriers of LCAT Gene Mutations Exhibit Increased Arterial Stiffness which is Associated with Carotid Intima-Media Thickness
van den Bogaard B¹, Holleboom AG¹, Duivenvoorden R¹, Kuivenhoven JA¹, Kastelein JJP¹, van den Born BJH¹, Stroes ESG¹
¹Netherlands

PS2/TUE/14
Exercise Central Hemodynamics Are Improved by Spironolactone in People with A Hypertensive Response to Exercise
Sharman JE¹, Hare J¹, Leano R¹, Jenkins C¹, Marwick TH¹
¹Australia

PS2/TUE/15
Aliskiren Reduces QT Dispersion In Hypertensive Diabetic Patients
Fogari R¹, Mugellini A¹, Preti P¹, Derosa G¹, Lazzari P¹
¹Italy

PS2/TUE/16
Angiotensin Receptor Blocker Prevented β-Amyloid-Induced Memory Impairment Associated with Recovery of Neurovascular Coupling
Takeda S¹, Sato N¹, Kano M¹, Ogihara T¹, Rakugi H¹, Morishita R¹
¹Japan

PS2/TUE/17
Riser Pattern is Associated with Impaired Cognitive Function in Heart Failure Patients
Komori T¹, Eguchi K¹, Hoshide S¹, Ishikawa J¹, Shimada K¹, Kario K¹
¹Japan

PS2/TUE/18
Blood Pressure Responses to Eprosartan-Based Therapy and Trends in Cognitive Function in Patients with Initial Resistant Hypertension: Sub-Analysis of the OSCAR Study
Petrella R¹, Shlyakhto E², Konradi A², Berrou J-P³, Sedefdjian A⁴, Pathak A⁴, Hughes P⁵, On behalf of the OSCAR Publication Group
¹Canada, ²Russian Federation, ³Switzerland, ⁴France, ⁵United Kingdom

PS2/TUE/19
Predictive Value of Central Systolic and Diastolic Pressure in Coronary Patients. Results from The Aortic Blood Pressure and Survival Study
Jankowski P¹, Kawecka Jaszcz K¹, Czarnecka D¹, Styczkiewicz K¹, Brzozowska Kiszka M¹, Loster M¹, Klocz Badelek M¹, Wilinski J¹
¹Poland
PS2/TUE/20
Myocardial Damage during Ischemia-Reperfusion: Role of Apoptosis Repressor with Caspase Recruitment Domain in Gender Differences
Mihailidou AS1, Le TYL1, Ashton AW1, Funder JW1, Mardini M1, Stanton PG1
1Australia

PS2/TUE/21
Preventive Effects of Exenatide on Endothelial Dysfunction Induced by Ischemia-Reperfusion Injury via KATP Channels
Kim W1, Ha S-J1, Kim W1, Cho S-G1
1Korea, Republic of

PS2/TUE/22
Effects of Olmesartan on Apelin/APJ And Akt/eNOS Pathway In Dahl Rats With End-Stage Heart Failure
Fukushima H1, Kobayashi N1, Takeshima H1, Koguchi W1, Ishikawa M1, Ohno T1, Ishimitsu T1
1Japan

PS2/TUE/23
Toll Like Receptor Upregulation Induced By AT1 Receptor Activation Evokes Inflammation in the Brainstem Associated with Sympathoexcitation in Mice with Heart Failure
Ogawa K1, Hirooka Y1, Kishi T1, Sunagawa K1
1Japan

PS2/TUE/24
Effects of Metoprolol on Epinephrine-Induced Takotsubo-Like Left Ventricular Dysfunction in Non-Human Primates
Iwao H1, Izumi Y1, Shiota M1, Nakao T1, Samukawa K1, Okatani H1, Ise R1, Kito G1
1Japan

PS2/TUE/25
Delay in Referral of High Risk Patients with Hypertension and Heart Failure to Specialized Clinics in Canada, 1999 to 2008
Arnold M1, Ignaszewski A1, Rajda M1, Zieroth S1, Howlett J1, Haddad H1, Le-Blanc M-H1, Liu P1, Kaan A-M1, Marchiori G1, Canadian Heart Failure Network
1Canada

PS2/TUE/26
STARLET-Study: Stress Associated Hypertension at the Work Place – 5-Years Follow-Up
Lueders S1, Kulschewski A1, Frieg R1, Frerichs A1, Sturm CD1, Lammers M1, Hahnheiser D1, Gansz A1, Schrader J1
1Germany
A Role for Arginase in Hypertension Induced Inflammation
Andrews KL¹, Michell D¹, Lumsden NG¹, Chin-Dusting JPF¹
¹Australia

The Role of Nuclear Factor Kappa B in L-NAME-Induced Hypertension
Pechanova O¹, Barta A¹, Vrankova S¹
¹Slovakia

Shear Stress Induced Nitric Oxide Production in Macula Densa Cells Is Mediated by the Primary Cilia
Liu H¹, Lu D¹, Fu Y¹, Zhu X¹, Juncos LA¹, Liu R¹
¹United States

Crosstalk between the Heme Oxygenase System, Atrial Natriuretic Peptide and Adiponectin in Mineralocorticoid-Induced Hypertension
Ndisang JF¹, Jadhav A¹
¹Canada

Plasmin Activation by Deficiency of Plasminogen-Activator-Inhibitor 1 Is Protective in Hypertension Induced Kidney Injury in Mice
Knier B¹, Cordasic N¹, Klanke B¹, Heusinger-Ribeiro J¹, Hartner A¹, Daniel C¹, Hilgers KF¹
¹Germany

Evidence That Renal Arginine Transport is Impaired in Hypertension
Rajapakse N¹, Evans R¹
¹Australia

Role of Oxidative Stress in Erythropoietin-Induced Hypertension in Uremic Rats
Rancourt M-È¹, Rodrigue M-È¹, Agharazii M¹, Lariviè re R¹, Lebel M¹
¹Canada

Examination of Biomarkers for Prediction of Stroke in Stroke-Prone Spontaneously Hypertensive Rats
Takemori K¹, Ito H¹
¹Japan
PS2/TUE/35
Gestational-Age-Specific Thresholds of Serum sFlt1/PIGF Ratio for the Onset of Preeclampsia are Higher in Earlier Gestational Age
Ohkuchi A1, Ohmaru T1, Eguchi K1, Hirashima C1, Takahashi K1, Suzuki H1, Matsubara S1, Suzuki M1
1Japan

PS2/TUE/36
Protective Effect of Exercise Training In Mouse Model of Superimposed Preeclampsia on Chronic Hypertension
Falcao S1, Michel C1, Lacasse A-A1, Vaillancourt C1, Jolanta G1, Lavoie JL1
1Canada

PS2/TUE/37
Identification of Potential Biomarkers for Hypertension in Pregnancy through Epigenetic Profiling of Human Placentas
Yuen RKC1, Peñaherrera MS1, von Dadelszen P1, McFadden DE1, Robinson WP1
1Canada

PS2/TUE/38
Prediction of Pre-Eclampsia by First Trimester E-Selectin
Delles C1, Carty DM1, Brennand JE1, McCulloch JW1, Johnstone J1, Welsh P1, Dominiczak AF1
1United Kingdom

PS2/TUE/39
Masked Hypertension around the 28th Week of Gestation Predicts Pregnancy-induced Hypertension
Eguchi K1, Ohkuchi A1, Ohmaru T1, Hirashima C1, Takahashi K1, Suzuki H1, Kario K1, Matsubara S1, Suzuki M1
1Japan

PS2/TUE/40
The Impact of Blood Pressure on Cardiovascular Events in A General Population: The Hisayama Study
Fukuhara M1, Ninomiya T1, Hata J1, Yonemoto K1, Doi Y1, Hirakawa Y1, Matsumura K1, Iida M1, Kiyohara Y1
1Japan

PS2/TUE/41
Transcriptomics-Based Search for Intracellular Na⁺ Sensor Involved in Regulation of Gene Expression
Orlov SN1, Haloui M1, Seda O1, Adarichev VA2, Tremblay J1, Hamet P1
1Canada, 2United States
PS2/TUE/42
Impact of Selective Aldosterone Blocker for Transcription and Post Transcriptional Modification of ENaC in Terminal Nephron
Ushio H1, Ishigami T1, Minegishi S1, Abe K1, Araki N1, Umemura M1, Uchino K1, Umemura S1
1Japan

PS2/TUE/43
A Novel Inhibitor of Transglutaminase Prevents Vascular Calcification
Moreau S1, Chabot N1, Keillor JW1, Moreau P1
1Canada

PS2/TUE/44
Resveratrol Reduces Vascular Cells Senescence through Attenuation of Oxidative Stress by SIRT1/NADPH Oxidase-Dependent Mechanisms
Tang Y1, Peng X1, Tian C1, Zhang C1, Ying C1, Sun X1, Hao L1
1China

PS2/TUE/45
Early Vascular Aging (EVA) Is Present In Subjects with Confirmed and Masked Hypertension
Kotsis V1, Stabouli S1, Karafilis I1, Papakatsika S1, Sion M1
1Greece

PS2/TUE/46
Prognostic Significance of Reduced Glomerular Filtration Rate and Interaction with Microalbuminuria in Resistant Hypertension
Salles G1, Pereira V1, Cardoso C1, Fiszman R1, Muxfeldt E1
1Brazil

PS2/TUE/47
Salt Causes Cardiovascular Damage Dose-Dependently, but Independently of Its Effect on Blood Pressure in General Population
Hagikura A1, Takase H1, Toriyama T1, Okado T1, Sonoda H1, Dohi Y1, Kimura G1
1Japan

PS2/TUE/48
Gene Network Involved in Salt Sensitive Hypertension
Simonini M1, Gatti G1, Delli Carpini S1, Querques ML1, Botticelli I1, Merlino L1, Lanzani C1, Brioni E1, Zagato L1, Manunta P1
1Italy
The Importance of Osteopontin for Renal Interstitial Fibrosis in Streptozotocin-induced Diabetic Mice
Nagao T1, Okura T1, Jotoku M1, Enomoto D1, Irita J1, Miyoshi K-I1, Higaki J1
1Japan

Increased Migration of Monocytes in Essential Hypertension is Associated with Increased Transient Receptor Potential Channel Canonical Type 3 (TRPC3) Channels
Zhao Z1, Zhong J1, Ni Y1, Chen J1, Yan Z1, Liu D1, Tepel M2, Zhu Z1
1China, 2Germany

11C-Metomidate PET-CT Scanning in Conn’s Syndrome
Burton TJ1, Bird N1, Soloviev D1, Azizan E1, Kottekkattu B1, Gurnell M1, Mackenzie I1, Elkhawad M1, Brown MJ1
1United Kingdom

Angiotensin II Type 1 Receptor Blocker Improves Short-Term Blood Pressure Variability and Cardiovascular Remodeling in Peritoneal Dialysis Patients with Hypertension
Ohsawa M1, Tamura K1, Shigenaga A-I1, Kanaoka T1, Azuma K1, Mitsuhashi H1, Toya Y1, Umemura S1
1Japan

Comparison of Ambulatory Blood Pressure Monitoring Profile between Untreated African Blacks and Caucasians Hypertensive Patients Matched For Age and Gender
Damasceno A1, Mavimbe C1, Barbosa L2, Silva JA2, Diogo D1, Madede T1, Polónia J2
1Mozambique, 2Portugal

Can Home Blood Pressure Monitoring replace Ambulatory Blood Pressure Monitoring in the Diagnosis and Management of Resistant Hypertension?
Muxfeldt ES1, Nascimento AC1, Dias VB1, Santos L1, Fiszman R1, Salles GF1
1Brazil

Effect of Angiotensin II Receptor Blockers on Variable Salt Diet in Dahl Salt-Sensitive Rats
Guo Q1, Mori T1, Jiang Y1, Hu C1, Yoneki Y1, Nakamichi T1, Kawamata A1, Ogawa S1, Ito S1
1Japan
PS2/TUE/56
The Relationship between ‘Guidelines Quality’ Manual Blood Pressure and Automated Office Blood Pressure Supports the Use of Automated Devices in Routine Clinical Practice
Myers MG1, Valdivieso M1, Chessman M1
1Canada

PS2/TUE/57
Non Invasive Pulse Wave Analysis and Measurement of Cardiac Output during Haemodialysis and Beyond
Neumann CL1, Claes V1, Wegener M1, Korth U1, Schwarz A1, Wolf A1, Schulz EG1
1Germany

PS2/TUE/58
Combination Noradrenaline with Epinephrine Result In the Regulation of Circadian Rhythm of Blood Pressure and the Synchronization of Clock Genes of Aortas in Rats
Zhuang X1, Sun N1
1China

PS2/TUE/59
Aliskiren/Amlodipine/Hydrochlorothiazide Combination Provides More Effective 24-h BP Reductions vs. Dual Combinations in Moderate-To-Severe Hypertension
Taddei S1, Lacourciere Y2, Konis G3, Salko T3, Fang H3, Zhang J3
1Italy, 2Canada, 3United States

PS2/TUE/60
Differences on Blood Pressure Values in Normotensive Men and Women Cohort
Domenech Feria-Carot M1, Sobrino J1, Camafort M1, Vinyoles E1, Coca A1, ESTHEN Group
1Spain

PS2/TUE/61
Antihypertensive Efficacy of High-Dose Valsartan at Bedtime in Non Dipper Hypertensive Patients
Pena Seijo M1, Hermida Ameijeiras A1, Lopez Paz JE1, Calvo Gonzalez G1, Romero Miguez ML1, Coca Payeras A1, Calvo Gomez C1
1Spain

PS2/TUE/62
Proportion of Masked Hypertension in Subjects with Prehypertension
Zhang B1, Yan K1, Lan Y1, Zhao J1, Sun W1, Liu Y1, Wang H1, Zhang S1, Sun L1, Wang Q1
1China
PS2/TUE/63
The Prevalence Masked Hypertension in a Large Outpatient 24hr ABPM Population
Armstrong D, Nault M, Brouillard D, Matangi MF
1Canada

PS2/TUE/64
Hypertension and Rheumatoid Arthritis – The Diurnal Variability of Blood Pressure
Říhaček I, Frana P, Plachy M, Souček M
1Czech Republic

PS2/TUE/65
Effects of Alopurinol on Blood Pressure in Hypertensive Subjects with Hyperuricemia
Calvo Gomez C, Lopez Paz JE, Hermida Ameijeiras A, Pena Seijo M, Calvo Gonzalez G, Coca Payeras A
1Spain

PS2/TUE/66
Clinical Risk Factors Associated with Ambulatory Blood Pressure Non-Dipping in Hypertensive African Americans
Mortoti SS, Randall OS, Kwagyan J
1United States

PS2/TUE/67
Aliskiren and Chronotherapy: Effects of Administration Time on Ambulatory Blood Pressure
1Spain

PS2/TUE/68
Left Ventricular Mass Index and Circadian and Circaseptan Amplitude Variations in Patients after Infarctus of Myocardium
1Czech Republic, 2United States

PS2/TUE/69
Losartane and Telmisartane in the Patients with Newly Diagnosed Hypertension and Metabolic Syndrome – Effect of One Year of Treatment to Clinical Blood Pressure, 24h Blood Pressure, Metabolic and Anthropometric Parameters
Říhaček I, Frana P, Schwarz D, Plachy M, Souček M
1Czech Republic
PS2/TUE/70
Effects of the Combination Therapy of Losartan/Hydrochlorothiazide on the Relationships between Base Blood Pressure, Autonomic Function, and Health-Related QOL
Okano Y1, Tochikubo O1, Tamura K1, Yabana M1, Azuma K1, Umemura S1
1Japan

PS2/TUE/71
Obesity Influence the Circadian Blood Pressure Pattern in Hypertension
Pyun WB1, Chung W-J1, Byun Y-S1, Rhyu S-K1, Rim S-J1, Shin GJ1
1Korea, Republic of

PS2/TUE/72
Sagliker Y1, Ocal F1, Sagliker Ozkaynak P1, Paylar N1, Sagliker C1, Inal T1, Kolasin P1, Sagliker HS1, Celik F1
1Turkey

PS2/TUE/73
Microarray Analysis Illustrates Possible Role of Potassium and Sodium Transport Abnormalities in Aldosterone-Producing Adenoma (APA)
Azizan EAB1, Newhouse S1, Burton TJ1, Brown MJ1
1United Kingdom

PS2/TUE/74
Effects of Phase of the Menstrual Cycle on the Aldosterone/Renin Ratio, Influence of Renin Assay Method (Direct Active Renin Concentration versus Plasma Renin Activity), and Comparison with Male Subjects
Ahmed A1, Gordon R1, Taylor P1, Ward G1, Pimenta E1, Stowasser M1
1Australia

PS2/TUE/75
Ligand-Independent Inhibition of Mineralocorticoid Receptor Activity by a Calcium Channel Blocker Azelnidipine
Kawarazaki W1, Nagase M1, Yoshida S1, Takeuchi M1, Ishizawa K1, Ayusawa N1, Fujita T1
1Japan

PS2/TUE/76
Mechanism of Increased Salt-Sensitivity in Young Uninephrectomized Sprague-Dawley Rats
Kawarazaki H1, Ando K1, Shibata S1, Fujita M1, Nagase M1, Fujita T1
1Japan
PS2/TUE/77
Higher Plasma Aldosterone Levels Relative to Renin Activity Are Associated With Lower Insulin Sensitivity in Residents of a Japanese Community
Nomura I¹, Kato J¹, Kitamura K¹
¹Japan

PS2/TUE/78
Glucocorticoid and Mineralocorticoid Receptor and 11-HSD Expression in the Visceral Adipose Tissue in Patients with Aldosterone-Producing Adenoma
Mori S¹, Karashima S¹, Cheng Y¹, Demura M¹, Yoneda T¹, Kometani M¹, Ohe M¹, Takeda Y¹
¹Japan

PS2/TUE/79
The Renal Damage in Patients with Primary Aldosteronism and Patients with Primary Hypertension
Gong Y¹, Guo J¹
¹China

PS2/TUE/80
Effect of Atenolol on Aldosterone/Renin Ratio Calculated by Both Plasma Renin Activity and Direct Renin Concentration in Healthy Male Volunteers
Ahmed A¹, Gordon R¹, Taylor P¹, Ward G¹, Pimenta E¹, Stowasser M¹
¹Australia

PS2/TUE/81
Decreased Klotho Expression in Early Aldosterone-Salt Induced Hypertension
Takenaka T¹, Inoue T¹, Okada H¹, Ohno Y¹, Miyazaki T¹, Suzuki H¹
¹Japan

PS2/TUE/82
Effects of Efonidipine, a L- and T-type Calcium Channel blocker, on the Renin-Angiotensin-Aldosterone System in Chronic Hemodialysis Patients
Nakano N¹, Ishimitsu T¹, Takahashi T¹, Ohta S¹, Inada H¹, Furukata S¹, Sudo Y¹, Ohba S¹, Okamura A¹, Matsuoka H¹
¹Japan

PS2/TUE/83
Endocrinological Evaluation of Successful Sampling from Right Adrenal Veins in Patients with Primary Aldosteronism
Morimoto R¹, Satoh F¹, Iwakura Y¹, Kudo M¹, Murakami O¹, Ito S¹
¹Japan
PS2/TUE/84
Salt Loading and Inappropriate Secretion of Aldosterone Contribute to the Renal Damage in Angiotensin II Overproducing Mice
Takeuchi M1, Nagase M1, Yoshida S1, Kawarazaki W1, Ishizawa K1, Ayusawa N1, Fujita T1
1Japan

PS2/TUE/85
The Prevalence of Primary Aldosteronism in Hypertensive Subjects with Dysglycemia
Li N1, Wang M1, Wang H1
1China

PS2/TUE/86
The Effect of Low Dose Diuretics on Aldosterone Level in Hypertensive Patients with Diabetes Mellitus in During Angiotensin II Receptor Blocker Treatment
Yoneda T1, Takeda Y1, Karashima S1, Demura M1, Usukura M1, Takata H1,
Nobushige O1, Yamamoto Y1, Hashimoto A1, Mori S1, Kometani M1, Ooe M1, Saeki M1, Yamagishi M1
1Japan

PS2/TUE/87
Telmisartan-Induced eNOS Gene Expression is Partially Independent of its PPAR-Gamma Agonist Property
Buset-Rios N1, Rodriguez-Esparragon F1, Hernandez-Trujillo Y1, Hernandez-Velazquez E1, Estupiñan-Quintana L1, Rodriguez-Perez JC1
1Spain

PS2/TUE/88
Differential Effects of Thiazide Diuretics as Add-on Therapy versus Monotherapy in Nondiabetic Essential Hypertension
Huang C-C1, Leu H-B1, Wu T-C1, Lin S-J1, Chen J-W1
1Taiwan, Republic of China

PS2/TUE/89
Effects of Losartan/Hydrochlorothiazide Combination Therapy versus High-Dose Amlodipine Monotherapy on 24-h Ambulatory Blood Pressure and Microalbuminuria: ALPHABET Study – ABPM
Fukutomi M1, Satoshi H1, Eguchi K1, Watanabe T1, Kabutoya T1, Ishikawa S1, Shimada K1, Kario K1
1Japan
PS2/TUE/90
The New Angiotensin Receptor Blocker Azilsartan Medoxomil Has Superior 24-hour Blood Pressure Lowering Efficacy to both Olmesartan and Valsartan
White WB1, Weber M1, Sica D1, Bakris G1, Perez A1, Cao C1, Kupfer S1
1United States

PS2/TUE/91
Usefulness of High-Dose ARB (Valsartan) on the Hypertensive Organ Damage – Sub-Analyses with/without Chronic Kidney Disease or Metabolic Syndrome
Geshi E1, Irie S1, Katagiri T1
1Japan

PS2/TUE/92
Valsartan Improves Maximal Exercise Capacity in Elderly Hypertensives: Results of A Randomized, Placebo-Controlled, Crossover Trial
De Rosa ML, Italy

PS2/TUE/93
The Relationship of Pre-Treatment Blood Pressure and Treatment Response to Amlodipine/Valsartan/Hydrochlorothiazide Triple Combination Therapy
Calhoun D1, Crikelair NA1, Glazer RD1, Jia Y1
1United States

PS2/TUE/94
Olmesartan and Amlodipine Combination and Chronotherapy Effects
Lopez Paz JE1, Hermida Ameijeiras A1, Pena Seijo M1, Calvo Gonzalez G1, Romero Miguez ML1, Coca Payeras A1, Calvo Gomez C1
1Spain

PS2/TUE/95
The Use of Ace Inhibitors, Angiotensin Receptor Blocker or Both in Advanced Chronic Kidney Disease Patients: A Single Nephrology Centre Audit
Wan Hassan WHH, Malaysia

PS2/TUE/96
Safety and Effectiveness of Amlodipine and Valsartan Combination in the Treatment of Arterial Hypertension: Real Life Results
Chazova I1, Dongre N2, Vigdorchik A1
1Russian Federation, 2Switzerland

PS2/TUE/97
Antihypertensive Efficacy of Aliskiren/Amlodipine/Hydrochlorothiazide Triple Combination in Patients with Severe Hypertension: Subgroup Analysis of a 54-Week Clinical Trial
Murray A1, Koenig W2, Garcia-Puig J3, Patel S1, Papst CC4, Zhang J1
1United States, 2Germany, 3Spain, 4Switzerland
PS2/TUE/98
The Effectiveness of a Single Pill Combination of Valsartan/Amlodipine in Japanese Patients Across Varying Levels of Baseline Systolic Blood Pressure
Zappe D¹, Curt V¹, Cheng J¹, Teshima R², Sawata H²
¹United States, ²Japan

PS2/TUE/99
Efficacy and Tolerability of Nebivolol in Four Different Age Groups: Pooled Analysis of Three Randomized, Placebo-Controlled Trials in Stage I-II Hypertension
Germino FW¹, Lin Y¹, Bowen L¹
¹United States

PS2/TUE/100
Translating Evidence into Action: Is the Prescribing Pattern of Antihypertensive Agents in Malaysian Primary Care Clinics in Accordance with Current Guidelines?
Ramli AS¹, Miskan M¹, Ng KK¹, Ambigga D¹, Nafiza MN¹, Mazapuspavina MY¹, Sajari J¹, Ishak R¹, Quality Improvement in Primary Care (QIPC) Study Group
¹Malaysia

PS2/TUE/101
Aliskiren/Hydrochlorothiazide Combination Lowers Blood Pressure Effectively in Obese or Non-Obese Patients Not Adequately Responsive to Hydrochlorothiazide Monotherapy
Blumenstein M¹, Romaszko J², Calderón A³, Andersen K⁴, Ibram G⁵, Papst CC⁶, Zhang J³
¹Germany, ²Poland, ³Spain, ⁴Iceland, ⁵United States, ⁶Switzerland

PS2/TUE/102
Dual Actions of Olmesartan on Catecholamine Release in the Rat Adrenal Medulla
Hong S-P¹, Lim D-Y¹
¹Korea, Republic of

PS2/TUE/103
Changes in Blood Concentrations of Uric Acid and Electrolytes After Long term Diuretic Therapy in Hypertensive Patients
Kim S-K¹, Park WC¹, Lim YH¹, Choi SI¹, Shin JH¹, Lee JU¹, Kim JH¹, Lim HK¹
¹Korea, Republic of

PS2/TUE/104
Reduction of Blood Pressure by Calcium Channel Blocker Benidipine Decreases Urinary Proteins Excretion in Hypertensive Patients
Kanda K¹, Kakinoki S¹, Takechi S¹, Fujimoto T¹, Nomura A¹
¹Japan
PS2/TUE/105
Mechanism for the Efficacy of Combination Therapy with Losartan and Hydrochlorothiazide in Rats with Salt-Sensitive Hypertension
1Japan

PS2/TUE/106
The Prevalence of Orthostatic Hypertension and Hypotension in Patients with Essential Hypertension
Li N, Zhang J, Jiang W
1China

PS2/TUE/107
Relationship between Central Aortic Pressures, Augmentation Pressure and Pulse Wave Velocity in Prehypertensive Patients
Hui P, Fanghong L, Yingxin Z, Zhendong L, Shujian W, Guangtao Y, Shengnan W
1China

PS2/TUE/108
Ceiling Dose of Angiotensin II type 1 Receptor Blockade Better Improves Ventricular-Vascular Coupling Index than Non-Ceiling in Heart Failure
1Korea, Republic of

PS2/TUE/109
The Correlation of Pulse Wave Velocity and Cardiovascular Risk Factors
1China

PS2/TUE/110
Relation between Target Organ Damage and Arterial Stiffness in Primary Hypertension
Junli Z, Yan L, Qian G, Pingjin G, Dingliang Z, Shaoli C
1China

PS2/TUE/111
Carotid – Femoral Pulse Wave Velocity Cut-Off Values in Cardiovascular Risk Prediction
Kopec G, Podolec M, Sobien B, Dziedzic H, Pajak A, Podolec P
1Poland
PS2/TUE/112
Comparison of Hemodynamic Parameters Between Two Tonometry-Based Devices
Zhang Y1,2, Agnoletti D1, Protogerou A3, Topouchian J1, El Assaad M1, Salvi P1, Safar ME1, Blacher J1
1France, 2China, 3Greece

PS2/TUE/113
The Arterial Stiffness and Response to Treatment in Resistant Hypertension
Emelyanov I1, Ivanenko V1, Konrady A1, Shlyakhto E1, Rotar O1
1Russian Federation

PS2/TUE/114
An Association between Chronic Kidney Disease and Arterial Stiffness in Hypertensive Patients
Zuo J1, Li Y1, Ge Q1, Zhu F1, Chang G1, Gao P1, Chu S1
1China

PS2/TUE/115
C-Reactive Protein is Not Involved in Aortic Stiffness Progression
Couture V1, Utescu MS1, Marquis K1, Marcel L1, Agharazii M1
1Canada

PS2/TUE/116
Comparison of Arterial Stiffness and Microcirculation Parameters in Elderly Hypertensives
Kanishcheva E1, Fedorovich A1, Loukianov M1, Boytsov S1
1Russian Federation

PS2/TUE/117
Relation between Arterial Stiffness in Hypertensive and Diabetic Subjects with Glomerular Filtration Rate (GFRr) and Urinary Albumin Excretion (UAE)
Lopez Paz JE1, Hermida Ameijeiras A1, Pena Seijo M1, Calvo Gonzalez G1, Romero Miguez ML1, Coca Payeras A1, Calvo Gomez C1
1Spain

PS2/TUE/118
Apocynin and Losartan Improve Aortic Stiffness in DOCA-Salt Hypertensive Rat
Chen Q1, Wu Y1, Zhu D1, Gao P1
1China
**PS2/TUE/119**  
**Blood Pressure Lowering, Circulating Endothelial Microparticles and Artery Elasticity**  
1China

**PS2/TUE/120**  
**Casein Hydrolysate Containing Val-Pro-Pro and Ile-Pro-Pro Improves Central Blood Pressure and Arterial Stiffness in Stage-I Hypertensive Subjects**  
Takazawa K, Nakamura T, Mizutani J, Takeshi M  
1Japan

**PS2/TUE/121**  
**Effects of Hemodialysis on Arterial Function in End-Stage Renal Disease Patients**  
Xi Y, Sun N, Wang L  
1China

**PS2/TUE/122**  
**Disassociation of Augmentation Index and Reflection Coefficient after Nitrovasodilation**  
Guilcher A, Cecelja M, Spector TD, Chowienczyk P  
1United Kingdom

**PS2/TUE/123**  
**Augmentation Index in Early Morning Hypertension**  
Shinaqawa T, Suzuki S  
1Japan

**PS2/TUE/124**  
**The Effects of Long-term Treatment of Angiotensin II Blocker on Arterial-Ventricular Stiffening: A Comparison with Calcium Channel Blocker**  
Tomiyama H, Shiina K, Matsumoto C, Odaira M, Yoshida M, Yamashina A  
1Japan

**PS2/TUE/125**  
**Long-term Treatment with Telmisartan Abolished Arterial Stiffness via Suppression of the Inflammation in Hypertensive Patients**  
Ashizawa N, Maemura K  
1Japan

**PS2/TUE/126**  
**Effects of Candesartan on Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertensive Patients with Metabolic Syndrome**  
Bokuda K, Ichihara A, Mito A, Sakoda M, Kinouchi K, Itoh H  
1Japan
PS2/TUE/127
Arterial Stiffness Is Associated with Improved Physical Fitness in Patients with Chronic Renal Failure IV-V
Shiraishi FG1, Martin LC1, Stringuetta F1, Gonçalves R1, Hueb JC1, Rodrigues AB1, Franco RJ1
1Brazil

PS2/TUE/128
Endothelial Dysfunction and Arterial Wall Stiffness in Survivors of Leningrad Siege
Konradi A1, Ivanenko V1, Kolesova E1, Yakovleva O1, Fursova I1, Litvinenko E1, Rotar O1
1Russian Federation

PS2/TUE/129
Longitudinal Associations between Blood Pressure and Dementia in the Very Old
Molander L1, Gustafson Y1, Lövheim H1
1Sweden

PS2/TUE/130
Systemic Treatment with Angiotensin II Type 2 Receptor Agonist, Compound 21, Improved Spatial Memory via Increase in Cerebral Blood Flow through Bradykinin B2 Receptor Activation
Fei J1, Masaki M1, Li-Juan M1, Jun I1, Kana T1, Akiko S1, Thomas U2, Björn D3, Masatsugu H1
1Japan, 2Germany, 3Sweden

PS2/TUE/131
Association of Cognitive Impairment in Hypertensive Patients and Asymptomatic White Matter Lesions by MRI a Brain
Afanasyeva N1, Mordovin V1
1Russian Federation

PS2/TUE/132
Impact of Midlife and Late-Life Blood Pressure on the Development of Dementia in Japanese Elderly: The Hisayama Study
Ninomiya T1, Ohara T1, Sekita A1, Doi Y1, Kanba S1, Kiyohara Y1, the Hisayama Study
1Japan

PS2/TUE/133
Cognitive Function and Effect of Blood Pressure Control Based on ARB-Therapy
Lueders S1, Gansz A1, Lammers M1, Hahnheiser D1, Sturm CD1, Froehlich L1, Diener HC1, Schrader J1
1Germany
PS2/TUE/134
The Chronic Oxidative Stress Attenuates Non-Genomic MR Action in the Rat Hippocampus. Chronic Kidney Disease Model with Uninephrectomy and High Salt Loading
Mori F1, Shimosawa T1, Jimbo R1, Mu S1, Uetake Y1, Fujita T1
1Japan

PS2/TUE/135
Effects of Switching Therapy from Free Combinations of Angiotensin II Receptor Blockers and Thiazides to a Fixed-Dose of Losartan/Hydrochlorothiazide on Blood Pressure, Adherence and Degree of Satisfaction with Medications
Sakima A1, Ohshiro K1, Nakada S1, Yamazato M1, Kohagura K1, Nakamoto M1, Shinzato T1, Tana T1, Ohya Y1
1Japan

PS2/TUE/136
Effect of Combination Therapy with Bone-Marrow Mononuclear Cells Implantation and Eicosapentaenoic Acid in Myocardial Ischemia
Takeshima H1, Kobayashi N1, Koguchi W1, Fukushima H1, Ishikawa M1, Ohno T1, Ishimitsu T1
1Japan

PS2/TUE/137
Hypertension and Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery
Kanic V1, Brguljan J1, Naji F1, Penko M1
1Slovenia

PS2/TUE/138
Mechanism Involved In the ‘Smoker’s Paradox’ In Patients with Acute Myocardial Infarction Associated with Cardiovascular Morbidities
Kim W1, Hwang S-H1, Kim W1
1Korea, Republic of

PS2/TUE/139
Clinical Values of Dual-Source CT Coronary Angiography for Elderly Patients
Zhou X1, Jing J1, Ping Z1
1China

PS2/TUE/140
Antiischemic Therapy in the Hypertensive Patients after Post Coronary Artery Graft Surgery
Riecansky I1, Pacak J1, Fridrich V1
1Slovakia
PS2/TUE/141
Tamoxifen Changes Coronary Vascular Reactivity in Ovariectomized Spontaneous Hypertensive Rats
Borgo MV¹, Bissoli NS¹, Moyses MR¹, Abreu GR¹
¹Brazil

PS2/TUE/142
Impact of Clopidogrel in Patients with ST-Elevation Myocardial Infarction and Failed Thrombolysis Not Undergoing Rescue or Early Angioplasty. A Ten Years Romanian Registry for ST-Elevation Myocardial Infarction (RO-STEMI)
Tatu-Chitoiu G¹, Dorobantu M¹, Benedek I¹, Craiu E¹, Sinescu C¹, Pop C¹, Arsenescu-Georgescu C¹, Vinereanu D¹, Tomescu C¹, Petrescu L¹, Firastrau V¹, Stanciulescu P¹, Minescu B¹, Ionescu DD¹, Macarie C¹, Vladoianu M¹, Topolnitchi O¹, Radoi M¹, Petrescu I¹, Petris A¹
¹Romania

PS2/TUE/143
Endogenous Sex Hormones and Clinical Course of Myocardial Infarction in Young Men
Karimova K¹, Bakhshaliyev A¹
¹Azerbaijan

PS2/TUE/144
Long Overtime Work Hours and the Risk of Hypertension, Dyslipidemia and Diabetes: Rosai Karoshi Study
Munakata M¹, Ikeda T¹, Wada Y¹, Morozumi T¹, Nishino M¹, Yamane K¹, Nanto S¹
¹Japan

PS2/TUE/145
Incidence of Arterial Hypertension, Among the Population of Belarus Injured of Chernobyl Accident
Kotava A, Belarus

PS2/TUE/146
The Impact of Environmental Factors on Blood Pressure
Batsolaki M¹, Anagnostou P¹, Bacalis N¹
¹Greece

PS2/TUE/147
Cardiometabolic Risk Management Guidelines in Primary Care: A Model for Change in Guideline Presentation
Almustafa BA¹, Al-Faraj N², Almarhoon F¹, Al-Eid N¹, Almobarak AA¹, Hehlis M¹, Cardiometabolic Risk Management Guideline Development Team
¹Saudi Arabia, ²Australia
PS2/TUE/148
Current Situation in the Treatment of Hypertension and Factors to Achieve Target Blood Pressure
Kawabe T, Hano T, Nanjo K
1Japan

PS2/TUE/149
The Prevalence of Hypertension and the Rate of Achieving Blood Pressure Goal in Patients with Type 2 Diabetes: An Investigation among 15 Communities in Beijing – PR China
Qin M-Z, Yuan S-Y, Fu H-J
1China

PS2/TUE/150
Awareness and Knowledge of Home Blood Pressure Monitoring Guidelines Among Community Based Physicians
Ananthasayanan AK, Schreiber Jr MJ, Butler R, Rafey MA
1United States

PS2/TUE/151
Achievement Rates of Target Clinic and Home Blood Pressure Levels in Treated Hypertensive Patients: Assessment According To the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2009)
1Japan

PS2/TUE/152
Hypertension Detection and Follow-up Program – A View through the Lens of the Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
Tweet M, Kumar G, Hayes S
1United States

PS2/TUE/153
Management of Arterial Hypertension in Type 2 Diabetic Patients
Zivkovic RR, Suric Lambic LD, Ugljesic MM, Ladjevic BS, Milovic OR
1Serbia
A New Approach of Implementation of Clinical Practice Guidelines for Cardiovascular and Related Diseases – A Multi-D Model for Intervention in Large Population
Zhang MQ¹, Kuang PG¹, Ji XM¹, Li RJ¹, Wang YF¹, Li Y¹, Li YC¹, Pu CQ¹, Wu WP¹, Guan WP¹, Tian CL¹, Ren ZY¹, Kong YM¹, Niu JY¹, Li XF¹, Wang XY¹, Zhang XS¹, Tian H¹, Tao GS¹, Coalition of Cardiovascular Diseases Prevention Program ¹China

Comorbidities and Mortality of Heart Failure in Canada
Dai S¹, Walsh P¹, Wielgosz A¹, Morrison H¹, Bancej C¹, Stewart P¹
¹Canada

Elevated Stress NT-ProBnp Levels Can Predict Significant Intraventricular Flow Abnormalities in Asymptomatic Hypertensives with Microvascular Disease
Kisko A¹, Kmec J¹, Vereb M¹, Babcak M¹, Cencarik J¹, Gazdic P¹, Stasko J¹, Mikulak M¹, Kishko N²
¹Slovakia, ²Ukraine

Effects of the Gamma Linolenic Acid on the Cardiac Remodeling After Myocardial Infarction in Rats
Ferrante FA¹, Edelmuth RCL¹, Vitor T¹, Souza PRM¹, Koike MK¹
¹Brazil

Molecular form of Brain Natriuretic Peptide (BNP) Secreted from Cultured Atrial and Ventricular Myocytes and its Processing System
Nishikimi T¹, Akimoto K¹, Ikeda M¹, Takeda Y¹, Koshikawa S¹, Tazuyoshi K¹, Ishimitsu T¹
¹Japan

The Influence of Cardiac Resynchronization Therapy in Chronic Heart Failure on Respiratory Profile and Autonomic Modulation
Styczkiewicz K¹, Czarnecka D¹, Kusiak A¹, Wilinski J¹, Wojciechowska W¹, Kloch Badelek M¹, Bacić B¹, Castiglioni P¹, Kawecka Jaszcz K¹
¹Poland
PS2/TUE/161
The Association between Serum Uric Acid and Blood Pressure in Japanese Men
Ohtsubo T¹, Matsumura K¹, Goto K¹, Oniki H¹, Yamasaki T¹, Fukuhara M¹, Ohta Y¹, Iida M¹
¹Japan

PS2/TUE/162
Analysis of the Prevalence of Hypertension and Cardiovascular Risk Factors among Drivers during the National Week of Traffic in Uberaba-MG, Brazil, 2009
da Silva MAV¹, Neves PDMM¹, Rodrigues de Resende LAP¹, Lopes LC¹, Duarte LA¹, Tintori JA¹, Mendonça HM¹, Marques VP¹, Zanardo FC¹, Accorsini JS¹, Aguiar CF¹
¹Brazil

PS2/TUE/163
How Often Untreated Hypertensive Employees Followed Their Industrial Health Care Office’s Advice to See Doctors after A Medical Check-Up for Metabolic Syndrome in Japan?
Ohtsuki T¹, Matsumoto M¹
¹Japan

PS2/TUE/164
Heart Rate but Not Age Is a Significant Predictor of Prehypertension in Young and Middle-Aged Hungarians
Steiner S¹, Sonkodi B², Hellis E¹, Sonkodi S², Fodor G¹
¹Canada, ²Hungary

PS2/TUE/165
Influence of Face-To-Face Interview or Brochure Advice to Hypertensive Employees by Industrial Health Care and Education upon the Subsequent 1-Year Stroke Occurrence
Ohtsuki T¹, Matsumoto M¹
¹Japan

PS2/TUE/166
Hepatocyte Growth Factor (HGF) Gene Therapy Reduces Hypertension and Inflammation in Spontaneously Hypertensive Rats (SHR)
Romero F¹, Chavez M¹, Rodriguez-iturbe B¹
¹Venezuela

PS2/TUE/167
Inflammatory Cytokine Expression in the Macrophage Cell Line in Response to Thrombin Cleaved Osteopontin
Kurata M¹, Okura T¹, Tanaka Y¹, Miyazaki T¹, Nagao T¹, Irita J¹, Fujino T¹, Higaki J¹, Nose M¹
¹Japan
PS2/TUE/168
The Association of Serum Inflammatory Biomarkers with Chronic Kidney Disease in Hypertensive Patients
Xu T¹, Zhang Y¹, Li Y¹, Chu S¹, Zhu D¹, Gao P¹
¹China

PS2/TUE/170
Influence of Telmisartan on Microinflammation Process in Obese Patients with Arterial Hypertension
Adamczak M¹, Kubik M¹, Chudek J¹, Wicek A¹
¹Poland

PS2/TUE/171
Hemodynamic Effects of Landiolol in Patients with Severe Infection and Tachyarrhythmia
Okajima M¹, Taniguchi T¹, Takashima S¹, Usui S¹, Takamura M¹, Kaneko S¹
¹Japan

PS2/TUE/172
Renoprotective Effect of Sildenafil Citrate in DOCA-Salt Hypertensive Rats
Bae E¹, Kim I¹, Park JW¹, Ma SK¹, Kim SW¹, Lee JU¹
¹Korea, Republic of

PS2/TUE/173
Males Exhibit Reduced ACE2 while Females Express Lower Neprilysin in the Kidney of the Diabetic mRen2.Lewis Rat
Gilliam-Davis S¹, Yamaleyeva LM¹, Chappell MC¹
¹United States

PS2/TUE/174
Expression of (Pro)Renin Receptor in The Nephron Segments of Rat Kidney: Regulation by High Salt Diet and Dehydration
Rong R¹, Mori N¹, Ito O¹, Muroya Y¹, Mori T¹, Ito S¹, Totsune K¹, Takahashi K¹, Kohzuuki M¹
¹Japan

PS2/TUE/175
Non-Dipper Status and Left Ventricular Hypertrophy (LVH) May Be the Risk Factors for the Development of Chronic Kidney Disease (CKD) in Non-Diabetic Hypertensive Patients
Park S¹, An HR¹, Ryu D-R¹
¹Korea, Republic of
PS2/TUE/176
Disparate Actions of the Angiotensin Type 1 Receptor Antagonist Candesartan and the Superoxide Dismutase Mimetic Tempol on Neural Control of the Kidney
Eppel GA1, Head GA1, Denton KM1, Evans RG1
1Australia

PS2/TUE/177
Effects of Exercise Training on Renal Oxidative Stress and Renal NO Production System in Spontaneously Hypertensive Rats
Cao PY1, Ito O1, Ito D1, Muroya Y1, Guo Q1, Rong R1, Mori T1, Ito S1, Kohzuki M1
1Japan

PS2/TUE/178
Effect of Uremia on Endothelial Function in the Rat Thoracic Aorta in Vitro
Nadeau M1, Lebel M1, Larivière R1
1Canada

PS2/TUE/179
Abnormal Function of the Vasopressin-Cyclic-AMP-Aquaporin2 Axis During Urine Concentrating And Diluting in Patients with Reduced Renal Function
Pedersen EB1, Thomsen IM1, Lauridsen TG1
1Denmark

PS2/TUE/180
Increased Methylglyoxal Formation with Changed Fructose-1,6-bisphosphatase Gene Expression in Kidneys of CSE-KO mice
Untereiner AA1, Wu L1
1Canada

PS2/TUE/181
Decreased Urinary Potassium Excretion in African Americans as Compared with Caucasian Americans Cannot Be Explained by Increased Gastrointestinal Excretion
Gmurczyk A1, Rosa R1, Dejesus E1, Breuer R1, Rosner KE1, Yu W1, Lerma E1, Suh A1, Sperling K1, Young J1
1United States

PS2/TUE/182
The Amount of Microalbuminuria Increases with Diminishing Blood Pressure Control
Etemadi BA1, Armstrong DW1, Brouillard D1, Nault M1, Matangi MF1
1Canada
PS2/TUE/183
Blockade of the Endothelin System and Renin-Angiotensin System in Partially Nephrectomized Ren-2 Rats
Vanekova I¹, Huskova Z¹, Vanourkova Z¹, Cervenka L¹
¹Czech Republic

PS2/TUE/184
Expression of (Pro)renin Receptor in the Renal Tubules of Dahl Salt-Sensitive Hypertensive Rats
Mori T, Japan

PS2/TUE/185
The Relationship between Antihypertensive Therapy and Renal Function in 152 Patients with Hypertension
Liu L¹, Zhao S¹, Zhu L¹, Yu W¹, Wang J¹
¹China

PS2/TUE/186
The Effect of Amlodipine and Valsartan in Hypertensive Renal Post-transplant Patients
Hong Y¹, Cai J¹, Huang Z¹
¹China

PS2/TUE/187
Significance of Strict Blood Pressure and Lipid Control on Kidney Protection in Very Early Stage Non-Diabetic CKD
Hasegawa C¹, Ohno S¹, Koizumi M¹, Kaneko K¹, Kato Y¹, Kikuchi Y¹, Seta K¹, Yahata K¹, Sugawara A¹
¹Japan

PS2/TUE/188
Achievement Status Toward Goal Blood Pressure Levels and Healthy Lifestyles Among Japanese Hypertensive Patients; Cross Sectional Survey Results From Fukushima Research Of Hypertension (FRESH)
Yokokawa H¹, Goto A¹, Sanada H¹, Watanabe T¹, Felder RA², Jose PA², Yasumura S¹
¹Japan, ²United States

PS2/TUE/189
Therapeutic Benefit of Internet-Based Lifestyle Counseling for Hypertension
Nolan RP¹, Shoemaker K¹, Hachinski V¹, Lynn H¹, Mikulis DJ¹, Wennberg RA¹, Moy Lum-Kwong M¹, Zbib A¹
¹Canada
PS2/TUE/190
Salt Intake in 3-Year-Old Japanese Children
Morinaga Y1, Tsuchihashi T1, Ohta Y1, Hasegawa E1, Matsumura K1, Iida M1
1Japan

PS2/TUE/191
Acute Effects of Alcohol on Plasma 20-Hete in Men
Barden AE1, Indrawan A1, Ledowski T1, Beilin LJ1, Puddey IB1, Croft KD1
1Australia

PS2/TUE/192
The Effects on Microalbuminuria by Okinawan Traditional Dietary Intervention in Healthy Volunteer
Nakamoto M1, Ohya Y1, Ttodoriki H1
1Japan

PS2/TUE/193
Risk of Body Weight Increase During Quitting Smoking
Srteck H1, Hlubik P1
1Czech Republic

PS2/TUE/194
Rimonabant Improves Cardiac Function 7 Days and 6 Weeks after Myocardial Infarction in the Rat
Slavic S1, Kemnitz UR1, Sommerfeld M1, Baulmanm J1, Unger T1, Kaschina E1
1Germany

PS2/TUE/195
Down-Regulation of Manganese Superoxide Dismutase by Angiotensin II in Cardiac Fibroblasts
Lijnen PJ1, Fagard RH1
1Belgium

PS2/TUE/196
Nitoso-Nifedipine is A New Class Drug to Protect Endothelial Function for Overcoming Organ Damage
Ishizawa K1, Imanishi M1, Horinouchi Y1, Fukuhara Y1, Izawa-Ishizawa Y1, Ikeda Y1, Kihira Y1, Tomita S1, Tsuchiya K1, Tamaki T1
1Japan

PS2/TUE/197
Nox Isoforms Are Differentially Regulated in Vascular Smooth Muscle Cells from WKY and SHR
Briones AM1, Tabet F1, Callera GE1, Montezano AC1, Yogi A1, He Y1, Quinn MT2, Salaices M3, Touyz RM1
1Canada, 2United States, 3Spain
PS2/TUE/198
From Antioxidants to the Roots of Oxidative Stress: Role of NADPH Oxidases in Vascular Function, Blood Pressure and Hypertension
Schmidt HHHW, Netherlands

PS2/TUE/199
Rosiglitazone Treatment Diminish the bmp7 to usag1 Relative Gene Expression Ratio in the Kidney of Hypercholesterolemic Mice
Rodriguez-Esparragon F1, Hernandez-Trujillo Y1, Buset-Rios N1, Hernandez-Velazquez E1, Estupiñan-Quintana L1, Rodriguez-Perez JC1
1Spain

PS2/TUE/200
Role of Aspirin Against Cardiac Hypertrophy and Oxidative Stress in Cardiomyopathic Hamsters
Wu R1, de Champlain J1, Lambert C1, Girouard H1
1Canada

PS2/TUE/201
Polymorphisms in CYP2C19, P2Y12 and Clopidogrel Resistance, and Cardiovascular Events: An Association Study
Chen H1, Xiao-ying Wu, Hong Sun, Lin Yu, Dan-dan Hong, Jian-jun Wang, Huan Wang
1China

PS2/TUE/202
Pharmacogenomic Response to Antihypertensive Medication: HOMED-BP-GENE Study
Katsuya T1, Asayama K1, Ohkubo T1, Sugimoto K1, Inoue R1, Metoki H1, Kamide K1, Obara T1, Ohishi M1, Morishita R1, Ogihara T1, Imai Y1, Rakugi H1
1Japan

PS2/TUE/203
Relationship between VKORC1-1639G>A and CYP2C9*,*3 Polymorphisms and Warfarin Maintenance Dosage in Chinese Patients of Atrial Fibrillation and Heart Valve Replacement
Wang X1, Yang Y1, Shen Y1, Liu X1, Wu L1, Zhu J1, Liu L1
1China

PS2/TUE/204
Prediction of Response to Angiotensin-Converting Enzyme Inhibition with Polymorphisms of Hypertensive Candidate Genes
Qian Y1, Zhang Y1, Gao P1, Zhu D1
1China
PS2/TUE/205
T174M Polymorphism Not M235T Polymorphism in the Angiotensinogen Gene Is Associated with the Antihypertensive Effect of Benazepril in Chinese Hypertensive Patients
Zhang Y¹, Huo Y¹, Xu X¹
¹China

PS2/TUE/206
Efficacy of Antihypertensive Treatment Depends on Individual Genotype Related Susceptibility: Five Genes vs Five Groups of Drugs
Sydorchuk L¹, Amosova K¹, Ursuliak J¹, Sydorchuk R¹, Sydorchuk I¹
¹Ukraine

PS2/TUE/207
Specific Endothelial Nitric Oxide Synthase (eNOS) Haplotypes Are Associated with Aura in Women with Migraine
Gonçalves FM¹, Martins-Oliveira A¹, Speciali JG¹, Izidoro-Toledo TC¹, Silva PS¹, Dach F¹, Tanus-Santos JE¹
¹Brazil

PS2/TUE/208
Influence of VEGF Polymorphisms on Therapy in Preeclampsia
Sandrim V¹, Palei AC¹, Izidoro-Toledo T¹, Cavalli R¹, Tanus-Santos JE¹
¹Brazil

PS2/TUE/209
Clinical Efficacy of Nebivolol in Uzbek Hypertensive Patients with Association Gln27Glu of β2-adrenoreceptor Gene
Khamidullaeva G, Uzbekistan

PS2/TUE/210
Specific Matrix Metalloproteinase 9 (MMP-9) Haplotype Affect the Circulating MMP-9 Levels in Women with Migraine
Martins-Oliveira A¹, Gonçalves FM¹, Speciali JG¹, Fontana V¹, Belo VA¹, Izidoro-Toledo T¹, Dach F¹, Tanus-Santos JE¹
¹Brazil

PS2/TUE/211
New Perspective for the Management of Preeclampsia: A Pharmacological Study of Endothelin-Dependent Vasoconstriction in Human Uterine Artery
Dechanet C¹, Fort A¹, Barbero-Camps E¹, Dechaud H¹, Richard S¹, Virsolvy A¹
¹France
PS2/TUE/212
Slower Ambulatory Pulse Rate Around 28 Weeks of Gestation Is An Independent Risk Factor of Pregnancy-Induced Hypertension
Japan

PS2/TUE/213
Association between Cytomegalovirus Infection and Preeclampsia
Xie F, Patrick D, Thomas E, Von Dadleszen P
Canada

PS2/TUE/214
White Coat Effect in Relation to Gestational Age in Pregnant Women: The BOSHI Study
Japan

PS2/TUE/215
Uric Acid Before Delivery Indicates Early Blood Pressure Reduction after Delivery in Pregnancy-Induced Hypertension
Japan

PS2/TUE/216
Quality of Life of Patients with Advanced Heart Failure Following Cardiac Resynchronization Therapy Depending on Hypertension History
Poland

PS2/TUE/217
Recent Life Events Are Positively Associated with Self-Reported Hypertension but Inversely Associated with Current Uncontrolled High Blood Pressure
Xu T, Li W, Chen T, Hu B, Liu B, Sun Y
China

PS2/TUE/218
Impact of Concomitant Diabetes and Chronic Kidney Disease on Preload-Induced Changes in Left Ventricular Diastolic Filling in Hypertensive Patients
Iwashima Y, Horio T, Suzuki Y, Takagi T, Kamide K, Ohishi M, Ogihara T, Kawano Y, Rakugi H
Japan
PS2/TUE/219
Relationship of Serum Uric Acid Concentration with Metabolic Syndrome and Its Components
Chen T1, Li W1, Wang Y1, Hu B1
1China

PS2/TUE/220
Cardiovascular Alterations in the Offspring Are Observed After Maternal Low Protein Diet but Not After Bilateral Ligation of the Uterine Arteries: Comparison of Two Models of Intrauterine Growth Restriction
Hartner A1, Nüsken K-D1, Menendez-Castro C1, Plank C1, Rascher W1, Hilgers KF1
1Germany

PS2/TUE/221
The Association between Serum Homocysteine and Inflammatory Cytokines in Patients with Essential Hypertension
Jotoku M1, Okura T1, Nagao T1, Enomoto D1, Irita J1, Miyoshi K-I1, Silva VD1, Higaki J1
1Japan

PS2/TUE/222
Circulating Endothelial Progenitor Cells in Patient with Essential Hypertension
Karelkina E1, Moiseeva O1, Irtuga O1, Moroshkin V1, Shlyakhto E1
1Russian Federation

PS2/TUE/223
Modifiable Risk Factors of Cardiovascular Diseases and Other Non-Communicable Diseases among Urban Dwellers – A Community Based Survey at Karachi, Pakistan
Kotak RM1, Mistry RF1, Siddiqui IA1
1Pakistan

PS2/TUE/224
Intrauterine Growth Restriction Induced by Maternal Low Protein Diet Leads to Fibrotic Changes in the Hearts of the Offspring
Menendez-Castro C1, Hilgers KF1, Fahlbusch F1, Plank C1, Rascher W1, Hartner A1
1Germany

PS2/TUE/225
Different Impacts of Atherogenic Dyslipidemia and Diabetes on the Incidence of Ischemic Cardiovascular Disease in Middle-aged Chinese with Normal and Elevated LDL Cholesterol Levels: 15-year Follow-up of the Chinese Multi-provincial Cohort Study
Liu J1, Zhao D1, Wang W1, Xie X1, Deng Y1, Wei Z1, Zheng J1, Wang M1, Sun J1, Wu Z1
1China
PS2/TUE/226
Young Hypertensive Patients: Cardiovascular Risk Profile
Martell N1, Galgo A1, Alvarez C1, OPENJOVEN Study group
1Spain

PS2/TUE/227
Cardiovascular Global Risk in A Cuban Population: “Martires de Corynthia”
Health Area Havana City, Cuba
de la Noval R1, Duenas A1, Armas N1
1Cuba

PS2/TUE/228
Marital Status and Risk for Acute Myocardial Infarction in Mainland China
INTER-HEART Study
Hu B1, Li W1, Cardiovascular Institute Fuwai Hospital
1China

PS2/TUE/229
Hypertension and Cardiovascular Risks in Brazilian Physicians and Nurses
from a Pre-Hospital Rescue Care Service
Cavagione LC1, Pierin AMG1
1Brazil

PS2/TUE/230
Prevalence of Alterations in the Lipid Profile and Their Relationship with
Cardiovascular Factors in Hypertensive and Dyslipemic Patients
Hermida Ameijeiras A1, Lopez Paz JE1, Pena Seijo M1, Calvo Gonzalez G1, Romero
Miguez ML1, Martinez Duran V1, Pascual Montes A1, Calvo Gomez C1
1Spain

PS2/TUE/231
Total Cardiovascular Risk among Women Aged ≥60 Years in a Havana Health
Area
Armas Rojas N1, Duenas Herrera A1, de la Noval Garcia R1, Nurys Bárbara Armas
Rojas MD, Alfredo F Dueñas Herrera MD, Reynaldo de la Noval García MD,
Yesenia de la Caridad Hernández Álvarez MD, Antonio Castillo Guzmán, MD,
1Cuba

PS2/TUE/232
Prevalence, Awareness and Control of Hyperlipidaemia and Diabetes in
Malaysia: Are there differences between men and women?
Maizatullifah M1, Mazapuspavina MY1, Nafiza MN1, Ng KK1, Nor-Ashikin MNK1,
Ramli AS1, Krishnapillai AD1, Than W1, Yusoff K1, CRisP Study Group
1Malaysia
**TUESDAY, SEPTEMBER 28**

**PS2/TUE/233**
Agreement across Three Cardiovascular Risk (CVR) Scoring Algorithms Employed on the Ethnic Malay Adults in Malaysia
Winn T1, Devi A1, Majid FA1, Dasiman R1, Razali R1, Ramli AS1, Nor- Ashikin MNK1, Ismail TST1, Nasir NM1, Ahmad R1, Nawawi HM1, Yusoff K1, Cardiovascular Risk Prevention (CRisP) Study Group. Faculty of Medicine, Universiti Teknologi MARA (UiTM), Shah Alam, Malaysia
1Malaysia

**PS2/TUE/234**
Cardiovascular Risk Factor Levels in Urban and Rural China—Preliminary Results of the Chinese Prospective Urban and Rural Epidemiology Study (PURE-China)
Li W1, Chen T1, Liu L1, Wang Y1, Hu B1, on behalf of PURE-China Study
1China

**PS2/TUE/235**
Complicated Pregnancy and Primary Prevention of Cardiovascular Disease
Firoz T1, Magee L1
1Canada

**PS2/TUE/236**
Comparison between Chronic Kidney Disease and Metabolic Syndrome Complicated with Hypertension for Cardiovascular Complications
Geshi E1, Irie S1, Katagiri T1
1Japan

**PS2/TUE/237**
Prevalence of Cardiovascular Risk Factors in a Nigerian Rural Community
Ejim EC1, Okafor C1, Emehel A1, Onyia U1, Onwubere B1
1Nigeria

**PS2/TUE/238**
Cardiovascular Risk and Biochemical Profile of Young Hypertensives in Malaysia; A Case Control Study
Aszrin A1, Azarisman MS1, Tariq AR1, Noriah MN1
1Malaysia

**PS2/TUE/239**
The Burden of Cardiovascular Risk Factors Among the Inhabitants of an Urban Congolese Community: Results of the VITARAA Study
M’Buyamba-Kabangu J-R1, Lemogoum D2, M’Buyamba-Kayamba J-R1, Bayauli PM1, Thijs L2, Richart T2, Fagard R2, Degaute JP2
1Congo, the Democratic Republic of the, 2Belgium
A Synergistic Relationship of Serum Albumin and Globulin with Coronary Heart Diseases
Wang M¹, Liu J¹, Wang W¹, Xie X¹, Wei Z¹, Guo M¹, Li Z¹, Ma C¹, Liu X¹, Lv Q¹, Sun J¹, Zhao D¹
¹China

Resulting Risk Assessment of Treated Hypertensive Patients
Kita T¹, Okita M¹, Kitamura K¹
¹Japan

Short Term Impacts of the Champlain “Give Your Head a Shake” Sodium Reduction Campaign on Knowledge, Attitudes and Behaviours
Papadakis S¹, Pipe A¹, Reid R¹, Moroz I¹, Blanchard C¹, Campbell N¹, Murkin E¹, Wielgosz A¹
¹Canada

Salt-sensitive Hypertension and Sympathetic Tone, Regulation of WNK4
Mu S¹, Shimosawa T¹, Ogura S¹, Wang H¹, Mori F¹, Uetake Y¹, Fujita T¹
¹Japan

Total Sodium Intake for Individuals with Diagnosis of High Blood Pressure, Cardiovascular Disease, or Diabetes in Japan, PRC, UK and US – Women and Men Ages 40-59: The INTERMAP Study
Anderson CAM¹, Chan Q², Appel L¹, Brown I², Miura K³, Okuda N³, Zhao L⁴, Elliott P², Stamler J¹, for the INTERMAP Research Group
¹United States, ²United Kingdom, ³Japan, ⁴China

The Effect of Salt Sensitivity and Potassium Sensitivity on Development of Blood Pressure in Normotensive Adult: A 5-years Cohort Followed up Study
Mu J¹, Liu F¹, Lian Q¹, Zheng S¹
¹China

Effects of Angiotensin-Converting Enzyme Inhibitor and Beta-Blocker on Obese Diabetic Hypertensive Heart and Aorta
Choi CU¹, Park CG¹, Na JO¹, Kim JW¹, Lim HE¹, Kim EJ¹, Rha S-W¹, Seo HS¹, Oh DJ¹
¹Korea, Republic of
PS2/TUE/247
Urinary 24h Sodium and Potassium Excretion in Subject with Non-Treated Hypertension. Comparison with Dietary Questionnaires
Szuba A1, Ilow R1, Zatonska K1, Wolyniec M1, Regulska-Ilow B1, Ferus M1, Polanska R1, Andrzejak R1, PURE Poland Study Group
1Poland

PS2/TUE/248
Does Exposure of Pregnant Rats to Cigarette Smoke Condensate Influence Blood Pressure and Podocytes Number in Their Offspring?
Adamczak M1, Zarzecki M1, Wystrychowski A1, Gross M-L2, Ritz E2, Wi cek A1
1Poland, 2Germany

PS2/TUE/249
Can N-Terminal Pro-B Type Natriuretic Peptide Predict Left Atrial Volume Index in Hypertensive Heart Disease?
Chung W-J1, Seo H-S1, Byun Y-S1, Ryu S-K1, Pyun W-B1, Rim S-J1
1Korea, Republic of

PS2/TUE/250
Impact of Warfarin Therapy on Vascular Calcification in Experimental Chronic Kidney Disease
McCabe K1, Holden R1, Adams M1
1Canada

PS2/TUE/251
Cardiac and Arterial Calcifications and All-cause Mortality in the Elderly: the PROTEGER study
Zhang Y1, Safar ME1, Iaria P1, Lieber A1, Peroz J1, Protogerou A2, Rajzbaum G1, Blacher J1
1France, 2Greece

PS2/TUE/252
Plasma Levels of Total Matrix GLA Protein Are Reduced in a Type 1 Diabetes Model: Potential Biomarker of Diabetes-Associated Vascular Calcification
Doyon M1, Côté N1, Mathieu P1, Moreau P1
1Canada

PS2/TUE/253
Brief Neonatal Hyperoxic Exposure Triggers Premature Vascular Aging: Role in Developmental Programming of Hypertension
Huyard F1, Germain N1, Cloutier F1, Yzydorczyk C1, Cloutier A1, Beauséjour CM1, Nuyt AM1
1Canada
PS2/TUE/254
Correlation between Left Ventricular Mass (LVM) and Ambulatory or Clinic Blood Pressure (BP) in Very Elderly Subjects
Carugo S1, Maisaidi M1, Pozzi M1, Esposito A1, Pernigotti A1, Caimi B1, Mancia G1
1Italy

PS2/TUE/255
Blood Pressure Response during Taking a Bath in the Japanese Elderly
Hano T1, Iwane N1, Kawabe T1
1Japan

PS2/TUE/256
Vascular Changes in Cellular Proliferation, Extracellular Matrix and Ros Production during Aging
Ratsep M1, Adams M1, Wang HD1
1Canada

PS2/TUE/257
Increased Dietary Protein Intake Lowers Blood Pressure in Overweight Subjects
Dopheide J1, Geleijnse JM1, Bakker SJL1, Brink EJ1, van Baak MA1
1Netherlands

PS2/TUE/258
Potassium Intakes and Population Blood Pressure
van Mierlo LAJ1, Greyling A1, Zock PL1, Kok FJ1, Geleijnse JM1
1Netherlands

PS2/TUE/259
Low Cardiovascular Risks in the Middle Aged Individuals Excreting Greater 24-hour Urinary Taurine in 41 WHO-CARDIAC Study Populations in the World
Taguchi T1, Mori M1, Mori H1, Yamori Y1
1Japan

PS2/TUE/260
Effect of a High-Calcium Energy-Reduced Diet on Inflammatory Stress and Endothelial Function in Brazilian Obese Subjects
Torres MRSG1, Rodrigues MLG1, Valença DCT1, Nogueira LP1, Nogueira Neto JF1, Oliveira S1, Sanjuliani AF1
1Brazil
TUESDAY, SEPTEMBER 28

PS2/TUE/261
Relation between Dietary Calcium Intake and Cardiovascular Risk Factors in Renal Transplant Patients
Gioseffi C1, Guimarães SSMS1, Souza E1, Barroso SG1, Sanjuliani AF1, Oliveira S1, Torres MRSG1
1Brazil

PS2/TUE/263
Dietary Calcium Intake and Its Relationship with Adiposity and Metabolic Profile in Hypertensive Patients
Ferreira TS1, Carvalho DC1, Torres MRSG1, Rodrigues MLG1, Valença DCT1, Oliveira S1, Sanjuliani AF1
1Brazil

PS2/TUE/264
Prospective Study of the Relationship between Plasma Norepinephrine and Prognosis in Hemodialysis Patients
Moriya H1, Mochida Y1, Ishioka K1, Maesato K1, Oka M1, Ikei R1, Hidaka S1, Ohtake T1, Kobayashi S1
1Japan

PS2/TUE/265
Prognostic Importance of Baseline and Serial Changes in Microalbuminuria in Patients with Resistant Hypertension
Salles G1, Pereira V1, Cardoso C1, Fiszman R1, Muxfeldt E1
1Brazil

PS2/TUE/266
Microalbuminuria and Cardiovascular Risk in Hypertension Patients. Annual Evolution of the Mauastur Study
Prieto Diaz MA1, Fernandez - Vega F1, Iglesias Garcia A1, Gorostidi M1, Sanchez E1, Gonzalez Lopez MB1, Bousquets L1, Alvarez R1, Suarez Garcia S1, Vidal C1
1Spain

PS2/TUE/267
Effects of Multiple Factorial Intervention on Ambulatory BP Profile and Renal Function in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy
Kanaoka T1, Tamura K1, Moriya T1, Tanaka K1, Konno Y1, Kondoh S1, Toyoda M1, Ohsawa M1, Dejima T1, Maeda A1, Wakuhi H1, Yanagi M1, Mitsuhashi H1, Ozawa M1, Okano Y1, Ogawa N1, Yamakawa T1, Suzuki D1, Umemura S1
1Japan
Regional Difference in the Inhibition of Increasing Rate of ESRD Incidence within Japan
Wakamatsu-Yamanaka T¹, Fukuda M¹, Mizuno M¹, Tomonari T¹, Miura T¹, Ichikawa T¹, Miyagi S¹, Shirasawa Y¹, Ito A¹, Yoshida A¹, Kimura G¹
¹Japan

Insulin Resistance is a Risk Factor for the Progression of Chronic Kidney Disease
Yoshizawa T¹, Kobayashi H¹, Hara Y¹, Sugano N¹, Endo S¹, Suetsugu Y¹, Takane K¹, Takahashi Y¹, Tokudome G¹, Kuriyama S¹, Hosoya T¹
¹Japan

Factors Relating to Chronic Kidney Disease in Health Check-Up Participants
Ohno E¹, Ishimitsu T¹, Honda T¹, Numbe A¹, Ohrui M¹, Matsuoka H¹
¹Japan

Study on the Prediction of Albuminuria to All-Cause Mortality and Cardiovascular Mortality in Middle-To-Old-Aged Chinese Population
Wang Z¹, Chen Z¹, Wang F¹, Zheng R¹, Zhu M¹, Wang S¹, Wang Y¹, Lu J¹, Wang H¹, Liu L¹
¹China

Total Body Potassium Estimated (TBK) by Bioelectrical Impedance Analysis (BIA) in Chronic Kidney Disease
Cigarran S¹, Barril G¹, Coronel F¹, Aguilera A¹, Pousa M¹, Castro MJ¹
¹Spain

Effect of Chronic Salt Loading on the Remodeling of Thoracic Aorta in Spontaneously Hypertensive Rats
Liu F¹, Mu J¹
¹China

Controlled-Release Nifedipine and Candesartan Combination Therapy Reduced Urinary Albumin Excretion without Decreasing Glomerular Filtration Rate: The NICE Combi Substudy
Nakagawa N¹, Fujino T¹, Sato N¹, Kikuchi K¹, Hasebe N¹
¹Japan
PS2/TUE/275
Proteomic Analysis of Renal Biopsy: The Search for Potential Biomarkers of Acute Rejection
Sakata MM1, Perez JD1, Spinelli GA1, Felipe CR1, Silva Júnior HT1, Medina Pestana JO1, Costa H1, Martins Ferreira Souza GH1, Casarini DE1
1Brazil

PS2/TUE/276
The Influence of Dose, Plasma Concentration of Tacrolimus on Blood Pressure in Renal Post-Transplant Patients
Hong Y1, Xi L1, Cheng K1, Zhu L-J1, Yang G1, Huang Z1, Cai J1
1China

PS2/TUE/277
Consequence of Masked Hypertension in Treated Hypertensive Outpatients: One-Year Follow-Up Study
Ohta Y1, Tsuchihashi T1, Hasegawa E1
1Japan

PS2/TUE/278
Relationship between eNOS Gene G894T Polymorphism and the Blood Pressure Response to Nifedipine GITS in A Chinese Population with Essential Hypertension
Sun X1, Hou X1, Liu S1, Zhang C1, Li L1, Jing Y1, Shi Y1
1China

PS2/TUE/279
LV Diastolic Function Evaluated by Tissue Doppler in Masked Hypertension
Komori T1, Kabutoya T1, Eguchi K1, Ishikawa J1, Hoshide S1, Shimada K1, Kario K1
1Japan

PS2/TUE/280
Comparison Semi-Automatic Method Based On Snake Model Vs Linear Model to Study of Hypertensive Retinopathy
Pena Seijo M1, Pose Reino A1, Lopez Paz JE1, Hermida Ameijeiras A1, Calvo Gomez C1, Gonzalez Penedo M1, Diaz Peromingo JA1, Suarez Tembra M1, Monte Secades R1, Diaz Diaz JL1
1Spain

PS2/TUE/281
Relationship between Renal Function and Left Ventricular Diastolic Function in Patients with Essential Hypertension
Yang Y1, Yan W1, Zhu DL1, Gao PJ1
1China
**PS2/TUE/282**
Clinical Values of Dual-Source CT Coronary Angiography for Elderly Patients
Xiafang Z, China

**PS2/TUE/283**
A study on Hypertensive Patients Versus Non-hypertensive Patients Presented with Acute ST Segment Elevation Myocardial Infarction and Underwent Primary Percutaneous Coronary Intervention: Single Centre Study
Tan VH¹, Tan CH¹, Chow J¹, Leong G¹, Tong KL¹, Lingamaanicker J¹, Tan KS¹, Lim V¹, Ong SH¹, Goh YS¹, Goh PP¹, Yeo C¹
¹Singapore

**PS2/TUE/284**
Cardio Renal Interaction in Blood Pressure Control for Prevention of Paroxysmal Atrial Fibrillation
Tanabe Y¹, Kawamura Y¹, Nakagawa N¹, Sato N¹, Kikuchi K¹, Hasebe N¹
¹Japan

**PS2/TUE/285**
A Unifying Theory of the Common Etiologies of Dyslipidemia, Oxidative Stress, and Autoimmunity as Illustrated by Preeclampsia
Hart NR, United States

**PS2/TUE/286**
Vitamin D and Hypertension in Pregnancy
Ringrose JS¹, PausJenssen AM¹, Wilson M¹, Blanco L¹, Ward H¹, Wilson TW¹
¹Canada

**PS2/TUE/287**
Serum Aldosterone Quantitation by Tandem Mass Spectrometry on the ABSciex API 5000 LC-MS/MS System
Dubland JA¹, Wang A², Liu H-F², Holmes DT¹
¹Canada, ²United States

**PS2/TUE/288**
Oxidative Stress in Soleus and Edl Muscles of Doca-Salt Hypertensive Rats
Hernández N¹, DeSanctis JB¹, Sosa A¹, Pérez MR¹
¹Venezuela

**PS2/TUE/289**
Decrease of Cardiovascular Risk Due to Therapy of Fixed Combination of Valsartan and Amlodipine in Patients with Severe Hypertension Accompanied by Metabolic Syndrome
Tarlovskaya EI¹, Maksimchuk NS¹
¹Russian Federation
WEDNESDAY,
SEPTEMBER 29
### Program by Day

<table>
<thead>
<tr>
<th>Time</th>
<th>Ballroom A, West Level 1</th>
<th>Ballroom B, West Level 1</th>
<th>Ballroom C, West Level 1</th>
<th>Rooms 211-214, West Level 2</th>
<th>Rooms 109-110, West Level 1</th>
<th>Room 220-222, West Level 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>Challenges in Achieving Population Blood Pressure Control 08:15-9:45</td>
<td>New Approaches to the Management of Refractory Hypertension 08:15-9:45</td>
<td>Unravelling the Genetics of Hypertension and Vascular Disease 08:15-9:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>GPCR Signalling: Dysregulation in Hypertension – A Tribute to Jacques de Champlain 10:30-12:00</td>
<td>Vascular Disease in Women 10:30-12:00</td>
<td>Recent Advances in Genomics and Epigenetics in the Understanding of Hypertension and its Relationship to Other Risk Factors 10:30-12:00</td>
<td>Vascular Aging 10:30-12:00</td>
<td>Prevention of Cardiovascular Disease with Worksite/Community Based Programs 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Global Cardiovascular Risk Reduction Statement 13:15-14:15</td>
<td>ISH General Meeting 13:00-14:00</td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>ISH Awards Ceremony, Presidential Lecture and Franz Volhard Lecture 16:30-18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

See the Optional Tours & Social Events section for the tours and social events schedule.
<table>
<thead>
<tr>
<th>Time</th>
<th>Room 203, West Level 2</th>
<th>Room 204, West Level 2</th>
<th>Room 205, West Level 2</th>
<th>Room 206, West Level 2</th>
<th>Room 207, West Level 2</th>
<th>Exhibition Hall C West Exhibition Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00-08:00</td>
<td>How to Session</td>
<td>How to Session</td>
<td>How to Session</td>
<td>How to Session</td>
<td>How to Session</td>
<td></td>
</tr>
<tr>
<td>09:45-10:30</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>12:00-14:15</td>
<td>Poster Session C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15-15:45</td>
<td>Special Workshop</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Special Workshop – PAHO Global Salt Reduction Initiative
14:15-15:45

Break
15:45-16:30
WEDNESDAY, SEPTEMBER 29

07:00-08:00  **Clinical Science**
How to Session

**What Can We Learn From 24-Hour Blood Pressure Monitoring?**
Room 203, L2

Clinical Lessons from Ambulatory Blood Pressure Measurement
Bulpitt C, United Kingdom

07:00-08:00  **Clinical Science**
How to Session

**Practical Tips for the Implementation of the DASH Diet**
Room 204, L2

Implementation of the Dash Diet
Appel LJ, United States

07:00-08:00  **Clinical Science**
How to Session

**Optimal Management for Type 2 Diabetes Mellitus**
Room 205, L2

Optimal Management for Type 2 Diabetes Mellitus
Leiter L, Canada

07:00-08:00  **Basic Science**
How to Session

How do you Assess Oxidant Stress?
Touyz R, Canada

07:00-08:00  **Clinical Science**
How to Session

**Practical Genomics: A Primer for Clinicians**
Room 207, L2

Hegele R, Canada
08:15-09:45 **Public Health – Population Science Symposium**
**Challenges in Achieving Population Blood Pressure Control**  
Ballroom A, L1

**Chair:** Alderman M, United States

08:15 **Addressing Challenges from the Population Perspective**  
Labarthe D, United States

08:45 **Enlisting Diverse Interest Groups to Effects Change: Lessons from an Environmental Health Experience**  
Vanderwal J, Canada

09:15 **Informing, Motivating and Improving Communication with Healthcare Professionals**  
Campbell N, Canada

08:15-09:45 **Clinical Science Symposium**
**New Approaches to the Management of Refractory Hypertension**  
Ballroom B, L1

**Chair:** Arakawa K, Japan

08:15 **Endothelin Receptor Antagonists in the Treatment of Resistant Hypertension**  
Lindholm L, Sweden

08:45 **Potential of Implantable Carotid Sinus Stimulator for Drug-Resistant Hypertension**  
Bakris G, United States

09:15 **Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Current State of Progress**  
Esler M, Australia
08:15-09:45 Translational – Clinical Science Symposium
Unravelling the Genetics of Hypertension and Vascular Disease
Ballroom C, L1
Sponsored by the University of Ottawa Heart Institute
Chair: Roberts R, Canada

08:15 Genome Wide Association Studies
Roberts R, Canada

08:45 Genetics of Hypertension and the Risk of Coronary Heart Disease
TBA

09:15 Identification of Candidate Genes Operative in People With Salt-Induced Hypertension
Leenen F, Canada

08:15-09:45 Basic – Translational Science Symposium
Hypertension and the Kidney
Room 211-214, L2
Sponsored by the International Society of Nephrology

08:15 The Role of Macrophages and VEGF C in Hypertension
Titze J, Germany

08:45 The Role of T Cells Infiltrating in the Kidney in the Pathogenesis of Hypertension
Rodriguez-Iturbe B, Venezuela

09:15 Salt, Obesity and Hypertension
Fujita T, Japan
**Clinical – Population Science**

**Oral Presentations**

**Cardiovascular Risk and its Management**

Room 109-110, L1

**Chair:** Abdulrahman Al Mahmeed W, United Arab Emirates

**08:15**  
**Improvement in Hypertension Control after a 2-Year Participation in a Web-Based Program on High BP Management**  
Gorostidi M1, de la Sierra A1, Segura J1, Banegas JR1, Llisterri JL1, Alonso J1, de la Cruz JJ1, Aranda P1, Roca-Cusachs A1, Ruilope LM1, Spanish Society of Hypertension ABPM Registry  
1Spain

**08:25**  
**Target Organ Damage in Adolescent White Coat Hypertension**  
Pall D1, Katona EM1, Juhasz M1, Molnar C1, Paragh G1, Fulesdi B1  
1Hungary

**08:35**  
**Treatment of Hypertension in Patients 85 Years of Age or Older**  
Saito I1, Suzuki H1, Kageyama S1, Saruta T1  
1Japan

**08:45**  
**J-Shaped Relationship between Blood Pressure and CVD Events in FEVER Study: Aid of MEPPA Approach**  
Zhang X1, Zhang Y1, Liu L1, Zanchetti A2  
1China, 2Italy

**08:55**  
**Hypertension and Hair Cuts In Baltimore City: Lessons Learned From the Hair, Heart and Health Barbershop Hypertension Screening Initiative**  
Werts N1, Charleston J1, Saunders E1  
1United States

**09:05**  
**Cardiovascular Risk in Hypertensive Patients without Previous Cardiovascular Events (The SINERGIA study)**  
de la Sierra A1, González-Segura D1, Viladrich M1, on behalf of the SINERGIA study investigators.  
1Spain

**09:15**  
**Assessment of Association of Increased Heart Rate to Cardiovascular (CV) Events among Healthy Subjects: An Electronic Medical Record (EMR) Data Analysis**  
Kim J1, Asche CV1, Kulkarni AS1, Chakravarti P1, Andersson K-E1  
1United States
Disorders of Orthostatic Blood Pressure Response are Associated with Cardiovascular Disease and Target Organ Damage in Hypertensive Patients
Fan XH¹, Wang YB¹, Sun K¹, Zhang WL¹, Wang H¹, Wu HY¹, Zhou XL¹, Hui RT¹
¹China

Systematic Cerebrovascular Risk Evaluation for Canada: SCORE Canada, a CV Risk Prediction Tool Calibrated for the Canadian Population
Tremblay JLG¹, Gagnon R¹, Drouin D¹, Fitzgerald AP²
¹Canada, ²Ireland

Basic Science Symposium

GPCR Signalling: Dysregulation in Hypertension – A Tribute to Jacques de Champlain

Chair: Moreau P, Canada

Novel G protein Coupled Receptor Signaling Paradigms: Opportunities for New Therapeutic Targets
Caron M, United States

Ligand-Based Signalling at β - Adrenergic Receptors; Potential Implications for the Treatment of Hypertension and Heart Failure
Bouvier M, Canada

Altered GPCR Signalling in Hypertension
Gros R, Canada
**Clinical Science**

**State of the Art – Oral Presentations**

**Vascular Disease in Women**

Ballroom B, L1

**Chairs:** Burgess E, Canada and Townsend R, United States

**Learning Objectives:**

- Attendees should appreciate the paradoxical nature of the observations that estrogens have vasoprotective effects in young women and young animal models but appear to be proinflammatory and precipitate vascular disease in older subjects.
- Attendees should understand the fundamental mechanisms by which estrogens inhibit inflammatory responses in injured blood vessels.
- Attendees should have an appreciation of the effects of aging on the vasculature and on the pathogenesis of vascular disease in women.

**10:30**

Pathogenesis of Vascular Disease in Women

Oparil S, United States

**11:00**

Arterial Stiffening Relates to Arterial Calcification but Not to Non-Calciﬁed Atheroma in Women: A Twin Study

Cecelja M1, Jiang BY1, Bevan L1, Frost ML1, Spector TD1, Chowiencyzk P1

1United Kingdom

**11:10**

Large Artery Structure and Function in Women with and Without a History of Pregnancy Induced Hypertension

Brown CM1, Duffy C1, Malone FD1, Walshe JJ1, Stanton AV1

1Ireland

**11:20**

The Influence of Antihypertensive Combination Therapy on the Sexual Function in Young and Middle-Aged Women with Hypertension

Yu J1, Xu D1, Liu P1, Guo X1, Zhao F1, Hu H1, Li X1, Chang P1, Chen X1, Shen X1, Zhang Y1, Bai F1

1China

**11:30**

Ambulatory Blood Pressure, Gonadotropines and Estradiol during Hot Flashes Signiﬁes Hormone Replacement Therapy

Stojanovic MM1, Ivovic M1, Tancic M1, Marina L1, Matic M1, Subotic B1, Marinkovic M1, Lovic D1, Stojanov V1, Vujovic S1

1Serbia
Aerobic Training Abolishes Ambulatory Blood Pressure Increase Induced By Estrogen Therapy: A Randomized, Placebo-Controlled Trial
Cardoso Jr. CG, Labes E, Tinucci T, Abrahão SB, Fonseca AM, Mion Jr. D, Forjaz CLM
Brazil

Risk of Target Organ Involvement in Premenopausal Women in the Early Stage of Hypertension
Italy

Basic – Translational Science Symposium
Recent Advances in Genomics and Epigenetics in the Understanding of Hypertension and its Relationship to Other Risk Factors
Ballroom C, L1

Impact of Genetic and Epigenetic Factors on the Development of Hypertension and Diabetes Mellitus and their Complications
Hamet P, Canada

Gene Polymorphisms and the Systemic Multiple Candidate Gene Approach to Identify Genes for Essential Hypertension
Ogihara T, Japan

Genes Regulating the Development and Prevention of Hypertension
Harrap S, Australia
10:30-12:00 Translational – Clinical Science
State of the Art – Oral Presentations
Vascular Aging

Chair: Pickering G, Canada

Learning Objectives:
• How can early vascular aging be defined?
• The mediating role of arterial stiffness
• Prevention of early vascular aging based on antihypertensive treatment

10:30 The Assessment of Early Vascular Aging
Kotsis V, Greece

11:00 Accelerated Vascular Aging and Progression of Aortic Stiffness in Hemodialyse Patients
Utescu MS, Couture V, LeBoeuf A, Marquis K, Agharazii M
1Canada

11:10 High-Intensity Resistance Training Does Not Change Cardiovascular Hemodynamics and Autonomic Modulation in Elderly
Kanegusuku H, Queiroz ACC, Chehuen MR, Costa LAR, Wallerstein LF, Mello MT, Ugrinowitsch C, Forjaz CLdM
1Brazil

11:20 Increased Calpain-1 within VSMC Modulates Age-Associated Procalcification
1United States

11:30 Age Reprograms Arterial microRNA Expression Profiling In Nonhuman Primates with or without High Cholesterol Diet
1United States, 2Italy

11:40 Silencing of PKG-1 Gene Mimics Effect of Aging and Sensitizes Vascular Smooth Muscle Cells to Pro-Fibrotic Effect of Marinobufagenin
Fedorova OV, Kashkin VA, Zakharova IO, Shapiro JI, Lakatta EG, Bagrov AY
1United States
Olmesartan Ameliorates Development of Vascular Senescence as well as Left Ventricular Dysfunction of Aged Rat
Morita T, Tatebe J, Kiuchi S, Masai N, Yoshino G, Yamasaki J
1Japan

10:30-12:00 Clinical – Population Science
Symposium
Prevention of Cardiovascular Disease with Worksite/Community Based Programs
Room 109-110, L1

Chair: Fodor G, Canada

10:30 Cardiovascular Risk Reduction at the Workplace: The Israeli Experience
Viskoper JR, Israel

11:00 The Chinese Experience
Zhang XH, China

11:30 Eastern European Experience
Fodor G, Canada

13:15-14:15 Global Cardiovascular Risk Reduction Statement
Room 109-110, L1

14:15-15:45 Translational Symposium
CHEP / Hypertension Canada Symposium and Presidential Lecture
Ballroom A, L1

Chair: Rabkin SW, Canada

14:15 Introduction of Hypertension Canada Presidential Lecturer
Adams M, Canada

14:20 Renal AT1 Angiotensin Receptors in Hypertension: Normal Physiology Gone Wrong
Coffman T, United States
2011 Draft CHEP Recommendations

14:45 Opening Remarks
Tobe S, Canada

14:50 Outcomes Assessments
McAlister F¹, Baclic O¹
¹Canada

15:00 Implementing Hypertension Evidence in Practice
Tobe S, Canada

15:15 New Evidence and the 2011 Draft CHEP Recommendations
Poirier L¹, Khan N¹
¹Canada

15:40 Q & A – Closing Comments
Rabkin SW, Canada

13:00-14:00 ISH General Meeting
Room 220-222, L2
An invitation is extended to all ISH members.

14:15-15:45 Clinical Science
State of the Art – Oral Presentations
Ambulatory Blood Pressure Monitoring
Ballroom B, L1

Chair: Chockalingam A, Canada and Lacourciere Y, Canada

14:15 Ideal Time Interval to Repeat Ambulatory Blood Pressure Monitoring in patients with White-Coat Resistant Hypertension
Muxfeldt ES¹, Nascimento AC¹, Dias VB¹, de Souza F¹, Fiszman R¹, Salles GF¹
¹Brazil

14:25 Inadequate Control of Ambulatory Blood Pressure Causes Progression of Chronic Kidney Disease in Hypertension
Sakima A¹, Nakada S¹, Ohya Y¹
¹Japan
14:35  Measuring Cardiovascular Risk in Normotensive People: Impact of a Non Dipper Pattern of Blood Pressure
Aranda P¹, de la Cruz JJ¹, Gorostidi M¹, de la Sierra A¹, Segura J¹, Listerri JL¹, Alonso J¹, Banegas JR¹, Roca-Cusachs A¹, Ruilope LM¹, Spanish Society of Hypertension ABPM Registry
¹Spain

14:45  Can We Increase the Reproducibility to Classification of Hypertensive Patients According to Circadian Pattern by Pushing a Simple Button?
Calvo Gomez C¹, Lopez Paz JE¹, Hermida Ameijeiras A¹, Pena Seijo M¹, Calvo Gonzalez G¹, Romero Miguez ML¹, Pascual Montes A¹, Martinez Duran V¹
¹Spain

14:55  The AAA-Registry: Discrepancies of Blood Pressure Control between Office and 24 Hour Ambulatory Readings in 6000 Treated Hypertensive Patients
Schmieder RE¹, Dechend R¹, Senges J¹, Klebs S¹, Zeymer U¹
¹Germany

15:05  Association between Ambulatory Arterial Stiffness Index and Pulse Wave Velocity in Prehypertensive Patients
Lu F¹, Liu Z¹, Zhao Y¹, Wang S¹, Sun S¹
¹China

15:15  The Utility of 24h Blood Pressure Monitoring as a Marker of Target Organ Damage
Kotsis V, Greece

14:15-15:45 Translational – Clinical Science Symposium
Hypertension and Pregnancy
Room 211-214, L2

Chair: von Dadelszen P, Canada

14:15  The Pathophysiology of Hypertension in Pregnancy
Karumanchi A, United States

14:45  Identifying the Risk Factors and Biomarkers for Hypertension in Pregnancy and Adverse Outcomes
von Dadelszen P, Canada
Controversies in the Management of Hypertension in Pregnancy
TBA

14:15-15:45 Basic Science
State of the Art – Oral Presentations
Cardiovascular Fibrosis and Hypertension
Room 109-110, L1

Learning Objectives:
- To update information regarding cardiac fibrosis and the ability of various receptors, in particular G-protein-coupled receptors (GPCR), to regulate such fibrosis
- To present new ideas and data related to mechanisms by which GPCRs that increase the second messenger cyclic AMP are anti-fibrotic in the heart and other tissues
- To propose that previous efforts likely have not assessed the most highly expressed GPCRs on cardiac fibroblasts but that these receptors may provide novel therapeutic targets for cardiovascular fibrosis

Chair: Funder JW, Australia and Husain M, Canada

14:15 Hepatocyte Growth Factor Reduces Cardiac Fibrosis Through Inhibiting Endothelial-Mesenchymal Transition and Proliferation of Myofibroblast
Okayama K1, Taniyama Y1, Dosaka N1, Azuma J1, Iekushi K1, Sanada F1, Kusunoki H1, Rakugi H1, Morishita R1
1Japan

14:25 Angiotensin AT2 Receptor Stimulation - Novel Therapeutic Approach for the Treatment of Chronic Kidney Disease (CKD) and Related Cardiac Fibrosis
Steckelings UM1, Krämer S1, Althoff N1, Loof T1, Neumeyer HH1, Peters H1, Unger T1
1Germany

14:35 Melatonin Reduces Myocardial Remodeling in Spontaneous and L-NAME-induced Hypertension in Rats: The Role of Oxidative Load and NO
Paulis L1,2, Pechanova O2, Celic P2, Gardlik R2, Barta A2, Bednarova K2, Mullerova M2, Pelouch V3, Adamcova M3, Kunes J3, Zicha J3, Simko F2
1Germany, 2Slovakia, 3Czech Republic
14:45 ATP6AP2/(Pro)Renin Receptor Is Essential for Assembly of the V-ATPase In Murine Cardiomyocytes
Kinouchi K1, Ichihara A1, Sano M1, Sun-Wada G-H1, Wada Y1, Oshima Y1, Sakoda M1, Kurauchi-Mito A1, Bokuda K1, Narita T1, Tamai Y1, Sato H1, Fukuda K1, Itoh H1
1Japan

14:55 DOCA-salt Hypertensive OLETF Rat; Effects of High BP on Obese Diabetic Heart and Aorta
Park CG1, Choi CW1, Na JO1, Rha SW1, Lim HE1, Kim EJ1, Oh DJ1, Seo HS1
1Korea, Republic of

15:05 Regression of LVH by Moxonidine Involves Selective Apoptotic Effects on Cardiac Fibroblasts
Aceros H1, Farah G1, Noiseux N1, Mukaddam-Daher S1
1Canada

15:15 Signal Transduction Mechanisms Mediating Cardiovascular Fibrosis
Insel P, United States

14:15-15:45 Finalists for the Austin Doyle Award
Room 220 to 222, L2

Chair: Harrap S, Australia

14:15 Morning Hypertension in Treated Hypertensives: The Baseline Characteristics and Clinical Implications
Lee J-H1, Kim D-W1, Bae J-W1, Cho M-C1, Park J-B1, Park C-G1, Youn H-J1, Choi D-J1, Ahn Y-K1, Shin J-H1, Rim S-J1, Bae J-H1, Korean Hypertension Research Network
1Korea, Republic of

14:33 Identification of Potential Biomarkers for Hypertension in Pregnancy through Epigenetic Profiling of Human Placentas
Yuen RKC1, Peñaherrera MS1, von Dadelszen P1, McFadden DE1, Robinson WP1
1Canada
Large Change in the Opinion on Antihypertensive Drug Treatment among General Practitioners in Sweden between 2002 and 2009
1Sweden

Prevalence of Adult Hypertension in the Greater Accra Region of Ghana and Related Health Behaviour
Bosu WK, Wellington E, Odoi AA, Wadieh B
1Ghana

Prehypertension and Risk of Stroke Subtypes: 11 Years of Follow-up in Korean Men and Women
Ahn SV, Kim HC, Suh I
1Korea, Republic of

Public Health – Population Science Workshop
Special Workshop – PAHO Global Salt Reduction Initiative
Room 203, L2

Learning objectives:
• To learn about different approaches to reduce dietary salt around the globe
• To learn about the strategy and tactics being advocated by the Pan American Health Organization Expert Group
• To facilitate attendees contributing to the global effort to reduce dietary salt

Global Salt Reduction Initiatives
Campbell N, MacGregor G, Neal B
1Canada, 2United Kingdom, 3Australia
ISH Awards Ceremony, Presidential Lecture and Franz Volhard Lecture

Ballroom A, L1

Chair: Professor AM Heagerty
Co-Chair: Professor S Harrap

Awards: The ISH, with the collaboration and generous support of corporate sponsors, is pleased to announce a variety awards and prizes. Winners will be announced.

ISH Presidential Lecture: The ISH Presidential Lecture will be given by Professor Gary Owens, Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia, United States.

Presidential Lecture: Epigenetic Control of Smooth Muscle Cell Differentiation and Phenotypic Plasticity in Cardiovascular Disease

Franz Volhard Lecture: Salt – A Pathophysiological Pursuit
WEDNESDAY, SEPTEMBER 29

POSTER SESSION

12:00-14:15  Poster Session C  Exhibition Hall C, West Exhibition Level

The following highest scored posters will be discussed during this session between 12:00 to 13:00: PS3/WED/1 through to PS3/WED/63 (all posters identified in green)

Chairs: Nyut AM, Canada and Unger T, United States

PS3/WED/1
Anti-Atherosclerotic Effects of the Vitamin D analog Paricalcitol
Ferder L1, Husain K1, Vazquez F1, Rivera-Suarez N1, Serrano G1, Suarez EB1
1Puerto Rico

PS3/WED/2
Up4A induce Monocyte Chemoattractant Protein-1 Production in VSMC in a NADPH Oxidase-Dependent Manner
Schuchardt M1, Tölle M1, Huang T1, van der Giet M1
1Germany

PS3/WED/4
Activation of TRPV1 Attenuates Atherosclerosis in Mice on High-Fat Diet
Ma L1, Luo Z1, Ma S1, Yang D1, Liu D1, Zhu Z1
1China

PS3/WED/5
Effect of Combination Therapy with Bone-Marrow Mononuclear Cells Implantation and Sarpogrelate Hydrochloride on Angiogenesis and Cardiac Performance in Myocardial Ischemia
Koguchi W1, Kobayashi N1, Takeshima H1, Fukushima H1, Ishikawa M1, Ohno T1, Ishimitsu T1
1Japan

PS3/WED/6
Carotid Artery Stenosis Reversion by Mononuclear cell Therapy in ApoE-Knockout Mice
Tonini CL1, Lima LCF1, Porto ML1, Pereira TMC1, Campagnaro BP1, Vasquez EC1, Meyrelles SS1
1Brazil

PS3/WED/7
Angiotensin II Type 1a Receptor Deficiency Attenuates Atherosclerotic Plaque Rupture
Aono J1, Suzuki J1, Ogimoto A1, Ohtsuka T1, Iwai M1, Horiuchi M1, Okayama H1, Higaki J1
1Japan
PS3/WED/8
Increased Arterial Pressure Response to Dynamic Exercise in Normotensive Subjects with Metabolic Syndrome
Yabu M1, Miyai N1, Arita M1, Ito K1, Uchikawa Y1, Shiozaki M1, Utsumi M1, Miyashita K1
1Japan

PS3/WED/9
Class Effects of BP-Lowering Drugs on Central Blood Pressure Measurement
Uetani E1, Tabara Y1, Igase M1, Kido T1, Ochi N1, Kohara K1, Miki T1
1Japan

PS3/WED/10
Measuring Blood Pressure in the Office Setting: Manual and Automated Office Measurements in Relation to Awake Ambulatory Blood Pressure Monitoring
Godwin M1, Birtwhistle R1, Delva D1, Lam M1, Casson I1, MacDonald S1, Seguin R2
1Canada, 2United States

PS3/WED/11
Plasticity in Central Oxytocinergic (OTergic) System: Different Effects of Hypertension and Exercise Training (T)
Zampieri TT1, Ruggeri A1, Silva Jr. SD1, Michelini LC1
1Brazil

PS3/WED/13
The Influence of Orally Administered Simvastatin on the Hypertensive Response to Centrally Administered Angiotensin II and Vasopressin
Ufnal M1, Sikora M1, Zera T1, Szczepanska-Sadowska E1
1Poland

PS3/WED/14
Reactive Oxygen Species in Rostral Ventrolateral Medulla Contribute to Sympathoexcitation Induced by Stimulation of Paraventricular Nucleus of the Hypothalamus in Spontaneously Hypertensive Rats
Nishihara M1, Hirooka Y1, Matsukawa R1, Ito K1, Kishi T1, Sunagawa K1
1Japan

PS3/WED/15
Increased Arterial Stiffness is Associated with Asymptomatic Intracranial Large Arterial Stenosis and Calcification in Chinese Hypertensive Patients
Zhang J1, Li Y1, Wang Y1, Niu W1, Zhang Y1, Gao P1, Zhang L1, Lin H1, Chen K1, Zhu D1
1China
PS3/WED/16
Neuregulin-1/erBB Signaling in the Rostral Ventrolateral Medulla of Brainstem is Involved in Neural Blood Pressure Control via Regulating Major Neurotransmitters
Matsukawa R1, Hirooka Y1, Ito K1, Sunagawa K1
1Japan

PS3/WED/17
Iron Deficiency during Pregnancy Predisposes Rat Offspring to Obesity and Hypertension
Bourque SL1, Komolova M1, Davidge ST1, Nakatsu K1, Adams MA1
1Canada

PS3/WED/18
Protection from Development of Obesity in High Fat Diet Fed Rats is Associated with Preservation of the Anticontractile Function of Perivascular Adipose Tissue
Park BH1, Aghamohammadzadeh R1, Greenstein AS1, Porter EL1, Edwards G1, Weston AH1, Heagerty AM1
1United Kingdom

PS3/WED/20
Dietary Acid Load and Risk of Hypertension: The Rotterdam Study
Engberink MF1, Bakker SJL1, Altorf-van der Kuil W1, Brink EJ1, van Rooij FJA1, Hofman A1, Witteman JCM1, Geleijnse JM1
1Netherlands

PS3/WED/21
Two Contrasting Canadian Populations Different in Hypertension and Cardiovascular Risks
Mori M1, Chockalingam A2, Hamet P2, George F2, Yamori Y1, CARDIAC Study group
1Japan, 2Canada

PS3/WED/22
Do Urinary Metabolic Differences Play A Role in the Reported Lower Coronary Heart Disease Risk of Moderate Drinkers than Teetotalers? The INTERMAP Study
Chan Q1, Yap IK1, Wijeyesekera A1, Brown IJ1, Stamler J2, Daviglus ML2, Miura K3, Zhao L4, Nicholson JK1, Holmes E1, Elliott P1, The INTERMAP Cooperative Research Group
1United Kingdom, 2United States, 3Japan, 4China
Asymptomatic Bilateral Pheochromocytoma Detection by Family Genetic Screening
Mori L1, Giacchè M1, Tacchetti MC1, Panarotto A1, Tosini R1, Tonegatti LG1, Pirola I1, Cappelli C1, Agabiti Rosei E1, Castellano M1
1Italy

Screening for Pheochromocytoma in Patients with Familial Medullary Thyroid Carcinoma
Giacchè M1, Panarotto A1, Mori L1, Tosini R1, Cappelli C1, Tacchetti MC1, Pirola I1, Agabiti Rosei E1, Castellano M1
1Italy

Acute Effects of ADMA on Endothelial Dysfunction
Slocum JL1, D’Alecy LG1, Gadegbeku CA1
1United States

Uridine Adenosine Tetraphosphate Induce Vasoactive Response Via P2Y Receptors
Tölle M1, Schuchardt M1, Huang T1, van der Giet M1
1Germany

Cardiovascular Disease Risk Scores Do Not Take the Effect of Treatment Into Account: A Systematic Review
Liew SM1,2, Doust J3, Glasziou P2
1Malaysia, 2United Kingdom, 3Australia

Long Term Variation of Blood Pressure is a Strong Predictor of Stroke for People with Normal Blood Pressure from a 22 Year Prospective Cohort Study
Zhang XH1, Guan TR1, Zheng RP1, Wang SY1, Liu LS1
1China

Association of the Elastin Microfibril Interfacer 1 (EMILIN1) Gene Polymorphisms with Essential Hypertension
Shimodaira M1, Nakayama T1, Sato N1, Naganuma T1, Yamaguchi M1, Aoi N1, Sato M1, Izumi Y1, Soma M1, Matsumoto K1
1Japan
PS3/WED/30
The Impact of β1-AR Polymorphism and Promoter Methylation on the Antihypertensive Efficacy of Metoprolol
Peng Y1, Zhang M1, Hong Y1, Huang Z1
1China

PS3/WED/31
The G Protein Regulator Phosducin Influences the Risk of Hypertension Only in Patients with Overweight
Ragazzo F1, Ceolotto G1, Frigo G1, Bratti P1, Saladini F1, Santonastaso M1, Mos L1, Cozio S1, Palatini P1
1Italy

PS3/WED/32
Genetic Variation in NEDD4L, an Epithelial Sodium Channel Regulator, is Associated with Total and Cardiovascular Mortality in Men
Dahlberg J1, Sjögren M1, von Wowern F1, Melander O1
1Sweden

PS3/WED/33
NMDA Receptor Mediated Glycine-Evoked Elevation in Mean Arterial Pressure Is Linked to Reduced Nitric Oxide Bioavailability in Hypertensive Rats
Tripathy S1, Tatchum-talom R1, Mishra RC1, Gandhi JD1, Desai KM1, Gopalakrishnan V1
1Canada

PS3/WED/34
Manidipine and Amlodipine Act Disparately on Intraglomerular Haemodynamics in Patients with Hypertension
Ott C1, Schneider MP1, Raff U1, Striepe K1, Alberici M2, Schmieder RE1
1Germany, 2Italy

PS3/WED/35
Tumor Necrosis Factor – Related Parameters Are Closely Linked With Chronic Inflammation, Insulin Resistance and Renal Dysfunction in Hypertension
Maruyama T1, Eguchi T1, Ohno Y1, Morii T1, Hirose H1, Kawabe H1, Saito I1, Hayashi M1
1Japan

PS3/WED/36
The Association between Blood Pressure and Glucagon-Like Peptide-1 (GLP-1) Concentration in a Japanese General Population (The Tanno and Sobetsu Study)
Akasaka H1, Saitoh S1, Ohnishi H1, Furugen M1, Yokoyama Y1, Shimamoto K1
1Japan
PS3/WED/37
Insulin Resistance, Functional Activity of Pancreatic Beta-Cells and Moxonidine Therapy in Hyperleptinemic and Hypertensive Postmenopausal Women with Metabolic Syndrome
Chubenko EA¹, Belyaeva OD¹, Bolshakova OO¹, Berkovich OO¹, Baranova EI¹, Shlyakhto EV¹
¹Russian Federation

PS3/WED/38
Electrical Stimulation of the Carotid Baroreceptors Using the Rheos® System Decreases Renal Artery Stiffness
Bakris G¹, Nadim M¹, Georgakopoulos D¹, Sica D¹
¹United States

PS3/WED/39
Effects of High Dose Candesartan versus Combination of Candesartan with Amlodipine on Kidney Function in Type 2 Diabetic Patients with Albuminuria
Yamashita S¹, Kojima M¹, Sugiura T¹, Dohi Y¹, Kimura G¹
¹Japan

PS3/WED/40
c-Src-regulated Redox-Dependent Signaling Pathways Play a Role in Angiotensin II-Induced Hypertension and Oxidative Renal Injury
Callera GE¹, Yogi A¹, Briones A¹, He Y¹, Touyz RM¹
¹Canada

PS3/WED/41
Body Composition Monitor (BCM) Is a Useful Tool to Assess Hydration Status And May Aid in Hypotensive Therapy in Hemodialyzed and Peritoneally Dialyzed Patients
Malyszko J¹, Malyszko J¹, Trusewicz W¹, Mysliwiec M¹
¹Poland

PS3/WED/42
Obesity Is Regulated by the Endogenous, Adipose Tissue Derived Angiogenesis Inhibitor Soluble fms-Like Tyrosine Kinase 1 (sFlt-1)
Herse F¹, Fain J², Jahnke J¹, Frey N¹, Luft FC¹, Staff AC³, Mueller DN¹, Dechend R¹
¹Germany, ²United States, ³Norway

PS3/WED/43
Critical Role for Hypothalamic mTOR Signaling in Mediating the Sympathetic and Hemodynamic Effects of Leptin
Rahmouni K¹, Guo D-F¹, Morgan DA¹
¹United States
PS3/WED/44
Preventing Obesity and Obesity-Related Disease with (Pro)Renin Receptor Blockade
Ahmed BA-M1, Bisotto S1, Michel C1, Nguyen TM-D1, Schiller PW1, Lavoie JL1
1Canada

PS3/WED/45
Effect of Fasudil, Rho-Kinase Inhibitor, On Endothelial Progenitor Cells in Rat Hindlimb Ischemia
Koguchi W1, Kobayashi N1, Takeshima H1, Fukushima H1, Ishikawa M1, Ohno T1, Fukuda N1, Ishimitsu T1
1Japan

PS3/WED/46
Androgen Receptor Participants in Ischemia-Induced Tissue Damage and Angiogenesis in Male Mice
Yoshida S1, Aihara K-I1, Ise T1, Ueda Y1, Ikeda Y1, Iwase T1, Akaike M1, Sata M1, Matsumoto T1
1Japan

PS3/WED/47
Novel Physical Activity Variability Index and Impact on Haemodynamics: Implications for Cardiovascular Prevention
Chan Y-H1, Tam W-S1, Wong H-W1, Ho L-M1, Chau Y-K1, Schooling C-M1, Leung G-M1, Lam T-H1, Hong Kong Jockey Club Family Project Cohort
1Hong Kong

PS3/WED/48
Implication of the STAT3/Pim1 axis in Human Pulmonary Hypertension
Paulin R1, Meloche J1, Courboulin A1, Bonnet S1
1Canada

PS3/WED/49
Angiotensin II Increases Plasma Microparticles through NADPH Oxidase-Dependent, Blood Pressure-Independent Processes in ApoE-/- Mice
Burger D1, Nishigaki N1, Montezano AC1, Touyz RM1
1Canada

PS3/WED/50
Short-Term Treatment with High-Dose Angiotensin Receptor Blocker (ARB) Induces Sustained Regression of Adriamycin-Induced Glomerulosclerosis and Albuminuria
Hayashi K1, Sasamura H1, Ishiguro K1, Sakamaki Y1, Azegami T1, Itoh H1
1Japan
PS3/WED/51
Plasmin Enhances ICAM-1 Induction in Human Endothelial Cells via NF-Kappa B / MAPKs-Dependent Pathways
Li Q1, Xu J1, Zhang Y1, Zhu D1, Wang H1, Gao P1
1China

PS3/WED/52
Critical Role of Circulating Advanced Glycation End-Products in the Etiology of Vascular Remodeling Diseases
Meloche J1, Paulin R1, Roy M1, Agharazii M1, Bonnet S1
1Canada

PS3/WED/53
Endothelial-Like Cells Derived From Mesenchymal Stem Cells Attenuate Neointimal Hyperplasia after Vascular Injury
Xu J1, Wu D1, Chen Q1, Ji K1, Gao P1
1China

PS3/WED/54
Atherosclerosis Exacerbates Endothelin-1-Induced Endothelial Dysfunction
Li MW1, Paradis P1, Schiffrin EL1
1Canada

PS3/WED/55
Intra-Peritoneal Application of Ribbon-Type Decoy Oligodeoxynucleotides against NFκB and ets Prevents Aneurysm Formation in Rats
Miyake T1, Aoki M1, Nakagami H1, Katsuya T1, Morishita R1
1Japan

PS3/WED/56
Mild Uremia Induces Aortic Outward Remodelling via NF-kappa B Activation
Kaschina E1, Akohov A1, Kemnitz UR1, Sommerfeld M1, Iliev B1, Peters H1, Unger T1, Krämer S1
1Germany

PS3/WED/57
Lox-1 Aggravate Vascular Injury by Western Diet
Uetake Y1, Shimosawa T1, Mu S1, Mori F1, Fujita T1
1Japan

PS3/WED/58
Intergenerational Programming of Nephron Deficit and High Blood Pressure for Male Rats Born Small
Wlodek ME1, Gallo LA1, Tran M1, Cullen-mcewen LA1, Moritz KM1
1Australia
PS3/WED/59
Prevention of Hypertension and Renal Injury by a Renin-Angiotensin System (RAS) Vaccine in L-NAME-Treated Spontaneously Hypertensive Rats (SHR)
Azegami T1, Sasamura H1, Hayashi K1, Ishiguro K1, Itoh H1
1Japan

PS3/WED/60
The Role of the T Regulatory Lymphocytes Response in the Pathogenesis of High Fructose Diet-Induced Metabolic Syndrome
Leibowitz A1, Rehman A1, Paradis P1, Schiffrin EL1
1Canada

PS3/WED/61
Vasodilatory Action of Both Voltage-Dependent (Kv) and Calcium-Activated (BKca) K+ Channels is Enhanced in Rats with Genetic Hypertension
Pinterova M1, Bencze M1, Dobesova Z1, Kunes J1, Zicha J1
1Czech Republic

PS3/WED/62
Sustained Blood Pressure Reduction by Baroreflex Activation Therapy with a Chronically Implanted System: 4-Year Data from the Rheos DEBuT-HT Study in Patients with Resistant Hypertension
Kroon A1, Schmidli J2, Tordoir J1, Mohaupt M2, Allemann Y2, Jordan J3, Engeli S3, Liebeskind U3, Luft F3, Eckert S3, Hansky B3, Elletson M4, de Leeuw P1
1Netherlands, 2Switzerland, 3Germany, 4United States

PS3/WED/63
VO2 max. As A Predictor of Autonomic Dysfunction in Diabetic Infarcted Rats Submitted to Exercise Training
Jorge L1, Rodrigues B1, Rosa KT1, De Angelis K1, Irigoyen MC1
1Brazil

PS3/WED/64
Carotid-Femoral Pulse Wave Velocity (cfPWV) is a Predictor of Incidence of Stroke in a Chinese Cohort
Zhang H1, Cai Y1, Zheng QL1, Huang XX1, Gao W1, Xing FL1, Liu LS1
1China

PS3/WED/65
Heart Rate Dependency of Pulse Wave Velocity in the Rat Aorta
Tan I1, Butlin M1, Liu Y-Y1, Ng K1, Avolio AP1
1Australia
PS3/WED/66
Does Aortic Pulse Wave Velocity Describe Vascular Risk Across Ethnic Groups Better Than Distending Pressures? A European Male Ageing (sub-)
Study (EMAS)
Rezai M¹, Finn J¹, Wu F¹, Cruickshank JK¹
¹United Kingdom

PS3/WED/67
Involvement of the Insulin Signalling Pathways in the Development of Arterial Calcification
Barrette M¹, Brodeur MR¹, Moreau P¹, Doyon M¹
¹Canada

PS3/WED/68
Palmitic Acid Increases Medial Calcification
Brodeur MR¹, Bouvet C¹, Moreau P¹
¹Canada

PS3/WED/69
Evaluation of Arterial Hypertension and Vascular Wall Remodelling Processes Prevalence among the Men-Former Participants in Warfare Operations
Goryacheva A¹, Shljager E¹, Barsukov A¹, Mizirenkova I¹
¹Russian Federation

PS3/WED/70
The Relationship of Ankle Brachial Index to Arterial stiffness is Dependent on the Methodology for Measurement of Arterial Stiffness
Rabkin SW¹, Chan SH¹, Sweeney C¹
¹Canada

PS3/WED/71
The Association between Microalbuminuria and Brachial-Ankle Pulse Wave Velocity in Type II Diabetic Patients with Hypertension
Nah D-Y¹, Bae J-H¹, Kim S-Y¹, Lee K¹, Lee Y-S¹, Kim YS¹, Rhee M-Y¹, Kim Y-K¹, Lee M-M¹
¹Korea, Republic of

PS3/WED/72
Estimation of Aortic Flow Velocity from Derived Aortic Pressure Waveforms
Adj A¹, Namasivayam M¹, O’Rourke MF¹, Avolio A¹, Weber T²
¹Australia, ²Austria
PS3/WED/73
Vascular Stiffness is Increased in Uncontrolled Hypertensive Patients Treated with Hydrochlorothiazide
Cunha AR¹, Medeiros F¹, Burlá A¹, d’El-Rei J¹, Casanova M¹, Oigman W¹, Neves MF¹
¹Brazil

PS3/WED/74
Correlation between Left Ventricular Mass Index and Central or Brachial Blood Pressure in Young Men
Kotovskaya Y¹, Safarova A¹, Kobzev R¹, Yurtaeva V¹, Tyulkina E¹, Kobalava Z¹
¹Russian Federation

PS3/WED/75
Arterial Stiffness in Patients with Type 2 Diabetes Mellitus with Coronary Artery Disease and Stroke
Singh A¹, Hashim Z¹, Prasad S¹, Jain S¹, Kumari S¹, Varma S¹
¹India

PS3/WED/76
Influence of Collagen Metabolism in Artery Stiffness of Hypertension Patients
Wang L, China

PS3/WED/77
The Influence of Antihypertensive Treatment on Arterial Stiffness, Shear Stress and Metalloproteinases Activity
Rajzer M¹, Wojciechowska W¹, Kłocek M¹, Brzozowska-Kiszka M¹, Kawecka-Jaszcz K¹
¹Poland

PS3/WED/78
The Effect of Hyperuricemia on Pulse Wave Velocity and Pressure Wave Reflection: A Cohort Study
Odaira M¹, Tomiyama H¹, Matsumoto C¹, Yoshida M¹, Shiina K¹, Yamashina A¹
¹Japan

PS3/WED/79
Acute Increase in Isobaric Aortic Stiffness in Rats Following Exposure to Ionizing Radiation
Liu Y-Y¹, Knittle T¹, Butlin M¹, Smee R¹, Avolio AP¹
¹Australia
PS3/WED/80
Endothelial Function and Pulse Wave Velocity in Renal Transplants: Influence of ESA Therapy
Reiermann S¹, Kliche K¹, Bartels V¹, Malyar V¹, Hillebrand U¹, Suwelack B¹, Pavenstädt H¹, Hausberg M¹
¹Germany

PS3/WED/81
Arterial Stiffness Levels and the Contribution of Pressure Wave Reflection to Central Blood Pressure in Non-Elderly Japanese Men
Odaira M¹, Tomiyama H¹, Matsumoto C¹, Yoshida M¹, Shiina K¹, Yamashina A¹
¹Japan

PS3/WED/82
Comparative Effects of Telmisartan-Based Therapy and Calcium Channel Blockers-Based Therapy on Cardio-Ankle Vascular Index in Hypertensive Patients
Kinouchi K¹, Ichihara A¹, Sakoda M¹, Kurauchi-Mito A¹, Murohashi-Bokuda K¹, Itoh H¹
¹Japan

PS3/WED/83
Distribution of CAVI (Cardio-Ankle Vascular Index) in Healthy and Hypertensive Subjects As A Part of Preventive Strategy in Adult Population
Dobsak P¹, Dusek J¹, Tomoyuki Y², Homolka P¹, Siegelova J¹, Spinarova L¹, Vitovec J¹, Soucek M¹, Eicher J-C², Wolf J-E³
¹Czech Republic, ²Japan, ³France

PS3/WED/84
Correlation between Non Dipping Nocturnal Blood Pressure and Increased Arterial Stiffness
Hermida Ameijeiras A¹, Lopez Paz JE¹, Pena Seijo M¹, Calvo Gonzalez G¹, Romero Miguez ML¹, Martinez Duran V¹, Pascual Montes A¹, Calvo Gomez C¹
¹Spain

PS3/WED/85
An Association between Coronary Heart Disease and Arterial Stiffness in Hypertensive Patients
Zuo J¹, Li Y¹, Yan Z¹, Zhang R¹, Gao P¹, Zhu D¹, Qu Y¹, Chu S¹
¹China
PS3/WED/86
Elevated Heart Rate Accelerates the Progression of Arterial Stiffness in the Early Stage of Hypertension
1Italy

PS3/WED/87
Do Left Ventricular Mass Index and Aortic Pulse Wave Velocity Measured by Magnetic Resonance Imaging Indicate Separate Burdens of Vascular Risk?
Rezai M, Cowan B, Young A, Finn J, Wu F, Cruickshank JK
1United Kingdom, 2New Zealand

PS3/WED/88
Gender Specified Effect: Association of Blood Pressure with Ankle-Brachial Index and Ankle-Brachial Pulse Wave Velocity in Hypertensive Chinese Adults
1China, 2United States

PS3/WED/89
Association of Arterial Stiffness with Inflammation Biomarkers in a Chinese General Population
1China

PS3/WED/90
Immediate Impact of Exercise on Arterial Stiffness in Humans
Seo JB, Chung WY, Kim SH, Kim MA, Zo ZH
1Korea, Republic of

PS3/WED/91
Acute Impact of Exercise on Arterial Stiffness in Humans
1Korea, Republic of

PS3/WED/92
Investigation of Influential Factors of Arterial Elasticity in Healthy Young People
Chen Y, Zhou L, Liu X, Sun N
1China
The Assessment of Complex Treatment Influence’s of Metabolic Syndrome with Hypertension 1-2 Degrees on the Blood Pressure and the Structural and Functional Arterial Properties
Matrosova I', Eliseeva I', Oleynikov V'
1Russian Federation

Systemic Mononuclear cells Therapy Delays the Progression of Atherosclerotic Plaque in ApoE-Knockout Mice
Campagnaro BP', Porto ML', Lima LCF', Nogueira BV', Pereira TMC', Tonini CL', Vasquez EC', Meyrelles SS'
1Brazil

Significant Changes in Circulating Adiponectin Levels, Gene Expression of Mitochondrial Proteins, Cardiac Architecture, and Triglycerides Levels Are Observed In the Heart of Atherosclerosis Mice Model Treated With Vitamin D Analog Paricalcitol and ACE Inhibitor Enalapril
Ferder L', Husain K', Saez W', Suarez-Martinez E'
1Puerto Rico

Measurement of CIMT Using Automatic Software: A Comparison of Two Edge Detection CIMT Software Packages
Jiang B', Chowienczyk P'
1United Kingdom

A Study of 5-Year Change of the Prevalence of Carotid Atherosclerosis and Influencing Factors in a Chinese Elderly Population
1China

Carotid Intima-Media Thickness and High-Sensitivity C-reactive Protein in a Population of Middle-Aged Koreans: Relation to Metabolic Syndrome
Suh M', Ha KH', Kim CS', Kim HC', Suh I'
1Korea, Republic of

Correlation of Carotid Artery Intima Media Thickness with Cardiovascular Risk Factors and Coronary Artery Disease Among Patients Admitted at Cardinal Santos Medical Center from January 2008 to December 2008
de Guia III MAD', Roll GD'
1Philippines
PS3/WED/100
Health Behavior Modification Subsequent to Electron Beam Computed Tomography (EBCT) Scan and Physician Consultation
Schwartz J¹, Allison M¹, Wright M¹
¹United States

PS3/WED/101
Joint Effect of Diabetes and Other Cardiovascular Risk Factors on Carotid Atherosclerosis
Sun J¹, Zhao D¹, Liu J¹, Wang W¹, Xie X¹, Wei Z¹, Zeng X¹, Gao Y¹, Wang M¹
¹China

PS3/WED/102
Influence of Systemic Hypertension on the Systolo-Diastolic Function of the Left Ventricle after a First Acute Coronary Syndrome with ST Elevation
Boughzala E¹, Ouali S¹, Hammam S¹, Hammami R¹, Jilani B¹, Gribaa R¹, Kacem S¹, Neffati E¹
¹Tunisia

PS3/WED/103
Arterial Hypertension and Coronary Revascularization Surgery: A Clinical Characterization.
Pupi LM¹, Leonardi M¹, Calabria F¹, Sampó E¹
¹Argentina

PS3/WED/104
Comparison of Four Blood Pressure Measurement Methods in 100 Hypertensive Patients
Ng Cheong N¹, Larochelle P¹, Lamarre-Cliche M¹
¹Canada

PS3/WED/105
Blood Pressure Device and Calibration in Home Health Care – A Cause for Concern? – A Pilot Survey
Germino FW¹, Germino MM¹
¹United States

PS3/WED/106
Postprandial Hypotension as a Risk Factor for Cognitive Decline in Community-Dwelling Elderly Persons
Uetani E¹, Tabara Y¹, Igase M¹, Kido T¹, Ochi N¹, Yamamoto M¹, Kohara K¹, Miki T¹
¹Japan
PS3/WED/107
Central Aortic Pressures in Hypertensive Patients Predicts Future CVE; Invasive Study
Park CG¹, Shin Y², Choi CU¹, Na JO¹, Lim HE¹, Kim EJ¹, Rha SW¹, Seo HS¹, Oh DJ¹
¹Korea, Republic of, ²Canada

PS3/WED/108
Non-Invasive Measurement of Beat-to-Beat Arterial Blood Pressure by the Korotkoff Sound Delay Time
Xiang H¹, Liu Y¹, Li Y¹, Qin Y¹, Yu M¹
¹China

PS3/WED/109
Radial Systolic Pressure Augmentation in Normal and Hypertensive Individuals: Pathogenesis and Clinical Impact
Izzo J¹, Osmond P¹, Khan S¹
¹United States

PS3/WED/110
Blood Pressure Estimation Method on the Wrist Using Photoplethysmography and Oscillometric Waveform
Song S¹, Kim T¹, An D¹, Kwon K¹, Lee J¹, Chee Y¹, Kim I¹
¹Korea, Republic of

PS3/WED/111
Blood Pressure Response to Active Standing in Medicated Essential Hypertension
Hua Li, China

PS3/WED/112
24-Hour Blood Pressure Monitoring Parameters in Essential Hypertensive Patients with Coronary Heart Disease and Positive Markers of Viral Hepatitis
Barsukov A¹, Zhdanov K¹, Talantzeva M¹
¹Russian Federation

PS3/WED/113
Home Blood Pressure Monitoring: A More Accurate Method Than Office Blood Pressure to Evaluate Systemic Arterial Hypertension After Renal Transplantation
Agena F¹, Prado ES¹, Fadel LM¹, Takaki KM¹, Silva GV¹, Mion Jr D¹, Nahas WC¹, David-Neto E¹, Kidney Transplantation Service
¹Brazil
PS3/WED/114
Age-Dependent Changes in Peripheral and Central Blood Pressure over 5 Years Follow-Up of a European Cohort
Wojciechowska W1, Stolarz-Skrzypek K1, Richart T2, Seidlerová J4, Cwynar M1, Thijs L2, Li Y5, Kuznetsova T2, Filipovsky J4, Grodzicki T1, Kawecka-Jaszcz K1, Staessen JA2,3
1Poland, 2Belgium, 3Netherlands, 4Czech Republic, 5China

PS3/WED/115
Statistical Validation of the Criterion Proposed by ESH to Evaluate the Accuracy of Blood Pressure Monitors
Wang Y1, Li W1, Yu L1
1China

PS3/WED/116
Office Blood Pressure Measurement in Elderly Hypertensive Patients
Zelaya Vargas JL, Peru

PS3/WED/117
Comparison Home Self Measurement Monitoring of Blood Pressure with Office and Ambulatory Blood Pressure Measurements
Radchenko GD1, Polyschuk SA1, Sirenko YM1
1Ukraine

PS3/WED/118
The See and Treat for the Management of Asymptomatic Pressure Increase
Lenti S1, Pietrelli S1, Corradini P1
1Italy

PS3/WED/119
The Difference of Central Aortic Pressure According to the Type of Antihypertensive Medicine
Furumoto T1, Fujii S1, Tsutsui H1
1Japan

PS3/WED/120
Clinical Significance of Self-measured Blood Pressure in Hospital at Pre-examination Timing
Yamashita S1, Takase H1, Tanaka S1, Sugiura T1, Sonoda H1, Dohi Y1, Kimura G1
1Japan

PS3/WED/121
Clinical and Ambulatory Blood Pressure (BP) Values in Centenarians
Carugo S1, Maisaidi M1, Pozzi M1, Esposito A1, Pernigotti A1, Caimi B1, Mancia G1
1Italy
PS3/WED/122
Blood Pressure Values Obtained with Different Instruments, Methods and Techniques: A Comparative Study
Lamas JLT¹, Ribeiro CCM¹
¹Brazil

PS3/WED/123
Blood Pressure Measurement Certificate: A Need for Better Hypertension Care
Almustafa BA¹, Al-Faraj N², Almobarak AA¹, Al-Eid N¹, Hehlis M¹, Alsalman EM¹, Blood Pressure Measurement Certificate
¹Saudi Arabia, ²Australia

PS3/WED/124
Blood Pressure Measured by the Doctor in the Clinic is Not Correct to Evaluate the Target Blood Pressure
Takeda K¹, Moriguchi J¹, Matsumoto S¹, Yagi T¹, Takanashi Y¹
¹Japan

PS3/WED/125
Neuronal Activation and Cardiovascular Responses Induced by Stress in Genetically Hypertensive Mice
Davern PJ¹, Nguyen-Huu T-P¹, La Greca L¹, Head GA¹
¹Australia

PS3/WED/126
Non-Invasive Estimation of Indices of Cerebral Vascular Compliance
Kim M-O¹, Avolio A¹
¹Australia

PS3/WED/127
Enhanced Pressor Responses of Angiotensin-(1-7) Into the Rostral Ventrolateral Medulla in Spontaneously Hypertensive Rats
Nakagaki T¹, Hirooka Y¹, Ito K¹, Hoka S¹, Sunagawa K¹
¹Japan

PS3/WED/128
Non-Invasive Estimation of Cerebral Critical Closing Pressure
Kim M-O¹, Qasem A¹, Avolio A¹
¹Australia

PS3/WED/129
Role of Nitric Oxide Synthase in Cardiovascular and Sympathetic Responses to Stress
Anilovitch JL¹, Davern P¹, Burke S¹, Evans R¹, Head G¹
¹Australia
PS3/WED/130
Relationship of Disturbances of Cerebral Venous Blood Flow and Structural Attributes of Hypertensive Angioencephalopathy in Hypertensive Patients
Afanasyeva N¹, Mordovin V¹
¹Russian Federation

PS3/WED/131
Brain Behavior Modifications in Patients with Arterial Hypertension
Ivanova S¹, Hristova K¹
¹Bulgaria

PS3/WED/132
Angiotensin-(1-12) Is Processed to Angiotensin II for Cardiovascular Actions within the Solitary Tract Nucleus
Arnold AC¹, Isa K¹, Shaltout HA¹, Nautiyal M¹, Ferrario CM¹, Chappell MC¹, Diz DI¹
¹United States

PS3/WED/133
Hypertension and Intracranial Stenosis
Pinzon R, Indonesia

PS3/WED/134
Puerarin Attenuates Cerebral Damage Though Improving Pia Mater Microcirculation in Spontaneously Hypertensive Rats
Liu XH¹, Wang XR¹, Zhang ZY¹, Liu FY¹, Fu Y¹, Liu LS¹
¹China

PS3/WED/135
Cardiovascular and Sympathetic Responses to Stress: Modulation by the Brain Renin-Angiotensin System
Anilovitch JL¹, Davern P¹, Burke S¹, Evans R¹, Head G¹
¹Australia

PS3/WED/136
Assessing of Carotid Pathology and Risk Factors in Hypertensive Patients for Cerebrovascular Disease
Hristova K¹, Titianova E¹, Velcheva I¹, Dimitrov N¹, Damianov P¹, Ramshev K¹, Antonova N¹
¹Bulgaria

PS3/WED/137
Perindopril-Based Blood Pressure Lowering Reduces Major Vascular Events in Asian and Western Subjects with Cerebrovascular Disease: The PROGRESS Trial
Arima H¹, Anderson C¹, Omae T², Liu L³, Christophe C⁴, Woodward M⁵, MacMahon S¹, Neal B¹, Rodgers A¹, Chalmers J¹, PROGRESS Collaborative Group
¹Australia, ²Japan, ³China, ⁴France, ⁵United States
PS3/WED/138
Comparison of Long-Term Effects of Candesartan and Amlodipine on Cardiovascular Risks in High-Risk Hypertensive Patients: A Subanalysis of the CASE-J Extension (CASE-J Ex)
Ogihara T1, Nakao K1, Fukiyama K1, Matsuoka H1, Fujimoto A1, Saruta T1, CASE-J Trial Group
1Japan

PS3/WED/139
Association of Methylenetetrahydrofolate Reductase C677T Polymorphism with Blood Homocysteine and Response to Folic Acid Treatment in Hypertensive Chinese Adults
Huo Y1, Li J1, Cui Y1, Liu Z1, Qin X1, Ge J1, Guan D1, Hu J1, Wang Y1, Zhang F1, Zhao Z1, Zhao L1, Wang H1, Wang R1, Chen H1, Wang B1,2, Xu X1, Xu X2
1China, 2United States

PS3/WED/140
Efficacy and Safety of Azilsartan Medoxomil, a Novel Angiotensin II Receptor Blocker, in African-Americans with Hypertension
Johnson W1, White WB1, Sica D1, Bakris GL1, Weber MA1, Perez A1, Cao C1, Kupfer S1, Saunders E1
1United States

PS3/WED/141
Comparison of the New Angiotensin II Receptor Blocker Azilsartan Medoxomil with Valsartan
Sica D1, White WB1, Weber MA1, Bakris GL1, Perez A1, Cao C1, Kupfer S1
1United States

PS3/WED/142
The Cardiovascular Risk of Electrocardiographic Left Ventricular Hypertrophy (ECG-LVH) Is Different In Chinese and Caucasian Very Elderly Hypertensive Patients – Results from the Hypertension in the Very Elderly Trial (HYVET)
Antikainen R1,2, Beckett N1, Peters R1, Bulpitt C1, on behalf of the HYVET Study Group
1United Kingdom, 2Finland

PS3/WED/143
Interim report of CHIEF : Chinese Hypertension Intervention Efficacy Study – Effects of Combination Treatment of Initial Low-Dose Amlodipine Plus Telmisartan or Composite Amiloride on Blood Pressure Control in Hypertensive Patients
Wang W1, Ma L-Y1, Liu L-S1, CHIEF Study Group
1China
Comparison of Long-Term Effects of Candesartan and Amlodipine on the Risks of New-Onset Diabetes in High-Risk Hypertensive Patients: A Subanalysis of the CASE-J Extension (CASE-J Ex)

Saruta T1, Ogihara T1, Fukiyama K1, Fukui T1, Nakao K1, CASE-J Trial Group
1Japan

Risk Characteristics and Components of Metabolic Syndrome in the Population of the Chinese High Normal Blood Pressure Management Study (CHINOM)

Zhang Y1, Liu L1, Xue H1, Li Y1, Wang J1, Zhang H1, CHINOM Study Group
1China

Impact of a Novel Angiotensin Receptor Blocker, Azilsartan Medoxomil, on Blood Pressure Lowering

Bakris G1, Sica D1, Weber M1, White WB1, Perez A1, Cao C1, Kupfer S1
1United States

Antihypertensive Efficacy of Azilsartan Medoxomil, a Novel Angiotensin Receptor Blocker, in Combination with Amlodipine

Weber MA1, White WB1, Sica D1, Bakris GL1, Perez A1, Cao C1, Kupfer S1
1United States

A Comparison of the Direct Renin Inhibitor Aliskiren and Angiotensin Receptor Blocker Losartan in Japanese Patients with Mild-to-Moderate Hypertension: A 8 Week Double Blind Study

Kushiro T1, Le Breton S2, Gotou H1, Keefe D3
1Japan, 2Switzerland, 3United States

Folic Acid Supplementation, Grain Fortification, and Stroke Prevention – A Meta Analysis

Huo Y1, Sun N1, Wu H1, Li J1, Qin X1, Wang B1,2, Xu X1, Chen G1, Gao R1, Liu L1, Xu X1,2, Hu D1, Wang X2
1China, 2United States

The Short Treatment with the Angiotensin Receptor Blocker Candesartan Surveyed by Telemedicine (STAR CAST) Study: Design and Preliminary Report

Sasamura H1, Nakaya H1, Julius S2, Sato Y1, Itoh H1, STAR CAST Investigators
1Japan, 2United States
A Comparative Study of Olmesartan and Valsartan on Insulin Sensitivity
Biro S1, Saikawa T1, Ikeda Y1, Kono S1, Sasaki J1
1Japan

Combination of Telmisartan 80 MG and Hydrochlorothiazide 25 MG Provides Clinically Relevant Blood Pressure Reductions in Hypertensive Patients Irrespective of Baseline Blood Pressure
McGill J1, Neldam S2, Schumacher H3, Guthrie R1
1United States, 2Denmark, 3Germany

Exploring Predictive Factors of Hypertension and Diabetes in High-Normal BP Individuals – CHINOM Study
Xue H1, Zhang Y1, Liu L1, on behalf of CHINOM group
1China

The Effect of a Single Tablet Formulation of Losartan/Hydrochlorothiazide in Patients with Refractory Hypertension: A Multicenter Prospective Trial
Kuriyama S1, Tokudome G1, Ishikawa M1, Hayashi H1, Soejima M1, Tomonari H1, Kanai T1, Akaba K1, Hosoya T1, on behalf of The JOINT study group
1Japan

Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Chinese Hypertensive Patients: a Post-marketing Double-blind Randomized Controlled Trial
Huo Y1, Liu L1, Li X1, Sun N1, Huang Y1, Wang Y1, Wang L1, Yao C1, Liu G1, Li J1, Cai Y1, Fu J1, He M1, Liao Y1, Yang T1, Zhao L1, Xu X1, Xing H1, Tang G1, Qin X1, Zhang Y1, Wang X2, Wang B1-2, Xu X2, CSPPT(China Stroke Primary Prevention Trail)
1China, 2United States

Lipids Profile and Insulin Resistance (IR) Changes under Pharmacogenetically Determined Treatment In Relation To Polymorphisms of ACE, AGTR1, eNOS, PPAR-Γ2 and ADRB1 Genes in Hypertensive (EAH) Patients
Sydorchuk R1, Sydorchuk L1, Ursuliak J1, Sydorchuk I1
1Ukraine
PS3/WED/157
Baroreflex Activation Therapy® (BAT®) Acutely Improves Central Arterial Properties in Resistant Hypertension Patients
Heusser K\textsuperscript{1}, Tank J\textsuperscript{1}, Engeli S\textsuperscript{1}, Menne J\textsuperscript{1}, Eckert S\textsuperscript{1}, Haller H\textsuperscript{1}, Georgakopoulos D\textsuperscript{2}, Pichlmaier AM\textsuperscript{1}, Luft FC\textsuperscript{1}, Jordan J\textsuperscript{1}
\textsuperscript{1}Germany, \textsuperscript{2}United States

PS3/WED/158
Baroreflex Activation Therapy® Improves Functional Capacity and Reduces Left Ventricular Mass Index: Results From European and United States Trials of the Rheos® System
Bisognano JD\textsuperscript{1}, Kroon AA\textsuperscript{2}, Bach DS\textsuperscript{1}, Kaufman CL\textsuperscript{1}, de Leeuw P\textsuperscript{2}
\textsuperscript{1}United States, \textsuperscript{2}Netherlands

PS3/WED/159
Analysis of Factors that Exacerbate Resistance to Antihypertensive Medication in Diabetes Mellitus
Tanaka S\textsuperscript{1}, Yamashita S\textsuperscript{1}, Sonoda H\textsuperscript{1}, Sugiura T\textsuperscript{1}, Dohi Y\textsuperscript{1}, Kimura G\textsuperscript{1}
\textsuperscript{1}Japan

PS3/WED/160
Effect of Cilostazol on Endothelial Progenitor Cells for Ischemic Hindlimb in Diabetic Rat Model
Ohno T\textsuperscript{1}, Kobayashi N\textsuperscript{1}, Takeshima H\textsuperscript{1}, Koguchi W\textsuperscript{1}, Fukushima H\textsuperscript{1}, Ishikawa M\textsuperscript{1}, Fukuda N\textsuperscript{1}, Ishimitsu T\textsuperscript{1}
\textsuperscript{1}Japan

PS3/WED/161
Effect of Osteopontin on Expression of Type I and Type III Collagen in Renal Fibroblasts Exposed to High Glucose
Silva VD\textsuperscript{1}, Okura T\textsuperscript{1}, Jotoku M\textsuperscript{1}, Nagao T\textsuperscript{1}, Enomoto D\textsuperscript{1}, Irita J\textsuperscript{1}, Miyoshi K-I\textsuperscript{1}, Higaki J\textsuperscript{1}
\textsuperscript{1}Japan

PS3/WED/162
Retinal Vessel Caliber and Retinal Vessel Dilation after Flickering Light in Normo- and Hypertensive Type 1 Diabetic Patients
Vilser W\textsuperscript{1}, Mandecka A\textsuperscript{1}, Dawczynski J\textsuperscript{1}, Schwefer M\textsuperscript{1}, Blum M\textsuperscript{1}, Müller N\textsuperscript{1}, Kloos C\textsuperscript{1}, Wolf G\textsuperscript{1}, Müller UA\textsuperscript{1}
\textsuperscript{1}Germany

PS3/WED/163
Active Lifestyle Improves Cardiac Autonomic Modulation in Offspring of Type II Diabetic Parents: Responses to an Isometric Handgrip Exercise
Sartori M\textsuperscript{1}, Pereira ES\textsuperscript{1}, Mostarda C\textsuperscript{1}, Nascimento RD\textsuperscript{1}, Irigoyen MC\textsuperscript{1}, De Angelis K\textsuperscript{1}
\textsuperscript{1}Brazil
Combined Exercise Training Attenuated Dysfunctions in an Experimental Model of Diabetes Associated With Menopause
Sanches IC\textsuperscript{1}, Conti FF\textsuperscript{1}, Bernardes N\textsuperscript{1}, Dias DS\textsuperscript{1}, Brito JO\textsuperscript{1}, Irigoyen M-C\textsuperscript{1}, De Angelis K\textsuperscript{1}
\textsuperscript{1}Brazil

Effects of Physical Preconditioning on Cardiovascular Changes in Streptozotocin-Induced Diabetes
Silva KA\textsuperscript{1}, Abreu NP\textsuperscript{1}, Orsi GC\textsuperscript{1}, Moreira ÉD\textsuperscript{1}, Mostarda CT\textsuperscript{1}, Malfitano C\textsuperscript{1}, De Angelis K\textsuperscript{1}, Irigoyen MC\textsuperscript{1}, Schor N\textsuperscript{1}
\textsuperscript{1}Brazil

Exercise Training Attenuates the Changes on Autonomic Modulation Induced by High Fructose Diet
Silva KA\textsuperscript{1}, Mostarda CT\textsuperscript{1}, Abad CCC\textsuperscript{1}, Barros CR\textsuperscript{1}, Galdino FDS\textsuperscript{1}, Ferreira DM\textsuperscript{1}, Malfitano C\textsuperscript{1}, Moraes-Silva IC\textsuperscript{1}, da Silva MB\textsuperscript{1}, Irigoyen MC\textsuperscript{1}
\textsuperscript{1}Brazil

Association of Fasting Plasma Glucose with Ankle-Brachial Index and Ankle-Brachial Pulse Wave Velocity in Hypertensive Chinese Adults
Yang Z\textsuperscript{1}, Dong Q\textsuperscript{1}, Sun N\textsuperscript{1}, Li X\textsuperscript{1}, Xu X\textsuperscript{1}, Ji L\textsuperscript{1}, Yang Y\textsuperscript{1}, Zha J\textsuperscript{1}, Sun L\textsuperscript{1}, Liao R\textsuperscript{1}, Jiang J\textsuperscript{1}, Wang Y\textsuperscript{1}, Xing H\textsuperscript{1}, Wang X\textsuperscript{2}, Liu L\textsuperscript{1}, Huo Y\textsuperscript{1}, Xu X\textsuperscript{2}, The Research Team of CSPPT
\textsuperscript{1}China, \textsuperscript{2}United States

Inhibition of Cyclooxygenase-2 Augments Vasoconstriction to Adrenaline in Rats with Streptozotocin-Induced Diabetes
Leung JYT\textsuperscript{1}, Lim SL\textsuperscript{1}, Pang CCY\textsuperscript{1}
\textsuperscript{1}Canada

Utilization of Medicinal Plants as a Source of Medicine for Diabetes Mellitus in Gazipur District of Bangladesh
Mollik MAH\textsuperscript{1}, Mcfield R\textsuperscript{1}, Hossain ABMA\textsuperscript{1}, Chowdhury A\textsuperscript{1}, Badruddaza M\textsuperscript{1}, Haque NMS\textsuperscript{1}, Rahman MS\textsuperscript{1}, Hassan AI\textsuperscript{1}
\textsuperscript{1}Bangladesh

Are we Effective in the Control of Arterial Hypertension and Macrovascular Risk for Type 2 Diabetic Patients without Cardiovascular Disease in a Primary Care Setting? Study Carried Out in Santoña, Cantabria (Spain)
Colas R\textsuperscript{1}, Puebla A\textsuperscript{1}, Gomez B\textsuperscript{1}, Gonzalez RM\textsuperscript{1}, Muñoz P\textsuperscript{1}
\textsuperscript{1}Spain
PS3/WED/171
Changes of Risk Factors for Left Ventricular Hypertrophy in Young Japanese Type 2 Diabetic Patients during 12 Years
Sakai K1, Sato A1, Harada M1, Kunugi T1, Nagai K1, Iwamoto Y1
1Japan

PS3/WED/172
Vitamin K Role in Arterial Stiffness during Metabolic Syndrome in Rat: Direct or Indirect Effect through Lipids Metabolism
Emonnot L1, Côté N1, Mathieu P1, Moreau P1
1Canada

PS3/WED/173
Time-Course Evaluation of Cardiac Function in Hypertension-Induced By Fructose Intake in Rats
Farah V1, Fiorino P1, Teodoro L1, Salvioni R1, Bechara A1, Mostarda C1, Sirvente R1, Fonteles M1, Maria Claudia I1
1Brazil

PS3/WED/174
Therapeutic Potential of Dietary Phase 2 Enzyme Inducer in Hypertension
Banigesh A1, Senanayake V1, Juurlink B1, Wu L1, Lee P1, Kulyk W1
1Canada

PS3/WED/175
Association between Salty Taste Preference and Sensitivity and Their Influence on Specific Eating Pattern in Patients with Life-Style Related Diseases
Mizuta E1, Hamada T1, Izawa S1, Yamada K1, Matsuzawa K1, Hirota Y1, Ohkura T1, Kato M1, Taniguchi S-I1, Hisatome I1, Shigemasa C1
1Japan

PS3/WED/176
The Association of Different Cardiovascular Risk Factors, Fructose and Salt, in Renal Function
Yokota R1, Muller CR1, Fiorino P1, Farah V1, Casarini DE1, Fonteles MC1
1Brazil

PS3/WED/177
Two Strongly Associated Dietary Markers with Hypertension and Cardiovascular Risks, Revealed by a World-wide Epidemiological Study
Yamori Y1, Taguchi T1, Mori H1, Mori M1, on behalf of WHO-CARDIAC Study group.
1Japan
PS3/WED/178
Quercetin Treatment Restores Nitrite and Nitroso Species Levels in Renovascular Hypertension
Montenegro MF1, Neto-Neves EM1, Dias-Junior CAC1, Ceron CS1, Castro MM1, Gomes VA1, Tanus-Santos JE1
1Brazil

PS3/WED/179
Blood Pressure Control and Endothelial Function in Type 2 Diabetes: Importance of Nutritional Educational Program
Masoni MC1, Ghiadoni L1, Scarpellini C1, Consani C1, Taddei S1, Giampietro O1, Matteucci E1
1Italy

PS3/WED/180
Effect of Fish and Olive Oil Supplementation on Cardiovascular and Biochemical Profile in Adults Spontaneously Hypertensive Rats (SHR)
Abreu GG1, Barros KV1, Xavier RAN1, Casarini DE1, Higa EM1, Ribeiro EB1, Silveira VL1
1Brazil

PS3/WED/181
Prevalence of Hypertension among Vegetarians in India – Madurai Mega Medical Survey
Muthusamy V, India

PS3/WED/182
Effects of Aldosterone Blockade, on the Visceral Adiposity in Patients with Primary Aldosteronism
Takeda Y1, Karashima S1, Yoneda T1, Demura M1, Kometani M1, Ohe M1
1Japan

PS3/WED/183
A Novel ELISA for the Detection of Elevated Plasma Free Metanephines in Pheochromocytoma Patients
Lenz T1, Zorner J1, Salewski L1
1Germany

PS3/WED/184
Modified Saline Loading Test as a Confirmatory Test for Primary Aldosteronism
Asano M1, Tanabe A1, Naruse M1, Tsuiki M1, Nakamura N1, Takano K1
1Japan
Clinical Characteristics of Aldosterone-Producing Microadenoma
Ohe M1, Karashima S1, Cheng Y1, Yoneda T1, Demura M1, Kometani M1, Mori S1, Takeda Y1
1Japan

Factors Determining Renal Function Before and After Adrenal Surgery in Patients with Primary Aldosteronism
Tsuiki M1, Tanabe A1, Naruse M1, Kimura H1, Tsumagari A1, Watanabe D1, Takagi S1, Takano K1
1Japan

Methylglyoxal, a Glucose Metabolite, Reduces Endothelial Nitric Oxide Synthase Activity and Induces Endothelial Dysfunction
Dhar A1, Wu L1, Desai K1
1Canada

Contributory Role of Endothelium and Voltage-Gated Potassium Channels in Apocynin-Induced Vasorelaxations
Han WQ1, Wong WT1, Tian XY1, Huang Y1, Wu LY1, Zhu DL1, Gao PJ1
1China

Resveratrol Ameliorate High Glucose Induced Hyperpermeability in Aortic Endothelial Cells – The role of Caveolin-1
Peng X-L1, Tian C1, Tang Y1, Zhang C1, Hao L1, Yamori Y2, Ying C1
1China, 2Japan

Attenuation of Norepinephrine-Induced Contraction of Femoral Arteries from Adult and Aged Wistar Rats by Acute Inhibition of Cyclooxygenase
Liskova S1, Petrova M2, Kunes J1, Zicha J1
1Czech Republic, 2Slovakia

Effects of Na-K-2Cl Cotranspoter NKCC1 on Endothelial Function in Arteries of Salt Sensitive Hypertensive Rats
Goto K1, Matsumura K1, Ohtsubo T1, lida M1
1Japan
Flow Induced Pressure Changes within Conduit Arteries Mask Instantaneous Shear Stress Induced Release of Nitric Oxide: Implications for Regulation of Conduit Artery Tone and Assessment of Endothelial Function
Jiang B , Seddon M , Chowienczyk P
1United Kingdom

Involvement of Modulated Lipid Microdomains in Anti-Inflammatory Effect of Eplerenone
Mutoh Matsushita A , Yasu T , Kobayashi M , Inoue T , Mori N , Ueda S
1Japan

Effect of Aliskiren on Endothelial Function in Hypertensive Patients
Margulis FH, lermoli R
1Argentina

Arginine Prevents High Glucose and Methylglyoxal-Induced Endothelial Dysfunction by an eNOS-Independent Mechanism
Dhar I , Dhar A , Wu L , Desai K
1Canada

Impact of Diabetes Mellitus on Flow Mediated Dilatation in African-Americans
Yonis MO , Cherqaoui R , Randall O , Xu S , Hussein S
1United States

Green Tea Polyphenols Ameliorate High Glucose-Induced Hyperpermeability in Endothelial Cells
Tian C , Peng X , Ye X , Meng Y , Sun X , Yamori Y , Ying C
1China, 2Japan

Blood Pressure Change and Antihypertensive Treatment in Old and Very Old People – Evidence of Age and Cohort Effects
Molander L , Lövheim H
1Sweden

Prehypertension. Its Relation With Cardiovascular Morbidity and Mortality
Duenas AF , Armas NB , Diaz M
1Cuba
PS3/WED/200
Control of Blood Pressure in Coronary Hypertensives over the Decade from 1997 to 2007
Jankowski P\(^1\), Kawecka-Jaszcz K\(^1\), Surowiec S\(^1\), Loster M\(^1\), Bednarek A\(^1\), Grodzicki T\(^1\), Pajak A\(^1\)
\(^1\)Poland

PS3/WED/201
The Impact of a 6-year Comprehensive Community Trial on the Awareness, Treatment and Control Rates of Hypertension in Iran: Experiences from the Isfahan Healthy Heart Program
Khosravi A\(^1\), Kianimehr G\(^1\), Gharipour M\(^1\), Kelishadi R\(^1\), Sarrafzadegan N\(^1\), Isfahan Healthy Heart Group
\(^1\)Iran, Islamic Republic of

PS3/WED/202
Improvement of Hypertension Control in Korea; Results from Korean National Health and Nutrition Examination Survey (KNHNES)
Kim K-I\(^1\), Oh K-W\(^1\), Kim S-G\(^1\), Kim C-H\(^1\)
\(^1\)Korea, Republic of

PS3/WED/203
Impact of Obesity, Marital Status, Education and Place of Residence on the Risk of Hypertension in Middle-Aged Population in Lower Silesia in Poland
Bolanowski J\(^1\), Bronowicz J\(^1\), Bolanowska B\(^1\), Lipowicz A\(^1\), Szklarska A\(^1\)
\(^1\)Poland

PS3/WED/204
Prevalence and Determinants of Hypertension in Middle-Aged Adults of Beijing
Hu B\(^1\), Li W\(^1\), Cardiovascular Institute Fuwai Hospital
\(^1\)China

PS3/WED/205
The Effects of Visceral Fat Index on Hypertension and Metabolic Syndrome
Bai Z\(^1\), Wei W\(^1\), Wang X\(^1\), Yan K\(^1\), Li G\(^1\), Li F\(^1\), Zhang H\(^1\)
\(^1\)China

PS3/WED/206
Relationship between Ratio of Serum Sodium to Potassium and Blood Pressure in Beijing Suburb Women
Yan K\(^1\), Zhang R\(^1\), Bai Z\(^1\), Li G\(^1\), Wang X\(^1\), Wei W\(^1\), Zhang H\(^1\)
\(^1\)China
PS3/WED/207
Differences in 24-h Urinary Metabolite Excretion Patterns between African Americans and non-African Americans and Association With Blood Pressure: INTERMAP Study
Yap IKS1, Brown IJ1, Chan Q1, Wijeyesekera A1, Holmes E1, Nicholson JK1, Elliott P1, Daviglus ML2, Stamler J2, INTERMAP Study Group
1United Kingdom, 2United States

PS3/WED/208
Ethnic Differences in Renin and Endothelial Dysfunction
Connell KL1, Chowienczyk P1, Cardiovascular Division, King’s College London
1United Kingdom

PS3/WED/209
Low Renin in Hypertensive Urbanised Black South Africans: The Influence on Cardiovascular Function
van Rooyen JM1, Huisman HW1, Schutte R1, Schutte AE1, Malan NT1, Fourie CM1, Malan L1
1South Africa

PS3/WED/210
Life Style in Adulthood Is an Important Factor for the Development of Non-Dipper Type Blood Pressure Variation in Kazakhs
Kawamura H1, Izumi Y1, Mitsubayashi H1, Kasamaki Y1, Nakayama T1, Ohta M1, Ozawa Y1, Mahmut M2, Cheng Z2, Ma Y2
1Japan, 2China

PS3/WED/211
Transcriptomics of Rat Genetic Hypertension: A Meta-Analysis
Marques FZ1, Campain AE1, Yang JY1, Morris BJ1
1Australia

PS3/WED/212
The Impact of RGS2 Deficiency on the Therapeutic Effect of Telmisartan in Angiotensin II-Induced Vascular Remodeling
Matsumoto S1, Kamide K1, Banno F1, Inoue N1, Mochizuki N1, Kawano Y1, Miyata T1
1Japan

PS3/WED/213
The Effect of Promoter Methylation on Regulation of β1-adrenoceptor Gene Expression in Rat Myocardial Cell
Huang Z1, Du X1, Hong Y1, Cai J1
1China
PS3/WED/214
Mouse Lacking ATP2B1 Gene, the New Hypertension Candidate Gene, in Vascular Smooth Muscle Using Cre-Loxp System Shows Blood Pressure Elevation
Kobayashi Y1, Hirawa N1, Tabara Y1, Yatsu K1, Wakui H1, Miyazaki N1, Yamamoto Y1, Saka S1, Yoshida S1, Fujiwara A1, Kita Y1, Ueshima H1, Miki T1, Umemura S1
1Japan

PS3/WED/215
The Impact of Pharmacological Environment on Capacity to Identify the Genetic Components of Hypertension
Noël A1, Seda O1, Tremblay J1, Gaudet D1, Kotchen TA2, Cowley AW2, Hamet P1
1Canada, 2United States

PS3/WED/216
Association Study of ELMO1 and ELMO2 Genes with Hypertension in a Japanese Population
Tsutaya S1, Sugimoto K1, Yasujima M1
1Japan

PS3/WED/217
Association of GGGCCG Haplotype of Beta-2 Adrenergic Receptor Gene with Primary Hypertension in a Chinese Singaporean Population
Oh VMS1, Heng CK1, Chua BM1, Yeo SB1, Yap EP-B1
1Singapore

PS3/WED/218
Orthostatic Hypotension: A New Prevalence for a New Technology (HIACE Study)
Cooke J1, Carew S1, Quinn C1, Curtin J1, O’Connor M1, O’Connor C1, Saunders J1, Humphreys E1, deBurca S1, Clinch D1, Lyons D1, Health Inequality and Ageing in the Community Evaluation (HIACE) Study Group
1Ireland

PS3/WED/219
Re-defining Orthostatic Hypotension: Pattern Analysis Techniques (HIACE study)
Cooke J1, Carew S1, Quinn C1, O’Connor M1, Curtin J1, O’Connor C1, Saunders J1, Humphreys E1, deBurca S1, Clinch D1, Lyons D1, Health Inequality and Ageing in the Community Evaluation (HIACE) Study Group
1Ireland
PS3/WED/220
Symptomatic Orthostatic Hypotension: It’s Not How Low You Go but How Fast You Fall
Cooke J¹, Carew S¹, Costelloe A¹, Sheehy C¹, Saunders J¹, Lyons D¹
¹Ireland

PS3/WED/221
Role of Hemodynamic and Other Factors in the Development Cardiovascular Complications in Long-Term Essential Hypertension
Zelenenka LI¹, Kupchynska O¹
¹Ukraine

PS3/WED/222
Some Pathogenetic Aspects of Orthostatic Hypotension in Young Subjects Suffering from out of Hospital Pneumonia
Barsukov A¹, Karimova A¹, Shustov S¹
¹Russian Federation

PS3/WED/223
Left Ventricular Concentric Geometry Is Associated With Dynamic Intraventricular Obstruction in Patients With Hypertension: Dobutamine Stress Echocardiography Study
Sohn I-S¹, Jang J-Y¹, Park J-H¹, Jin E-S¹, Cho J-M¹, Kim C-J¹, Bae J-H¹
¹Korea, Republic of

PS3/WED/224
OPG-RANK-RANKL System Contribute to Insulin Resistance
Nakagami F¹, Nakagami H¹, Osako MK¹, Morishita R¹, Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine
¹Japan

PS3/WED/225
The Role of Cytoskeleton in Camp-Dependent Regulation of Electrical and Contractile Activity in Smooth Muscle Cells
Gusakova S¹, Baskakov M¹, Kovalev I¹, Popov A¹, Melnik O¹, Zheludeva A¹, Smaglii L¹, Medvedev M¹, Orlov S²
¹Russian Federation, ²Canada

PS3/WED/226
Vasodilator Capacity of Endogenous Prostacyclin is Enhanced in Rats with Spontaneous or NO-Deficient Hypertension
Zicha J¹, Behuliak M², Pinterova M¹, Kunes J¹
¹Czech Republic, ²Slovakia
PS3/WED/227
Molecular Origin of Na⁺/Li⁺ Countertransport: Evidence Against Na⁺-coupled Pi Cotransporter
Koltsova SV, Akimova OA, Tremblay J, Kotelevtsev SV, Hamet P, Orlov SN
Canada, Russian Federation

PS3/WED/228
Cilnidipine Inhibited Proteinuria and Renal Renin-Angiotensin-Aldosterone System in Deoxycorticosterone-Salt Hypertensive Rats
Toba H, Yoshida M, Tojo C, Nakano A, Kobara M, Nakata T
Japan

PS3/WED/229
Renal Vasoconstrictor and Systemic Hypertensive Responses to Chronic Inhibition of Hydrogen Sulfide Producing Enzymes in Rats
Khan MAH, Roy AP, Islam MT, Prieto MC, Majid DSA
United States

PS3/WED/230
Contribution of Coagulation Factor XIIa to Hypertension in Chronic Renal Failure
Papageorgiou PC, Backx PH, Chan CT, Yeo EL, Floras JS
Canada

PS3/WED/231
Serum Uric Acid Is an Independent Risk Factor for Microalbuminuria in the General Population: The Watari Study
Munakata M, Ohshima M, Miura Y, Ito S, Watari Study Group
Japan

PS3/WED/232
Treatment of Essential Hypertension with Inhibitors of the Renin-Angiotensin System Does Not Prevent Renal Dysfunction When Compared to Other Treatments: A Meta-Analysis and Systematic Review
Daïen V, Duny Y, Rlbstein J, Mimran A, Villain M, Daures JP, Fesler P
France

PS3/WED/233
The Prevalence of Chronic Kidney Disease (CKD) In Patients with Primary Aldosteronism – Overestimated Renal Function by Aldosterone and Presence of “Masked CKD”
Japan
PS3/WED/234
Impact of 2007 ESH-ESC Guidelines on Cardiovascular Risk Stratification in Patients with Uncomplicated Arterial Hypertension
Villevalde S1, Tyulkina E2, Moiseev V1, Kobalava Z1
1Russian Federation, 2Rwanda

PS3/WED/235
Association of Estimated Glomerular Filtration Rate with Ambulatory Arterial Stiffness Index and Pulse Pressure in Hypertensive Patients
Wang Y-Q1, Li Y1, Hu Y-R1, Li H1, Gao L-L1, Chu S-L1, Zhu D-L1, Gao P-J1
1China

PS3/WED/236
Low Dose of Erythropoietin Improved Endothelial Dysfunction and Inflammation in Hypertensive 5/6 Nephrectomized Rat Aorta Beyond Hematopoiesis
Toba H1, Morishita M1, Oshima Y1, Kojima Y1, Tojo C1, Nakano A1, Nakashima K1, Yoshida M1, Kobara M1, Nakata T1
1Japan

PS3/WED/237
Increased Renal Sodium Absorption by Inhibition of Prostaglandin Synthesis During Fasting in Healthy Man. A Possible Role of the Epithelial Sodium Channels
Lauridsen TG1, Vase H1, Starklint J1, Graffe CC1, Bech JN1, Nielsen S1, Pedersen EB1
1Denmark

PS3/WED/238
Plasma Levels of Lipocalin-Type Prostaglandin D2 Synthase Predict Cardiovascular Risk in Hemodialysis Patients
Hirawa N1, Yamaguchi S1, Yamamoto Y1, Saka S1, Dobashi Y1, Miyazaki Y1, Kobayashi Y1, Fujiwara A1, Kobayashi M1, Yoshida S1, Yatsu K1, Ogawa N1, Oda H1, Toya Y1, Yasuda G1, Ohnishi T1, Uehara Y1, Umemura S1
1Japan

PS3/WED/239
Impact of Uric Acid on the Renal Function and Cardiovascular Event in CKD Patient – from J-HELTH STUDY
Ito S, Japan

PS3/WED/240
Circadian Variation of the Total Vascular Tone in Hypertensive Patients with Chronic Kidney Disease
Mori H1, Narita T1, Koeda J1, Okitsu K1, Tanno M1
1Japan
PS3/WED/241
Detection of Microalbuminuria and Clinical Albuminuria in Hypertensive Patients in China
Sun N¹, Zhu D¹, Liao Y¹, Lin S¹, Zhang T¹, Wu Y¹, Pan C¹, Zhu J¹
¹China

PS3/WED/242
Usefulness of the Resistive Index in Renal Doppler Ultrasonography in the Management of Patients with Risk Factors of Cardiovascular Diseases
Kawai T¹, Kamide K¹, Ohnishi M¹, Takeya Y¹, Hanasaki H¹, Tatara Y¹, Baba Y¹, Shimaoka I¹, Ohishi M¹, Rakugi H¹
¹Japan

PS3/WED/243
Circadian Rhythms of Urinary Potassium and Chloride Excretion in Patients with CKD
Miura T¹, Fukuda M¹, Naito T¹, Tomonari T¹, Wakamatsu-Yamanaka T¹, Mizuno M¹, Ichikawa T¹, Miyagi S¹, Shirasawa Y¹, Ito A¹, Yoshida A¹, Kimura G¹
¹Japan

PS3/WED/244
Does the Elevation of Blood Pressure Influence the Urinary Proteins Excretion?
Takechi S¹, Kakinoki S¹, Kanda K¹, Kobayashi T¹, Fujimoto T¹, Nomura A¹
¹Japan

PS3/WED/245
Urinary Type Collagen Is Useful Parameters to Evaluate the Renal Peripheral Artery Sclerosis in Patients with Essential Hypertension
Enomoto D¹, Okura T¹, Nagao T¹, Jotoku M¹, Irita J¹, Miyoshi K-I¹, Rasika V¹, Higaki J¹
¹Japan

PS3/WED/246
Maximum Intrarenal Resistive Index: A Possible Cardiometabolic Marker in Uncomplicated Essential Arterial Hypertension
Napoli V¹, Fommei E¹, Turini F¹, Donatelli G¹, Bartolozzi C¹
¹Italy

PS3/WED/247
Decreased Adiposity in Angiotensin II Receptor Type 1a (AT₁a) Knockout Mice
Weir NM¹, Morris M¹, Elased K¹
¹United States
Rosuvastatin and Chronotherapy: Effects on Blood Pressure in Hypertensive Subjects with Dyslipidemia
Pena Seijo M¹, Lopez Paz JE¹, Hermida Ameijeiras A¹, Calvo Gonzalez G¹, Romero Miguez ML¹, Pose Reino A¹, Coca Payeras A¹, Calvo Gomez C¹
¹Spain

The Effects of Telmisartan and Indapamide on Lipid Metabolism and Renal Function in High-Normal Blood Pressure Population
Liu L¹, Zhao S¹, Chen Y¹, Yu W¹, Wang A¹
¹China

Impact of HDL Cholesterol Level in Hypertensive Patients in India
Veerappan Muthusamy MAK, India

Common Polymorphisms in GCKR and APOA5 Gene Are Associated with Levels of HDL and LDL Cholesterol in the Chinese Population
Liu X¹, Shen Y¹, Wang D¹, Zhang F¹, Zhang Y¹, Wang X¹, Liu L¹
¹China

Association of Genetic Variations of STEAP4 Gene with the Lipids Uygur Male in Chinese Xinjiang
Li N¹, Liang D¹, Zhang J¹, Wu Z¹
¹China

Serum Lipid Abnormalities and Risk Factors in Chinese Urban and Rural Populations of Jilin
Shi X¹, Sun J¹, He S¹, Jiang Y¹, Feng X¹, Niu J¹
¹China

Imidazoline I1-Receptor Regulation in the Heart Occurs Preferentially in Fibroblasts
Farah G¹, Aceros H¹, Mukaddam-Daher S¹
¹Canada

L-Arginine Depletion Promotes Hypertension in Obese Zucker Rats
Durante W¹, Johnson FK¹, Johnson RA¹, Azam MA¹, Shebib AR¹, Peyton KJ¹
¹United States
PS3/WED/256
Stretch-induced Activation of Rho/Rho-kinase Pathway as a Determinant of Malignant Phenotype of Adipose Tissue in Diet-induced Obesity
Hara Y1, Wakino S1, Tanabe Y1, Saito M1, Tokuyama H1, Hasegawa K1, Minakuchi H1, Washida N1, Fujimura K1, Hayashi K1, Nakayama K1, Itoh H1
1Japan

PS3/WED/257
Melatonin Decreases Blood Pressure via Increased Brain Nitric Oxide Synthase Activity in Rats with Metabolic Syndrome
Pechanova O1, Parohova J1, Vrankova S1, Barta A1, Paulis L1, Kovaczova M1
1Slovakia

PS3/WED/258
Exercise and Remote Monitoring to Improve Blood Pressure and Heart Rate Variability in a Rural Population
Stuckey MI1, Russell-Minda E1, Kiviniemi A1, Fulkerson R1, Read E1, Munoz C1, Petrella RJ1
1Canada

PS3/WED/259
Metabolic Changes and Hypertension Associated with Antipsychotic Use in Schizophrenia
Saddichha S1, Akhtar S1
1India

PS3/WED/260
Hypertensive Patients with Metabolic Syndrome Attended by Different Medical Specialities Show some Distinctive Features
de la Sierra A1, Alegria E1, Martinez-Castelao A1, Morillas C1, Gonzalez-Segura D1
1Spain

PS3/WED/261
Blood Pressure Control and Therapeutical Inertia in Hypertensive Patients with Metabolic Syndrome Attended by Referral Specialists
de la Sierra A1, Alegria E1, Martinez-Castelao A1, Morillas C1, Gonzalez-Segura D1
1Spain

PS3/WED/262
Aberrations in Plasma and Platelet Cytochrome P450 Epoxideicosatrienoic Acids in the Metabolic Syndrome
Barden AE1, Tsai I-J1, Indrawan A1, Puddey IB1, Beilin LJ1, Croft KD1
1Australia
Tubulo-Interstitial Involvement in Hypertensive Patients with Metabolic Syndrome
Berni A¹, Ciani E¹, Bernetti M¹, Berardino S¹, Poggesi L¹, Boddi M¹
¹Italy

Association of Cytokines with Metabolic Syndrome in Bank Employers
Rotar OP¹, Fursova IV¹, Ivanenko VV¹, Yakovleva Ol¹, Degili EV¹, Solntsev VN¹, Konradi AO¹
¹Russian Federation

Adherence to Dietary Recommendations and Risk of Metabolic Syndrome: Tehran Lipid and Glucose Study
Mirmiran P¹, Hosseini Esfahani F¹, Jesri M¹, Bastan S¹, Azizi F¹
¹Iran, Islamic Republic of

Stability of the Factor Structure of the Metabolic Syndrome Components across the Follow-Up Survey in Children and Adolescents: Tehran Lipid and Glucose Study
Hosseini Esfahani F¹, Bahar A¹, Asghari Jafarabadi M¹, Mehrabi Y¹, Azizi F¹
¹Iran, Islamic Republic of

A New Approach to Determining the Structural TPR-Amplifier in Renal Cellophane Wrap (Page) Hypertension in Conscious Rabbits
Korner PI¹, Wright CE¹, Angus JA¹
¹Australia

Wall-To-Lumen Ratio of Retinal Arterioles Is Related to Alterations of Aortic Pulse Wave in Patients with a History of a Cerebrovascular Event
Ritt M¹, Harazny JM¹,², Schellinger P¹, Baleanu D¹, Schwab S¹, Michelson G¹, Schmieder RE¹
¹Germany, ²Poland

Coronary Angiogenesis during Experimental Hypertension in Rats. Is it Reversible?
Khazaei M¹, Zarei M¹, Sharifi M¹, Pourshanazari A¹
¹Iran, Islamic Republic of
PS3/WED/270
Parameters of Microcirculation Measured By Laser Doppler Flowmetry in Hypertensives and Normotensives in Age Group of 60-80 Years
Kanishcheva E1, Fedorovich A1, Loukianov M1, Boytsov S1
1Russian Federation

PS3/WED/271
Hypertension Control with Telmisartan Improve Retinal Microcirculation
Pena Seijo M1, Pose Reino A1, Hermida Ameijeiras A1, Lopez Paz JE1, Calvo Gomez C1, Diaz Diaz JL1, Suarez Tembra M1, Diaz Peromingo JA1, Monte Secades R1
1Spain

PS3/WED/272
Hypertension and Pre-Hypertension Are Associated with Cataract in Adult Taiwanese
Lin W-Y1, Hsu H-S1, Lin T1, Lin J-M1, Liu C-S1, Li T-C1, Li C-I1, Huang K-C1, Lin C-C1
1Taiwan, Republic of China

PS3/WED/273
Hypertension and Microcirculation
Guo YC1, Liu XH1, Li YZ1, Xu FF1, Liu FY1
1China

PS3/WED/274
Association of Body Mass Index with Glomerular Filtration Rate in Japanese Men
Matsumura K1, Ohtsubo T1, Goto K1, Yamasaki T1, Fukuhara M1, Oniki H1, Ohta Y1, Iida M1
1Japan

PS3/WED/275
Effect of Visceral Obesity on Left Ventricular Ejection Fraction As Assessed By 64-Multidetector-Row Computed Tomography
Mitsutake R1, Miura S-I1, Shiga Y1, Saku K1
1Japan

PS3/WED/276
Gender Specific Relations between Indices of Adiposity and Ambulatory Blood Pressure
Sibiya MJ1, Majane OH1, Norton G1, Woodiwiss A1
1South Africa
Contribution of Sympathetic Nervous System Activity to Obesity-Induced Subclinical Organ Damage in Young Adults
Lambert EA1, Sari C1, Dawood T1, Nguyen J1, Grima M1, Eikelis N1, Chopra R1, Wong C1, Chatzivlastou K1, Head GA1, Straznicky N1, Esler M1, Schlaich M1, Lambert G1
1Australia

Cardiometabolic Alterations in Hypertensive Women with Abdominal Obesity
Isbele TA1, Silva MT1, Cunha AR1, Oigman W1, Neves MF1
1Brazil

Caloric Restriction Alone Blunts the Accumulation of Visceral Adipose Tissue and Prevents Negative Neurovascular Outcomes such as Erectile Dysfunction in a Rat Model
Maio MT1, Komolova M1, Adams M1
1Canada

Effects of Metabolic Syndrome and Hypertension on Incidence of Peripheral Artery Disease: Adult Health Study in Hiroshima
Tatsukawa Y1, Masunari N1, Yamada M1, Fujiwara S1
1Japan

Calcineurin Mediates the Involvement of Calreticulin in the Protective Effect of Postconditioning on Skeleton Muscle
Li YZ1, Zhang ZY1, Guo XS1, Liu FY1, Liu XH1
1China

Prevalence of Lower ABI in 1040 Middle-Old Aged Cases and Related Risk Factors
Yang XM1, Sun G1, Ding YC1, Yan XL1, Wang C1, Wang F1, Zuo YX1
1China

Progressive Deterioration of Limb Ischemia Is Associated with Impaired Coronary Microcirculation in Patients with Thromboangiitis Obliterans
Takano H1, Miyamoto M1, Takagi G1, Tara S1, Kato K1, Kirinoki S1, Yamamoto E1, Yasutake M1, Mizuno K1
1Japan
PS3/WED/284
Intimal Thickening in the Leg Arteries as an Early Indicator of Atherosclerosis in Hypertensive Patients
Agarwal SK¹, Agarwal NK¹
¹United States

PS3/WED/285
Supervised Exercise Training may Improve the Ambulatory Blood Pressure Monitoring and Stiffness Parameters
Iurciuc M¹, Avram C¹, Vlad A¹
¹Romania

PS3/WED/286
The Mechanism of Exaggerated Blood Pressure Response during Outdoor Exercise in the Morning during Winter in Patients with Essential Hypertension
Mori H¹, Narita T¹, Koeda J¹, Okitsu K¹, Tanno M¹
¹Japan

PS3/WED/287
Oral Estrogen Therapy and Aerobic Training Effects on Insulin Sensitivity, and Hemodynamic and Autonomic Responses to Acute Hyperinsulinemia in Postmenopausal Women: A Randomized Placebo-Controlled Trial
Cardoso Jr. CG¹, Medina FL¹, Pinto LG¹, Labes E¹, Gusmão JL¹, Abrahão SB¹, Tinucci T¹, Mion Jr. D¹, Fonseca AM¹, Forjaz CLM¹
¹Brazil

PS3/WED/288
Contraction Intensity Determines Cardiovascular and Autonomic Responses Following Isometric Handgrip Exercise
Millar PJ¹, MacDonald MJ¹, McCartney N¹
¹Canada

PS3/WED/289
Exercise Decreases Erythropoietin-Induced Hypertension and Oxidative Stress in Mice Overexpressing Human Endothelin-1
Barhoumi T¹,², Kasal DAB¹,³, Shbat L¹, Laurant P², Neves MF³, Paradis P¹, Schiffrin EL¹
¹Canada, ²France, ³Brazil

PS3/WED/290
Alterations of Atrial Natriuretic Peptide (ANP) in Spontaneously Hypertensive Rats (SHR) Submitted to the Chronic Training of Running or Swimming
Endlich PW¹, Firmes L¹, Gonçalves WLS¹, Moysés MR¹, Bissoli NS¹, dos Reis AM¹, Abreu GR¹
¹Brazil
Chronic Exercise Training in Myocardial Infarction

PS3/WED/291

Effects of Acute Isometric Handgrip on Cardiovascular Stress Reactivity and Recovery

Leisure Physical Activity and Cardiovascular Risk Factors in Hypertensive Patients

Association between Blood Pressure, Body Mass Index and Physical Activity in a Rural Population Residing in Dikgale Demographic Surveillance Site (DSS) in South Africa

Exercise Blood Pressure in Middle-Aged Men as a Predictor of Future Blood Pressure: A 10-Year Follow-Up

The miR-204/STAT3/NFAT Axis Can Be Therapeutically Targeted in both Human and Experimental Pulmonary Arterial Hypertension

(Pro)Renin Receptor from the Human Umbilical Vein Endothelial Cells Binds and Activates Recombinant Human Prorenin
PS3/WED/298
Significantly Greater Ambulatory BP Lowering In High Renin Hypertensive Patients with High-Dose Angiotensin Receptor Blockade than with ACE-Inhibition or Direct Renin Inhibition
Quinn U¹, Maguire B¹, Mc Adam B¹, Stanton A¹
¹Ireland

PS3/WED/299
Mechanism of Losartan-Enhanced Regulator of G Protein Signaling 2 mRNA Expression in Vascular Smooth Muscle Cells
Wu Y¹, Takahashi H¹, Nakagawa S¹, Suzuki E¹, Numabe A¹, Yanagi Y¹, Tamaki Y¹, Yamazaki A¹, Fujita T¹, Araie M¹, Nagai R¹, Uehara Y¹
¹Japan

PS3/WED/300
Aliskiren Binds to the Complexes of Renin and Prorenin with (Pro)Renin Receptor
Biswa KB¹, Nabi AHMN¹, Arai Y¹, Nakagawa T¹, Ebihara A¹, Ichihara A¹, Watanabe T¹, Inagami T², Suzuki F¹
¹Japan, ²United States

PS3/WED/301
MAS Receptor Activation Contributes to the Improvement of Vascular Remodelling Induced by the Angiotensin Receptor Blocker Olmesartan in Spontaneously Hypertensive Rats
Savoia C¹, Rossi C¹, Arrabito E¹, Parente R¹, Rizzi J¹, Nicoletti C¹, Zezza L¹, Alonzo A¹, Volpe M¹, Schiffrin EL²
¹Italy, ²Canada

PS3/WED/302
Increased Dietary NaCl Potentiates the Effects of Elevated Prorenin Levels on Blood Pressure and Organ Pathology
Campbell DJ¹, Karam H², Bruneval P², Mullins JJ³, Ménard J²
¹Australia, ²France, ³United Kingdom

PS3/WED/303
Effect of Aliskiren Addition to Amlodipine on Ankle Edema and Subcutaneous Tissue Pressure in Hypertensive Patients
Mugellini A¹, Fogari R¹, Preti P¹, Derosa G¹, Malamani G¹
¹Italy

PS3/WED/304
Attenuation of Stretch Induced-ANP Secretion by Endogenously Generated Angiotensin II via AT1 Receptor Pathway
Shah A¹, Oh YB¹, Shan G¹, Park WH¹, Kim SH¹
¹Korea, Republic of
PS3/WED/305
Angiotensin Converting Enzyme 2: A Novel Marker of Coronary Artery Disease
Freeman M1, Patel SK1, Velkoska E1, Dean RG1, Griggs K1, Al-Fiadh A1, Horrigan M1, Farouque HMO1, Burrell LM1
1Australia

PS3/WED/306
Blood Pressure in Mice and its Dependency on ACE2 Activity
Ye M1, Wysocki J1, Soler MJ2, Kalea A1, Gurley SB1, Batlle D1
1United States, 2Spain

PS3/WED/307
Arterial Compliance and Angiotensin Converting Enzyme Gene I/D Polymorphism with Acute High Altitude Reaction
Chen Y1, Sun N1, Wang L1, Xi Y1
1China

PS3/WED/308
Aliskiren/HCTZ Is Effective in Obese Patients with Stage 2 Hypertension Regardless of Pretreatment Plasma Renin Activity (PRA) with Accentuated Efficacy in Moderate-To-High Pretreatment PRA
Whaley-Connell A1, Yadao A1, Purkayastha D1, Sowers JR1
1United States

PS3/WED/309
Urinary Angiotensinogen Reflects Clinico-Pathological Findings in Iga Nephropathy
Ihm CG1, Jeong KH1, Lee TW1
1Korea, Republic of

PS3/WED/310
Effect of Subpressor Dose of Angiotensin II in Modulation of the Composition of Vascular Extracellular Matrix
Viegas KAS1, Lacchini S1, Souza TC1, Rabechi NB1, Piva C1, Silva JCC1, Ribeiro TF1, Lima CT1, Laboratory of Cardiovascular Disfunction
1Brazil

PS3/WED/311
Treating ACI-Induced Coughing By the Use of Direct Renin Blockage
Landers B, Germany

PS3/WED/312
Voltage-Gated Na+ Channels Regulate Contraction of Arteries: Coupling with the Na/Ca Exchanger
Fort A1, Thollon C1, Richard S1, Virsolvy A1
1France
PS3/WED/313
Myogenic Tone in Mesenteric Arteries Involves P2Y Receptor-Mediated, NKCC1-Dependent Signaling
Koltsova SV1, Maximov GV2, Lavoie JL1, Kotelevtsev SV2, Tremblay J1, Grygorczyk R1, Hamet P1, Orlov SN1,2
1Canada, 2Russian Federation

PS3/WED/314
Expression and Function of Osteopontin in Vascular Adventitial Remodeling
Jin X1, Fu GX1, Zheng L1, Zhu DL1, Gao PJ1
1China

PS3/WED/315
Urotensin II Induces Interleukin 8 Expression in Human Umbilical Vein Endothelial Cells
Cheng T-H1, Chen J-J1, Tsai C-S1
1Taiwan, Republic of China

PS3/WED/316
Cystamine Reduces Blood Pressure in SHR and Attenuates Inward Eutrophic Remodelling in Vitro
Pedersen ME1, Eftekhar A1, Bald E2, Mulvany MJ1
1Denmark, 2Poland

PS3/WED/317
Gamma-Glutamyl Transaminase Level Predicts the Development of Hypertension
Cheung BMY1, Ong KL1, Tso AWK1, Cherny SS1, Sham PC1, Lam TH1, Lam KSL1
1China

PS3/WED/318
Urinary Albumin Excretion >15 mg/g Is Significantly Associated With ABPM Parameters in Resistant Hypertensives
Oliveras A1, Armario P1, Hernández del Rey R1, Suárez C1, Martell N1, Cuadrado LM1, Gómez P1, Veiga A1, Redón J1, de la Sierra À1, Spanish Resistant Hypertension Registry
1Spain

PS3/WED/319
Vascular and Cardiac Functional and Structural Screening to Identify Risk of Future Cardiovascular Morbid Events
Duprez DA1, Florea N1, Zhong W1, Grandits GA1, Hawthorne CK1, Hoke L1, Cohn JN1
1United States
PS3/WED/320
The Relationship of Endothelin-1 and Hypertension in Javanese Population, Mlati, Sleman Yogyakarta, Indonesia
Bawazier LA¹, Sja’bani M¹, Haryana SM¹, Soesatyo M¹, Sadewa AH¹
¹Indonesia

PS3/WED/321
Cystatin C is Better as a Marker and Predictor Factor in Hypertension Population (Mlati, Sleman, Yogyakarta, Indonesia)
Sja’bani M¹, Bawazier LA¹, Irijanto F¹, Prasanto H¹, Kuswadi I¹, Hariawan H¹, Taufiq N¹, Tomino Y²
¹Indonesia, ²Japan

PS3/WED/322
Attenuation of Cardiovascular Responses to Endomorphin-2 Microinjections into the Nucleus Tractus Solitarius of the Spontaneously Hypertensive Rat
Kawabe T¹, Ueyama T¹, Tsuruo Y¹, Hano T¹
¹Japan

PS3/WED/323
Baroreceptor Dysfunction Induces Right Ventricular Hypertrophy Associated with Fetal Markers and Collagen Type I and III Genes Expression in Hypertensive and Normotensive Rats
Flues K¹, Moraes-Silva I², Mostarda C¹, Diniz GP¹, Moreira ED¹, Piratello A¹, Chaves MLB¹, De Angelis K¹, Caldine EG¹, Irigoyen MC¹
¹Brazil, ²Bosnia and Herzegovina

PS3/WED/324
Exercise Training Differentially Affects Skeletal Muscle Sympathetic Outflow in Normotensive and Hypertensive Rats
Michelini LC¹, Antunes VR¹, Burgi K¹
¹Brazil

PS3/WED/325
Single-Unit Muscle Sympathetic Nerve Activity Responsiveness to Lower Body Negative and Positive Pressure in Healthy Humans
Murai H¹, Notarius CF¹, Morris BL¹, Kimmerly D¹, Picton P¹, Floras JS¹
¹Canada

PS3/WED/326
Functional Discrimination of Different Capsaicin-Sensitive Renal Afferent Nerve Fibers
Ditting T¹, Freisinger W¹, Rodionova K¹, Heinlein S¹, Veelken R¹
¹Germany
PS3/WED/327
Autonomic Control of Heart Rate Is Altered During Orthostatic Stress in Premenopausal Estrogen Deficient Physically Active Women
O’Donnell E1, Goodman JM1, Murai H1, Morris B1, Floras JF1, Harvey PJ1
1Canada

PS3/WED/328
Early Autonomic Changes in Patients with Newly Diagnosed Arterial Hypertension
Frana P1, Řiháček I1, Plachy M1, Jurák P1, Halámek J1, Pinková L1, Souček M1, Bartošíková L1, Fra ová J1
1Czech Republic

PS3/WED/329
Hypertension Is Associated With Greater Blood Pressure Responses to Aversive but Not Non-Aversive Stress in BPH/2J Mice
Davern PJ1, Jackson KL1, Nguyen-Huu T-P1, La Greca L1, Head GA1
1Australia

PS3/WED/330
Higher Muscle Sympathetic Nerve Activity is Associated with Diastolic Dysfunction in Hypertensive Patients without Increase in Left Ventricular Mass
Souza SBC1, Borile S1, Ferreira-Filho JCA1, Cuoco MAR1, Negrao CE1, Rondon MU1, Krieger EM1, Consolim-Colombo FM1
1Brazil

PS3/WED/331
Baroreflex Impairment Decreases Aerobic Capacity Associated with Reduced Cardiac Capillary Density in Hypertensive Rats
Moraes-Silva IC1, Mostarda C1, de La Fuente RN1, Caldini EG1, Krieger EM1, De Angelis K1, Irigoyen MC1, Experimental Hypertension Laboratory
1Brazil

PS3/WED/332
Neural and Structural Remodeling of Arteries in SHR during Blood Pressure Increasing
Xi Y1, Sun N1
1China

PS3/WED/333
Standing Test after the Blood Donation Can Predict the Incidence of Late Phase Vasovagal Reaction
Yoshida M1, Ando S-I1, Dan E1, Narita S1, Momii H1, Kadokami T1, Sato Y1, Kiyokawa T1, Nakao C1
1Japan
PS3/WED/334
Cardiovascular Autonomic Modulation and Heart Lipoperoxidation in an Experimental Model of Menopause: Role of Hypertension and Fructose Overload
Brito JO¹, Bernardes N¹, Sanches IC¹, Fernandes T¹, Irigoyen MC¹, Belló-Klein A¹, De Angelis K¹
¹Brazil

PS3/WED/335
Myocardial Protective Effects of Doxycycline during Experimental Acute Pulmonary Embolism
Tanus-Santos JE¹, Neves EMN¹, Rizzi E¹, Castro MM¹, Gerlach RF¹
¹Brazil

PS3/WED/336
Effects of Doxycycline in the Mortality and Right Ventricular Damage Following Acute Pulmonary Embolism in Rats
Cau SBA¹, Barato RC¹, Muniz JJ¹, Tanus-Santos JE¹
¹Brazil

PS3/WED/337
The Effects of Aldosterone and Eplerenone on Perivascular Adipose Tissue-Induced Anticontractility in Isolated Mesenteric Arteries; Role of Bkca Channels
Lynch FM¹, Withers SB¹, Werner M¹, Heagerty AM¹
¹United Kingdom

PS3/WED/338
Clinical Implication of Isolated Spontaneous Dissection of Superior Mesenteric Artery
Jung K-T, Korea, Republic of

PS3/WED/339
Adventitial ET-1 and its Receptor Expression
Ratsep M¹, Adams M¹, Wang HD¹
¹Canada

PS3/WED/340
The Prevalence of Erectile Dysfunction and the Associated Risk Factors Among Hypertensive Patients in the Rural Malaysian Community
Md Ariff F¹, Md. Ikhsan S¹, Rodi I¹, Mariam M¹, N. Nairan A¹, Ariza A¹, Nor Aini MN¹
¹Malaysia
PS3/WED/341
Normal Values for Common Carotid Artery IMT Should be Adjusted for Age in Both Men and Women
Armstrong DW\textsuperscript{1}, Nault M\textsuperscript{1}, Brouillard D\textsuperscript{1}, Matangi M\textsuperscript{1}
\textsuperscript{1}Canada

PS3/WED/342
The Analysis of Clinical Characteristics and Prognosis of 246 Patients with Aortic Dissection
Ling-Gen G\textsuperscript{1}, Xian-Liang Z\textsuperscript{1}, Ru-Tai H\textsuperscript{1}
\textsuperscript{1}China

PS3/WED/343
Selective Expression of an NAD Regenerating Enzyme in Small and Medium Sized Arteries
Watson A\textsuperscript{1}, Nong Z\textsuperscript{1}, O'Neil C\textsuperscript{1}, Chen S\textsuperscript{1}, Pickering JG\textsuperscript{1}
\textsuperscript{1}Canada

PS3/WED/344
Comparative Study of Vascular Function in Chinese and Japanese Women
Wang H\textsuperscript{1}, Kohji S\textsuperscript{2}, Lu N\textsuperscript{1}
\textsuperscript{1}China, \textsuperscript{2}Japan

PS3/WED/345
The Prevalence of Carotid Disease in Patients with Low and Intermediate Framingham Risk Scores
Matangi MF\textsuperscript{1}, Armstrong DW\textsuperscript{1}, Nault M\textsuperscript{1}, Brouillard D\textsuperscript{1}
\textsuperscript{1}Canada

PS3/WED/346
The Analysis of Clinical Characteristics and Survey of Long-Term Results and Health Problems of 125 Marfan Patients After Aortic Surgical Treatment
Ling-Gen G\textsuperscript{1}, Fang L\textsuperscript{1}, Xian-Liang Z\textsuperscript{1}, Ru-Tai H\textsuperscript{1}, Qian C\textsuperscript{1}, Yong-Bo W\textsuperscript{1}
\textsuperscript{1}China

PS3/WED/347
The Role of Vascular Risk Factors in Progression of Dementia
Suvorova I, Russian Federation

PS3/WED/348
High Levels of Norepinephrine and Epineprine Is not Correlated with High Blood Pressure in Transgenic Mouse Expressing Tonin of Rat
Palomino Jara Z\textsuperscript{1}, Ribeiro AA\textsuperscript{1}, Souza LE\textsuperscript{1}, Higuchi DA\textsuperscript{1}, Irigoyen MC\textsuperscript{1}, Pesquero JL\textsuperscript{1}, Casarini DE\textsuperscript{1}
\textsuperscript{1}Brazil
PS3/WED/349
Normal Blood Pressure Tables by Automatic Oscillometric Devices in Korean Children and Adolescents
Lee CG¹, Moon JS¹, Choi JM¹, Kim YT¹
¹Korea, Republic of

PS3/WED/350
Trajectories of Systolic Blood Pressure and Depressive/Anxious Mood in Childhood
Louise S¹, Warrington N¹, McCaskie PA¹, Oddy WH¹, Zubrick SR¹, Hands B¹, Mori TA¹, Silburn S¹, Palmer LJ¹, Mattes E¹, Beilin LJ¹
¹Australia

PS3/WED/351
Measurement of Aortic Pulse Wave Velocity in Children – Comparison of the SphygmoCor and the Vicorder Device
Kracht D¹, Doyon A¹, Jacobi C¹, Schaefer F¹, Sorrentino S¹, Schmidt BM¹, Wuehl E¹, Melk A¹
¹Germany

PS3/WED/352
Aortic Pulse Wave Velocity Increases with Age in Children and Adolescents
Kracht D¹, Baig S¹, Doyon A¹, Jacobi C¹, Schaefer F¹, Wuehl E¹, Melk A¹, Schmidt BM¹
¹Germany

PS3/WED/353
24-Hour Blood Pressure Monitoring (ABPM) versus Casual Blood Pressure Measuring and Target – Organ Damage in Children and Adolescents
Schusterova I¹, Riecansky I¹, Kuchta M¹, Sabol F¹, Saligova J¹
¹Slovakia

PS3/WED/354
Relationship between Carotid Arteries Intima Media Thickness, Obesity and Blood Pressure in Obese Adolescents
Stabouli S¹, Kotsis V¹, Papamichail C¹, Constantopoulos A¹, Zakopoulos N¹
¹Greece

PS3/WED/355
Mirmiran P¹, Hosseini F¹, Mousavi Nasl Khameneh ,A¹, Azizi F¹
¹Iran, Islamic Republic of
WEDNESDAY, SEPTEMBER 29

PS3/WED/356
Early Detection and Treatment of Cardiovascular Diseases in Children: An Analysis of School Health Programme in Gujarat
Vajpeyee SK, India

PS3/WED/357
Pre-Hypertension in Adolescents: Prevalence and Risk Factors
Silva E1, Villasmil J1, Bermudez G1, Gonzalez A1, Bracho M1, Esis C1, Romero V1, Calmon G1
1Venezuela

PS3/WED/358
Vascular Structure, Inflammatory Mediators and Oxidative Stress in Childhood Hypertension
Ahmed M1, Touyz RM1, Feber J1, Burns K1
1Canada

PS3/WED/359
Effect of the Treatment of Aortic Coarctation on the Arterial Pressure in Young Adult Patients
Boughzala E1, Hammas S1, Ouali S1, Gribaa R1, Hammami R1, Laroussi L1, Fradi S1, Jilani B1, Neffeti E1
1Tunisia

PS3/WED/360
Influence of Gender on Anthropometric Indices and Arterial Pressure in Children
Ornelas E1, Miranda JM1, Machi J1, da Silva CB1, Consolim-Colombo F1, Wichi R1
1Brazil

PS3/WED/361
Vascular Gene Expression in Mice Overexpressing Human Endothelin-1 Targeted to the Endothelium
Simeone SMC1, Li MW1, Paradis P1, Schiffrin EL1
1Canada

PS3/WED/362
Complement C3 is Involved in Adventitial Fibroblast Phenotypic Differentiation Induced by Angiotensin-II and TGF-beta 1
Guo S1, Wu L1, Gao P1, Zhu D1
1China
PS3/WED/363
Development of a Multiplexed, Quantitative Immuno-MALDI Mass Spectrometry Assay for Angiotensin I and II
Reid JD¹, Mason RD¹, Holmes DT¹, Borchers CH¹
¹Canada

PS3/WED/364
Application of Proteomic Methods for Evaluation of Kidney Transplant Rejection Using Blood Sample
Perez JD¹, Sakata MM¹, Cunha TS¹, Arita DY¹, Souza GHMF¹, Silva Júnior HT¹, Pestana JOMDA¹, Casarini DE¹
¹Brazil

PS3/WED/365
Vasorelaxant Actions of Nitroxy1 (Hno) in Human Saphenous Veins and Radial Arteries
Lumsden NG¹, Andrews KL¹, Kemp-Harper BK¹, Chin-Dusting JP¹
¹Australia

PS3/WED/366
Moderate Prenatal Ethanol Exposure Impairs the Pressor Responsiveness to Stress and Alters Vascular Function
Denton KM¹, Tjongue M¹, Tare M¹, Probyn M¹, Bertram JF¹, Moritz K¹
¹Australia

PS3/WED/367
Two-Hour Glucose Level from an Oral Glucose Tolerance Test Predicts the Development of Hypertension Over 5 Years
Chae SC¹, Lee JH¹, Yang DH¹, Kim B-W¹, Chun B-Y¹, Kam S¹, Park W-H¹
¹Korea, Republic of

PS3/WED/368
The N- and L-Type Calcium Channel Blocker Cilnidipine Reduces Albuminuria in Diabetic DB/DB Mice
Kasahara M¹, Yokoi H¹, Mori K¹, Iga N¹, Ishimura T¹, Ogawa Y¹, Kuwabara T¹, Imamaki H¹, Kawanishi T¹, Koga K-I¹, Ishii A¹, Sugawara A¹, Mukoyama M¹, Nakao K¹
¹Japan

PS3/WED/369
TNF-α Neutralization Reduces Hypertension and Renal Inflammation in Rats with Chronic Renal Failure: Role of NF-κB
Therrien FJ¹, Agharazii M¹, Lebel M¹, Lariviére R¹
¹Canada
Microalbuminuria and Cardiovascular Risk in Hypertension Patients, is it Correlated at Low Levels? Annual Evolution of the Mauastur Study
Fernandez-Vega F1, Prieto Diaz MA1, Gorostidi M1, Sanchez E1, Alvarez A1, Alvarez R1, Hevia E1, Marin R1, Gonzalez Lopez MB1, Bousquets L1
1Spain

Effect of Oral Vitamin C on Hypertension in Patients with Chronic Renal Failure Receiving Hemodialysis
Esmaeilpour Zanjani S1, Sajadi A1, Farahani B1, Dormanesh B1, Zare M1
1Iran, Islamic Republic of

Dose Thirty Percent Rule in the Elevation of Serum Creatinine Hold True for Mineralocorticoid Receptor Antagonist?
Takahashi K1, Fujita T1
1Japan

Target Organ Damage Changes Due To Lercanidipine Treatment in Hypertensive Patients with Decreased Kidney Function
Bezrodnyy V1, Mishchenko L1, Svyshchenko Y1, Bezrodna L1
1Ukraine

Effects of the Telehealth Program in Knowledge, Self-Efficacy, and Blood Sugar Control in Diabetes Mellitus Clients
Wu M-C1, Lin Z-C1, Sung H-C1
1Taiwan, Republic of China

Suboptimal Control of Arterial Hypertension in Greek Obese Patients
Sarigianni M1, Bekiari E1, Paschos P1, Karagiannis T1, Tsapas A1, Paletas K1
1Greece

The Barriers of Arterial Hypertension Management at Primary Healthcare Level
Tsinamdzgvrishvili B1, Trapaidze D1, Abesadze T1, Sturua L1, Baramidze L1
1Georgia
PS3/WED/378
Inadequate Treatment of Hypertension in Korea - Data from the Third Korean National Health and Nutrition Examination Survey
Liew D1, Lee H-Y2
1Australia, 2Korea, Republic of

PS3/WED/379
Reduced Expression of FXYD Domain Containing Ion Transport Regulator 5 (FXYD5) Associated with Hypertension
Yang D1, Shi X1, Huang X1, Fang F1, Chen C1, Huang F1, Zhou X1, Lin N1, Geng Y-J2
1China, 2United States

PS3/WED/380
Losartan/HCTZ Is More Effective Than Titration to Maximum-Dose ARBs for Uncontrolled Hypertension in Multi-Center Randomized Controlled Trial: The J-HOME AI Study
Metoki H1, Ohkubo T1, Katada S1, Obara T1, Kanno A1, Imai Y1, the J-HOME AI Study Group
1Japan

PS3/WED/381
Losartan/Hydrochlorothiazide Excels High-dose Angiotensin Receptor Blockers in Lowering Morning Home Blood Pressure
Hanayama Y1, Nakamura Y1, Uchida HA1, Makino H1
1Japan

PS3/WED/382
Physician’s Awareness of Home Blood Pressure Measurement in Hypertensive Patients with Chronic Kidney Disease in Japan
Sugano N1, Kuriyama S1, Hara Y1, Endo S1, Yoshizawa T1, Suetsugu Y1, Takane K1, Takahashi Y1, Hayashi H1, Ishikawa M1, Tokudome G1, Hosoya T1
1Japan

PS3/WED/383
Validated Home Blood Pressure Education Programs: Essential to Cardiovascular Risk Prediction
Cloutier L1, Leblanc M-È1
1Canada

PS3/WED/384
Measuring Days and Readings for Home Blood Pressure Monitoring in the Assessment of Blood Pressure in Chinese with Hypertension and Diabetes Mellitus
Sheng C1, Cui Y1, Chen H1, Fan W1, Chen X1, Huang Q1, Li Y1, Wang J1
1China
PS3/WED/385
A Randomized Control Trial of Home Blood Pressure Monitoring on the Management of the Stages 2 And 3 Hypertension in Chinese
Wang J-G1, Li Y1, Sheng C-S1, Huang Q-F1, Zhang Y1
1China

PS3/WED/386
Clinical Impact of Home BP Profiles of Treated Hypertensive Patients Having Diabetes
Lee J-H1, Kim D-W1, Bae J-W1, Cho M-C1, Park J-B1, Park C-G1, Youn H-J1, Choi D-J1, Ahn Y-K1, Shin J-H1, Rim S-J1, Bae J-H1, Korean Hypertension Research Network
1Korea, Republic of

PS3/WED/387
Hypertension Control and Influence Factors: Results of the China Status (Survey of hypertensive patients blood pressure control rate in daily clinic service)
Hu D1, Liu L1
1China

PS3/WED/388
Urinary Calcium and Magnesium Excretion and Blood Pressure: INTERMAP Study
Tzoulaki I1, Kesteloot H2, Brown IJ1, Stamler J3, Elliott P1, International Collaborative Research Group on Macro-/Micronutrients and Blood Pressure
1United Kingdom, 2Belgium, 3United States

PS3/WED/389
Impact of Metabolic Syndrome on the Adequacy of Therapeutic Targets among Hypertensive Patients
Rodrigues CJ1, Ferreira H1, Kohlmann Jr O1, Ribeiro AB1, Zanella MT1, Batista MC1
1Brazil

PS3/WED/390
Trends in Hypertension Control and Antihypertensive Drug Use in Turkey from 2003 To 2007
Arici M1, Turgan C1, Derici U1, Altun B1, Sindel S1, Erdem Y1, Erbay B1, Karatan O1, Hasanoglu E1, Caglar S1, Turkish Society of Hypertension and Renal Diseases
1Turkey
PS3/WED/391
A Comprehensive Assessment of Implementation of Guidelines: Hypertension and Related Diseases
Zhang MQ¹, Kuang PG¹, Li RJ¹, Wang YF¹, Ji XM¹, Li XF¹, Niu JY¹, Wang XY¹, Liu YQ¹, Zhang LP¹, Li Y¹, Li YC¹, Ren ZY¹, Kong YM¹, Wang RD¹, Wang SY¹, Zhang XS¹, Liu Q¹, Xie ZQ¹, Zhou MW¹, Tian Y¹, Chen H¹, Pu CQ¹, Tian CL¹, Guan WP¹, Liu LS¹, Coalition of Cardiovascular Diseases Prevention Program
¹China

PS3/WED/392
The Impact of Arterial Hypertension on Right Ventricular Deformation
Hristova K¹, La Gerche A², Katova T¹, Simova J¹, Kostova V¹
¹Bulgaria, ²Belgium

PS3/WED/393
Methylenetetrahydrofolate Reductase C677T Polymorphism, Hypertension, and Risks of Stroke: A Prospective Nested Case-Control Study
Wang J¹, Hu D¹, Liao Y¹, Lin J¹, Yang T¹, Jiang S¹, Zhao Z¹, Wang Y¹, Xing H¹, Huang Y¹, Wang B¹,², Huo Y¹, Xu X²
¹China, ²United States

PS3/WED/394
PPARγ-Mediated Modulation of GRK-2 Signaling is Involved in the Regulation of Blood Pressure in SHR
Yousefipour Z¹, Newaz M¹
¹United States

PS3/WED/395
Efficacy and Safety of Single-Pill Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 25 mg as First Line Therapy for Patients with Grade 2 or Grade 3 Hypertension
Zhu D¹, Bays H², Gao P¹, Guw V¹, Mattheus M³, Ruilope LM⁴
¹China, ²United States, ³Germany, ⁴Spain

PS3/WED/396
Prevalence of Pulmonary Hypertension in Asymptomatic Subjects with Schistosomal Infection in Nile Delta
Farrag AAM¹, El Aroussy W¹, Zaghloul S¹, El Guindy MS¹, Yacoub MH²
¹Egypt, ²United Kingdom
PS3/WED/397
Young Diabetic Patients Had Increased Coronary and Extracoronary Atherosclerotic Burden as Detected by Multidetector Computed Tomography
Farrag AAM\textsuperscript{1}, Bakhoum S\textsuperscript{1}, Ali M\textsuperscript{1}, El Faramawy AAA\textsuperscript{1}, Guirquis E\textsuperscript{1}
\textsuperscript{1}Egypt

PS3/WED/398
Hypertension and Acute Coronary Syndrome without ST Elevation
Abid L\textsuperscript{1}, Abid D\textsuperscript{1}, Hentati M\textsuperscript{1}, Kammoun S\textsuperscript{1}
\textsuperscript{1}Tunisia

PS3/WED/399
Efficacy of Hypolipidemic Therapy with Generic and Original Medications “Simvastatin”
Balandina Y\textsuperscript{1}, Tarlovskaya E\textsuperscript{1}, Sapozhnikova I\textsuperscript{1}, Maksimchuk N\textsuperscript{1}
\textsuperscript{1}Russian Federation

PS3/WED/400
Risk Factors Related to Low Ankle-Brachial Index Evaluated by Two Different Methods in Hypertensive Elderly Patients
Monteiro R\textsuperscript{1}, Marto RH\textsuperscript{1}, Oigman W\textsuperscript{1}, Neves MF\textsuperscript{1}
\textsuperscript{1}Brazil

PS3/WED/401
High Oxygen Exposure in Newborn Rats Impairs Nephrogenesis: Role of HIF-1\textalpha in Developmental Programming of Hypertension
Popescu CR\textsuperscript{1}, Bertagnolli M\textsuperscript{1}, Sartelet H\textsuperscript{1}, Phan V\textsuperscript{1}, Yzydorczyk C\textsuperscript{1}, Germain N\textsuperscript{1}, Cloutier A\textsuperscript{1}, Nuyt AM\textsuperscript{1}
\textsuperscript{1}Canada

PS3/WED/402
Electrolyte Levels and Creatinine Clearance during the Development of Hypertension in Two Rat Models
Sosa A\textsuperscript{1}, Hernández N\textsuperscript{1}, Diaz E\textsuperscript{1}, Pérez MR\textsuperscript{1}
\textsuperscript{1}Venezuela
# Program by Day

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 203, West Level 2</th>
<th>Room 204, West Level 2</th>
<th>Room 205, West Level 2</th>
<th>Room 206, West Level 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>How to Session 07:00-08:00</td>
<td>How to Session 07:00-08:00</td>
<td>How to Session 07:00-08:00</td>
<td>How to Session 07:00-08:00</td>
</tr>
<tr>
<td>07:30</td>
<td>How to Session 07:00-08:00</td>
<td>How to Session 07:00-08:00</td>
<td>How to Session 07:00-08:00</td>
<td>How to Session 07:00-08:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Ballroom A, West Level 1</th>
<th>Ballroom B, West Level 1</th>
<th>Ballroom C, West Level 1</th>
<th>Rooms 211-214, West Level 2</th>
<th>Rooms 109-110, West Level 1</th>
<th>Exhibition Hall C West Exhibition Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Hypertension Treatment and the Risk of Developing Diabetes Mellitus 08:15-9:45</td>
<td>Chronic Disease Prevention 08:15-9:45</td>
<td>All About Salt 08:15-9:45</td>
<td>New Antihypertensive Drugs, New Drug Targets 08:15-9:45</td>
<td>Role of Nurse Clinical in Hypertension Management 08:15-9:45</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>Hypertension Treatment and the Risk of Developing Diabetes Mellitus 08:15-9:45</td>
<td>Chronic Disease Prevention 08:15-9:45</td>
<td>All About Salt 08:15-9:45</td>
<td>New Antihypertensive Drugs, New Drug Targets 08:15-9:45</td>
<td>Role of Nurse Clinical in Hypertension Management 08:15-9:45</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>Hypertension Treatment and the Risk of Developing Diabetes Mellitus 08:15-9:45</td>
<td>Chronic Disease Prevention 08:15-9:45</td>
<td>All About Salt 08:15-9:45</td>
<td>New Antihypertensive Drugs, New Drug Targets 08:15-9:45</td>
<td>Role of Nurse Clinical in Hypertension Management 08:15-9:45</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>Hypertension Treatment and the Risk of Developing Diabetes Mellitus 08:15-9:45</td>
<td>Chronic Disease Prevention 08:15-9:45</td>
<td>All About Salt 08:15-9:45</td>
<td>New Antihypertensive Drugs, New Drug Targets 08:15-9:45</td>
<td>Role of Nurse Clinical in Hypertension Management 08:15-9:45</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications 10:30-12:00</td>
<td>Developing Countries 10:30-12:00</td>
<td>Genetics of Hypertension and Atherosclerosis 10:30-12:00</td>
<td>The Expanding 'Kinome' in Vascular Regulation 10:30-12:00</td>
<td>Asia Pacific Young Investigator Session 10:30-12:00</td>
<td></td>
</tr>
</tbody>
</table>

See the Optional Tours & Social Events section for the tours and social events schedule.
07:00-08:00  **Clinical Science**  
**How to Session**  
**How to Implement Newer Strategies for the Medical Management of Obesity**  
Room 203, L2

The Medical Management of Obesity  
Sharma A, Canada

07:00-08:00  **Public Health – Population Science**  
**How to Session**  
Room 204, L2

Approach to Management of Hypertension in Developing Countries  
Seedat YK, South Africa

07:00-08:00  **Clinical Science**  
**How to Session**  
**How to Session for Pharmacists**  
Room 205, L2

**Learning Objectives:**
- To learn when to recommend the use of home blood pressure monitors  
- To improve skills in assessing and improving adherence with antihypertensive drugs  
- To learn more about important drug intolerances that can commonly manifest from the use of antihypertensive, either alone or in combination with other drugs or OTC products, and how to assess patients for them

**Chair:** Semchuk W, Canada

Patient Assessment by the Pharmacist: Beyond Counselling – Monitoring Drug Therapy  
Semchuk W¹, Thompson A¹  
¹Canada
THURSDAY, SEPTEMBER 30

07:00-08:00  Clinical Science
How to Session
Core Competency in Hypertension for Nursing
Room 206, L2

Home, Ambulatory and Office Blood Pressure Measurement:
Finding the Best Approach for Your Patient
Cloutier L1, McLean D1, Pham T1, Gaudet L1, Morris D1
1Canada

08:15-09:45  Clinical Science
Symposium
Hypertension Treatment and the Risk of Developing Diabetes Mellitus
Ballroom A, L1

Chair: Lewanczuk R, Canada

08:15  The Importance of Diabetes and Pre-Diabetes in Hypertension Management
Haffner S, United States

08:45  How Aggressive Should Hypoglycemic Therapy Be After ACCORD
Cushman W1, Simons-Morton D1
1United States

09:15  Advances in Reducing the Burden of Vascular Disease in Diabetes
Chalmers J, Australia
THURSDAY, SEPTEMBER 30

08:15-09:45  Public Health – Population Science
State of the Art – Oral Presentations
Chronic Disease Prevention  Ballroom B, L1

Chair: Ezzati M, United States

08:15  Translating Knowledge on Hypertension to Action, Steps Along the Way
Hutchinson H, Canada

08:45  Primary Prevention of Cardiovascular Risk Factor – Éducoeur Study
Larochelle P¹, Goyer L¹, Dufour R¹, Janelle C¹, Blais C¹, L’Abbé C¹, Raymond É¹, Gauthier M¹, Perrault V¹, de Champlain J¹
¹Canada

08:55  Large Change in the Opinion on Antihypertensive Drug Treatment among General Practitioners in Sweden between 2002 and 2009
Dahlström J¹, Persson M¹, Lönnerg G¹, Nyström L¹, Norberg M¹, Weinehall L¹, Carlberg B¹, Lindholm LH¹, Swedish Stroke Prevention Study (SSPS)
¹Sweden

09:05  Physical Activity Intensity and Fitness as Determinants of Blood Pressure in a Population-based Sample of Youth
McGavock J¹, Torrance B¹, Rinaldi R¹, Wozny P¹, Lewanczuk R¹, Healthy Hearts Investigator Team
¹Canada

09:15  Prevalence of Adult Hypertension in the Greater Accra Region of Ghana and Related Health Behaviour
Bosu WK¹, Wellington E¹, Odoi AA¹, Wadieh B¹
¹Ghana

09:25  Cost Benefit of Salt Reduction to Complement Existing Clinical Hypertension Programs
Webster J¹, Dunford E¹, Chalmers J¹, Corbett S¹, Neal B¹
¹Australia
09:35  Ethnicity and the Association of Low Cardiovascular Disease Risk with Nutrient Intakes in the United States: The International Study of Macronutrients, Micronutrients and Blood Pressure (INTERMAP)
Shay CM1, Dyer AR1, Brown IJ2, Chan Q2, Elliott P2, Carnethon MR1, Okuda N3, Daviglus ML1, Van Horn L1, Stamler J1
1United States, 2United Kingdom, 3Japan

08:15-09:45 Translational – Clinical Science
State of the Art – Oral Presentations
All About Salt  Ballroom C, L1

Chair: Konradi A, Russian Federation

08:15  Nonpressor Detrimental Effects of Sodium
Mimran A, France

08:45  Effect of Modest Salt Reduction on Skin Capillary Rarefaction In White, Black And Asian Individuals With Mild Hypertension
He FJ1, Marciniak M1, Markandu ND1, Antonios TF1, MacGregor GA1
1United Kingdom

08:55  Magnitude of Marinobufagenin-Induced Na/K-ATPase Inhibition Are Associated With Salt-Sensitivity of Blood Pressure in Male Patients with Resistant Hypertension
Konradi AO1, Emelyanov IV1, Frolova EV1, Fedorova OV2, Bagrov AY2
1Russian Federation, 2United States

09:05  Relation between Urinary Sodium Excretion and Blood Pressure in the Observational Follow-Up of 1499 Subjects from 5 European Populations
Stolarz-Skrzypek K1,2, Kuznetsova T1, Thijs L1, Tikhonoff V3, Seidlerova J4, Olszanecka A2, Malyutina S5, Casiglia E3, Filipovsky J4, Kawecka-Jaszcz K2, Nikitin Y5, Staessen JA1,6, European Project on Genes in Hypertension (EPOGH) Investigators
1Belgium, 2Poland, 3Italy, 4Czech Republic, 5Russian Federation, 6Netherlands

09:15  Dietary Salt Intake Correlates With Left Ventricular Mass in Patients with Primary Aldosteronism, But Not in Normotensive Control Subjects
Pimenta E1, Gordon RD1, Ahmed AHA-A1, Cowley D1, Kogovsek C1, Robson D1, Leano R1, Marwick TH1, Stowasser M1
1Australia
Variability of the Response to Low-Sodium Diet in Essential Hypertension: Therapeutic Effect and Pharmacogenomics
Gatti G1, Lanzani C1, Pozzoli S1, Simonini M1, Citterio L1, Delli Carpini S1, Jancarikova M1, Brioni E1, Manunta P1
1Italy

The Relation of Salt and Urinary Protein Excretion in Patients with Aldosterone Producing Adenoma is Not Reversed with Adrenalectomy
Pimenta E1, Gordon RD1, Ahmed AHA-A1, Cowley D1, Robson D1, Kogovsek C1, Stowasser M1
1Australia

Basic – Translational Science Symposium
New Antihypertensive Drugs, New Drug Targets
Room 211-214, L2

Chair: Gopalakrishnan V, Canada

New Drugs and New Targets for the Treatment of Hypertension
Unger T, Germany

Drug Development between Academia and Industry
Steckelings UM, Germany

Long-Term Normalization of Blood Pressure in SHR and 1-Kidney 1-Clip Rats by Synthetic Precursor of Stable PAF Analogue without Systemic Effects in Normotensive Rats
Malekin SI1, Kotelevtsev SV1, Gavrilova SA1, Fadyukova OE1, Golubeva AV1, Grinchenko MI1, Koshelev VB1, Kotelevtsev YV2, Hamet P3, Orlov SN1,3
1Russian Federation, 2United Kingdom, 3Canada

Vasoactive Intestinal Peptide: A New Target for Blood Pressure Lowering and Treatment of End Organ Damage
Duggan KA1, Ha H1, Hodge G1, Chen J1, Ye VZC1, He X1, Ryan S1, Yong JLC1, Macdonald GJ1
1Australia
08:15-09:45  **Clinical Science**  
State of the Art – Oral Presentations  
**Role of Nurse Clinician in Hypertension Management**  
Room 109-110, L1  
Chair: Jayasinghe J, Canada

08:15  
**Multidisciplinary Approaches to Management of Hypertension: Role of the Nurse Clinician**  
Dennison C, United States

08:45  
**A Nurse-Run Collaborative Care Program For Hypertensive Patients in A Community Practice**  
Islik SR1, Gelfer ME1, House WP1, Koehle MS1  
1Canada

08:55  
**Impact of the Hypertension Education Program on Blood Pressure and Self-efficacy to Change Health Behaviors in Men and Women with Hypertension**  
McFetridge-Durdle J1, Tucker B1, O’Connell C1  
1Canada

09:05  
**Treating the Hypertensive Patient in a Nurse-Led Hypertension Clinic**  
Andersen UO1, Simper AM1, Ibsen H1, Svendsen TL1  
1Denmark

09:15  
**Perception, Lifestyle Behavior, and Total Cardiovascular Risk in Urban and Rural Hypertensive Thais**  
Leelacharas S1, Kerdonfag P1, Chontichachalalauk J1, Sa-nongdej W1  
1Thailand

09:25  
**Hypertension: Translational Research for Nurses to Keep Recipients Well**  
Kirkpatrick MK, United States

09:35  
**Can a Single Nurse Have a Positive Impact on The Blood Pressure of Their Patients?? YES We Can!**  
Buckley S, Canada
THURSDAY, SEPTEMBER 30

10:30-12:00  **Clinical Science**

**Symposium**

**Mechanisms of Obesity and Obesity-Related Cardiometabolic Complications**  Ballroom A, L1

Session is a part of the Cardiometabolic Tract of Sessions, sponsored in part by an unrestricted educational grant from Boehringer Ingelheim

10:30  Pathophysiologic Mechanisms Linking Obesity and Hypertension  
**Hall J**, United States

11:00  The Role of Vascular Fat in the Interaction of Obesity and Hypertension  
**Heagerty AM**, United Kingdom

11:30  Stemming the Tide of Obesity: Management of Obesity in Children and Adolescence  
**Chanoine J-P**, Canada

10:30-12:00  **Public Health – Population Science**

**State of the Art – Oral Presentations**  
**Developing Countries**  Ballroom B, L1

**Chair:** Zhao D, China

10:30  Management of Hypertension in Developing Countries  
**Mendis S**, Switzerland

11:00  Education is the Independent Predictor for the Development of Hypertension but Not Income and Occupation in A 27-Year Cohort from Thailand.  
**Vathesatoqkit P**, **Sritara P**, **Unkurapinun N**, **Tanomsup S**  
1Thailand, 2Australia

11:10  Descriptive Analysis of Blood Pressure Control among Treated Hypertensive Patients in a Tertiary Hospital in Sub-Saharan Africa  
**Olanrewaju TO**, **Aderibigbe A**, **Chijioke A**  
1Nigeria
THURSDAY, SEPTEMBER 30

Yang TL1, Zhou H1, Xia K1, Sheikh A1, Peng LM1, Wang CL1, Li QH, Li X
1China

11:30  A Revisit of Blood Pressure Control in Nigerian Hypertensive Population on Pharmacotherapy
Ogundele SO1, Ogunleye OO1
1Nigeria

11:40  Increasing Prevalence of Hypertension and Cardiovascular Risk Factors Associated with Low Level of Awareness in a Low Income Country
Onwubere BJ1, Ulasi II1, Ijoma CK1, Arodiwe EB1, Onodugo O1, Ekenze OS1
1Nigeria

11:50  Evaluation of Therapeutic Control in a Pakistani Population with Hypertension
Ishaq M1, Rasheed A1, Saleheen D1,2
1Pakistan, 2United Kingdom

10:30-12:00  Translational – Clinical Science
Oral Presentations
Genetics of Hypertension and Atherosclerosis

Ballroom C, L1

Chairs: Charchar FJ, Australia and Hamet P, Canada

10:30  Genetic Architecture of Ambulatory Blood Pressure in the General Population - Insights from Large-Scale Cardiovascular Gene-Centric Analysis
Tomaszewski M1, Debiec R1, Braund PS1, Nelson CP1, Hardwick R1, Christofidou P1, Denniff M1, Vollenweider P2, Waeber G2, Zukowska-Szczechowska E3, Mooser V4, Charchar FJ5, Tobin MD1, Samani NJ1, Leicester Blood Pressure Genetics Study Group
1United Kingdom, 2Switzerland, 3Poland, 4United States, 5Australia
10:40 Increased Susceptibility to Coronary Artery Disease Linked To Y Chromosome Haplogroup In Males
Charchar FJ\(^1,2\), Barnes T\(^2\), Nelson CP\(^2\), Wang Y\(^2\), Debiec R\(^2\), Christofidou P\(^2\), Bani-Mustafa A\(^2\), Dominiczak AF\(^2\), Hall AS\(^2\), Ford I\(^2\), Tomaszewski M\(^2\), Samani NJ\(^2\)
\(^1\)Australia, \(^2\)United Kingdom

10:50 Copy Number Variant within VAP-1 Gene Is Associated with Hypertension and Macrovascular Complications of Type 2 Diabetes at Baseline of ADVANCE Trial
Ivanga M\(^1\), Seda O\(^1\), Tremblay J\(^1\), Sandoval J\(^1\), Caron M\(^1\), Chalmers J\(^2\), Harrap S\(^2\), MacMahon S\(^2\), Marre M\(^3\), Woodward M\(^2\), Hamet P\(^1\)
\(^1\)Canada, \(^2\)Australia, \(^3\)France

11:00 Genetics of Hypertension. Differential Effect of Two Haplotypes of Human Angiotensinogen Gene on Blood Pressure in Transgenic Mice
Kumar A\(^1\), Pandey V\(^1\), Mopidevi B\(^1\), Tillinger A\(^1\), Jain S\(^1\)
\(^1\)United States

11:10 Genetic Analysis of Fibroblast Growth Factor 1 Signaling Pathway Uncovers Association of Fibroblast Growth Factor Binding Protein 1 with Human Hypertension
Tomaszewski M\(^1\), Charchar FJ\(^2\), Nelson CP\(^1\), Barnes T\(^1\), Denniff M\(^1\), Debiec R\(^1\), Christofidou P\(^1\), Maric C\(^2\), Zukowska-Szczechowska E\(^4\), Samani NJ\(^1\)
\(^1\)United Kingdom, \(^2\)Australia, \(^3\)United States, \(^4\)Poland

11:20 Genetic Mapping of a Modifier Locus Affecting Hypertension in Soluble Guanylate Cyclase alpha 1 Deficient Mice
Buys ES\(^1\), Raher MJ\(^1\), Kirby A\(^1\), Hayton SR\(^1\), Sips PY\(^1\), Brouckaert P\(^2\), Daly MJ\(^1\), Bloch KD\(^1\)
\(^1\)United States, \(^2\)Belgium

11:30 Blood Pressure and Hypertension Are Associated With Seven Loci in the Japanese Population
Takeuchi F\(^1\), Isono M\(^1\), Katsuya T\(^1\), Yamamoto K\(^1\), Yokota M\(^1\), Sugiyama T\(^1\), Nabika T\(^1\), Fujioka A\(^1\), Ohnaka K\(^1\), Asano H\(^1\), Yamori Y\(^1\), Yamaguchi S\(^1\), Kobayashi S\(^1\), Takayanagi R\(^1\), Ogihara T\(^1\), Kato N\(^1\)
\(^1\)Japan

11:40 Myosin XVI Gene is Associated with Salt Sensitive Hypertension
Simonini M\(^1\), Devoto M\(^2\), Gatti G\(^1\), Casamassima N\(^1\), Querques ML\(^1\), Botticelli I\(^1\), Lanzani C\(^1\), Brioni E\(^1\), Citterio L\(^1\), Manunta P\(^1\)
\(^1\)Italy, \(^2\)United States
THURSDAY, SEPTEMBER 30

11:50 Novel Genes for Neurogenic Hypertension in the Schlager Hypertensive Mouse
Marques FZ¹, Lin RC¹, Davern PJ¹, Head GA¹, Morris BJ¹
¹Australia

10:30-12:00 Basic Science
State of the Art – Oral Presentations
The Expanding “Kinome” in Vascular Regulation
Room 211-214, L2

Learning Objectives:
• A vast network of at least 515 human protein kinases through the process of phosphorylation regulates all of the functions carried out by about 23,000 different proteins in cells. Defective signalling in this molecular intelligence system underlies over 400 human diseases, including cancer, diabetes, cardiovascular and neurological diseases.
• Using microarrays with phospho-site antibodies and kinase substrate peptides, it is feasible to track hundreds of these kinase at once in clinical specimens. Although about 500,000 human phospho-sites in proteins are likely to exist, a small subset of a few thousand phospho-sites may serve as particularly powerful biomarkers for disease diagnosis and prognosis.
• Protein kinases have emerged as important targets for drug development. Over 17 small molecule kinase inhibitors have already been approved for use in the clinic, over 150 are in clinical trials and another 500 appear to be in pre-clinical development. With the availability of an arsenal of selective kinases inhibitors coupled with the development of protein microarrays for diagnostics, the prospects for delivery of more effective personalized medicine is close at hand.

10:30 Mapping Protein Kinases Networks for Diagnostics and Therapeutics Development
Pelech S, Canada

11:00 Angiotensin II-Induced Transglutaminase 2 Modulates P-38 MAP-Kinase Long Term Expression in Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats
Savoia C¹, Ebrahimian T², Rossi C¹, Parente R¹, Rizzi J¹, Alonzo A¹, Arfa O², Paradis P², Wassmann S², Volpe M¹, Schiffrin EL²
¹Italy, ²Canada
P-38 Mitogen-Activated Protein Kinase (MAPK) Increases Arginase Activity and Contributes to Diabetes-Induced Vascular Endothelial Dysfunction
Toque HA¹, Nunes KP¹, Yao L¹, Caldwell RB¹, Caldwell RW¹
¹United States

GPR30-Mediated ERK Phosphorylation in Vascular Endothelial Cells
Ding Q¹, Chorazyczewski J¹, Gros R¹, Feldman R¹
¹Canada

Natriuretic Peptides/ cGMP-dependent Protein Kinase Cascades Increase Muscle Mitochondrial Content and Prevent Obesity
Miyashita K¹, Nakao K¹, Itoh H¹
¹Japan

Different Pattern of MAPK Activation and Oxidant Stress in SHR Pathological and Exercise-Induced Physiological Models of Cardiac Hypertrophy
Bertagnolli M¹,², Ribeiro MF¹, Viegas VU¹, Casali KR¹, Campos C¹, Bello-Klein A¹, Rigatto K¹, Irigoyen MC¹
¹Brazil, ²Canada

EphB6 Kinase and its Ligand EFNBs Control Vascular Smooth Muscle Contraction and Regulates Blood Pressure through Reverse Signalling via EFNBs
Luo H¹, Wu Z¹, Tremblay J¹, Thorin E¹, Peng J¹, Lavoie J¹, Qi S¹, Wu T¹, Cameron M¹, Kotlikoff M², Wu J¹
¹Canada, ²United States

Clinical Science Symposium
Asia Pacific Young Investigator Session
Room 109-110, L1

Chairs: Morgan T, Australia and Soentara AA, Indonesia

RANKL System as the Common Mechanism of Osteoporosis and Vascular Calcification
Osako MK¹, Nakagami H¹, Rakugi H¹, Morishita R¹
¹Japan
10:45  Cardiovascular Effects of Novel Peptidomimetic \( \text{AT}_2 \) Receptor-Selective Ligands
Jones ES\(^1\), Kirsch JF\(^1\), Bosnyak S\(^1\), Unabia S\(^1\), Del Borgo MP\(^1\), Perlmutter P\(^1\), Thomas WG\(^1\), Aguilar M-I\(^1\), Widdop RE\(^1\)
\(^1\)Australia

11:00  Prognostic Value of Isolated Nocturnal Hypertension on Ambulatory Measurement in 8711 Subjects from 10 Populations
Fan H-Q\(^1\), Li Y\(^1\), Thijs L\(^2\), Hansen TW\(^3\), Boggia J\(^4\), Kikuya M\(^5\), Björklund-Bodegård K\(^6\), Richart T\(^2\), Ohkubo T\(^5\), Jeppesen J\(^3\), Torp Pedersen C\(^3\), Dolan E\(^7\), Kuznetsova T\(^2\), Stoliarz-Skrzypek K\(^8\), Tikhonoff V\(^9\), Malyutina S\(^10\), Casiglia E\(^9\), Nikitin Y\(^10\), Lind L\(^6\), Sandoya E\(^8\), Kawecka-Jaszcz K\(^8\), Imai Y\(^5\), Ibsen H\(^2\), O’Brien E\(^11\), Wang J-G\(^1\), Staessen JA\(^2\), on behalf of the International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) investigators
\(^1\)China, \(^2\)Belgium, \(^3\)Denmark, \(^4\)Uruguay, \(^5\)Japan, \(^6\)Sweden, \(^7\)United Kingdom, \(^8\)Poland, \(^9\)Italy, \(^10\)Russian Federation, \(^11\)Ireland

11:15  N-Terminal pro Brain Natriuretic Peptide and Left Atrial Volume Index in the Evaluation of Early Left Ventricular Diastolic Function: Comparison with Tissue Doppler Imaging In Patients with Essential Hypertension
Yang Y\(^1\), Wang Y\(^1\), Zhu DL\(^1\), Gao PJ\(^1\)
\(^1\)China

11:30  Morning Hypertension in Treated Hypertensives: The Baseline Characteristics and Clinical Implications
Lee J-H\(^1\), Kim D-W\(^1\), Bae J-W\(^1\), Cho M-C\(^1\), Park J-B\(^1\), Park C-G\(^1\), Youn H-J\(^1\), Choi D-J\(^1\), Ahn Y-K\(^1\), Shin J-H\(^1\), Rim S-J\(^1\), Bae J-H\(^1\), Korean Hypertension Research Network
\(^1\)Korea, Republic of

11:45  Podocyte-Specific Conditional Knockout of (Pro)Renin Receptor in Mice
Oshima Y\(^1\), Ichihara A\(^1\), Kinouchi K\(^1\), Kurauchi-Mito A\(^1\), Bokuda K\(^1\), Narita T\(^1\), Sakoda M\(^1\), Sun-Wada G-H\(^1\), Wada Y\(^1\), Tamai Y\(^1\), Sato H\(^1\), Itoh H\(^1\)
\(^1\)Japan
THURSDAY, SEPTEMBER 30

14:30-15:30  **Clinical Science**  
**Late Breaker Presentations**  
*Do ARBs Cause Cancer?*  
Ballroom A, L1

**Chair:** Elliott HL, United Kingdom

Angiotensin Receptor Blockade and Risk of Cancer  
TBA

15:30-16:30  **Clinical Science**  
**Late Breaker Presentations**  
**Late Breaking Clinical Trials**  
Ballroom A, L1

**Chair:** Elliott HL, United Kingdom

15:30  **Final Analysis of the Destination Study: A Real-Life Effectiveness Study of Valsartan-Based Regimens in Hypertensive Patients**  
Tardif J-C¹, Myers MG¹, Leclerc J-M¹, Vaillancourt M¹  
¹Canada

15:40  **Efficacy and Safety of Olmesartan Medoxomil (OM) Compared with Losartan Potassium (LOS) in Patients with Hypertension (HTN)**  
Weir MR¹, Punzi HA¹, Flack JM¹, Chavanu KJ¹, Li W¹, Dubiel R¹  
¹United States

15:50  **Prevention of Cardiovascular Events with Calcium Antagonist-Based Combination Therapies in Patients with Hypertension: A Randomized Controlled Trial – Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial**  
Ogihara T¹, Matsuaki M¹, Umemoto S¹, Rakugi H¹, Matsuoka H¹, Shimada K¹, Abe K¹, Suzuki N¹, Eto T¹, Higaki J¹, Ito S¹, Kamiya A¹, Kikuchi K¹, Suzuki H¹, Tei C¹, Ohashi Y¹, Saruta T¹, for the COPE Trial Group  
¹Japan

16:00  **Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension (ACCELERATE): A Randomized, Double-Blind, Study of the Early and Late Efficacy and Safety of Initiating Treatment with Combination Therapy in Patients with Essential Hypertension**  
Brown MJ¹, Macdonald TM¹, Mcinnes G¹, Cherif Papst C², Zhang J²  
¹United Kingdom, ²Switzerland
16:10 Long-Term Efficacy and Safety of Combination Olmesartan Medoxomil/Amlodipine Besylate+Hydrochlorothiazide in Patients With Hypertension: The TRINITY Study
Chrysant S1, Oparil S1, Kereiakes D1, Izzo J1, Littlejohn T1, Melino M1, Fernandez V1, Lee J1, Heyrman R1
1United States

16:20 Preferential Benefits of Nifedipine Gits in Systolic Hypertension: Further Analysis of the “Action” Database in Patients with Angina
Elliott HL1, Meredith PA1
1United Kingdom

14:30-15:20 Population Science Late Breaker Presentations
Population Featured Research Ballroom B, L1

Chair: Chockalingam A, Canada

14:30 Cluster Randomized Trial of a Population-Based Program to Reduce Cardiovascular Morbidity
Chambers LW1, Kaczorowski J1, Dolovich L1
1Canada

14:40 Risk of Hypertension in Rural Outpatient Population of Anhui Province, P.R. China
Hu S-L1, Wu L1, Fang X1, Chen Y1, Shen G1
1China

14:50 Awareness, Treatment and Control of Hypertension in an Urban Low-Income Asian Community: A Case Study in Singapore
Wee LE1, Koh GC-H1
1Singapore

15:00 Effort-Reward Imbalance at Work and Blood Pressure
Milot A1, Gilbert-Ouimet M1, Brisson C1, Blanchette C1
1Canada
Community-Based Cardiovascular Risk Factors Intervention Strategies (CORFIS) in Managing Hypertension: A Randomized Controlled Trial
Ramli AS1, Low WH1, Jamaiyah H1, Seet W1, Teng CL1, Lee VK1, Tong SF1, Ng KK1, Mastura I1, Chua SS1, Faridah AM1, Karupaiah T1, Chee WS1, Goh PP1, Zaki MZ1, Lim TO1, CORFIS Study Group
1Malaysia

Public Health – Population Science
Late Breaker Presentations
Should We Change the Paradigm for Blood Pressure Measurement; How, Where and by Whom Should Blood Pressure be Measured
Ballroom B, L1
Chair: Chockalingam A, Canada
Kaczorowski J, Canada

Late Breaker Presentations
Featured Clinical Research Clinical Diagnosis of Hypertension and/or Vascular Disease
Ballroom B, L1
Chair: Chockalingam A, Canada and Onrot J, Canada

Adrenal Venous Sampling in the Real World: Review of 94 Cases in British Columbia
Zolein M1, Al Riyami N2, Holmes DT1
1Canada, 2Oman

Dynamic Gadolinium-Enhanced Three Dimensional MR Angiography in the Whole Body Atherosclerosis
Pollice F1, Pollice P1, Calderon A2
1Italy, 2Spain

Endothelial Dysfunction in African Americans with Masked Hypertension
Veerabhadrappa P1, Kashem A1, Diaz K1, Alkhouli M1, Feairheller DL1, Sturgeon KM1, Williamson ST1, Kretzschmar J1, Crabbe DL1, Brown M1
1United States
16:20  Age-Related Change of Shape-Indicating Factor of Radial Pulse Waveforms Measured by 5-step Tonometric Method  
Kwon SM1, Kang HJ1, Yim YK1, Lee YH1  
1Korea, Republic of

14:30-15:30  **Basic Science**  
**Late Breaking Presentations**  
**Late Breaking Studies Pathobiology**  
Ballroom C, L1  

**Chairs:** Burrell L, Australia and Schiffrin EL, Canada

14:30  *Signaling for Angiogenesis in vitro and in vivo Involves Nox4 NADPH Oxidase: A Boost for Cardiac Tissue Engineering?*  
Dusting GJ1, Peshavariya H1, Chan E1, Wingler K1, Schmidt H1, Jiang F1,2  
1Australia, 2China

14:40  *Non-Peptide VIP Agonists – A New Class of Antihypertensive Antifibrotic Agents*  
Duggan KA1, Hodge G1, Lee LY1, Tay YC1, Chen J1, Ha H1, Macdonald GJ1  
1Australia

14:50  *Type 1 Diabetes Mellitus (DM1) but not High Salt Intake Increases Renal Susceptibility to Hypertensive Injury in 2 Kidney-1 Clip (2K1C) Hypertensive Rats*  
Sima CA1, Koeners M1,2, Joles JA2, Waring J1, Lau C1, Magil AB1, Cupples WA1  
1Canada, 2Netherlands

15:00  *The Renin Inhibitor, Aliskiren, Reduces Vascular Pathology in Diabetic Retinopathy and Oxygen Induced Retinopathy*  
Wilkinson-Berka JL1, Tan G1, Binger KJ1, Sutton L1, McMaster K1, Perera G1, Campbell DJ1, Miller AG1  
1Australia

15:10  *Morphological Changes of Intramyocardial Arteries Induced by Obesity in Young Rats are Attenuated by Metformin*  
Burlá AK1, Lobato NDS1, Fortes ZB1, Oigman W1, Neves MF1  
1Brazil
THURSDAY, SEPTEMBER 30

Kuruppu S¹, Smith AI¹  
¹Australia

15:30-16:30  **Basic Science**  
**Late Breaker Presentations**  
**Late Breaking Studies Pathobiology**  
Ballroom C, L1

Chairs: Burrell L, Australia and Schiffrin EL, Canada

15:30  Inhibition of Apop Gene Expression Prevents Hypoxia/reoxygenation-Induced Death of Cardiomyocytes  
Yamamoto E¹, Yasuda O¹, Mitsuyama SK¹, Ogawa H¹  
¹Japan

15:40  Ca²⁺-Sensitive Phosphorylation and Proteasomal Degradation of p27Kip1 in Vascular Smooth Muscle Cells  
Hui S¹, Husain M¹  
¹Canada

15:50  Hyperuricemia Induces Oxidative Stress and Decreased Nitric Oxide Availability via the Angiotensin Type 1 Receptor  
Tuck M¹, Wijesuriya J¹, Smutko V¹, Nyby M¹, Corry D¹  
¹United States

16:00  L-NAME Inhibits Aortic Hypertrophy Regression Induced by Enalapril in SHR Via Increased Aortic SMC Proliferation and Turnover  
Huot-Marchand J-É¹, deBlois D¹  
¹Canada

16:10  Regulation of Renin Gene Expression by Oxidative Stress  
Itani HA¹,², Liu X², Sarsour EH², Goswami PC², Born E², Keen HL², Sigmund CD²  
¹Saudi Arabia, ²United States

16:20  BDNF-TrkB – A Novel Neuroprotective Pathway Initiated by the Angiotensin AT2 Receptor  
Namsolleck P¹, Boato F¹, Schwengel K¹, Thöne-Reineke C¹, Seidel K¹, Lucht K¹, Hallberg A², Dahlöf B², Hendrix S³, Unger T¹, Steckelings UM¹  
¹Germany, ²Sweden, ³Belgium
THURSDAY, SEPTEMBER 30

16:30-17:00  Closing Announcement and Handover to Hypertension Sydney 2012

Ballroom A, L1
THURSDAY, SEPTEMBER 30

POSTER SESSION

12:00-14:15  Poster session D  Exhibition Hall C, West Exhibition Level

The following highest scored posters will be discussed during this session:

PS4/THU/1, PS4/THU/2

Chair: Gopalakrishnan V, Canada

PS4/THU/1
Growth, But Not Apoptosis, is Regulated by the Cross Talk between Aldosterone and Angiotensin II in Vascular Smooth Muscle cells: Role of c-src and RhoA/Rho Kinase
Montezano AC, Burger D, Yusuf H, Touyz RM
1Canada

PS4/THU/2
Ace Activity and Expression Profiles in Chronic Renal Failure Patients
Arita DY, Cunha TS, Perez JD, Colucci JA, Nogueira MD, Arita LS, Thomaz MG, Onaga PY, Souza NKG, Casarini DE
1Brazil

PS4/THU/3
Hypertension Treatment with Amlodipine and Valsartan Combination in a Russian Population of Patients
Chazova I, Karpov Y, Vigidorchik A, Zazulina A
1Russian Federation

PS4/THU/4
The Effect of Combination Therapy with Angiotensin-II Receptor Blocker and Statin on Endothelial Function and Arterial Stiffness in Patients with Essential Hypertension
1Korea, Republic of

PS4/THU/5
Angiotensin II Receptor Blockade Blunted Mental Stress-Induced Blood Pressure Elevation and Reduction of Skin Blood Flow Compared with Calcium Blockade
Hano T, Tomari H, Kawabe T
1Japan

PS4/THU/6
Two-Month Effect of Combined Antihypertensive Therapy on Blood Pressure
Lovic D, Stojanov V, Jakovljevic B
1Serbia
Combination of Angiotensin II Receptor Antagonist with Calcium Channel Blocker or Diuretic as Antihypertensive Therapy for Patients with Chronic Kidney Disease  
Sudo Y, Furukata S, Nakano N, Akashiba A, Numabe A, Ishimitsu T  
1Japan

Effects of Nebivolol Added to Ongoing Antihypertensive Therapy on the Incidence of Adverse Events in Patients with Stage I-II Hypertension  
Wright HM, Bowen L, Mori AD  
1United States

Effect of Indapamide on Metabolism in Hypertensive Patients without Metabolic Syndrome  
Guo J, Gong Y-C  
1China

Chikushi Anti-Hypertension Trial – Preminent (CHAT-P) Results of an Observational Regional Cohort Study using Losartan-Hydrochlorothiazide Combined Drug (PRE) in Japanese Essential Hypertension  
1Japan

The Effects of Lisinopril Therapy on Blood Pressure and Hemodynamic Parameters  
Stojanov V, Jakovljevic B, Lovic D  
1Serbia

Add-on Lower Diuretics Eliminates Chronic Kidney Disease but not Diabetes from the Risk Factor for the Inadequate Blood Pressure Control in Hypertension Treated with Angiotensin Receptor Blockers  
1Japan
PS4/THU/13
Influence of Lozartan on Indicators of Serum Uric Acid, Renal Function, Markers of Inflammatory In Patients with Hypertension and Hyperuricacidemia
Golovach IY1, Golovach DV1, Mytnyk ZM1, Vershynin SV1, Lazorenko OO1, Matijko VM1
Ukraine

PS4/THU/14
Optimizing Antihypertensive Therapy in Postmenopausal Women with Metabolic Syndrome
Dadashova GM1, Bakhshaliyev AB1
Azerbaijan

PS4/THU/15
Essential Hypertension in Guinea: Prevalence And Development Of Antihypertensive Phytomedicines From The Traditional Medicine Data
Baldé AM1, Cissé A1, Baldé D1, Baldé N1, Kaba ML1, Bah F1, Ewane O1, Bah SM1, Traoré SM1, Oularé K1, Diallo A1, Magassouba FB1, Kéita A1, Mara E1
Guinea

PS4/THU/16
Reversal of Stage-I Hypertension by Behavioural Intervention: 18 Month Study in Urban Bangladesh
Alamgir AKM1, Ali SMK1, Haque KMHSS1
Bangladesh

PS4/THU/17
Characteristics and Health Behaviours of Canadians Who Report That They Have Uncontrolled Hypertension
Nichol ME1, Campbell NR1, Joffres MR1, Bienek A1, Walker RL1, Kaczorowski J1, Robitaille C1, Dai S1, Bancej CM1
Canada

PS4/THU/18
Impact of Integrated Approach on Blood Pressure Control in Non Adherent Motivated Hypertensive Patients in General Practice
Kobalava Z1, Villevalde S1, Kotovskaya Y1, Isikova K1
Russian Federation

PS4/THU/19
The Relationship between Lifestyle Factors, Coping With Stress and Hypertension
Md Ariff F1, Zubaidi A1, Suthahar A1, Ramli M1
Malaysia
PS4/THU/20
Attitude and Behavior of Physicians from Tamilnau, India towards their Own Cardiovascular Health
Mathavan A1, Chockalingam A2, Chockalingam S1
1India, 2Canada

PS4/THU/21
Controlling Hypertension in African American Men: The Effects of Two Coaching Models on Hypertension Self-Management Using a Qualitative Improvement Approach
Ross WR1, Scharff DP1, Elliot M1, Krishnamurthy A1, Kurz RS1
1United States

PS4/THU/22
Factors Influencing Medication-Taking Behavior of Hypertensive Patients
Prakobchai S1, Sareewiwatthana P1, Na Ayuthya SK1, Buranakijcharoen P1
1Thailand

PS4/THU/23
Motivation, Problem-Solving Skills and Perception of Adherence to Diet Regimen in Cardiac Rehabilitation Patients
Radi SM1, Moore S2
1Saudi Arabia, 2United States

PS4/THU/24
Blood Pressure Cardio Gram – Towards a New Definition of Blood Pressure
Baron E, Japan

PS4/THU/25
Measurement of Blood Pressure Using a Condenser Microphone
An D1, Kim T1, Kwon K1, Song S1, Lee J1, Chee Y1, Kim I1
1Korea, Republic of

PS4/THU/26
Hardware Design of Electronic Blood Pressure Monitor Based on Korotkoff Sound
Liu YY1, Xiang HY1, Qin YF1, Li YH1, Yu MS1
1China

PS4/THU/27
The AAA-Registry: Real Life Analysis of Blood Pressure Control in 15.000 Hypertensive Patients in Germany Classified by Comorbidities
Dechend R1, Schmieder RE1, Senges J1, Klebs S1, Zeymer U1
1Germany
PS4/THU/28
Decreased Glomerular Filtration Attenuates a Hypotensive Response to Therapy: Real Life-Medicine
Lietava J1, Murin J1, Bartko D1, for STAIRS investigators
1Slovakia

PS4/THU/29
Physician-Pharmacist Cooperative Program for Blood Pressure Control in Hypertensive Patients: 1.5-Year Follow-Up after a Randomized-Controlled Trial
Tobari H1, Arimoto T1, Shimojo N1, Yuhara K1, Noda H2, Yamagishi K1, Iso H1
1Japan, 2United States

PS4/THU/30
The Counseling African Americans to Control Hypertension (CAATCH) Trial: Sample Baseline Demographic, Clinical, and Psychosocial Characteristics
Fernandez S1, Tobin J1, Diaz-Gloster M1, Cassells A1, Khalida C1, Ogedegbe G1
1United States

PS4/THU/31
Prevalence of Microalbuminuria in Hypertension Patients and Clinical Practice
Brquljan J1, Accetto R1, Salobir B1, Dolenc P1
1Slovenia

PS4/THU/32
Blood Pressure Control by Ukrainian Generic Drugs in Diabetic Hypertensive Patients in Primary Care Setting: Results of Multicentre Open Trial
Radchenko GD1, Sirenko YM1, Marzovenko IM1
1Ukraine

PS4/THU/33
Valsartan Max Dose Study in Saitama(Valmax): 80mg Twice A Day Is Efficient Then 160mg Once a Day to Suppress the Morning Blood Pressure in Hypertensive Diabetics
Noguchi Y1, Inokuma S1, Minagawa S1, Yanagisawa M1, Kashiwabara H1, Miura S1, Hayashida K1, Amano N1, Shimizu J1, Miyata S1, Oohori T1, Yagi S1, Izumida T1, Yamamoto H1, Hatano M1, Inaba M1, Katayama S1
1Japan

PS4/THU/34
Prevalence of Development of Hypertension over a 10 Year Period amongst Patients from a Primary Care Clinic in Malaysia
Chia YC1, Keevil V2
1Malaysia, 2United Kingdom
Blood Pressure Control of Medical Out-Patients with Systemic Hypertension in a Health Care Centre in a North-Western State, Nigeria
Adamu UG1, Aiyedun TA1, Adamu DA1, Kabir BS1, Abdullahi A1, Katibi I1
1Nigeria

Blood Pressure Control and Detailed Management of Hypertension in Shanghai Community Hospitals
Zhang Y1, Chen M1, Chen S1, Qian Y1, Li X1, Lu W1, Zhu D1
1China

Bhimaraj A1, Palusinski R1, Cena M1, Ovalle A1, Danek A1, Kelly RF1
1United States

The Role of Cardiovascular Diseases (CVD) in Solution of National Demographic Security Programme in the Republic of Belarus
Podpalov VP1, Zhurova VM1, Podpalov VV1, Prakashyna NR1
1Belarus

Current Status of Hypertension in Korean People: Data from a Heart Day Campaign
Kwon SU, Korea, Republic of

Adherence to Hypertension Medications and Its Influencing Factors in an Australian Population: A Pilot Survey
Saksena A, Australia

Gender, Age and Race Differences in the Utilization of Hypertension Health Care Resources in Ambulatory Care Clinic
Alefan Q1, M. Ibrahim MI1, Ab. Razak T1, Ayub A1
1Malaysia
THURSDAY, SEPTEMBER 30

PS4/THU/42
Comparison of Costs between Angiotensin Receptor Blocker (ARB) and Angiotensin-Converting-Enzyme (ACE) Inhibitor in Patients with Cardiovascular Disease or High Risk Diabetes, From the ONTARGET Trial
Nakaya H¹, Sasamura H¹, Sakamaki Y¹, Ikeda S¹, Sato Y¹, Itoh H¹
¹Japan

PS4/THU/43
Construction and Use of an Internet-Based Program for Improvement of Patient Care
Suzuki H¹, Evidence Station
¹Japan

PS4/THU/44
Offspring Birth Weight and Risk of Mortality from Diabetes in Mothers
Li C-Y¹, Chen H-F¹, Sung F-C¹, Hsieh P-C¹, Tsung-Hsueh L¹
¹Taiwan, Republic of China

PS4/THU/45
Effectiveness of Losartan/Hydrochlorothiazide Combination for Treatment of Japanese Hypertensive Patients with Type 2 Diabetes Mellitus
Toyoda M¹, Umezono T¹, Suzuki D¹
¹Japan

PS4/THU/46
Antihypertensive Efficacy and Safety of Fixed-Dose Combination Therapy with Losartan plus Hydrochlorothiazide in Japanese Diabetics with Hypertension
Yamamoto H¹, Izumida T¹, Ohori T¹, Hatano M¹, Noguchi Y¹, Inaba M¹, Senda T¹, Yanagisawa M¹, Tanaka M¹, Awata T¹, Katayama S¹
¹Japan

PS4/THU/47
Single-Pill Amlodipine/Atorvastatin Versus Usual Care for Cardiovascular Risk Factor Management in Patients with Diabetes, Hypertension and Additional Risk Factors – A CRUCIAL Trial Sub-Analysis
Zamorano J¹, Erdine S², Pavia Lopez A³, Kim J-H⁴, Al Khadra A⁵, Westergaard M⁶, Sutradhar S⁶, Yunis C⁶, on behalf of the CRUCIAL Investigators
¹Spain, ²Turkey, ³Mexico, ⁴Korea, Republic of, ⁵Saudi Arabia, ⁶United States

PS4/THU/48
Incidence of Hyperglycemia in Hypertensive Patients and Predictor of Postload Hyperglycemia in Patients with Normal Fasting Glucose Levels
Kim Y-K¹, Kim Y-S¹, Rhee M-Y¹, Lee M-M¹, Cho EJ¹, Kwon BJ¹
¹Korea, Republic of
Ambulatory Blood Pressure Monitoring Parameters Are Better Correlates of Degenerative Complications in Type 2 Diabetic Patients than Office Blood Pressures
Cardoso C¹, Iendrick S¹, Sissi M¹, Leite N¹, Muxfeldt E¹, Salles G¹
¹Brazil

Abnormal Vascular Programming of Acid Arachidonic Metabolism Could Explain Hypertension in Rats Exposed in utero to Maternal Diabetes
Fassot C¹, Vessiere E¹, Duong Van Huyen J-P¹, Perret C¹, Laurent S¹, Henrion D¹, Lelièvre-Pégier M¹
¹France

Diagnostic Accuracy of a Novel Iontophoresis Technology for Diabetes and Prediabetes
Sheng C¹, Li Y¹, Wang J¹
¹China

High Prevalence of Diabetes among Urban and Rural Populations in Malaysia
Ng KK¹, Miskan M¹, Mazapuspavina MY¹, Nafiza MN¹, Krishnapillai AD¹, Ramli AS¹, Yusoff K¹, Winn T¹, CRisP Study Group
¹Malaysia

Microvascular Complications Associated with the Coronary Artery Calcifications in Type 2 Diabetes
Kunuqi T¹, Sato A¹, Nagai K¹, Harada M¹, Sakai K¹, Hasumi S¹, Iwamoto Y¹
¹Japan

Prevalence of Hypertension, Dyslipidemia, Renal Involvement and Co-morbid Conditions in Type 2 Diabetic Subjects – Observations from BNDC Trial in Bangladesh
Iqbal MM¹, Banerjee SK¹, Mansur MA¹, Ahmed Z¹, Nahar N¹, Choudhury S¹, Ali S¹, Ahmed T¹, Islam MN¹, Rashid MA¹, Khan ZA¹, Hassan MS¹, Azad Khan AK¹, BNDC Trial, BIRDEM, Bangladesh
¹Bangladesh

Determinants of Arterial Blood Pressure in Polish Diabetic Patients
Abramczyk A, Poland
THURSDAY, SEPTEMBER 30

PS4/THU/56
Early Experience with a Novel System for Enhancing Patient-Physician Collaboration in Hypertension Management
Au-Yeung KY1, Intondi A1, Abdel-Aleem S1, Moon G1, Behzadi Y1, Beaulieu P1, Hafezi H1, Omidvar F1, Robertson T1, Weinstein R1
1United States

PS4/THU/57
Different Antihypertensive Effect between Diabetic Patients and Patients with Impaired Fasting Glucose
Jia L1, Wang X1, Li Y1, Liu X1, Li S1, Chen J1, Li W1, Zhen Y1, Hui R1
1China

PS4/THU/58
NSAID’s Cardiovascular Toxicity Study: Effects of Selective and Non-Selective Cyclooxygenase Inhibitors
Chopey IV1, Debretseni KO1, Chopey KI1, Bratasyuk AM1, Hechko MM1, Hoydash IM1, Studenyak VM1
1Ukraine

PS4/THU/59
Results of Specialised Ambulatory Diabetes Care among Diabetes Patients – A Polish National Study
Abramczyk A, Poland

PS4/THU/60
Hyperuricemia and Endothelial Dysfunction in Metabolic Syndrome
Yoshida M1, Tomiyama H1, Higashi Y1, Takase B1, Yamashina A1
1Japan

PS4/THU/61
Effects of a Chronic Treatment with Tempol on Vascular Reactivity and Insulin Signalling Pathway in a Rat Model with Dietary Acquired Obesity and Insulin Resistance
Bachelard H1, Bourgoin F1, Pitre M1, Larivière R1
1Canada

PS4/THU/62
Crucial Role of Kidney Function in Diurnal Variation of Endothelial Function in Essential Hypertension
Yamamoto K1, Takeda Y1, Yamashita S1, Sugiura T1, Wakamatsu Y1, Fukuda M1, Ohte N1, Dohi Y1, Kimura G1
1Japan
Possible Participation of Ca\(^{2+}\)-Dependent Cl\(^{-}\) Channels in Edcf-Mediated Norepinephrine-Induced Contraction of Femoral Arteries of Wistar Rats
Liskova S\(^{1}\), Petrova M\(^{2}\), Kunes J\(^{1}\), Zicha J\(^{1}\)
\(^{1}\)Czech Republic, \(^{2}\)Slovakia

The Relationship between Immune Complex and Collagen Synthesis or Endothelial Cell Damage in Patients with Essential Hypertension
Wu CE\(^{1}\), Ye P\(^{1}\)
\(^{1}\)China

The Significance of Flow-mediated Vasodilatation and Brachial Arterial Diameter as a Marker of Sub-clinical Organ Damage in Hypertension
Yoshida M\(^{1}\), Tomiyama H\(^{1}\), Odaira M\(^{1}\), Matsumoto C\(^{1}\), Shiina K\(^{1}\), Yamashina A\(^{1}\)
\(^{1}\)Japan

Impact of LDL-Cholesterol/HDL-Cholesterol Ratio and High Blood Pressure on Endothelial Damage
Sugiura T\(^{1}\), Dohi Y\(^{1}\), Yamashita S\(^{1}\), Yamamoto K\(^{1}\), Wakamatsu Y\(^{1}\), Tanaka S\(^{1}\), Takeda Y\(^{1}\), Ohte N\(^{1}\), Kimura G\(^{1}\)
\(^{1}\)Japan

Hypoxic Preconditioning Attenuates Endoplasmic Reticulum Stress-Induced Injury in Microvascular Endothelial Cells
Liu XH\(^{1}\), Zhang ZY\(^{1}\), Cai LR\(^{1}\), Sun S\(^{1}\), Li YZ\(^{1}\)
\(^{1}\)China

Endothelial Dysfunction Measured As Flow-Mediated Vasodilation Is Associated with High-Risk Masked Hypertension Patients: The Japan Morning Surge Home Blood Pressure (J-HOP) Study
Kabutoya T\(^{1}\), Eguchi K\(^{1}\), Hoshide S\(^{1}\), Ishikawa J\(^{1}\), Shimada K\(^{1}\), Kario K\(^{1}\)
\(^{1}\)Japan

Effect of Losartan on Diastolic Function of Aorta Endothelium in Diabetic Nephropathy Rats
Huanzhen C\(^{1}\), Hui L\(^{1}\)
\(^{1}\)China
THURSDAY, SEPTEMBER 30

PS4/THU/72
Evaluation of Endothelial Function in Patients with Non-Alcoholic Fatty Liver Disease
Colussi G\(^1\), Catena C\(^1\), Donnini D\(^1\), Iogna-Prat L\(^1\), Carnelutti A\(^1\), Di Fabio A\(^1\), Soardo G\(^1\), Sechi LA\(^1\)
\(^1\)Italy

PS4/THU/73
Novel Mechanism of the Beneficial Effects of Dihydropyridine Calcium Channel Blocker on Vascular Endothelial Dysfunction in Obesity and Type 2 Diabetes
Yamamoto E\(^1\), Yasuda O\(^1\), Ogawa H\(^1\), Mitsuyama SK\(^1\)
\(^1\)Japan

PS4/THU/74
Effect of Anti-Hypertensive Drugs on Cellular Arginine Transport
Nel MJ\(^1\), Woodiwiss AJ\(^1\), Candy GP\(^1\)
\(^1\)South Africa

PS4/THU/75
Attenuation of Endothelial Function and Changes of Vascular and Heart Structure, Advantage of Indapamide
Ripp T\(^1\), Mordovin V\(^1\), Karpov R\(^1\)
\(^1\)Russian Federation

PS4/THU/76
Raloxifene and Tamoxifen Normalized Mesenteric Artery Reactivity by a Mechanism Dependent on the IL-6 and TNF-α Levels in Female Rats
Bissoli NS\(^1\), Lamas AZ\(^1\), Abreu GR\(^1\), Moyses MR\(^1\)
\(^1\)Brazil

PS4/THU/77
Diagnostic and Therapeutic Conditions of Hospitalized Aged Patients with Essential Hypertension in Beijing
Wang H\(^1\), Jing S\(^1\), Sun N\(^1\)
\(^1\)China

PS4/THU/78
Prognosis of Fatal Complications in Patients with Hypertension
Prakoshyna NR\(^1\), Manak MA\(^1\), Podpalov VP\(^1\), Deev AD\(^2\), Stchastlivenko AI\(^1\)
\(^1\)Belarus, \(^2\)Russian Federation
PS4/THU/79
Evaluation of Cardiovascular High Risk Population in Specialists Ambulance ESA
Zizka J¹, Souček M¹
¹Czech Republic

PS4/THU/80
Association of Nutrition with Hypertension and Other Cardiovascular Risks in Australian Urban and Rural Aboriginals
Hamada A¹, Taguchi T¹, Mori M¹, Mori H¹, Throrpe M², Clark G², Clark V², Yamori Y¹, on behalf of WHO-CARDIAC Study group
¹Japan, ²Australia

PS4/THU/81
Association between Oral Health and Risk Factors for Hypertension among Australian Aboriginals Revealed By a Pilot Epidemiological Study
Asai K¹, Yamori M¹, Hamada A¹, Yamazaki T¹, Taguchi T¹, Tanoue M¹, Mori M¹, Throrpe M², Clark G², Clark V², Yamori Y¹, Bessho K¹
¹Japan, ²Australia

PS4/THU/82
The Etiological Analysis of in-Patients With Hypertension – Report from Department of Hypertension of People’s Hospital of Xinjiang Autonomous Region
Li N¹, Lin L¹, Wang L¹, Wang X¹, Albulikem Z¹
¹China

PS4/THU/83
High Prevalence (29%) of High Blood Pressure in Adults in A Walk-In Clinic. A One Week Survey in a Primary Care Setting
Drouin D¹, Chartrand C¹
¹Canada

PS4/THU/84
Blood Pressure and “Normal” Kidney Function in African and Caucasian Men of Similar Socio-Economic Status
Schutte R¹, Schutte AE¹, van Rooyen JM¹, Huisman HW¹, Malan NT¹, Fourie CM¹, Malan L¹
¹South Africa

PS4/THU/85
Prevalence of Hypertension, Obesity and Dyslipidaemia in Women in Semi-Urban and Rural Communities of South-East Nigeria
Ulasi II¹, Onwubere BJ¹, Ijoma CK¹, Cardiovascular and Kidney Disease Research Group
¹Nigeria
THURSDAY, SEPTEMBER 30

PS4/THU/86
Differences in Direct Costs of Uncomplicated Hypertension Associated with Gender, Age and Race Groups in Malaysia
Alefan Q¹, M. Ibrahim MI¹, A. Razak T¹, Ayub A¹
¹Malaysia

PS4/THU/87
Alternative Medicinal Practitioners in Satkhira District of Bangladesh: Their Knowledge on Hypertension and Possible Role in Primary Health Care
Mollik MAH¹, Akter K¹, Faruque MR¹, Sen D¹, Islam MT¹, Khan MS¹
¹Bangladesh

PS4/THU/88
Influence of Genetic Polymorphism in SLCO1B1 on Pitavastatin Anti-hypercholesterolemia Therapy
Yang G¹, Hong Y¹, Huang Z¹, Tang B¹, Cai J¹
¹China

PS4/THU/89
Relation of Candidate Genes That Encode for Endothelial Function to the Development of Myocardial Infarction in Patients with Arterial Hypertension
Andreenko EY¹, Makarevich PI¹, Balatsky AV¹, Samokhodskaya LM¹, Boytsov SA¹
¹Russian Federation

PS4/THU/90
Genotype Predictors of Coronary Artery Disease (CAD) and Acute Coronary Syndrome (ACS)
Ursuliak JV¹, Amosova KM¹, Sydorchuk LP¹, Sydorchuk RI¹
¹Ukraine

PS4/THU/91
CD36 Is a Pharmacogenetic Determinant of Dexamethasone-Induced Glucose Intolerance and Dyslipidemia
Krupkova M¹, Sedova L¹, Liska F¹, Krenova D¹, Kren V¹, Seda O¹, Seda O²
¹Czech Republic, ²Canada

PS4/THU/92
α-Adducin Gene Polymorphism Predicts Cardiac and Vascular Response to Treatment in Hypertensive Women
Catena C¹, Zagato L¹, Novello M¹, Citterio L¹, Colussi G¹, Di Fabio A¹, Sechi LA¹, Manunta P¹
¹Italy
THURSDAY, SEPTEMBER 30

PS4/THU/93
Myospryn K2960N Gene Variant and LVH in Russian Hypertensive Patients
Konradi AO¹, Rotar OP¹, Kostareva AA¹, Klyushina A¹, Smolina N¹, Fursova IV¹, Ivanenko VV¹, Dzubenko NA¹, Dubrovskaya OB¹, Malev EG¹
¹Russian Federation

PS4/THU/94
APOE Gene Polymorphisms are Associated with Serum Lipid Levels in Chinese Hypertensive Patients
Zhang Y¹, Huo Y¹, Xu X¹
¹China

PS4/THU/95
The Impact of Race on Nitric Oxide Biodisponibility: eNOS Gene Haplotype Frequencies and Plasma Nitrite Levels in Health Black Population
Metzger IF¹, Ishizawa MH¹, Rios-Santos F¹, Carvalho WA¹, Tanus-Santos JE¹
¹Brazil

PS4/THU/96
Gene Polymorphism and Organ Damage in Uzbek Hypertensive Patients
Eliseyeva M¹, Khamidullaeva G¹, Kevorkov A¹, Nagay A¹
¹Uzbekistan

PS4/THU/97
Characteristics of Circadian Variations of Blood Pressure, Heart rate and Locomotor Activity in Congenic Rats
Kawamura H¹, Mitsubayashi H¹, Saito N¹, Ikeda K¹, Kawakami K¹, Nabika T¹
¹Japan

PS4/THU/98
New Hypertension-Related Genes Determined in Adrenal Glands of Three Spontaneously Hypertensive Rat (SHR) Substrains
Ashenagar MS¹, Tabuchi M¹, Shimada K¹, Watanabe Y¹, Yamanishi H¹, Higashino H¹
¹Japan

PS4/THU/99
Renal RAS Homeostasis in Mice Having Quantitative Changes in Angiotensin-Converting Enzyme Gene
Cunha TS¹, Onaga PY¹, Arita DY¹, Perez JD¹, Colucci JA¹, Arita LS¹, Thomaz MG¹, Irigoyen MC¹, Casarini DE¹
¹Brazil
PS4/THU/100
(Pro)renin Receptor Gene Polymorphism Is Associated with Blood Pressure in Men
Ott C1, Schneider MP1, Hilgers KF1, Schmieder RE1
1Germany

PS4/THU/101
Interactions between Sleep Duration and Genetic Variations in Incident Hypertension: A 6 year of follow-up in Korean Genome Epidemiology Study (KGES)
Lee SK1, Baik I1, Kim SH1, Kim S1, Lee J1, Cho N1, Han B-G1, Chol S1
1Korea, Republic of

PS4/THU/102
Genetic Analysis of Habitual Substance Use, Obesity-Related Traits, Response to Mental and Physical Stress and Heart Rate and Blood Pressure Data in French Canadian Families Pointed to Synaptic Plasticity
Nikpay M1, Šeda O1, Tremblay J1, Gaudet D1, Merlo E1, Kotchen TA2, Cowley, Jr AW2, Hamet P1
1Canada, 2United States

PS4/THU/103
Furin Gene Play a Potential Role in Hypertension in Kazaks Population of Xinjiang
Yao X1, Li N1, Luo W1
1China

PS4/THU/104
Association Study of the Genetic Polymorphisms of the STAMP2 Gene and Essential Hypertension in Uygur Xinjiang Population
Li N1, Bi Y1, Yan Z1
1China

PS4/THU/105
Association of CAPN10 Gene with Insulin Sensitivity, Glucose Tolerance and Renal Function in Essential Hypertensive Patients
Zhou XO1, Wang Y1, Zhang Y1, Gao PJ1, Zhu DL1
1China

PS4/THU/106
Predictive Role of CYBA and NOS3 Genes Polymorphism in Essential Hypertension in Russian Males
Makarevich P1, Andreenko E1, Balatskiy A1, Kolotvin A1, Yarovaya E1, Samokhodskaya L1, Tkachuk V1
1Russian Federation
THURSDAY, SEPTEMBER 30

PS4/THU/108
Interrelation of Mutations in HV1 Region of Mitochondrial DNA with RAAS Genes Polymorphism in Uzbek Hypertensive Patients
Nagay A1, Eliseyeva M1, Kevorkov A1, Srojidinova N1
1Uzbekistan

PS4/THU/109
Gene Polymorphisms of FTO Are Partially Associated with Future Blood Pressure Elevation in Japanese
Shimaoka I1, Kamide K1, Katsuya T1, Akasaka H1, Saitoh S1, Sugimoro K1, Oguro R1, Congrains A1, Ohishi M1, Shimamoto K1, Ogihara T1, Rakugi H1
1Japan

PS4/THU/110
Susceptible and Protective NOS3 Tagging SNP Haplotypes in Hypertension and Resistant Hypertension
Luizon MR1, Sandrim VC1, Coelho EB1, Izidoro-Toledo TC1, Tanus-Santos JE1
1Brazil

PS4/THU/111
Intima-Media and Endothelium – Target-Organs in Hypertensive Patients: Regress of Damaging Under the Influence of Pharmacogenetically Determined Treatment In Relation to Five Genes Polymorphism
Sydorchuk LP1, Amosova KM1, Pishak VP1, Volkov RA1, Sydorchuk II1, Ursuliak JV1, Sydorchuk RI1
1Ukraine

PS4/THU/112
Association Study of Aromatase Gene (CYP19A1) in Essential Hypertension
Shimodaira M1, Nakayama T1, Sato N1, Saito K1, Morita A1, Sato I1, Takahashi T1, Soma M1, Izumi Y1
1Japan

PS4/THU/113
Non-Invasive Assessment of Global Left Ventricular Function in Black Hypertensive Subjects Using the Tei Index of Myocardial Performance: Correlation with Other Conventional Indices
Akintunde A1, Akinwusi O1, Opadijo G1
1Nigeria

PS4/THU/114
Role of Matrix Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinase-1 on Vascular Remodeling in Prehypertensives
Wang S1, Lu F1, Liu Z1, Zhao Y1
1China
THURSDAY, SEPTEMBER 30

PS4/THU/115
Effect of an Excessive Salt Intake on the Blood Pressure and Heart Rate in Young Male Normotensive African Tanzanians
Ikeda K1, Yasui N1, Njelekela M2, Negishi H1, Yamamoto J1, Noguchi T1, Miki T1, Nara Y1, Mtabaji J2, Yamori Y1
1Japan, 2Tanzania, United Republic of

PS4/THU/116
Blood Pressure and 10-Year Cardiovascular Risk Profile of Young Hypertensives in Malaysia; A Single Centre Study
Aszrin A1, Azarisman MS1, Tariq AR1, Noriah MN1
1Malaysia

PS4/THU/117
Prevalence, Awareness and Control of Hypertension in Malaysia: Is there an Urban-Rural Divide?
Mat-Nasir N1, Nor-Ashikin MNK1, Md Yasin M1, Miskan M1, Kien Keat N1, Ramli AS1, S. Krishnapillai AD1, Than W1, Nawawi H1, Yusoff K1, CRisP
1Malaysia

PS4/THU/118
High Risks of Hypertension and Metabolic Syndrome in an Indonesian Farming Area
Mori M1, Mori H1, Tatefuji T1, Yamori Y1, on behalf of HEART Study Group
1Japan

PS4/THU/119
Isolated Systolic Hypertension in Saudi Patients with Diabetic Nephropathy: A Serious Health Concern
Al Wakeel J1, Hammad D1, Isnani A1, Al Suwaida A1, Al Harbi A1
1Saudi Arabia

PS4/THU/120
Effect of Treating Hypothyroidism in Hypertensive Patients in India
Muthusamy V1, India

PS4/THU/121
Ethnotherapeutic and Phytochemical Investigations of *Uapaca Somon* and *Uapaca Heudelotii* Used in the Treatment of Hypertension in the Guinean Traditional Medicine
Balde AM1, Camara AK1, Diallo AS1, Traore MS1, Pieters L2, Diallo MST1
1Guinea, 2Belgium
PS4/THU/122
Rates of Awareness, Treatment and Control of Hypertension in Outpatients Attending the University of Nigeria Teaching Hospital, Enugu, Nigeria
1Nigeria

PS4/THU/123
Gender Inequalities in the Risk of Hypertension in a Rural Disadvantaged Community in India
Thrift AG, Evans RG, Kartik K, Kamakshi K, Fitzgerald SM, Srikanth V
1Australia, 2India

PS4/THU/124
Relationship between Lung Function and Prehypertension in a Malaysian Population
1Malaysia

PS4/THU/125
Polymorphism Endothelial Nitric Oxide Synthase G894T (eNOS), Angiotensin II Type 1 receptor A1166C (AT-1R) and Interleukin-6 174 G/C (IL-6) Genes in Javanese Hypertensive Population
1Indonesia, 2Japan

PS4/THU/127
Which Criterion is Better When We Screen for Left Ventricular Hypertrophy by Electrocardiogram?
Song A, Li T, Wang N, Liang Y, Peng Y, Handan Eye Study
1China

PS4/THU/128
Heart Failure in Hypertensive Patients Presenting with Acute Myocardial Infarction
SaifurRohman M, Hersunati N
1Indonesia

PS4/THU/129
Association of Angiotensin Converting Enzyme Gene (I/D) Polymorphism with Hypertension and Type 2 Diabetes
Zarouk WA, Hussein IR, Raslan HM, Abdel Reheim HA, Moguib O, Emara NA, Aly AA, Hamed M
1Egypt
THURSDAY, SEPTEMBER 30

PS4/THU/130
Challenges Faced in Controlling Hypertension in a Resource-Constrained Environment: The Bangladesh Perspective
Khandaker RK, Bangladesh

PS4/THU/131
Comparison of Cardiovascular Disease Risk Factors in Hypertensive versus Normotensive Patients in a Primary Care Clinic in Malaysia
Chia YC¹, Keevil V²
¹Malaysia, ²United Kingdom

PS4/THU/132
The Current Situation and Future Challenge of Hypertension in Indonesia
Pinzon R¹, Widyo K¹
¹Indonesia

PS4/THU/133
Serum Uric Acid Levels in Elderly Hypertensive Outpatients Aged For 60 To 95: How Do We Work Out in Clinical Practice?
Hamada T¹, Mizuta E¹, Matsuzawa K¹, Izawa S¹, Yamada K¹, Yanagihara K¹, Sugihara S¹, Kato M¹, Ohtahara A¹, Hisatome I¹, Shigemasa C¹
¹Japan

PS4/THU/134
Antihypertensive Response to Thiazide Diuretic or Angiotensin Receptor Blocker in Elderly Hypertensives Is Not Influenced by Pretreatment Plasma Renin Activity
Weintraub H¹, Duprez D¹, Cushman W¹, Samuel R¹, Purkayastha D¹, Zappe DH¹, Izzo Jr. J¹
¹United States

PS4/THU/135
Single-Pill Amlodipine/Atorvastatin Versus Usual Care for Cardiovascular Risk Factor Management in Patients Aged 65 years or More with Hypertension and Additional Risk Factors – A CRUCIAL Trial Sub-Analysis
Zamorano J¹, Erdine S², Pavia Lopez A³, Kim J-H⁴, Al Khadra A⁵, Westergaard M⁶, Sutradhar S⁶, Yunis C⁶, on behalf of the CRUCIAL Investigators
¹Spain, ²Turkey, ³Mexico, ⁴Korea, Republic of, ⁵Saudi Arabia, ⁶United States

PS4/THU/136
Factors Affecting the Time Course of Systolic Blood Pressure in the MRC Older Adults Trial
Carr MJ¹, Cruickshank K¹, McNamee R¹
¹United Kingdom
Hypertension and Its Impact on Activities Of Daily Living (ADL) Among Elderly Persons: A Community Based Study In South India
Ba PK¹, Naik VA¹, Md M¹
¹India

Hypertension and Cardiovascular Risks Profile among the Elderly in a Developing Country
Ambigga D¹, Ramli AS¹, Winn T¹, Suthahar A¹, Aqil MD¹, Mazapuspavina MY¹, Miskan M¹, Ng KK¹, Nafiza MN¹, Nor Ashikin MN¹, Majid FA¹, Nawawi HM¹, Yusoff K¹, Cardiovascular RISks Prevention (CRISP) Investigators
¹Malaysia

Association between Blood Pressure Variability and Cognitive Function in Very Elderly Patients with Essential Hypertension
Liu Z¹, Lu F¹, Zhao Y¹, Wang S¹, Sun S¹, Liu L¹
¹China

Effect of Chronotherapy with Valsartan/Amlodipine Combination in Elderly Hypertensive Patients
Lopez Paz JE¹, Hermida Ameijeiras A¹, Pena Seijo M¹, Calvo Gonzalez G¹, Romero Miguez ML¹, Coca Payeras A¹, Calvo Gomez C¹
¹Spain

Physiotherapy Intervention for Knee Osteoarthritis May Elevate Blood Pressure in Hypertensive and Normotensive Patients: A Controlled Clinical Trial
de Freitas Gonçalves KS¹, Tataqiba Lamas JL¹, Arterial Pressure Research and Study Group
¹Brazil

The Long-Term Efficacy and Safety of Benidipine Therapy of Essential Hypertension in Elderly Chinese Patients
Qi W¹, Fan W¹, Lu G¹, Wu Z¹, Ni Y¹, Wu S¹, Zheng X¹, Zhang J¹, He B¹, Li Y¹, Dai Q¹, Rapid SH, Rapid SH
¹China
PS4/THU/143
The Clinical Characteristics Analysis of the Elder Hospitalized Hypertensive Patients
Liu W¹, Li Y¹, Li H¹
¹China

PS4/THU/144
Disparate Effect of ACE Inhibitor and Thiazide Diuretic on Day/Night Blood Pressure Fall in Postmenopausal Hypertensive Women According to Hormone Replacement Therapy (HRT) Taking
Posadzy-Malaczynska A¹, Stryczynski L¹, Rajpold K¹
¹Poland

PS4/THU/145
Relation between Adipocytokines Values and Renal Failure in Postmenopausal Women with Metabolic Syndrome
Minerva M¹, Gabriela A¹, Mariana A¹
¹Romania

PS4/THU/146
Cardiovascular Effects of Chronic Tamoxifen Treatment in Normotensive and Hypertensive Ovariectomized Rats
Romero WG¹, Borgo MV¹, Bissoli NS¹, Moysés MR¹, Abreu GR¹
¹Brazil

PS4/THU/147
Noliprel-Forte in the Treatment of Essential Hypertension in Postmenopausal Women
Qabiyeva NN¹, Bakhaliyev AB¹, Usubova FN¹, Qasimov Z¹
¹Azerbaijan

PS4/THU/148
Prevalence of Cardiovascular Disease Risk Factors in Women with Different Types of Professional Activity
Gasimov ZI¹, Kocharli M¹, Bakhshaliyev AB¹, Ibrahimov A¹, Mailova N, Shirinova T, Kocharli A, Usubova F, Qabiyeva N, Aleskerzade S, Behbudova J, Ahmedova T
¹Azerbaijan

PS4/THU/149
Transient Treatment with High-Dose Angiotensin Receptor Blocker (ARB) Causes Regression of Hypertension in a Rat Model of Metabolic Syndrome (SHR/Ndmcrr-Cp Rats)
Ishiguro K¹, Sasamura H¹, Hayashi K¹, Sakamaki Y¹, Azegami T¹, Itoh H¹
¹Japan
THURSDAY, SEPTEMBER 30

PS4/THU/150
Association Study of STEAP4 Genetic Polymorphisms and Metabolic Syndrome in Uygur Chinese
Li N1, Guo Y1, Wang H1, Yan Z1, Zhang J1, Zhou L1, Luo W1
1China

PS4/THU/151
Association between the Bone Morphogenetic Protein 7(BMP7) Gene Polymorphism and the Metabolic Syndrome
Li N1, Yan Z1, Yao X1
1China

PS4/THU/152
Plasma Aldosterone Associated with the Components of Metabolic Syndrome in Chinese Elderly Farmers
Li G1, Huang X1, Liu G1, Liang S1, Yan K1, Bai Z1, Wang X1, Zhang H1
1China

PS4/THU/153
Treatment with Manidipine vs. Amlodipine Reduces the Risk of New-onset Diabetes Mellitus in Hypertensive Patients with the Metabolic Syndrome
Martinez-Martin FJ1, Soriano-Perera P1
1Spain

PS4/THU/154
Increased Inflammation in Centrally Obese and Metabolic Syndrome Subjects with Different Glycaemic Status
Tengku Ismail TS1, A Razak A1, Mohamad Taib MR1, Abd Muid S1, Syed Baharuddin SNH1, Osman MT1, Yusoff K1, Nawawi H1
1Malaysia

PS4/THU/155
A Selective PPARγ Modulating Angiotensin II Receptor Blockade Regulates Mitochondrial Biogenesis in Skeletal Muscle
Sugimoto K1, Fujisawa T1, Shindo N1, Wang X1, Ohishi M1, Rakugi H1
1Japan

PS4/THU/156
Metabolic Syndrome and High Cardiovascular Risk in Out-Ward Patients: Are We Able to Detect and to Treat Them?
Lietava J1, Kosmalova V1, Fodor GJ2, for NEMESYS investigators
1Slovakia, 2Canada
THURSDAY, SEPTEMBER 30

PS4/THU/157
Prevalence of Metabolic Syndrome in Malaysian Population
Nor-Ashikin MNK, Mat Nasir N, Md Yasin M, Miskan M, Ng KK, Ramli AS, S. Krishnapillai AD, Than W, Nawawi H, Yusoff K, CRisp
'Malaysia

PS4/THU/158
Impact of Metabolic Syndrome on Subclinical Atherosclerosis in Normotensive and Hypertensive Korean Subjects
'Korea, Republic of

PS4/THU/159
Metabolic Syndrome Prevalence in Arterial Hypertension Unit of Granada (South of Spain)
Mediavilla García JD, Jaén Águila F, Fernández Torres C, Jiménez Alonso J
'Spain

PS4/THU/160
Prevalence of Metabolic Syndrome and Clustering of Cardiovascular Risk Factors in Newly Diagnosed Non-Diabetic Nigerian Hypertensives
Akintunde AA, Ayodele OE, Akinwusi O, Opadijo G
'Nigeria

PS4/THU/161
Effect of Lifestyle Intervention on the Prevalence of Metabolic Syndrome and Its Components in an Urban Population: Tehran Lipid and Glucose Study
Azizi F, Mirmiran P, Momenan A, Hadaegh F, Moeini AS, Zahedi Asl S, Hosseinpanah F, Amouzegar A
'Iran, Islamic Republic of

PS4/THU/162
Relation of Abdominal Obesity, Metabolic Risk Factors, and Left Ventricular Hypertrophy in Healthy Middle-aged and Older Men
'Korea, Republic of

PS4/THU/163
Prevalence of Metabolic Factors among the Patient with Essential Hypertension: A Single Center Registry
Siddique MA, Bangladesh
THURSDAY, SEPTEMBER 30

PS4/THU/164
Attenuation of Endothelial Function, Fatty Liver, and Non-alcoholic Steatohepatitis (NASH) by Metabosartan, Telmisartan
Nakagami H1, Rakugi H1, Morishita R1
1Japan

PS4/THU/165
Pharmacological Treatment of Cardiovascular Risk Factors in Individuals with Metabolic Syndrome Before and After Interventions: Findings from the Isfahan Healthy Heart Program
Gharipour M1, Kelishadi R1, Sarrafzadegan N1, Khosravi A1, Toghyanfar N1, Noori F1
1Iran, Islamic Republic of

PS4/THU/166
Arginase 2 Deficient Mice: Metabolic Effects
Stevenson A1, Fu H1, Huang L1, Tu H1, Tsai C1, Small K1, Olearczyk J1, Mudgett J1, Combe R2, Monassier L2, Bedu E2, Champy M-F2, Muller S2, Fricker B2, Lassman M1, Rohm R1, Hernandez M1, Struthers M1, Roy S1, Crook M1
1United States, 2France

PS4/THU/167
Obesity and Metabolic Syndrome
Hlubík J1, Hlúbík P1, Stritecka H1
1Czech Republic

PS4/THU/168
IM28: The Gabonese Contribution for Infections and Cardiovascular Disease Treatments
Mavoungou D1, Maka G1, Akoume Ndong MY1, Mavoungou P-V1, Ongali B1, Mavoungou E1
1Gabon

PS4/THU/169
A Call for Action! Registered Nurses Implementing the 2010 Canadian Hypertension Education Program Recommendations
McLean DL1, Cloutier L1, Pham T1, Morris D1, Costello J-A1, Gaudet L1, Mooney J1
1Canada

PS4/THU/170
Knowledge Translation: Canadian Cardiovascular Nurses Embrace National Public and Professional Recommendations for Hypertension Care
Morris DA1, Mclean D1, Cloutier L1, Pham T1
1Canada
PS4/THU/171
Lifestyle of Hypertensive Patients Attending Cardiac Clinic of B.P.Koirala Institute of Health Science, Dharan, Nepal
Shrestha RN, Nepal

PS4/THU/172
Specific Matrix Metalloproteinase-9 (MMP-9) Genotype and Haplotype Affect the Circulating MMP-9 Levels Obese Children and Adolescents
Belo VA¹, Souza-Costa DC¹, Lanna CM¹, Gerlach RF¹, Tanus-Santos JE¹
¹Brazil

PS4/THU/173
Lack of Association of the Uncoupling Protein-2 I-45/D and 3 C-55T Gene Polymorphisms and the Mild Obese Chinese Population
Wang X¹, Shen Y¹, Liu X¹, Ma L¹, Xing J¹, Chen L¹, Liu L¹
¹China

PS4/THU/174
Association between Body Mass Index and All-Cause Mortality in Lean Population Considering the Presence of Cardiovascular Risk Factors: Korea Medical Insurance Corporation study
Lee JY¹, Kim HC¹, Ahn SV¹, Suh I¹
¹Korea, Republic of

PS4/THU/175
Role of Xanthine Oxidoreductase in High Fat Diet-induced Obesity Mice
Ohtsubo T¹, Matsumura K¹, Goto K¹, Noguchi H¹, Oniki H¹, Iida M¹
¹Japan

PS4/THU/176
Cognitive Function in the Presence of Obesity: The Role of Carotid Intima-Media Thickness
Zueva IB¹, Vanaeva KI¹, Barisheva AV¹, Sanez EL¹, Piotrovskaya VR¹, Shlyahto EV¹
¹Russian Federation

PS4/THU/177
Association of Carotid Intima Media Thickness and Presence of Carotid Plaques with Body Mass Index and Waist Circumference in Chinese Hypertensive Adults
Li J¹, Huo Y¹, Zha J¹, Yang Y¹, He M¹, Dong Q¹, Fu J¹, Shen Y¹, Ma W¹, Sun N¹, Xu X¹, Xing H¹, Tang G¹, Qin X¹, Wang X², Liu L¹, Xu X², The Research Team of CSPPT
¹China, ²United States
THURSDAY, SEPTEMBER 30

**PS4/THU/178**
The Relationship between the Body Fat Percentage and Obesity
Bai Z¹, Zhang H¹, Zhang R¹, Yan K¹, Wei W¹, Li G¹, Wang X¹, Li F¹
¹China

**PS4/THU/179**
Prevalence of Obesity Related Hypertension in Urban Residents in Shanxi Province and in Rural Residents in Heilongjiang Province, China
Li Y-F¹, Xiao C-S¹, Hui R-T¹, Bian Y-F¹, Li H¹, Li S-H¹, Jia L¹
¹China

**PS4/THU/180**
Left Ventricular Function in Adult Nigerians with Central Obesity
Akintunde U¹, Oke A¹, Mbakwem AC¹
¹Nigeria

**PS4/THU/181**
Overweight Prevalence and Associated Risk Factors among Adult Population in Northeast China
Sun J¹, Shi X¹, Tao Y¹, Li B¹, He S¹, Niu J¹
¹China

**PS4/THU/182**
Genetic Variations of PRDM16 with Human Obesity
Li N¹, Zhang J¹
¹China

**PS4/THU/183**
R904Q Variant in the SLC12A3 is Associated with Bone Mineral Density in Japanese Women
Tsutaya S¹, Sugimoto K¹, Yasujima M¹
¹Japan

**PS4/THU/184**
Large and Small Artery Elasticity Are Related to Impaired Lung Function: The Multi-Ethnic Study of Atherosclerosis (MESA)
Duprez DA¹, Hoffman E¹, Jacobs Jr D¹, Jiang R¹, Mc Allister D¹, Barr RG¹
¹United States

**PS4/THU/185**
Salt Reduction Strategies: Key Elements for Success
Webster J¹, Hawkes C², Dunford E¹, Neal B¹
¹Australia, ²Brazil
PS4/THU/186
Occurrence of Potential Risk Markers of CVD in Czech Soldiers
Střítecká H1, Hlubík P1
1Czech Republic

PS4/THU/187
Equity and Cardiovascular Disease in Australian Women
Stewart Williams J1, Cunich M1
1Australia

PS4/THU/188
Quality of Life in Patients with Abdominal Obesity
Shlyakhto EV1, Berezina AV1, Belyaeva O1, Berkovich OA1, Baranova EI1,
Bazhnenova EA1, Karonova TL1
1Russian Federation

PS4/THU/189
Increased Kidney Angiotensin II in Virgin But Not Pregnant ACE2 Knock Out Mice
Brosnihan KB1, Strawn WB1, Bharadwaj M1, Gallagher P1, Busalacchi KB1, Gurley SB1, Coffman TM1
1United States

PS4/THU/190
Angiotensin II Type 2 Receptor Agonist C21 Reduced Vascular Damage in Stroke-Prone Spontaneously Hypertensive Rats
Rehman A1, Leibowitz A1, Paradis P1, Schiffrin EL1
1Canada

PS4/THU/191
Role of Angiotensin II in Plasma PAI-1 Changes Induced By Imidapril or Candesartan in Hypertensive Patients With Metabolic Syndrome
Fogari R1, Mugellini A1, Preti P1, Derosa G1, Destro M1
1Italy

PS4/THU/192
Adoptive Transfer of T-Regulatory Lymphocytes Attenuates Aldosterone-Induced Hypertension and Vascular Injury
Kasal DAB1,2, Barhoumi T1,3, Shbat L1, Laurant P3, Neves MF2, Paradis P1, Schiffrin EL1
1Canada, 2Brazil, 3France
THURSDAY, SEPTEMBER 30

PS4/THU/193
Cardiac-Specific Activation of AT1 Receptor-Associated Protein Completely Suppresses Cardiac Hypertrophy in Chronic Angiotensin II-Infused Mice
Wakui H¹, Tamura K¹, Tanaka Y¹, Matsuda M¹, Masuda S-I¹, Shigenaga A¹, Dejima T¹, Maeda A¹, Kanaoka T¹, Osawa M¹, Mitsuhashi H¹, Ikeya-Tsurumi Y¹, Kobayashi Y¹, Ichihara N¹, Hirawa N¹, Okano Y¹, Azuma K¹, Ozawa M¹, Yabana M¹, Toya Y¹, Minamisawa S¹, Umemura S¹
¹Japan

PS4/THU/194
Angiotensin-(1-7) Attenuates Hyposmolarity-Induced ANP Secretion via Na⁺-K⁺ Pump
Shah A¹, Shan G¹, Oh YB¹, Park WH¹, Kim SZ¹, Kim SH¹
¹Korea, Republic of

PS4/THU/195
Novel Relevance: Resting APJ but Not Activated APJ through Apelin Attenuates Angiotensin II Type 1 Receptor
Sun X¹, Yoshikawa A¹, Aizaki Y¹, Iida S¹, Matsumura M¹, Muramatsu T¹, Komiyama N¹, Nishimura S¹, Inagami T², Senbonmatsu T¹
¹Japan, ²United States

PS4/THU/196
Sustained Activation of Renal ATRAP Expression Is Involved In the Long-Term Therapeutic Effects by Transient Blockade of Ang II Type 1 Receptor in Salt Sensitive Hypertension
Dejima T¹, Tamura K¹, Wakui H¹, Shigenaga A-I¹, Masuda S-I¹, Maeda A¹, Kanaoka T¹, Osawa M¹, Azuma K¹, Matsuda M¹, Umemura S¹
¹Japan

PS4/THU/197
Cardioprotective Effects of AT1 Receptor Antagonist in Experimental Model Rats of Metabolic Syndrome
Tanabe A¹, Tsuiki M¹, Tsumagari A¹, Kimura H¹, Asano M¹, Naruse M¹, Takano K¹
¹Japan

PS4/THU/198
Brief Cryoactivation Markedly Affects Plasma Renin Activity and Direct Renin Measurement in Low Renin Samples
Morganti A, Italy
THURSDAY, SEPTEMBER 30

PS4/THU/199
Tonin As an Important Modulator of Renal Renin-Angiotensin System (RAS) in Transgenic Mouse Expressing Rat Tonin
Ribeiro AA1, Palomino Jara Z1, Lima MP1, Higuchi DA1, Irigoyen MC1, Pesquero JL1, Casarini DE1
1Brazil

PS4/THU/200
Hepatocyte Growth Factor Attenuates TGF-b- Angiotensin II Crosstalk by Down Regulation of Angiotensin II Type 1 Receptor through PTEN/Akt Pathway
Kusunoki H1, Taniyama Y1, Iekushi K1, Azuma J1, Sanada F1, Dosaka N1, Okayama K1, Rakugi H1, Morishita R1
1Japan

PS4/THU/201
Effect of Renin Inhibitor on the Activity of Recombinant Human Renin Was Different From That on the Renin Activity in Human Plasma
Iwai M1, Senba I1, Kanno H1, Nakaoka H1, Sone H1, Inaba S1, Horiuchi M1
1Japan

PS4/THU/202
Potential Role of the Renin-Angiotensin System in Maintaining Cerebral Vascular Relaxation in 2 Kidney/1 Clip Hypertension
Beyer AM1, Kunert MP1, Lombard JH1
1United States

PS4/THU/203
Dual Inhibition of the Renin-Angiotensin System by Aliskiren and Losartan Produces Additive Effects on the Vascular Remodeling in Renovascular Hypertension
Martins-Oliveira A1, Castro MM2, Machado-Oliveira DM1, Rizzi E1, Ceron CS1, Guimaraes D1, Gerlach RF1, Tanus-Santos JE1
1Brazil, 2Canada

PS4/THU/204
Effects of Antioxidants Treatment on Cardiac Dysfunction and MMP-2 Levels in Renovascular Hypertension
Rizzi E1, Castro MM2, Ceron CS1, Neto-Neves E1, Tanus-Santos JE1, Gerlach RF1
1Brazil, 2Canada

PS4/THU/205
Stenting for Atherosclerotic Renal Artery Stenosis is Effective in Selected Patients: 6 Year of Follow-up Clinical Outcomes in a Single Center
Jiang X1, Yang Q1, Yang Y1, Wu H1, Hui R1, Liu L1
1China
PS4/THU/206
Effects of Renal Revascularization on Renal and Cardiac Function in Hypertensive Patients
Catena C1, Colussi G1, Casanova-Borca A1, Di Fabio A1, Sechi LA1
1Italy

PS4/THU/207
Dose-Dependent Inhibition of Metalloproteinase-2 Attenuates the Vascular Changes in Renovascular Hypertension
Ceron CS1, Guimarães DA1, Rizzi E1, de Oliveira AM1, de Oliveira DMM1, Tirapelli CR1, Gerlach RF1, Tanus-Santos JE1
1Brazil

PS4/THU/208
Progressive Decline in Reciprocal of Serum Creatinine May Select Candidates for Stent Angioplasty in Ischemic Renal Disease
Hagmann R1, Silva VS1, Martin LC1, Carvalho F1, Bregagnollo E1, Franco RJ1
1Brazil

PS4/THU/209
Effects of Different Dihydropyridines on Vascular Alterations in Renovascular Hypertension Model (2K-1C)
Marçal DM1, Rizzi E1, Ceron CS1, Martins-Oliveira A1, Guimaraes D1, Gerlach RF1, Tanus-Santos JE1
1Brazil

PS4/THU/210
Percutaneous Treatment of the Renovascular Hypertension
Boughzala E1, Laroussi L1, Hammas S1, Ouali S1, Fradi S1, Ajlani B1
1Tunisia

PS4/THU/211
Analysis of Cardiovascular Risk Factors in Patients with Renovascular Hypertension Whose Aetiology is Atherosclerosis
da Silva MAV1, Neves PDMM1, Oliveira AAO1, Resende LAPR1, Mendonça HM1, Marques VP1, Oliveira RSM1, Lopes LC1, Tintori JA1, Zanardo FC1, Aguiar CF1, Duarte LA1, Accorsini JS1
1Brazil

PS4/THU/212
Impact of Salt Intake on Pulse Pressure and Central Aortic Haemodynamics Independent of Static Blood Pressure, in the General Population
Majane OHI1, Maseko MJ1, Redelinghuys M1, Norton GR1, Woodiwiss AJ1
1South Africa
PS4/THU/213
The Study of Endothelial Function in Normotensive Salt-sensitive Subject
Mu J¹, Zheng S¹, Lian Q¹, Liu F¹
¹China

PS4/THU/214
China Salt Pilot Study
Zhang H¹, Wang Q², Wei W¹, Morgan TO³, Hans R. Brunner B³, Liu LS¹, on behalf of China Salt Collaborative Group
¹China, ²Switzerland, ³Australia

PS4/THU/215
Compliance to Hyposodic Diet in Patients with Chronic Renal Failure Followed In a Specific Ambulatory for Conservatory Treatment to Prevent End-Stage Renal Disease
Faig-Leite FS¹, Martin LC¹, Contti M¹, Teixeira R¹, Habermann F¹, Barretti P¹, Franco RJ¹
¹Brazil

PS4/THU/216
Dietary and Neural Factors Involved in Salt-sensitive Hypertension
Yamori Y¹, Taguchi T¹, Mori H¹, Mori M¹, on behalf of WHO-CARDIAC Study Group
¹Japan

PS4/THU/217
Appreciable Contribution of Smoking to Ambulatory Blood Pressure in a Population with a High Prevalence of the Angiotensin-Converting Enzyme Gene DD Genotype
Maseko JM¹, Majane OH¹, Woodiwiss A¹, Norton G¹
¹South Africa

PS4/THU/218
Cardiovascular Risk Profiles Associated with Smoking Status in Malaysian-Malay
Md Yasin M¹, Mat Nasir N¹, Miskan M¹, Kien Keat N¹, Muhammad Noor Khan N-A¹, Ramli AS¹, Krishnapillai AD¹, Abdul Majid F¹, Razali R¹, Dasiman R¹, Ahmad R¹, Nawawi H¹, Ismail TS¹, Mohammad M¹, Yusoff K¹, Winn T¹, CRISP Study Group
¹Malaysia

PS4/THU/219
Survey Audit on Thrombolysis in Stroke - West Midlands
Carr FM¹, Naqvi S¹, Senthil V¹, Agarwal A¹
¹United Kingdom
THURSDAY, SEPTEMBER 30

PS4/THU/220
The Profile of Blood Pressure in Acute Stroke
Pinzon R, Indonesia

PS4/THU/221
Blood Pressure Control in Patients after Ischemic Stroke
Wloch-Kopec D, Slowik A, Szczudlik A
1Poland

PS4/THU/222
The Adaptation of the Bilingual Aphasia Test (BAT) English-Bemba
Kankinza N1,2
1Netherlands, 2Germany

PS4/THU/223
Seasonal and Weekly Variability of Telemedicine Mediated Home Blood Pressure and Seasonal Changes of Plasma Catecholamine in Hemodialyzed Patients
Ryuzaki M1, Kobayashi E1, Takimoto C1, Shishido T1, Nakamoto H1, Suzuki Y1, Suzuki Y1, Nagare T1
1Japan

PS4/THU/224
Anti-Atherosclerotic Di-Peptide, Trp-His, Can Suppress Intracellular [Ca2+] in Vascular Smooth Muscle Cells in a Similar Manner to Dihydropyridine Type Ca2+ Channel Blocker
Wang ZQ1, Tanaka M1, Watanabe S1, Kobayashi Y1, Matsui T1
1Japan

PS4/THU/225
Knowledge & Skill Retention after the Advanced Cardiac Life Support Workshop – A Study in Nursing Practitioners at the Udonthani Hospital, Thailand
Wichitkosoom W, Thailand

PS4/THU/226
The Expert Nurse in Chronic Care Model Arterial Hypertension: A Step into Management Assistance
Lenti S1, Corradini P1, Frigerio C1, Pietrelli S1
1Italy
THURSDAY, SEPTEMBER 30

PS4/THU/227
Investigation on Post-Stroke Rehabilitation Training Needs of Community Health Workers in Shanghai
Pan CR1, Wu Y1, Zhou Y1, Hsu L1
1China

PS4/THU/228
Overweight and Central Obesity Disorders in Different Chinese Populations
Zhou L1, Li N1
1China

PS4/THU/229
Drop the Pressure – The Need for Reformulation of Fast Food Products
Dunford E1, Webster J1, Barzi F1, Neal B1
1Australia

PS4/THU/230
Prevalence of Cardiovascular Disease Risk Factors among the Kazakh, Uygur, Mongolia and Han Population of Xinjiang
Li N1, Wang H1, Zhou L1, Luo W1, Chang J1
1China

PS4/THU/231
Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod versus Naproxen and Ibuprofen on 24-hour BP in Patients with Osteoarthritis and Hypertension
White WB1, Schnitzer TJ1, Longlade P2, Fleming R2, Djian J2
1United States, 2France

PS4/THU/232
Long-Term Effects of Strict and Less Strict Control of Home Blood Pressure with Amlodipine- Or Losartan-Based Regimen on Urinary Albumin Excretion and Renal Function in Hypertensive Patients: 5 Years of Hosp Substudy
Kawano Y1, Horio T1, Kamide K1, Yoshihara F1, Tokudome T1, Iwashima Y1, Nakamura S1
1Japan

PS4/THU/233
The Regression towards the Mean and Blood Pressure Changes under Placebo in the IDEAL Trial and in a Simulation Model: Practical Lessons
Erpeldinger S1, Bejan-Angoulvant T1, Farhat S1, Richet A1, Zerbib Y1, Roojee N1, Le Goaziou M-F1, Moreau A1, Gueyffier F1
1France
THE NITRIC OXIDE DONATOR NAPROXINOD HAS BLOOD PRESSURE EFFECTS SIMILAR TO PLACEBO IN PATIENTS WITH OSTEOPOROSIS

White WB1, Schnitzer TJ1, Djian J2, Fraysinet H2, Duquesnoix B2, Weber M1
1United States, 2France

MAGNESIUM SUPPLEMENTATION ON BLOOD PRESSURE, INTRACELLULAR IONS LEVEL AND INSULIN RESISTANCE IN HYPERTENSIVE PATIENTS USING DIURETICS

Maluly VG1, Rodrigues MLG1, Valença DCT1, Torres MRSG1, Argolo S1, Nogueira Neto JF1, Sanjuliani AF1
1Brazil

THE EFFECT OF TRANDOLAPRIL AND ITS FIXED-DOSE COMBINATION WITH VERAPAMIL ON TGF-B1 LEVELS IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES

Rubio-Guerra AF1, Vargas-Robles H1, Vargas-Ayala G1, Rodriguez-Lopez L1, Escalante-Acosta BA1
1Mexico

THE EFFECT OF TRANDOLAPRIL AND ITS FIXED-DOSE COMBINATION WITH VERAPAMIL ON TGF-B1 LEVELS IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES - COMPARISON BETWEEN AZELNIDIPINE AND NIFEDIPINE CR-

Yokoi T1, Nakade S1, Yoshika M1, Masuda M1, Komiyama Y1, Masaki H1, Takahashi H1
1Japan

EFFICACY AND SAFETY OF THE FIXED COMBINATION OF IRBESARTAN/HYDROCHLOROTHIAZIDE IN STAGES 2 AND 3 HYPERTENSION IN CHINESE

Huang Q-F1, Li Y1, Zhang Y1, Sheng C-S1, Liu L1, Wang J-G1
1China

ASSOCIATION OF INCREASED MYOCARDIAL FIBROSIS WITH DECREASED LEFT VENTRICULAR LONGITUDINAL STRAIN IN UNTREATED HYPERTENSION

Tsai W-C1, Liu Y-W1, Lin C-C1, Huang Y-Y1, Tsai L-M1
1Taiwan, Republic of China

PROTECTIVE EFFECTS OF ANGIOTENSIN AT1 AND ENDOTHELIN ETA RECEPTOR BLOCKADE IN MALIGNANT HYPERTENSION IN THE RAT

Therrien FJ1, Lemieux P1, Bélanger S1, Agharazii M1, Lebel M1, Larivière R1
1Canada
THURSDAY, SEPTEMBER 30

**PS4/THU/241**  
Elevated Sympathetic Nervous Activity Plays an Important Role in the Development of Renal Complications in Patients with Diabetes Mellitus and Hypertension  
Masuo K, Australia

**PS4/THU/242**  
Isolated Baroreflex Deficit Induces Cardiac and Hemodynamic Impairment in Normotensive Rats  
Moreira ED, Moraes-Silva IC, Jorge L, Paulini JA, Moraes PR, Rosa KT, Mostarda C, De Angelis K, Irigoyen MC, Krieger EM  
'Brazil

**PS4/THU/243**  
Correlation Circadian Variability of Blood Pressure with Target Organ Damage  
'Spain

**PS4/THU/244**  
Target-Organ Damage and Risk Factors in Mentally Working Subjects  
Rotar O, Dubrovskaya O, Dzubenko N, Sokaliskaya E, Malev E, Ivanenko V, Solntsev V, Litvinenko E, Konradi A  
'Russian Federation

**PS4/THU/245**  
Association of Left Ventricular Mass and Cardiovascular Risk Factors at Patients with Arterial Hypertension and Metabolic Syndrome  
Kaspruk G, Romanov V, Mitchenko O  
'Ukraine

**PS4/THU/246**  
Effects of One-Ear Treatment with Angiotensin II Receptor Blocker or Calcium Channel Blocker on Cardiovascular System  
Takeda K, Takanashi Y, Moriguchi J, Matsumoto S, Yagi T  
'Japan

**PS4/THU/247**  
Parathyroid Hormone Is Associated with Body Mass Index, Blood Pressure, Diastolic and Renal Dysfunction in Essential Hypertension  
Reznik EV, Gendlin GE, Storozhakov GI, Guschina VM, Tursheva ME, Baranich II, Volinkina VM, Academician Storozhakov's Group  
'Russian Federation
THURSDAY, SEPTEMBER 30

PS4/THU/248
Association between Retinopathy and CV Diseases in Patients with Essential Hypertension
Kwon SU, Korea, Republic of

PS4/THU/249
Simple Clinical Characteristics May Differentiate Hypertensives with and Without Nephroangiosclerosis Confirmed by Renal Biopsy
D'Oliveira CH1, Martin LC1, Viero RM1, Habermann F1, Moraes CF1, Silva CE1, Franco RJ1
1Brazil

PS4/THU/250
Inferred Blood Pressure Levels Switching from a Health Promotion to Antihypertensive Medications in Success Rate – Oriented Models
Ohno Y1, Takenaka T1, Suzuki H1
1Japan

PS4/THU/251
Knowledge of Acute Myocardial Infarction Symptoms and Emergency Phone Number in Patients with Hypertension
Kopec G1, Sobien B1, Dziedzic H1, Podolec M1, Pajak A1, Podolec P1
1Poland

PS4/THU/252
A Single Nucleotide Polymorphism In TIMP-3 Gene Is Associated with Coronary Artery Diseases and Hypertension
Oguro R1, Kamide K1, Katsuya T1, Shimaoka I1, Congrains A1, Sugimoto K1, Kato N1, Awata N1, Ohishi M1, Rakugi H1
1Japan

PS4/THU/253
Transcript in the Locus 9p21 Is Associated With Atherosclerosis by Regulating Expression of CDKN2B and CDKN2A in Vascular Smooth Muscle Cells
Congrains A1, Kamide K1, Katsuya T1, Oguro R1, Shimaoka I1, Takemura Y1, Yamamoto K1, Sugimoto K1, Yasuda O1, Ohishi M1, Rakugi H1
1Japan

PS4/THU/254
Blood Pressure in Patients After Coronary Revascularization is Unsatisfactory Controlled Despite Guidelines – Compliance Problem in Patients or in Physicians
Roseva-Nielsen N1, Kristensen K1, Andersen U1, Svendsen TL1
1Denmark
THURSDAY, SEPTEMBER 30

PS4/THU/255
Hypercholesterolemia as an Independent Predictor of Blood Pressure Inadequacy in a Brazilian Hypertensive Cohort
Ferreira H1, Rodrigues CJ1, Araujo L1, Tavares A1, Kohlmann Jr O1, Ribeiro AB1, Zanella MT1, Batista MC1
1Brazil

PS4/THU/256
Study on the Relationship between Smoking and Hypertension
Quan-Yong X, China

PS4/THU/257
Association of Central Obesity, Hyperinsulinemia and Dyslipidemia with High Grade Prostate Cancer – A Cross Sectional Study
Tewari R1, Prabhat P1, Natu SM1, Goel MM1, Dalela D1, Goel A1, Tandon P1
1India

PS4/THU/258
Are we missing the Boat between Alliance of Benign Prostatic Hyperplasia (BPH) with Metabolic Syndrome (MS) and its Components?
Tewari R1, Prabhat P1, Natu SM1, Goel MM1, Dalela D1, Goel A1, Tandon P1
1India

PS4/THU/259
Delay in Reaching Hospital in Stroke and In-patient Mortality; A Prospective Hospital Based Study from Southern India
Nagaraja V1, Bhat S G1, Khan MA1
1India

PS4/THU/260
Relationship of Anthropometric Indicators with Blood Pressure Levels Among Undergraduate Students at National University of Rwanda
Manzi Muhire RS1, Rasoloherimampiononi RM1, Baganizi E1, Cechetto D2, Slatnik M2
1Rwanda, 2Canada

PS4/THU/261
Coronary Heart Disease in Patients with Diabetes
Pollice P1,2, Pollice F2
1Italy, 2Spain

PS4/THU/262
A Single Nucleotide Polymorphism in CYP17A1 is Associated with Hypertension in the Chinese Children
Wu L1, Xi B1, Zhang M1, Shen Y1, Zhao X1, Wang T1, Cheng H1, Hou D1, Wang X1, Mi J1
1China
THURSDAY, SEPTEMBER 30

**PS4/THU/263**
Prevalence and Risk Factors of Hypertension in Boloor Diabetes Study in South India
Pathak R¹, Prabha Adhikari MR¹, Pemminati S¹, Kotian MS¹, Boloor Diabetes Study Group
¹India

**PS4/THU/264**
Enhancing Compliance and Quality of Life in Elderly Patients with Arterial Hypertension
Chernyavskaya T, Russian Federation

**PS4/THU/265**
Impaired Glucose Tolerance is Associated with Alterations in Blood Pressure, Pulse Rate, Hemorheological and Laboratory Parameters
Persson SU, Sweden

**PS4/THU/266**
Impact of Diabetes Mellitus in Middle East Patients Undergoing Coronary Artery Bypass Grafting
Farrag AAM¹, Salama SA¹, El Adeeb K¹, Khalifa E¹, El Ramly MZ¹
¹Egypt

**PS4/THU/267**
Impact of Obesity on Perioperative Morbidity and Mortality in Egyptian Patients Undergoing Coronary Artery Bypass Grafting
Farrag AAM¹, Salama SA¹, El Adeeb K¹
¹Egypt

**PS4/THU/268**
Exforge® for Primary Prevention of Stroke in Hypertensive Patients
Shen Y¹, Zhou L¹, Zhang Y¹, Tao L¹
¹China

**PS4/THU/269**
Acupuncture in Managing of Spasticity of Post Stroke Survivor: A Systematic Review
Lee SH¹, Wong YO¹, Zhao Y², Chu MK¹, Che CT¹
¹Hong Kong, ²China

**PS4/THU/270**
Role of Potassium on Target Organ Protection
Wang Q¹,²
¹Switzerland, ²China
PS4/THU/272
The Relationship between the Sleep Quality and Blood Pressure Values Before and After Therapy with Rilmenidine
Farsky S¹, Sidlo R¹
¹Slovakia

PS4/THU/273
The Long-Term Safety and Tolerability of Combination Olmesartan Medoxomil/Amlodipine Besylate+Hydrochlorothiazide in Patients With Hypertension: The TRINITY Study
Kereiakes D¹, Izzo J¹, Chrysant S¹, Littlejohn T¹, Oparil S¹, Melino M¹, Fernandez V¹, Lee J¹, Heyrman R¹
¹United States

PS4/THU/274
Efficacy of Combination Olmesartan Medoxomil+Amlodipine Besylate+Hydrochlorothiazide in Patients with Hypertension and Diabetes, Chronic Kidney Disease, or Chronic Cardiovascular Disease: The TRINITY Study
Oparil S¹, Chrysant S¹, Izzo J¹, Kereiakes D¹, Littlejohn T¹, Melino M¹, Fernandez V¹, Lee J¹, Heyrman R¹
¹United States

PS4/THU/275
Biomarkers of Oxidative Stress in Patients with Hypertensive Nephropathy
Radenkovic S¹, Kocic G¹, Kalezic V¹
¹Serbia

PS4/THU/276
Single OGTT Can Overestimate the Prevalence of Impaired Glucose Tolerance and Diabetes – A Sub-Study of Chinom
Zhang YQ¹, Zhang B¹, Li M¹, Wang J¹, Li Y¹, Xue H¹, Liu L¹, CHINOM Study Group
¹China

PS4/THU/277
Obesity Induced Gestational Diabetes Mellitus Vascular Effects: Role of Endothelium
Tufiño C¹, Bobadilla RA¹
¹Mexico

PS4/THU/278
Vascular AT₁/AT₂ Receptor Ratio Impact on Vasoconstriction in Experimental Gestational Diabetes
Bobadilla RA¹, Tufiño C¹, Velazquez Roman JA¹, Villafaña S¹, Fernandez Vallin E¹, Lopez P¹
¹Mexico
PS4/THU/279
Conventional and Ambulatory Blood Pressure in Patients with Abdominal Obesity in Two Methodological Approaches of Metabolic Syndrome
Pello EV, Malyutina SK, Simonova GI, Nikitin YP
1Russian Federation

PS4/THU/280
Using Comparative Mapping to Identify Candidate Human Genetic Regions for Cardiovascular Diseases in the Jackson Heart Study
Buxbaum S, Tribune S, Ruiz A, Deng AY, Dutil J
1United States, 2Puerto Rico, 3Canada

PS4/THU/281
Plasma B-type Natriuretic Peptide Levels Predict Post-Operative Atrial Fibrillation in Patients Undergoing Thoracic Surgery
Pollice F, Pollice P, Calderon A
1Italy, 2Spain

PS4/THU/282
Improving Outcome in Elderly Patients after Acute Coronary Syndrome – A Nationwide Analysis of Taiwan
Hsieh T-H, Tsai L-M
1Taiwan, Republic of China

PS4/THU/283
Prevalence, Clinical and Angiographic Characteristics of Coronary Artery Ectasia in Low Risk Patients Undergoing Computed Tomography Coronary Angiography
Farraq AAM, El Faramawy AAA, Ali M, Abdel Wahab R, Ghareeb S
1Egypt

PS4/THU/284
Clinical and Echocardiography Characteristics in Patients with ST-Segment Elevation Myocardial Infarction (STEMI) According to Gender in an So-Called Epidemical Transition Country, Algeria
Ali-Tatar Chentir NN, Algeria

PS4/THU/285
Biometal Cadmium and Hypertension
Puri VN, India

PS4/THU/286
A New Public Health Policy Initiative to Reduce Sodium Consumption – Turkey
1Turkey
INDEX
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdulrahman Al Mahmeed W</td>
<td>153</td>
</tr>
<tr>
<td>Abid L</td>
<td>221</td>
</tr>
<tr>
<td>Abramczyk A</td>
<td>250, 251</td>
</tr>
<tr>
<td>Abreu GG</td>
<td>190</td>
</tr>
<tr>
<td>Abreu GR</td>
<td>263</td>
</tr>
<tr>
<td>Aceros H</td>
<td>162</td>
</tr>
<tr>
<td>Adamczak M</td>
<td>130, 141</td>
</tr>
<tr>
<td>Adams M</td>
<td>94, 158</td>
</tr>
<tr>
<td>Adami UG</td>
<td>248</td>
</tr>
<tr>
<td>Adji A</td>
<td>174</td>
</tr>
<tr>
<td>Afanasyeva N</td>
<td>124, 183</td>
</tr>
<tr>
<td>Agarwal D</td>
<td>94</td>
</tr>
<tr>
<td>Agarwal SK</td>
<td>205</td>
</tr>
<tr>
<td>Agena F</td>
<td>180</td>
</tr>
<tr>
<td>Aghamohammadzadeh R</td>
<td>167</td>
</tr>
<tr>
<td>Ahmed A</td>
<td>116, 117</td>
</tr>
<tr>
<td>Ahmed M</td>
<td>74, 215</td>
</tr>
<tr>
<td>Ahn SV</td>
<td>72, 163</td>
</tr>
<tr>
<td>Aizaki Y</td>
<td>82</td>
</tr>
<tr>
<td>Akasaka H</td>
<td>169</td>
</tr>
<tr>
<td>Akintunde A</td>
<td>258</td>
</tr>
<tr>
<td>Akintunde AA</td>
<td>265</td>
</tr>
<tr>
<td>Al Wakeel J</td>
<td>259</td>
</tr>
<tr>
<td>Alamir AKM</td>
<td>245</td>
</tr>
<tr>
<td>Alderman M</td>
<td>151</td>
</tr>
<tr>
<td>Alefan Q</td>
<td>248, 255</td>
</tr>
<tr>
<td>Ali-Tatar Chentir NN</td>
<td>282</td>
</tr>
<tr>
<td>Almustafa BA</td>
<td>126, 182</td>
</tr>
<tr>
<td>Ambigga D</td>
<td>262</td>
</tr>
<tr>
<td>An D</td>
<td>246</td>
</tr>
<tr>
<td>Andersen UO</td>
<td>80, 230</td>
</tr>
<tr>
<td>Anderson CAM</td>
<td>140</td>
</tr>
<tr>
<td>Andreenko EY</td>
<td>255</td>
</tr>
<tr>
<td>Andrews KL</td>
<td>110</td>
</tr>
<tr>
<td>Anilovitch JL</td>
<td>182, 183</td>
</tr>
<tr>
<td>Anjum B</td>
<td>73</td>
</tr>
<tr>
<td>Aoki A</td>
<td>70</td>
</tr>
<tr>
<td>Aono J</td>
<td>165</td>
</tr>
<tr>
<td>Appel LJ</td>
<td>99, 150</td>
</tr>
<tr>
<td>Arakawa K</td>
<td>151</td>
</tr>
<tr>
<td>Aranda P</td>
<td>160</td>
</tr>
<tr>
<td>Arici M</td>
<td>219</td>
</tr>
<tr>
<td>Arima H</td>
<td>54, 183</td>
</tr>
<tr>
<td>Aristegui R</td>
<td>93</td>
</tr>
<tr>
<td>Arita DY</td>
<td>243</td>
</tr>
<tr>
<td>Armas Rojas N</td>
<td>138</td>
</tr>
<tr>
<td>Armstrong D</td>
<td>115</td>
</tr>
<tr>
<td>Armstrong DW</td>
<td>213</td>
</tr>
<tr>
<td>Arno Schmidt-Trucksäss</td>
<td>50</td>
</tr>
<tr>
<td>Arnold M</td>
<td>62, 63, 109</td>
</tr>
<tr>
<td>Asai K</td>
<td>254</td>
</tr>
<tr>
<td>Asano M</td>
<td>190</td>
</tr>
<tr>
<td>Asche CV</td>
<td>153</td>
</tr>
<tr>
<td>Ashenagar MS</td>
<td>256</td>
</tr>
<tr>
<td>Ashizawa N</td>
<td>123</td>
</tr>
<tr>
<td>Asico LD</td>
<td>.66</td>
</tr>
<tr>
<td>Aszrin A</td>
<td>139, 259</td>
</tr>
<tr>
<td>Aviv A</td>
<td>101</td>
</tr>
<tr>
<td>Azegami T</td>
<td>173</td>
</tr>
<tr>
<td>Azizan EAB</td>
<td>116</td>
</tr>
<tr>
<td>Azizi F</td>
<td>265</td>
</tr>
<tr>
<td>Ba PK</td>
<td>262</td>
</tr>
<tr>
<td>Bachelard H</td>
<td>251</td>
</tr>
<tr>
<td>Baclic O</td>
<td>159</td>
</tr>
<tr>
<td>Bacon S</td>
<td>.95</td>
</tr>
<tr>
<td>Bae E</td>
<td>130</td>
</tr>
<tr>
<td>Bae H-J</td>
<td>.84</td>
</tr>
<tr>
<td>Bai Z</td>
<td>193, 268</td>
</tr>
<tr>
<td>Bakris G</td>
<td>101, 151, 170, 185</td>
</tr>
<tr>
<td>Balandina Y</td>
<td>221</td>
</tr>
<tr>
<td>Balde AM</td>
<td>259</td>
</tr>
<tr>
<td>Baldé AM</td>
<td>245</td>
</tr>
<tr>
<td>Banerjee SK</td>
<td>250</td>
</tr>
<tr>
<td>Banigesh A</td>
<td>189</td>
</tr>
<tr>
<td>Barden AE</td>
<td>133, 201</td>
</tr>
<tr>
<td>Barhoumi T</td>
<td>104, 205</td>
</tr>
<tr>
<td>Baron E</td>
<td>246</td>
</tr>
<tr>
<td>Barr S</td>
<td>.99</td>
</tr>
<tr>
<td>Barsukov A</td>
<td>180, 196</td>
</tr>
<tr>
<td>Batista MC</td>
<td>219, 279</td>
</tr>
<tr>
<td>Batsolaki M</td>
<td>126</td>
</tr>
<tr>
<td>Baumann M</td>
<td>103</td>
</tr>
<tr>
<td>Bawazier LA</td>
<td>210</td>
</tr>
<tr>
<td>Beckett N</td>
<td>184</td>
</tr>
<tr>
<td>Beilin L</td>
<td>.99</td>
</tr>
<tr>
<td>Belo VA</td>
<td>267</td>
</tr>
<tr>
<td>Berezina AV</td>
<td>269</td>
</tr>
<tr>
<td>Berni A</td>
<td>202</td>
</tr>
<tr>
<td>Bertagnolli M</td>
<td>221, 235</td>
</tr>
<tr>
<td>Beyer AM</td>
<td>271</td>
</tr>
<tr>
<td>Bezrodnyy V</td>
<td>217</td>
</tr>
<tr>
<td>Bhat S G</td>
<td>279</td>
</tr>
<tr>
<td>Bi Y</td>
<td>257</td>
</tr>
<tr>
<td>Biro S</td>
<td>186</td>
</tr>
<tr>
<td>Bisognano J</td>
<td>.54</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Bisognano JD</td>
<td>187</td>
</tr>
<tr>
<td>Bissoli NS</td>
<td>253</td>
</tr>
<tr>
<td>Biswas KB</td>
<td>207</td>
</tr>
<tr>
<td>Blacher J</td>
<td>.76, 122</td>
</tr>
<tr>
<td>Blumentein M</td>
<td>120</td>
</tr>
<tr>
<td>Bobadilla RA</td>
<td>281</td>
</tr>
<tr>
<td>Bokuda K</td>
<td>123</td>
</tr>
<tr>
<td>Bomanowski J</td>
<td>193</td>
</tr>
<tr>
<td>Bolli P</td>
<td>.57</td>
</tr>
<tr>
<td>Bolz S-S</td>
<td>.98</td>
</tr>
<tr>
<td>Bosu WK</td>
<td>163, 227</td>
</tr>
<tr>
<td>Boughala E</td>
<td>215, 272</td>
</tr>
<tr>
<td>Bourque SL</td>
<td>167</td>
</tr>
<tr>
<td>Bouvier M</td>
<td>154</td>
</tr>
<tr>
<td>Bram B</td>
<td>.65</td>
</tr>
<tr>
<td>Branco Braam</td>
<td>.49</td>
</tr>
<tr>
<td>Broguljan J</td>
<td>247</td>
</tr>
<tr>
<td>Brink EJ</td>
<td>167</td>
</tr>
<tr>
<td>Briones AM</td>
<td>133</td>
</tr>
<tr>
<td>Brito JO</td>
<td>212</td>
</tr>
<tr>
<td>Brosnihan KB</td>
<td>269</td>
</tr>
<tr>
<td>Brown CM</td>
<td>155</td>
</tr>
<tr>
<td>Brown MJ</td>
<td>113, 237</td>
</tr>
<tr>
<td>Brown N</td>
<td>.56</td>
</tr>
<tr>
<td>Buckley S</td>
<td>230</td>
</tr>
<tr>
<td>Bulpitt C</td>
<td>103, 150</td>
</tr>
<tr>
<td>Burger D</td>
<td>104, 171</td>
</tr>
<tr>
<td>Burgess E</td>
<td>155</td>
</tr>
<tr>
<td>Burla AK</td>
<td>240</td>
</tr>
<tr>
<td>Burrell L</td>
<td>240, 241</td>
</tr>
<tr>
<td>Burrell LM</td>
<td>.92</td>
</tr>
<tr>
<td>Butler-Jones D</td>
<td>.57</td>
</tr>
<tr>
<td>Buxbauma S</td>
<td>282</td>
</tr>
<tr>
<td>Buys ES</td>
<td>233</td>
</tr>
<tr>
<td>Carlberg B</td>
<td>.97</td>
</tr>
<tr>
<td>Caron B</td>
<td>154</td>
</tr>
<tr>
<td>Carr FM</td>
<td>273</td>
</tr>
<tr>
<td>Carugo S</td>
<td>142, 181</td>
</tr>
<tr>
<td>Cassi L</td>
<td>.60</td>
</tr>
<tr>
<td>Cassi LA</td>
<td>.56</td>
</tr>
<tr>
<td>Catena C</td>
<td>206, 272</td>
</tr>
<tr>
<td>Cau SBA</td>
<td>.212</td>
</tr>
<tr>
<td>Cecelja M</td>
<td>96, 155</td>
</tr>
<tr>
<td>Ceron CS</td>
<td>272</td>
</tr>
<tr>
<td>Chae SC</td>
<td>.216</td>
</tr>
<tr>
<td>Chalmers J</td>
<td>226</td>
</tr>
<tr>
<td>Chambers LW</td>
<td>238</td>
</tr>
<tr>
<td>Chan JCN</td>
<td>90, 92</td>
</tr>
<tr>
<td>Chan P</td>
<td>.82</td>
</tr>
<tr>
<td>Chan Y-H</td>
<td>98, 171</td>
</tr>
<tr>
<td>Chanoine J-P</td>
<td>231</td>
</tr>
<tr>
<td>Charchar FJ</td>
<td>.81, 232, 233</td>
</tr>
<tr>
<td>Chazova I</td>
<td>119, 243</td>
</tr>
<tr>
<td>Chen H</td>
<td>134</td>
</tr>
<tr>
<td>Chen Q</td>
<td>122</td>
</tr>
<tr>
<td>Chen T</td>
<td>137</td>
</tr>
<tr>
<td>Chen Y</td>
<td>.177, 208</td>
</tr>
<tr>
<td>Cheung BMY</td>
<td>59, 209</td>
</tr>
<tr>
<td>Chia YC</td>
<td>247, 261</td>
</tr>
<tr>
<td>Chiba T</td>
<td>.72</td>
</tr>
<tr>
<td>Chien K-L</td>
<td>.84</td>
</tr>
<tr>
<td>Cho M-C</td>
<td>.81</td>
</tr>
<tr>
<td>Chockalingam A</td>
<td>.49, 159, 238, 239, 246</td>
</tr>
<tr>
<td>Choi CU</td>
<td>.140</td>
</tr>
<tr>
<td>Chopey IV</td>
<td>.251</td>
</tr>
<tr>
<td>Chrysant S</td>
<td>.238</td>
</tr>
<tr>
<td>Chumburidze S</td>
<td>.74</td>
</tr>
<tr>
<td>Chung W-J</td>
<td>121, 141</td>
</tr>
<tr>
<td>Cigarran S</td>
<td>.144</td>
</tr>
<tr>
<td>Cinza Sanjurjo S</td>
<td>.277</td>
</tr>
<tr>
<td>Clarke BJ</td>
<td>.84</td>
</tr>
<tr>
<td>Cloutier L</td>
<td>.57, 218, 226</td>
</tr>
<tr>
<td>Coffman T</td>
<td>.158</td>
</tr>
<tr>
<td>Colas R</td>
<td>.188</td>
</tr>
<tr>
<td>Colussi G</td>
<td>.253</td>
</tr>
<tr>
<td>Congrains A</td>
<td>.278</td>
</tr>
<tr>
<td>Connell KL</td>
<td>.194</td>
</tr>
<tr>
<td>Cooke J</td>
<td>.195</td>
</tr>
<tr>
<td>Courboulin A</td>
<td>.206</td>
</tr>
<tr>
<td>Couture V</td>
<td>.122</td>
</tr>
</tbody>
</table>
# INDEX

Crippa G ............................................. 58  
Cruickshank JK ................................. 174, 177  
Cruickshank K ..................................... 261  
Culman J ........................................... 72  
Cunha TS ........................................... 256  
Cushman W ....................................... 102, 226  

D  
da Silva MAV ..................................... 129, 272  
Dadashova GM .................................. 245  
Dahlberg J .......................................... 169  
Dahlander J ......................................... 163, 227  
Dai S .................................................. 128  
Danos P ............................................. 84  
Davaalkham D ..................................... 79  
Davern PJ .......................................... 182, 211  
Davidge S ........................................... 66  
de de Guia III MAD .............................. 178  
de la Noval R ....................................... 138  
de la Sierra A .................................... 72, 153, 201, 138  
de Lemos Neto M ................................ 206  
de Rosa ML ......................................... 119  
de Souza F ......................................... 93, 159  
Dechanet C ......................................... 135  
Dechend R .......................................... 170, 246  
Dejima T ........................................... 270  
Delles C ............................................ 70, 11  
Dennison C ........................................ 230  
Denton KM .......................................... 216  
Dhar A ................................................ 191  
Dhar I ................................................ 192  
Ditting T ........................................... 210  
Diz DI ................................................ 183  
Dobsak P ........................................... 176  
Dohi Y .............................................. 181  
Domanski D ....................................... 96  
Domenech Feria-Carot M .................... 114  
Doyon M ........................................... 141, 174  
Doyon P ............................................ 103  
Drouin D ........................................... 254  
Dubland JA ......................................... 146  
Duenas AF ......................................... 192  
Dugan KA .......................................... 229, 240  
Dunford E .......................................... 275  
Duprez DA ......................................... 209, 268  
Durante W ......................................... 200  
Dusting GJ .......................................... 240  

E  
Eguchi K ........................................... 81, 111  
Ejim EC ............................................. 139  
El Aroussy W ...................................... 220  
Eliseyeva M ...................................... 256  
Elliott HL .......................................... 237, 238  
Emonnot L ......................................... 189  
Endlich PW ...................................... 205  
Enhorning S ....................................... 59  
Enomoto D ......................................... 113, 199  
Ertugrul E ........................................... 282  
Esler M ............................................. 151  
Esmailpour Zanjani S .......................... 217  
Etemadi BA ......................................... 131  
Evans RG .......................................... 131  
Ezzati M ............................................. 64, 227  

F  
Fagard R ........................................... 91  
Fama RP ............................................ 79  
Fan W-X ............................................ 56  
Farah G ............................................. 200  
Farah V ............................................ 189  
Farrag AAM ........................................ 280, 282  
Farsky S ............................................ 281  
Fassot C ............................................ 250  
Fedorova OV ....................................... 157  
Feldman R ......................................... 63, 99  
Ferder L ............................................ 165, 178  
Fernandez S ....................................... 247  
Fernandez-Vega F .............................. 217, 143  
Ferrante FA ........................................ 128  
Firoz T .............................................. 139  
Floras JS .......................................... 46, 65, 104  
Flues K ............................................. 210  
Fodor G ............................................ 129, 158  
Fogari R ........................................... 108, 269  
Forjaz ClDM ....................................... 157  
Forrester T ........................................ 59  
Fot A ............................................... 208  
Franca P .......................................... 211  
Franco RJ .......................................... 124, 272  
Freeman M ........................................ 208  
Fujishima S ........................................ 78  
Fujita M ............................................ 94  
Fujita T ............................................ 100, 152, 217  
Fukuhara M ...................................... 111  
Fukushima H ..................................... 109  
Fukutomi M ...................................... 118
INDEX

Funder J ..................................................63  
Funder JW ............................................161  
Furumoto T .........................................181  
Fuster V ...............................................97  

G
Gahramanova S .....................................76  
Gao PJ ..............................................191, 209  
Gasimov ZI ...........................................263  
Gatti G ..................................................229  
Gerlach RF ............................................272  
Germino FW ..........................................120, 179  
Geshi E ..............................................119, 139  
Gatti G ..................................................229  
Gharipour M- .......................................266  
Giacchini M ..........................................168  
Gilliam-Davis S ....................................130  
Glazer RD .............................................119  
Gmuczyk A ............................................131  
Godwin M ............................................166  
Golovach Y .........................................245  
Gonçalves FM .......................................135  
Gong Y ...............................................117  
Gopalakrishnan V....................................169, 229, 243  
Gorostidi M .........................................153  
Goryacheva A .......................................174  
Goswami H ..........................................98  
Goto K ...............................................191  
Green B ..............................................102  
Greiling A ............................................142  
Gros R .................................................90, 154, 235  
Grover S .............................................62  
Guan TR ...............................................98  
Guelffier F ..........................................97, 275  
Gulicher A ............................................123  
Guirguis E ..........................................221  
Guo J ..................................................244  
Guo S ..................................................215  
Guo Y ..................................................264  
Guo YC ...............................................203  
Gupta AK ............................................54  
Gusakova S .........................................196  

H
Ha J-W ..................................................63  
Habermann F ......................................273, 278  
Haffner S ............................................226  
Hagikura A ..........................................58, 112  
Hale TM .............................................82  
Hall J ..................................................231  

Hamada A .............................................254  
Hamada T ..........................................261  
Hamet P ...........................................156, 232, 257  
Hanayama Y ........................................218  
Hankinson A ........................................60  
Hano T ..............................................142, 243  
Hao L ...............................................112  
Hara Y ...............................................201  
Harrap S ...........................................62, 156, 162, 164  
Hart NR .............................................146  
Hasegawa C .......................................132  
Hayashi K ..........................................100, 171  
Hayden M ..........................................102  
He FJ ...............................................228  
Head GA ..........................................73, 74  
Heagerty AM ....................................62, 67, 164, 231  
Hegele R ..........................................92, 102, 150  
Heidernreich SN ...................................101  
Hendrikx T .........................................85  
Hermida Ameijeiras A .........................115, 176  
Hernández N ......................................146  
Hersunati N .........................................260  
Hilgers KF .........................................110, 137  
Hill M ...............................................99  
Hillebrand U ......................................176  
Hirawa N ..........................................198  
Hiroi N ...............................................77  
Hirose H .............................................75  
Hlubik J ..............................................266  
Hollenberg N ....................................64, 67, 104  
Holmes DT .........................................239  
Hong S-P ...........................................63, 120  
Hong Y ..............................................132, 145  
Horio T .............................................127  
Horiuchi M .........................................95, 101  
Hosseini Esfahani F .........................202  
Hristova K .........................................183, 220  
Hsieh-T T-H ........................................282  
Hu B ...............................................138, 193  
Hu D ...............................................219  
Hu S-L ..............................................238  
Hua Li ...............................................180  
Huang BS ..........................................94  
Huang C-C .........................................118  
Huang P-H ..........................................84  
Huang Q-F .........................................276  
Huang Z ............................................194  
Huanzhen C .......................................252  
Hui P ...............................................121
INDEX

Hui R-T ................................................. 82, 268
Hui RT ............................................... 154
Hui S ............................................... 241
Huo Y ............................................... 186
Huot-Marchand J-E 76, 241
Husain M ....................................... 72, 161
Hutchinson H ................................. 227
Huyard F ........................................ 141

I
Ihm CG ........................................... 208
Ikeda K .......................................... 259
Insel P .......................................... 162
Iseri K ........................................... 95
Isbele TA ........................................ 204
Ishaq M .......................................... 232
Ishiguro K ...................................... 263
Ishikawa M .................................... 82
Ishizawa K ...................................... 133
Islik SR ........................................... 230
Ismail TS ........................................ 260
Itani TS .......................................... 241
Ito D ............................................... 71
Ito K ............................................... 206
Ito O ............................................... 130
Ito S .............................................. 113, 198
Iurciuc M ........................................ 205
Ivanga M ....................................... 233
Ivanova S ...................................... 183
Iwai M .......................................... 57, 60, 271
Iwakura Y ...................................... 197
Iwao H ............................................. 109
Iwasaki H ....................................... 75
Iwashima Y .................................... 136
Izzo J ............................................. 180

J
Jadhav AB ....................................... 107
Jaén Águila F .................................. 265
Jakovljevic B .................................. 60
Jayasinghe J .................................. 230
Jennings G .................................... 103
Jiang B ............................................ 178, 192
Jiang L .......................................... 157
Jiang X .......................................... 271
Johnson W .................................... 184
Jones ES ....................................... 236
Jordan J ......................................... 187
Jorge L ......................................... 173
Jotoku M ....................................... 137, 187
Julius S ......................................... 104
Juncos L ........................................ 53
Jung HO ........................................... 77
Jung K-T ......................................... 212
Junli Z ........................................... 121

K
Kabutoya T ..................................... 252
Kaczorowski J ................................. 58, 239
Kagitan H ....................................... 71
Kanaoka T ....................................... 143
Kanda K .......................................... 120
Kanic V ......................................... 125
Kankinza N ................................. 274
Karelkina E ..................................... 137
Karimova K .................................... 126
Kario K .......................................... 58
Karman M ..................................... 160
Kasahara M ................................... 216
Kasal DAB ...................................... 269
Kaschma E ....................................... 172
Kaspruk G ...................................... 277
Kato N ............................................. 233
Katsuya T ....................................... 134
Kawabe H ....................................... 77
Kawabe T ....................................... 127, 210
Kawai T .......................................... 199
Kawamura H .................................. 194, 256
Kawano Y ...................................... 275
Kawarazaki H ................................. 116
Kawarazaki W ................................. 116
Kawecka Jaszcz K .......................... 108
Kawecka-Jaszcz K ......................... 193
Kenji U .......................................... 97
Kerr C ............................................ 63
Kevorkov A .................................... 258
Khachatryan AH ............................ 83
Khamidullaeva G ............................ 135
Khan N .......................................... 159
Khandaker RK ................................ 261
Khazaai M ...................................... 202
Khong SML ...................................... 71
Khosravi A ....................................... 193
Kim C-J .......................................... 196, 265
Kim J-H .......................................... 249, 261
Kim K-I .......................................... 193
Kim M-O ....................................... 182
Kim S-K .......................................... 120
INDEX

Kim SH .............................................. 80
Kim W ........................................ 109, 125, 243
Kim Y-K ............................................ 249, 265
Kinouchi K .................................. 162, 176
Kirkpatrick MK .................................. 230
Kisko A ............................................. 128
Kita T ............................................... 140
Kobayashi Y .................................. 195
Koguchi W .................................... 165, 171
Koltsova SV ................................ 197, 209
Komori T ............................................ 108, 145
Konradi A ...................................... 124, 228
Konradi AO ..................................... 83, 228, 256
Kopec G ........................................... 121, 278
Korner PI ........................................... 45, 94, 202
Kosmalova V .................................. 78
Kotak RM ........................................... 137
Kotava A ............................................ 126
Kotovskaya Y ................................. 55, 175
Kotseva K ...................................... 69, 70
Kotsis V ............................................. 75, 112, 157, 160
Kou H ............................................... 74
Kroon A ............................................. 173
Kumar A .......................................... 233
Kunes J ............................................ 156
Kunugi T ........................................... 250
Kurata M .......................................... 129
Kurita T ........................................... 186
Kuruppu S ...................................... 241
Kushihiro T .................................... 185
Kusunoki H ........................................ 271
Kwon SM ............................................ 240
Kwon SU ........................................... 248, 278

Lee CG ............................................. 214
Lee J-H ........................................... 162, 219, 236
Lee JY ............................................ 267
Lee MM ............................................ 107
Lee SK ............................................. 257
Leeb-Lundberg LMF ...................... 64, 103
Leechacharas S .................................. 230
Leen T .............................................. 190
Leopold Schmetterer .................. 50
Leung JYT ...................................... 188
Levy D ............................................. 102
Lewanczuk R .................................. 226
Li C-Y .............................................. 249
Li F-H .............................................. 177
Li G .................................................. 121, 264
Li J .................................................... 184, 267
Li MW .............................................. 67, 172
Li N ................................................... 83, 257
Li Q ................................................... 172
Li W ................................................... 139
Li Y ................................................... 236
Li YZ ............................................... 204
Liang D ............................................ 200
Lietava J .......................................... 247, 264
Liew D .............................................. 218
Liew SM .......................................... 168
Lim D-Y ............................................ 133
Lim SY .............................................. 78
Lin L ................................................... 254
Lin W-Y ............................................ 203
Lindholmen L ................................ 62, 92, 151
Ling-Gen G .................................... 213
Liskova S ....................................... 191, 252
Liu D ................................................. 113
Liu F ................................................. 144
Liu J ................................................... 137
Liu L ................................................. 103, 132, 200
Liu Lisheng ................................ 49
Liu M ................................................... 69
Liu R ................................................... 110
Liu W ................................................. 263
Liu X ................................................... 200
Liu XH .............................................. 183, 252
Liu YY .............................................. 246

L
Labarthe D ...................................... 96, 151
Lacchini S ......................................... 208
Lacourciere Y ................................... 107, 159
Lakatta E ........................................... 55, 101
Lamas JLT ........................................ 182
Lambert EA ..................................... 204
Landers B ........................................ 208
Lariviére R ...................................... 216, 276
Larochelle P .................................... 67, 99, 227
Lauridsen TG .................................. 198
Lavoie JL ......................................... 111, 171
Lear S ............................................. 64
Lebel M .......................................... 110, 131

www.vancouverhypertension2010.com 289
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liu Z</td>
<td>262</td>
</tr>
<tr>
<td>Listersti JL</td>
<td>59</td>
</tr>
<tr>
<td>Lopez Paz JE</td>
<td>119, 122</td>
</tr>
<tr>
<td>Louise S</td>
<td>214</td>
</tr>
<tr>
<td>Loukianov M</td>
<td>122, 203</td>
</tr>
<tr>
<td>Lovic D</td>
<td>243</td>
</tr>
<tr>
<td>Lu F</td>
<td>160</td>
</tr>
<tr>
<td>Lueders S</td>
<td>109, 124</td>
</tr>
<tr>
<td>Luizon MR</td>
<td>258</td>
</tr>
<tr>
<td>Lumsden NG</td>
<td>216</td>
</tr>
<tr>
<td>Lynch FM</td>
<td>212</td>
</tr>
<tr>
<td>McAlister F</td>
<td>159</td>
</tr>
<tr>
<td>Mayer Jr. O</td>
<td>55</td>
</tr>
<tr>
<td>Martin CA</td>
<td>73</td>
</tr>
<tr>
<td>Martell N</td>
<td>138</td>
</tr>
<tr>
<td>Marques FZ</td>
<td>277</td>
</tr>
<tr>
<td>Majane OHI</td>
<td>272</td>
</tr>
<tr>
<td>Majid DSA</td>
<td>197</td>
</tr>
<tr>
<td>Makarevich P</td>
<td>257</td>
</tr>
<tr>
<td>Malyszko J</td>
<td>100, 170</td>
</tr>
<tr>
<td>Manzi Muhire RS</td>
<td>279</td>
</tr>
<tr>
<td>Margallo V</td>
<td>83</td>
</tr>
<tr>
<td>Magno JDA</td>
<td>79</td>
</tr>
<tr>
<td>Maio MT</td>
<td>204</td>
</tr>
<tr>
<td>Maizatullahfah M</td>
<td>138</td>
</tr>
<tr>
<td>Majane OHI</td>
<td>272</td>
</tr>
<tr>
<td>Majid DSA</td>
<td>197</td>
</tr>
<tr>
<td>Makarevich P</td>
<td>257</td>
</tr>
<tr>
<td>Malyszko J</td>
<td>100, 170</td>
</tr>
<tr>
<td>Manzi Muhire RS</td>
<td>279</td>
</tr>
<tr>
<td>Margallo V</td>
<td>83</td>
</tr>
<tr>
<td>Margulis FH</td>
<td>192</td>
</tr>
<tr>
<td>Marques FZ</td>
<td>194, 234</td>
</tr>
<tr>
<td>Martell N</td>
<td>138</td>
</tr>
<tr>
<td>Martin CA</td>
<td>73</td>
</tr>
<tr>
<td>Martinez-Martin FJ</td>
<td>75, 264</td>
</tr>
<tr>
<td>Martins-Oliveira A</td>
<td>135, 271</td>
</tr>
<tr>
<td>Masaki M</td>
<td>124</td>
</tr>
<tr>
<td>Maseko JM</td>
<td>273</td>
</tr>
<tr>
<td>Masoni MC</td>
<td>190</td>
</tr>
<tr>
<td>Masuo K</td>
<td>80, 277</td>
</tr>
<tr>
<td>Mat-Nasir N</td>
<td>259</td>
</tr>
<tr>
<td>Matangi MF</td>
<td>213</td>
</tr>
<tr>
<td>Matrosova I</td>
<td>178</td>
</tr>
<tr>
<td>Matsukawa R</td>
<td>167</td>
</tr>
<tr>
<td>Matsumoto K</td>
<td>75, 244</td>
</tr>
<tr>
<td>Matsumoto S</td>
<td>85, 194</td>
</tr>
<tr>
<td>Matsumura K</td>
<td>203</td>
</tr>
<tr>
<td>Mavimbe C</td>
<td>113</td>
</tr>
<tr>
<td>Mavoungou D</td>
<td>266</td>
</tr>
<tr>
<td>Mayer Jr. O</td>
<td>55</td>
</tr>
<tr>
<td>Mbakwem AC</td>
<td>82, 268</td>
</tr>
<tr>
<td>McAlister F</td>
<td>159</td>
</tr>
<tr>
<td>McCabe K</td>
<td>141</td>
</tr>
<tr>
<td>McFarlane P</td>
<td>99, 100</td>
</tr>
<tr>
<td>McFarlane P</td>
<td>99, 100</td>
</tr>
<tr>
<td>McGavock J</td>
<td>227</td>
</tr>
<tr>
<td>McGill J</td>
<td>186</td>
</tr>
<tr>
<td>McKay D</td>
<td>62</td>
</tr>
<tr>
<td>McLachlan J</td>
<td>104</td>
</tr>
<tr>
<td>Md Ariff F</td>
<td>212, 245</td>
</tr>
<tr>
<td>Md Yasin M</td>
<td>273</td>
</tr>
<tr>
<td>Meloche J</td>
<td>172</td>
</tr>
<tr>
<td>Mendis S</td>
<td>53, 57, 231</td>
</tr>
<tr>
<td>Meredith P</td>
<td>53</td>
</tr>
<tr>
<td>Meredith PA</td>
<td>54</td>
</tr>
<tr>
<td>Metoki H</td>
<td>136, 218</td>
</tr>
<tr>
<td>Metzger IF</td>
<td>256</td>
</tr>
<tr>
<td>Michelini LC</td>
<td>210</td>
</tr>
<tr>
<td>Mihailidou AS</td>
<td>109</td>
</tr>
<tr>
<td>Millar PJ</td>
<td>205, 206</td>
</tr>
<tr>
<td>Milot A</td>
<td>62, 238</td>
</tr>
<tr>
<td>Mimran A</td>
<td>95, 197, 228</td>
</tr>
<tr>
<td>Minakuchi H</td>
<td>100</td>
</tr>
<tr>
<td>Minerva M</td>
<td>263</td>
</tr>
<tr>
<td>Mirmiran P</td>
<td>202, 214</td>
</tr>
<tr>
<td>Mizuta E</td>
<td>189</td>
</tr>
<tr>
<td>Mkkhonto SS</td>
<td>206</td>
</tr>
<tr>
<td>Mogi M</td>
<td>61</td>
</tr>
<tr>
<td>Molander L</td>
<td>124, 192</td>
</tr>
<tr>
<td>Mollik MAH</td>
<td>188, 255</td>
</tr>
<tr>
<td>Monteiro R</td>
<td>221</td>
</tr>
<tr>
<td>Montenegro MF</td>
<td>190</td>
</tr>
<tr>
<td>Moon G</td>
<td>251</td>
</tr>
<tr>
<td>Mooney J</td>
<td>266</td>
</tr>
<tr>
<td>Moraes-Silva IC</td>
<td>211</td>
</tr>
<tr>
<td>Moreau P</td>
<td>112, 154, 174</td>
</tr>
<tr>
<td>Moreira ED</td>
<td>277</td>
</tr>
<tr>
<td>Morgan T</td>
<td>235</td>
</tr>
<tr>
<td>Morganti A</td>
<td>270</td>
</tr>
<tr>
<td>Mori F</td>
<td>125</td>
</tr>
<tr>
<td>Mori H</td>
<td>198, 205, 259</td>
</tr>
<tr>
<td>Mori L</td>
<td>168</td>
</tr>
<tr>
<td>Mori M</td>
<td>167</td>
</tr>
<tr>
<td>Mori S</td>
<td>117</td>
</tr>
<tr>
<td>Mori T</td>
<td>132</td>
</tr>
<tr>
<td>Morimoto R</td>
<td>117</td>
</tr>
<tr>
<td>Morinaga Y</td>
<td>133</td>
</tr>
<tr>
<td>Moon G</td>
<td>251</td>
</tr>
<tr>
<td>Moreau P</td>
<td>112, 154, 174</td>
</tr>
<tr>
<td>Moreira ED</td>
<td>277</td>
</tr>
<tr>
<td>Morgan T</td>
<td>235</td>
</tr>
<tr>
<td>Morganti A</td>
<td>270</td>
</tr>
<tr>
<td>Mori F</td>
<td>125</td>
</tr>
<tr>
<td>Mori H</td>
<td>198, 205, 259</td>
</tr>
<tr>
<td>Mori L</td>
<td>168</td>
</tr>
<tr>
<td>Mori M</td>
<td>167</td>
</tr>
<tr>
<td>Mori S</td>
<td>117</td>
</tr>
<tr>
<td>Mori T</td>
<td>132</td>
</tr>
<tr>
<td>Morimoto R</td>
<td>117</td>
</tr>
<tr>
<td>Morinaga Y</td>
<td>133</td>
</tr>
</tbody>
</table>
INDEX

Morita T.................................158
Moriya H.................................143
Morris DA...............................266
Mortot SS...............................115
Moy Lum-Kwong M .................69
Moyses MR.........................126
Mu J.................................140, 273
Mu S.................................140
Mugellini A.........................207
Munakata M.........................126, 197
Murai H...............................210
Murray A...............................119
Muthusamy V......................190, 259
Mutoh Matsushita A..............192
Muxfeldt ES...........................113
Myers M...............................57, 59, 91
Myers MG...........................114

N
Na JO.................................75
Nabi AHMN.........................206
Nagata K.............................121
Nah D-Y.............................174
Nakagaki T...........................182
Nakagami F.........................196
Nakagami H.........................266
Nakagawa N.........................144
Nakamoto M........................76, 133
Nakano N.............................117
Nakaya H.............................249
Namsolleck P.........................241
Napoli V.............................199
Narita S...............................73
Nawawi H.............................264
Ndisang JF............................110
Neal B................................57, 95, 163
Nel MJ...............................100, 253
Nelson SA..........................69
Neves MF............................85, 175
Ng Cheong N........................179
Ng KK...............................250
Nguyen Dinh Cat A..............106
Nichol ME...........................245
Ninomiya T.........................124
Nishihara M.........................166
Nishikimi T..........................72, 128
Nodaira Y.........................136
Noguchi Y...........................247
Nolan RP.............................46, 132
Nomura I..............................117
Nor-Ashikin MNK.................265
Nyut AM...............................165

O
O’Donnell E.........................211
Odaira M............................175, 176
Ogawa K..............................109
Ogihara T............................156, 184, 237
Ogun dele SO.........................232
Oguro R...............................96, 278
Oh VMS...............................195
Ohanyan DV.........................83
Ohe M.................................191
Ohkuchi A...........................111
Ohmaru T...........................136
Ohnishi H.............................70
Ohno E...............................144
Ohno T...............................187
Ohno Y...............................169, 278
Ohsawa M...........................113
Ohta Y.................................145
Ohtsubo T.........................129, 267
Ohtsuki T...........................129
Okajima M...........................130
Okano Y...............................116
Okayama K...........................161
Okolo T...............................260
Olanrewaju TO......................231
Oleynikov V........................73, 79
Oliveira S...........................143
Oliveras A.........................93, 209
Omboni S.............................91
Onrot J...............................239
Onwubere BJ........................232
Oparil S.............................54, 92, 155, 281
Orlov S...............................106
Orlov SN.............................111, 229
Ornelas E.............................215
Ortiz E...............................91, 102
Osako MK............................235
Oshima Y.............................236
Ott C.................................169, 257
Ouali S...............................179

P
Palatini P.............................156
Paletas K.............................217
Pall D...............................153
INDEX

Q
- Qabiyeva NN ................................................. 263
- Qi W ......................................................... 262
- Qian Y ....................................................... 134
- Qin M-Z ...................................................... 127
- Quan-Yong X ............................................. 279
- Quinn U ...................................................... 207

R
- Rabkin SW ........................................ 53, 104, 158, 159, 174
- Radchenko GD .......................................... 181, 247
- Radenkovic S ........................................... 281
- Radi SM ...................................................... 246
- Raff U ....................................................... 93
- Raff UG ....................................................... 71
- Ragazzo F .................................................. 169
- Rahmouni K ................................................ 170
- Rajapakse N .............................................. 110
- Rajzer M ..................................................... 175
- Rakugi H ..................................................... 54
- Ramli AS .................................................... 120, 239
- Ratsep M .................................................... 142, 212
- Rehman A ................................................... 173, 269
- Reid CM ....................................................... 70
- Reid JD ....................................................... 216
- Reznik EV .................................................... 277
- Ribeiro AA ................................................... 271
- Říčánský I ................................................. 125, 214
- Říhaček I ..................................................... 115
- Ringrose JS ............................................... 146
- Ripp T ......................................................... 253
- Rizzi E ......................................................... 271
- Roberts R .................................................... 152
- Robitaille C ................................................ 53, 70
- Rodriguez-Esparragon F .................. 118, 134
- Rodriguez-Iturbe B .................................. 152
- Romero F ..................................................... 129
- Romero Miguez ML .................................. 77, 262
- Rosenthal T ................................................ 68, 92
- Roseva-Nielsen N ..................................... 278
- Ross WR ..................................................... 246
- Rossi GP ..................................................... 68
- Rotar O ....................................................... 122, 277
- Rotar OP ..................................................... 202
- Ruan Q ....................................................... 71
- Rubio-Guerra AF ........................................ 276
- Ruilope LM ............................................... 54, 91
- Ruzicka M .................................................. 93
- Ryu D-R ..................................................... 130
- Ryuzaki M .................................................. 274

Palomino Jara Z .................................................. 213
- Palusinski R .................................................. 248
- Pan CR ........................................................ 275
- Pandey KN ................................................... 56
- Pang C ........................................................ 59, 68
- Papadakis S .................................................. 140
- Papageorgiou PC ........................................ 197
- Paradis P ..................................................... 215
- Parati G ....................................................... 91
- Park CG ...................................................... 162, 180
- Park J-M ...................................................... 98
- Park JB ....................................................... 55, 56, 59
- Paulin R ....................................................... 171
- Paulis L ....................................................... 161, 201
- Pechanova O .............................................. 82, 110
- Pedersen EB .............................................. 131
- Pedersen ME .............................................. 209
- Pelech S ....................................................... 234
- Pello EV ...................................................... 282
- Pemminati S ................................................ 280
- Pena Seijo M .............................................. 114, 200
- Peng X-L ....................................................... 191
- Peng Y ......................................................... 169
- Perez JD ....................................................... 216
- Persson SU ................................................... 280
- Petrella R ..................................................... 108
- Pickering G .................................................. 101, 157
- Pierin AMG .................................................. 77, 138
- Pimenta E ................................................. 65, 228, 229
- Pinterova M .................................................. 173
- Pinzon R ...................................................... 183, 274
- Pipe A ......................................................... 90, 97
- Podpalov VP .............................................. 248
- Poirier L ....................................................... 159
- Pollak PT ...................................................... 78
- Pollice P ...................................................... 239, 279, 282
- Pool JL ......................................................... 107
- Posadzy-Malaczynska A .................. 263
- Pose Reino A .............................................. 145, 203
- Postel-Vinay NG ......................................... 78, 97
- Poulter NR ................................................... 53, 64
- Prakobchai S ................................................ 246
- Prakashnya NR ............................................ 253
- Protogerou AD ............................................ 55
- Punzi HA ...................................................... 237
- Pupi LM ....................................................... 179
- Puri VN ....................................................... 282
- Pyun WB ...................................................... 116
# INDEX

| S | Shinzato T | 244 |
|  | Shlyakhto E | 78  |
|  | Shlyakhto EV | 77, 170 |
|  | Shobeiri N | 81  |
|  | Shrestha RN | 267 |
|  | Sibiya MJ | 203 |
|  | Sica D | 93, 119, 184 |
|  | Siddique MA | 265 |
|  | Siegelova J | 115 |
|  | Silva E | 215 |
|  | Silva KA | 188 |
|  | Sima CA | 240 |
|  | Simonini M | 112, 233 |
|  | Simons-Morton D | 101, 226 |
|  | Singh A | 175 |
|  | Sja'bani M | 210, 260 |
|  | Slavíček M | 67, 133 |
|  | Sločum JL | 168 |
|  | Soentara AA | 235 |
|  | Song A | 260 |
|  | Song S | 180 |
|  | Sosa A | 221 |
|  | Souza SBC | 211 |
|  | Spence D | 67 |
|  | Spiegeli S | 98 |
|  | Stabouli S | 214 |
|  | Steckelings UM | 161, 229 |
|  | Steinbach SK | 84 |
|  | Stern N | 60, 61, 85 |
|  | Stevenson A | 266 |
|  | Stewart Williams J | 269 |
|  | Stojanov V | 244 |
|  | Stojanovic MM | 155 |
|  | Stolarz-Skrzypek K | 228 |
|  | Straznicky N | 60 |
|  | Štreitecká H | 133, 269 |
|  | Stuckey MI | 201 |
|  | Styczkiewicz K | 128 |
|  | Sudo Y | 244 |
|  | Sugano N | 218 |
|  | Sugimoto K | 264 |
|  | Sugiura T | 252 |
|  | Suh A | 131 |
|  | Suh M | 178 |
|  | Sun J | 179, 268 |
|  | Sun N | 71, 188, 199 |
|  | Sun S-W | 107 |
|  | Sun X | 145, 270 |
|  | Suvorova I | 213 |

Saddichha S | 201 |
Sagliker Y | 116 |
Saito I | 153 |
Sakai K | 189 |
Sakata MM | 145 |
Sakata S | 71 |
Sakima A | 125, 159 |
Sako H | 56 |
Saksena A | 248 |
Saladini F | 177 |
Salles G | 112, 143 |
Sampson AK | 106 |
Sanches IC | 188 |
Sandrim V | 135 |
Sartori M | 187 |
Saruta T | 185 |
Sasamura H | 185 |
Schiffrin EL | 104, 207, 234, 240, 241 |
Schlaich M | 93 |
Schmidt BM | 214 |
Schmidt HHHW | 134 |
Schmidt-Trucksäss A | 67 |
Schmieder RE | 160, 202 |
Schnitzer TJ | 276 |
Schreiber Jr MJ | 127 |
Schulz EG | 114 |
Schutte R | 254 |
Schwartz J | 179 |
Schwengel K | 94 |
Sechi LA | 255 |
Seda O | 195, 255 |
Sedeek M | 61 |
Seedat YK | 225 |
Semchuk W | 225 |
Seo JB | 177 |
Shah A | 207, 270 |
Sharma A | 59, 225 |
Sharma JN | 55, 108 |
Shay CM | 228 |
Shen Y | 134, 280 |
Sheng C | 218, 250 |
Shi X | 200 |
Shiina K | 83 |
Shimamoto K | 64, 96 |
Shimaoka I | 258 |
Shimizu H | 69 |
Shimodaira M | 168, 258 |
Shinagawa T | 123 |
Shinagawa T | 123 |
Shimaoka I | 258 |
Shay CM | 228 |
Sakai K | 189 |
Sakata MM | 145 |
Sakata S | 71 |
Sakima A | 125, 159 |
Sako H | 56 |
Saksena A | 248 |
Saladini F | 177 |
Salles G | 112, 143 |
Sampson AK | 106 |
Sanches IC | 188 |
Sandrim V | 135 |
Sartori M | 187 |
Saruta T | 185 |
Sasamura H | 185 |
Schiffrin EL | 104, 207, 234, 240, 241 |
Schlaich M | 93 |
Schmidt BM | 214 |
Schmidt HHHW | 134 |
Schmidt-Trucksäss A | 67 |
Schmieder RE | 160, 202 |
Schnitzer TJ | 276 |
Schreiber Jr MJ | 127 |
Schulz EG | 114 |
Schutte R | 254 |
Schwartz J | 179 |
Schwengel K | 94 |
Sechi LA | 255 |
Seda O | 195, 255 |
Sedeek M | 61 |
Seedat YK | 225 |
Semchuk W | 225 |
Seo JB | 177 |
Shah A | 207, 270 |
Sharma A | 59, 225 |
Sharma JN | 55, 108 |
Shay CM | 228 |
Shen Y | 134, 280 |
Sheng C | 218, 250 |
Shi X | 200 |
Shiina K | 83 |
Shimamoto K | 64, 96 |
Shimaoka I | 258 |
Shimizu H | 69 |
Shimodaira M | 168, 258 |
Shinagawa T | 123 |
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suzuki H</td>
<td>76, 249</td>
</tr>
<tr>
<td>Sydorchuk L</td>
<td>135</td>
</tr>
<tr>
<td>Sydorchuk LP</td>
<td>258</td>
</tr>
<tr>
<td>Sydorchuk R</td>
<td>186</td>
</tr>
<tr>
<td>Szuba A</td>
<td>141</td>
</tr>
<tr>
<td>Tatus-Santos JE</td>
<td>212</td>
</tr>
<tr>
<td>Takeuchi M</td>
<td>118</td>
</tr>
<tr>
<td>Takeshima H</td>
<td>125</td>
</tr>
<tr>
<td>Takenaka T</td>
<td>117</td>
</tr>
<tr>
<td>Takeda Y</td>
<td>204</td>
</tr>
<tr>
<td>Takeda S</td>
<td>199</td>
</tr>
<tr>
<td>Takeda K</td>
<td>182, 277</td>
</tr>
<tr>
<td>Takeda S</td>
<td>61, 108</td>
</tr>
<tr>
<td>Takemori K</td>
<td>190</td>
</tr>
<tr>
<td>Takenaka T</td>
<td>110</td>
</tr>
<tr>
<td>Takano H</td>
<td>270</td>
</tr>
<tr>
<td>Takai S</td>
<td>69</td>
</tr>
<tr>
<td>Takazawa K</td>
<td>123</td>
</tr>
<tr>
<td>Takechi S</td>
<td>199</td>
</tr>
<tr>
<td>Tardif J-C</td>
<td>237</td>
</tr>
<tr>
<td>Tarlovskaya EI</td>
<td>146</td>
</tr>
<tr>
<td>Tatagiba Lamas JL</td>
<td>262</td>
</tr>
<tr>
<td>Tatsukawa Y</td>
<td>204</td>
</tr>
<tr>
<td>Tatu-Chitoiu G</td>
<td>126</td>
</tr>
<tr>
<td>Tewari R</td>
<td>279</td>
</tr>
<tr>
<td>Thompson A</td>
<td>225</td>
</tr>
<tr>
<td>Thrift AG</td>
<td>260</td>
</tr>
<tr>
<td>Tian C</td>
<td>192</td>
</tr>
<tr>
<td>Titze J</td>
<td>152</td>
</tr>
<tr>
<td>Toba H</td>
<td>197, 198</td>
</tr>
<tr>
<td>Tobari H</td>
<td>247</td>
</tr>
<tr>
<td>Tobe S</td>
<td>91, 159</td>
</tr>
<tr>
<td>Tomaszewski M</td>
<td>102, 232, 233</td>
</tr>
<tr>
<td>Tomiyama H</td>
<td>123</td>
</tr>
<tr>
<td>Tonini CL</td>
<td>165</td>
</tr>
<tr>
<td>Toque HA</td>
<td>235</td>
</tr>
<tr>
<td>Tordjman KM</td>
<td>.94</td>
</tr>
<tr>
<td>Torres MRSG</td>
<td>142, 276</td>
</tr>
<tr>
<td>Touyz R</td>
<td>56, 67, 95, 150</td>
</tr>
<tr>
<td>Tovar JL</td>
<td>66</td>
</tr>
<tr>
<td>Townsend R</td>
<td>103, 155</td>
</tr>
<tr>
<td>Toyoda M</td>
<td>249</td>
</tr>
<tr>
<td>Tremblay JLG</td>
<td>154</td>
</tr>
<tr>
<td>Trudeau L</td>
<td>.95</td>
</tr>
<tr>
<td>Tsai W-C</td>
<td>276</td>
</tr>
<tr>
<td>Tsinamdzgvurishvili B</td>
<td>217</td>
</tr>
<tr>
<td>Tsuki M</td>
<td>191</td>
</tr>
<tr>
<td>Tsutaya S</td>
<td>195, 268</td>
</tr>
<tr>
<td>Tucker B</td>
<td>230</td>
</tr>
<tr>
<td>Tufiño C</td>
<td>281</td>
</tr>
<tr>
<td>Tweet M</td>
<td>127</td>
</tr>
<tr>
<td>Tzoulaki I</td>
<td>219</td>
</tr>
<tr>
<td>U</td>
<td></td>
</tr>
<tr>
<td>Uetake Y</td>
<td>172</td>
</tr>
<tr>
<td>Ufna M</td>
<td>166</td>
</tr>
<tr>
<td>Ulasl II</td>
<td>254</td>
</tr>
<tr>
<td>Uner T</td>
<td>165, 229</td>
</tr>
<tr>
<td>Untereiner AA</td>
<td>131</td>
</tr>
<tr>
<td>Ursuljak JV</td>
<td>255</td>
</tr>
<tr>
<td>Ushio H</td>
<td>112</td>
</tr>
<tr>
<td>Utescu MS</td>
<td>157</td>
</tr>
<tr>
<td>V</td>
<td></td>
</tr>
<tr>
<td>Vajpeey SK</td>
<td>215</td>
</tr>
<tr>
<td>van Baak MA</td>
<td>142</td>
</tr>
<tr>
<td>van den Bogaard B</td>
<td>55, 108</td>
</tr>
<tr>
<td>van der Giet M</td>
<td>98, 165, 168</td>
</tr>
<tr>
<td>Van der Poel L</td>
<td>.66</td>
</tr>
<tr>
<td>van Rooyen JM</td>
<td>194</td>
</tr>
<tr>
<td>Vanderwal J</td>
<td>151</td>
</tr>
<tr>
<td>Vanekova I</td>
<td>132</td>
</tr>
<tr>
<td>Vase H</td>
<td>.76</td>
</tr>
<tr>
<td>Vathesatogkit P</td>
<td>231</td>
</tr>
<tr>
<td>Vaysettes-Courchay C</td>
<td>107</td>
</tr>
<tr>
<td>Veerabhadrapa P</td>
<td>239</td>
</tr>
<tr>
<td>Veerappan Muthusamy MAK</td>
<td>200</td>
</tr>
<tr>
<td>Vettoretti S</td>
<td>.81</td>
</tr>
<tr>
<td>Villevalde S</td>
<td>198</td>
</tr>
<tr>
<td>Vilsar W</td>
<td>187</td>
</tr>
<tr>
<td>Viskoper JR</td>
<td>158</td>
</tr>
<tr>
<td>von Dadelszen P</td>
<td>160</td>
</tr>
<tr>
<td>W</td>
<td></td>
</tr>
<tr>
<td>Wai B</td>
<td>63, 81</td>
</tr>
<tr>
<td>Wakamatsu Y</td>
<td>.73</td>
</tr>
<tr>
<td>Wakamatsu-Yamanaka T</td>
<td>144</td>
</tr>
<tr>
<td>Wakui H</td>
<td>270</td>
</tr>
<tr>
<td>Wan Hassan WHH</td>
<td>119</td>
</tr>
<tr>
<td>Wang F</td>
<td>106</td>
</tr>
<tr>
<td>Wang H</td>
<td>79, 213, 253, 275</td>
</tr>
<tr>
<td>Wang Huimin CH</td>
<td>.79</td>
</tr>
<tr>
<td>Wang J</td>
<td>.220</td>
</tr>
</tbody>
</table>
INDEX

Wang J-G ................................................ 219
Wang L .................................................... 175
Wang M ............................................... 118, 140
Wang Q .................................................. 280
Wang S ................................................... 258
Wang W .................................................. 178, 184
Wang X .............................................. 85, 251, 267
Wang Y ............................................... 85, 93, 181, 257
Wang Y-Q ............................................ 198
Wang Z .................................................. 69, 144
Wang ZQ ................................................ 274
Watson A ................................................ 213
Weber MA ............................................... 185
Webster J ............................................. 227, 268
Wee LE ................................................... 238
Weir NM .................................................. 199
Werts N ................................................... 153
White WB ............................................... 275
Wichitkosoom W ...................................... 274
Widyo K ................................................... 261
Wijesuriya J ............................................. 241
Wijeyesekera A ....................................... 167, 194
Wilkinson-Berka JL .................................. 240
Wilson TW .............................................. 57
Winn T .................................................... 139
Withers SB ............................................. 104
Wloch-Kopec D ....................................... 274
Wlodek ME ............................................. 172
Wohlfahrt P ............................................. 81
Wojciechowska W .................................... 136, 181
Wong YO ................................................ 280
Wozniak M ............................................... 78
Wright HM ............................................ 244
Wu CE ..................................................... 252
Wu J ....................................................... 235
Wu L ....................................................... 279
Wu M-C ................................................... 217
Wu R ....................................................... 134
Wu Y ....................................................... 207

X

Xi Y ......................................................... 123, 211
Xiafang Z ................................................ 146
Xiang H .................................................. 180
Xie F ....................................................... 136
Xu J ......................................................... 172
Xu T ......................................................... 55, 130, 136
Xu X ......................................................... 177, 185
Xue H ...................................................... 186, 281

Y

Yabu M ..................................................... 166
Yadao A ................................................... 208
Yamamoto E .......................................... 241, 253
Yamamoto H .......................................... 249
Yamamoto K .......................................... 251
Yamashita S .......................................... 170
Yamashita T ........................................... 60
Yamori Y ................................................ 189, 273
Yan K ..................................................... 193
Yan Z ..................................................... 264
Yang D .................................................... 68, 218
Yang G ..................................................... 255
Yang J ..................................................... 65
Yang TL ................................................... 232
Yang XM ................................................ 204
Yang Y ................................................... 145, 236
Ye M ....................................................... 208
Yeo C ..................................................... 146
Yogi A ..................................................... 106
Yokoi T ................................................... 276
Yokokawa H .......................................... 132
Yokota R ................................................. 189
Yoneda T ................................................ 118
Yonis MO ............................................... 192
Yoshida M ............................................. 211, 251, 252
Yoshida S .............................................. 106, 171
Yoshizawa T .......................................... 144
Yousefi pour Z ........................................ 220
Yu J ......................................................... 68, 155
Yuan SH ................................................... 79
Yuen RKC .............................................. 111, 162
Yusoff K ................................................ 53, 64

Z

Zampieri TT ............................................ 166
Zanella MT ............................................ 68
Zappe D ................................................... 120
Zappe DH ............................................... 77, 261
Zarouk WA ............................................. 260
Zelaya Vargas JL ..................................... 181
Zelenenka LI ......................................... 196
Zhang B ................................................... 114
Zhang D ................................................... 60
Zhang H ................................................... 173, 273
Zhang J ................................................... 66, 121, 166, 268
Zhang MQ ............................................. 128, 220
Zhang X .................................................. 153
Zhang XH .............................................. 84, 158, 168
Zhang Y ............................................. 63, 96, 135, 141, 185, 248, 256

www.vancouverhypertension2010.com
INDEX

Zhao D ...........................................53, 92, 231
Zhao Y .............................................75
Zheng RP ...........................................98
Zhou L .............................................275
Zhou X .............................................125
Zhu D .............................................220
Zhu Z ..................................................67, 165

Zhuang X .........................................114
Zicha J ...............................................196
Zivkovic RR .......................................127
Zizka J ...............................................254
Zo J-H ...............................................177
Zueva IB ...........................................267
Zuo J .................................................122, 176
Bayer HealthCare is deeply committed to providing patients with the best medicine and continues to invest in the research and development of innovative pharmaceutical products to improve the lives of patients. We have a rich pipeline of cardiovascular products and remain committed to the cardiovascular health of Canadians.

Bayer HealthCare invested over €1.5 billion into pharmaceutical research and development in 2009.
OPTIONAL TOURS & SOCIAL EVENTS
TOURS & SOCIAL EVENTS

Program at a Glance

OPTIONAL TOURS

Tours depart from in front of the West Facility, street level (between Burrard Street and Thurlow Street). Please be ready to depart 15 minutes prior to the tour departure time indicated below. Prices exclude 12% HST.

<table>
<thead>
<tr>
<th>Tour</th>
<th>Vancouver City Tour</th>
<th>Forests &amp; Mountains Tour (North Shore)</th>
<th>Fjords &amp; Glaciers – Whistler Day Tour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schedule</td>
<td>DAILY</td>
<td>DAILY</td>
<td>DAILY</td>
</tr>
<tr>
<td>Duration</td>
<td>Four Hours</td>
<td>Six Hours</td>
<td>Ten Hours</td>
</tr>
<tr>
<td>Price</td>
<td>$55</td>
<td>$120</td>
<td>$103</td>
</tr>
<tr>
<td>Departure Time</td>
<td>08:00 (Sunday, Sept 26) 10:30 (Daily) 13:00 (Monday, Sept 27) 14:00 (Daily)</td>
<td>08:30 10:30 14:00</td>
<td>08:30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tour</th>
<th>Victoria &amp; Butchart Gardens Day Tour</th>
<th>Bowen Island Excursion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schedule</td>
<td>DAILY</td>
<td>SUNDAY, SEPT 26</td>
</tr>
<tr>
<td>Duration</td>
<td>Twelve to Thirteen Hours</td>
<td>Six Hours</td>
</tr>
<tr>
<td>Price</td>
<td>$170</td>
<td>Float Plane: $284 Ferry: $189</td>
</tr>
<tr>
<td>Departure Time</td>
<td>07:30 09:30</td>
<td>09:00</td>
</tr>
</tbody>
</table>

SOCIAL EVENTS

Departure points are indicated below. Prices exclude 12% HST.

<table>
<thead>
<tr>
<th>Event</th>
<th>Sunset Dinner Cruise</th>
<th>Fun Run Through Stanley Park</th>
<th>Gala Evening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schedule</td>
<td>MONDAY, SEPT 27 Three Hours</td>
<td>TUESDAY, SEPT 28 Two Hours</td>
<td>WEDNESDAY, SEPT 29 Four Hours</td>
</tr>
<tr>
<td>Duration</td>
<td>$90</td>
<td>Complimentary for Attendees</td>
<td>$99</td>
</tr>
<tr>
<td>Price</td>
<td>19:00 Harbour Cruises Marina (foot of Denman Street)</td>
<td>17:00 (rain or shine) Thurlow St. Entrance</td>
<td>19:00 Ballroom C&amp;D, West Level 1</td>
</tr>
</tbody>
</table>

Pre-purchased Tickets

Pre-purchased tickets for tours and social events are provided with your name badge upon registering onsite.

Purchase Tickets Onsite

To purchase tickets for tours and social events, please visit the "Tours and Social Events" Registration Desk located in the Foyer, West Level 1.
TOURS & SOCIAL EVENTS

Optional Daily Tours

**Vancouver City Tour**

**Dates & Departure times:**
- 08:00 (Sunday, September 26)
- 10:30 (Daily)
- 13:00 (Monday, September 27)
- 14:00 (Daily)

**Duration of tour:** Four hours

**Pickup point:** In front of the West Facility, street level (between Burrard Street and Thurlow Street)

**Price per person:** $55

**Highlights:** Experienced local guide, Stanley Park, English Bay, Robson Street, Chinatown, Gastown, Granville Island

**Includes:**
- Deluxe coach transportation
- Professional guide
- Gratuities

**Does not include:**
- Food or beverage
- Applicable taxes
Forests & Mountains (North Shore) – Capilano Suspension Bridge & Grouse Mountain Tour

Dates: Daily
Departure times: 10:30, 14:00
Duration of tour: Six hours
Pickup point: In front of the West Facility, street level (between Burrard Street and Thurlow Street)
Price per person: $120

Highlights: Capilano Suspension Bridge, Capilano Salmon Hatchery, Cleveland Dam Reservoir, Skyride, Grouse Mountain

Includes:
- Deluxe coach transportation
- Professional guide
- Admission to the Capilano Suspension Bridge which includes:
  - The world famous Capilano Suspension Bridge
  - The thrilling Treetops Adventure and the dramatic Cliffhanger Walk
  - A guided tour of the park
  - The interactive Living Forest exhibit
  - Seven acres of West Coast rain forest
  - The world’s largest private Totem Pole collection
  - First Nations Artisans depicting their artistic techniques, skills and heritage*
TOURS & SOCIAL EVENTS

• Admission to Grouse Mountain which includes:
  ◊ The Grouse Mountain Skyride
  ◊ The Theatre in the Sky presentation
  ◊ The Refuge for Endangered Wildlife
  ◊ The World Famous Lumberjack Show* & Birds in Motion Demonstrations*
  ◊ Scenic Chairlift Rides*
• Stop at Capilano Fish Hatchery and Cleveland Dam Reservoir
• Gratuities

Does not include:
• Food or beverage
• SeaBus fare
• Applicable taxes

*Activities are scheduled by the facilities and may not be available during the visit.
Fjords & Glaciers – Whistler Day Tour

Dates: Daily
Departure time: 08:30
Duration of tour: Ten hours
Pickup point: In front of the West Facility, street level (between Burrard Street and Thurlow Street)
Price per person: $103

Highlights: Spectacular drive along the Sea to Sky highway, Britannia Beach, Shannon Falls, Brandywine Falls, Whistler (free time to explore)

Includes:
- Deluxe coach transportation to and from Whistler
- Professional guide
- Gratuities

Does not include:
- Food or beverage
- Optional activities such as chairlifts, helicopter or floatplane tours, etc.
- Applicable taxes
TOURS & SOCIAL EVENTS

Victoria & Butchart Gardens Day Tour

Dates: Daily
Departure times: 07:30, 09:30
Duration of tour: Twelve to thirteen hours
Pickup point: In front of the West Facility, street level (between Burrard Street and Thurlow Street)
Price per person: $170

Highlights: Scenic ferry cruise, Butchart Gardens, downtown Victoria

Includes:
• Deluxe coach transportation to and from Victoria
• Professional guide
• Ferry tolls
• Admission to Butchart Gardens
• Gratuities

Does not include:
• Food or beverage
• Applicable taxes

Optional: Return by Floatplane

Spend a couple of extra hours or extra nights (accommodation at own expense) in Victoria and then take a spectacular floatplane ride back to Vancouver! Floatplane departs from the Victoria Inner Harbour, a few hundred metres from the Fairmont Empress. Cost for floatplane return trip to Vancouver and flight and hotel reservations are the responsibility of the attendee.
Bowen Island Excursion

Date: Sunday, September 26  
Departure time: 09:00  
Duration of tour: Six hours  
Pickup point: In front of the West Facility, street level (between Burrard Street and Thurlow Street)

Price per person:  
- Return by floatplane: $284  
- Return by ferry: $189

Highlights: Scenic ferry cruise, Bowen Island, Snug Cove Harbour, guided nature walk, gourmet picnic lunch

Includes:
- All transportation for either return option including ferry tolls
- Professional guide / nature interpreter
- Gourmet picnic lunch
- Guide gratuities

Does not include:
- Applicable taxes
Optional Social Events

Sunset Dinner Cruise
Date: Monday, September 27
Boarding time: 18:30
Departure time: 19:00
Duration of cruise: Three hours
Pickup point: Harbour Cruises Marina (foot of Denman Street)
Leaving the VCC, walk for about 15 minutes along the seawall towards Stanley Park (in a westerly direction) until you reach Harbour Cruises at the foot of Denman Street. If you wish to take a taxi, the closest taxi stand to the West Facility is across the street next to the main entrance of the Fairmont Pacific Rim Hotel.
Price per person: $90

Highlights: Cruise of Vancouver’s harbour, West Coast-themed dinner

Includes:
• Exclusive cruise
• Professionally catered West Coast-themed buffet dinner
• Professional guide
• Gratuities

Does not include:
• Beverages other than coffee and tea
• Applicable taxes
TOURS & SOCIAL EVENTS

Experience Vancouver – Fun Run through Stanley Park

Date: Tuesday, September 28
Departure time: 17:00 (rain or shine)
Duration of run: Two hours
Departure point: Thurlow Street Entrance
Price per person: Complimentary for ISH 2010 Attendees

Highlights: 5 km fun run/walk along the Stanley Park Seawall

Includes:
• Bottle of water
• Fun Run t-shirt*

Does not include:
• Additional activities
• Food and beverage
• Transportation to and from Stanley Park
• Applicable taxes

*Must be pre-registered for the run to receive a t-shirt
TOURS & SOCIAL EVENTS

Gala Evening
Date: Wednesday, September 29
Doors open: 19:00
Duration: Four hours
Location: Ballroom C & D, West Level 1
Price per person: $99

Highlights: Canadian entertainment, Pacific Northwest cuisine

Includes:
• West Coast inspired plated dinner
• Entertainment
• Gratuities
Setting Innovation in Motion

We’re driven to improve people’s lives. Takeda strives toward better health for individuals and progress in medicine by developing superior pharmaceutical products. At Takeda, we make a commitment to make a difference.
EXHIBITION
EXHIBITION

Exhibition

Please visit the Exhibition to discover new products and services from some of the industry’s leading organizations.

Location: Exhibition Hall C, West Exhibition Level
Opening times:
- Monday, September 27: 09:30 – 18:00
- Tuesday, September 28: 09:30 – 18:00
- Wednesday, September 29: 09:30 – 18:00
- Thursday, September 30: 09:30 – 15:00

Lunches and refreshment breaks take place in amongst the Exhibits. A ticket for each lunch was provided with your name badge upon registering onsite, if you registered for the Standard registration fee.

Also visit the Exhibit Hall to view posters, and use the Internet Cafés and Business Centres.
Exhibitor Profiles

**Platinum Sponsor**

Boehringer Ingelheim

www.boehringer-ingelheim.com

Boehringer Ingelheim was founded in 1885 and is a family-owned company committed to researching, developing, manufacturing and marketing novel products of high therapeutic value. MICARDIS® (telmisartan) is indicated for the treatment of hypertension, and the reduction of CV morbidity in patients with manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or diabetes patients with documented target organ damage. The exhibition space will feature the product MICARDIS® as well as scientific information on the clinical development of the direct thrombin inhibitor dabigatran etexilate for stroke prevention in atrial fibrillation and the DPP4 inhibitor linagliptin+ in type 2 diabetes.

**Silver Sponsors**

Boryung Pharmaceutical Company

www.boryung.co.kr

Fimasartan is a synthetic compound for the treatment of hypertension and a novel nonpeptide angiotensin II receptor antagonist. It has been shown to exert its effects predominantly through blockade of the Angiotensin II, selectively AT1 receptor. Fimasartan is a white to off-white crystalline powder, called “BR-A657•K” whose pharmacological activity has been investigated in several in vivo and in vitro studies.
Microlife Corporation
www.microlife.com

Microlife is one of the world leaders in the development and manufacturing of medical diagnostic equipment for home monitoring and professional use. Blood pressure monitors, digital thermometers, asthma monitors and flexible heating products are Microlife’s core business. Microlife WatchBP offers the world’s first and only blood pressure measurement devices embedded with physician-recommended blood pressure measurement protocol – the ESH, AHA, and JSH. This solution is the result of over four years of dialogue and collaboration between Microlife and hypertension specialists, hypertension societies, and leading primary care physicians.

Novartis Pharmaceuticals Canada Inc.
www.novartis.com

Novartis is the maker of Diovan (valsartan), Diovan HCT (valsartan plus hydrochlorothiazide), Rasilez (aliskiren, a direct renin inhibitor), Galvus (vildagliptin, a DPP-4 inhibitor) and Exforge (single pill combination of an ARB valsartan and amlodipine). Novartis has a strong pipeline of CV products.

Servier Canada Inc.
www.servier.com

Servier Canada is the Canadian affiliate of the Servier Research Group, the leading French independent pharmaceutical company; second French pharmaceutical company worldwide. In its 55 years, the Servier Research Group has developed in stature from a family-owned, provincial pharmacy employing nine people to a multi-national operation with over 20,000 employees in 140 countries, including 3,000 in R&D specialising in ethical pharmaceuticals. The company is privately owned and still passionately committed to remaining independent. Founded in 1978 in Canada, its head office is based in Laval, Quebec. Looking forward to the future, Servier Canada is set for dramatic growth.
EXHIBITION

Corporate Supporters

Abbott Laboratories, Limited
www.abbott.ca
Abbott is a global, broad-based health care company committed to delivering breakthrough products that make a significant impact on medical practice, on quality of care and on the lives of the people who need them.

AstraZeneca Canada Inc.
www.astrazeneca.ca
AstraZeneca is committed to the research, development and manufacturing of valuable prescription medicines. We have an extensive product portfolio spanning six therapeutic areas: gastrointestinal, cardiovascular, infection, neuroscience, oncology and respiratory. AstraZeneca Canadian headquarters are located in Mississauga, Ontario, and a state-of-the art drug discovery centre is based in Montreal, Quebec.

Bayer HealthCare Pharmaceuticals
www.bayer.ca
Bayer HealthCare is a business of Bayer AG, an international research-based group, and comprises Animal Health, Consumer Care, Diabetes Care and Pharmaceutical businesses. Bayer HealthCare is deeply committed to providing patients with the best medicine and continues to invest in the research and development of innovative pharmaceutical products to improve the lives of patients. We have a rich pipeline of cardiovascular products and remain committed to the cardiovascular health of Canadians.
Omron Healthcare Group, headquartered in Kyoto, Japan, is a global leader of blood pressure monitors for home use with over 100 million units sold worldwide to date. Omron also offers a wide range of clinically proven and innovative products and services to help prevent, treat and manage lifestyle diseases both at home and in clinical practice in more than 100 countries in the world. With our vision “Healthcare at Home,” intended to effectively use home-measured biomedical information and behavioral data for patient diagnosis and treatment at clinical practice, we continue to create high quality products and services for the health for all.
Exhibitors

A&D Medical
www.andmedical.com

For over 30 years, A&D Medical has manufactured and distributed a full line of advanced electronic blood pressure monitoring equipment and health care products for home and professional use.

Asian Pacific Society of Hypertension
www.apsh.org

Meetings of the Asian Pacific Society of Hypertension are held on a two year cycle. The 8th meeting is to be held in Taipei, Taiwan, from November 24 -27, 2011 on the theme “Hypertension Prevention: Metabolic Syndrome and Beyond”. An invitation is extended to you to attend. More details are available at www.apch2011.tw.

AtCor Medical, Inc. (USA)
www.atcormedical.com

AtCor Medical developed and markets SphygmoCor® systems, the global gold standard in noninvasive assessment of central blood pressures and arterial stiffness. SphygmoCor systems are used worldwide in research, clinical practice and in pharmaceutical clinical trials, and have been featured in over 600 published studies. Visit us for a complimentary central pressures assessment.

Biovail Pharmaceuticals Canada
www.biovail.com

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets.
Exhibition

BpTRU Medical Devices

www.bptru.com

BpTRU is the recognized standard for Automated Office Blood Pressure Devices. The BpTRU ‘Average’ better predicts ambulatory blood pressure monitoring (ABPM) than does the average manual reading. Studies have proven that the BpTRU ‘Average’ is equivalent to the ‘daytime’ ABPM reading.

The reputation of the Canadian manufactured BpTRU has been built on superior technology and service. The objective of the company is to ensure the highest level of quality while focusing on the scientific and medical purpose of the device and the market it serves.

Canadian Cardiovascular Society

www.ccs.ca

The Canadian Cardiovascular Society™ (CCS) is the national voice for cardiovascular physicians and scientists. The CCS is over 1800 members strong. We are known nationally and internationally by cardiovascular healthcare professionals for the Canadian Cardiovascular Congress, the CCS Angina classification system, the pan-Canadian Access to Care Benchmarks for the entire continuum of cardiovascular care, and the development of Canadian recommendations for the diagnosis and treatment of heart failure. We invite you to drop by the CCS booth (#806) to learn about programs and services available to cardiovascular professionals through CCS and its Affiliates.

Canadian Council of Cardiovascular Nurses

www.cccn.ca

The Canadian Council of Cardiovascular Nurses (CCNN) is the voice for cardiovascular nursing in Canada, promoting the health of Canadians through standards, research, education, health promotion, specialty certification, advocacy and strategic alliances. At local, provincial and national levels, CCCN chapters and individual members facilitate ongoing professional nursing education, health promotion and advocacy in the cardiovascular field. Often working collaboratively with other organizations, CCCN members promote a heart healthy lifestyle for patients, their families and the general public. Enacting its slogan “Health promotion starts with us,” CCCN also works to improve the health and well-being of its members and fellow nurses.
DMT-USA Inc.  
www.dmt-usa.com

DMT is a biotechnology and bioengineering company with more than 20 years of experience in the design, development, and manufacture of myography systems. Our systems are used by world-renown investigators studying mechanisms associated with changes in vascular structure and function of isolated vessels in vascular diseases such as, but not limited to, hypertension, diabetes, and atherosclerosis. We incorporate state-of-the-art mechanical, electrical, and software engineering in our designs and manufacturing to create wire and pressure myographs, as well as tissue organ baths, of unparalleled quality.

Hypertension Canada  
www.hypertension.ca

The mission of Hypertension Canada is to advance health by the prevention and control of high blood pressure through research, advocacy, education and knowledge development and translation. Hypertension Canada is a newly integrated volunteer-based, not-for-profit organization representing over 50 years of expertise in the field of hypertension. Our vision is to bring about positive benefits for the millions of people in Canada who, on a daily basis, deal with the dangers and harmful effects of hypertension.

Imedos Systems UG  
www.imedos.de

IMEDOS is the pioneer of retinal vessel analysis, adding innovative diagnostics of micro circulation to known methods of macro circulation. We offer different instrument lines for retinal vessel analysis (DVA, SVA, RVA) based on the measurement of micro vascular state and functions. There is evidence that retinal micro vascular changes mirror systemic changes of other organs like the heart, brain, and kidney. The devices provide information about therapeutic effects and give different risk factors, indicators and predictors for early recognition and prevention of cardio and cerebra and other vascular diseases extending applications far beyond ophthalmology. The Eye is a unique diagnostic window for vascular medicine that is non-invasive, quick and easy.
Established in 1966, the International Society of Hypertension (ISH) is a fast growing, worldwide, membership organisation dedicated to the detection and treatment of high blood pressure, with research and the education of both physicians and patients at the centre of its mission. Key activities include: organization of Biennial Scientific Meetings, a new Research Scholar Fellowship Award, development and publication of recommendations in conjunction with the World Health Organization, and a visiting faculty programme to economically disadvantaged countries in Asia, Africa, Eastern Europe and South America. We invite you to visit our stand (#102) to gain further information on how to join the Society.

“Hypertension Sydney 2012” will be the 24th Meeting of the International Society of Hypertension (ISH) in collaboration with the Asian Pacific Society of Hypertension and the High Blood Pressure Research Council of Australia. The backdrop will be the world famous Sydney Harbour for a program of the very highest scientific calibre and opportunities to interact with international leaders in the field. Australian meetings are renowned not only for their first class organisation but also for a relaxed atmosphere, where friendships can be renewed and exciting collaborations forged. We look forward to welcoming you to Sydney in 2012.

Lippincott Williams & Wilkins, a Wolters Kluwer Health company is a leading international publisher of medical books, journals, and electronic media. We proudly offer specialized publications and software for physicians, nurses, students and clinicians. Please visit our booth (#101) to browse our comprehensive product line.
Nature Publishing Group  
www.nature.com  

Nature Publishing Group (NPG) brings leading scientific and medical research to your desktop. The NPG portfolio combines the continued excellence of Nature, its associated research, review journals and over 45 leading academic and society journals in the life, physical and clinical sciences. Visit Booth #802 for free sample copies.

Pfizer Inc.  
www.pfizer.com  

Founded in 1849, Pfizer is the world’s largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and provide better quality healthcare and health system support. At Pfizer, nearly 90,000 colleagues in more than 150 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.

Public Health Agency of Canada  
www.phac-aspc.gc.ca/index-eng.php  

The Public Health Agency of Canada’s goal is to help Canadians achieve and maintain physical and mental wellness and to protect them from ongoing and future health threats. The Public Health Agency of Canada prepares for national public health emergencies; exploring the causes of disease and injury; and works to raise awareness of the fundamental determinants of poor health.

Spacelabs Healthcare Inc.  
www.spacelabshealthcare.com  

Spacelabs Healthcare, Inc., a wholly-owned subsidiary of OSI Systems, Inc., is an international developer, manufacturer and distributor of medical equipment and services including solutions for patient monitoring and connectivity, anesthesia delivery and ventilation, diagnostic cardiology and supplies and accessories selling to hospitals, clinics and physician offices. The Company has offices in the United States, United Kingdom, Canada, France, Germany, Italy, China, India and Singapore and distribution partners in more than 100 countries around
the world. At the ISH Spacelabs will show its range of ABP monitoring products, resting ECG devices, and the latest cardiology information management product.

Tiba Medical
www.tibamedical.com
Our Ambulo 2400 ambulatory blood pressure monitoring (ABPM) systems provide physicians and researchers with an advanced tool for better diagnosis and care of hypertensive patients. Easy to use, highly accurate (BHS Grade A/A) and complete, the Ambulo 2400 ABPM system incorporates innovative features such as built-in actigraphy and powerful software. In 2010, we are also introducing blood pressure data management services for efficacy and cardiac safety clinical trials involving ambulatory, clinic and home blood pressure measurements. We invite you to visit with us in Vancouver and online and look forward to supporting your needs.

World Hypertension League
www.worldhypertensionleague.org
The World Hypertension League (WHL) is a federation of leagues, societies, and other national bodies devoted to the goal of acting in liaison with the member organizations, promoting the exchange of information among them, and offering internationally applicable methods and programs for hypertension control. Currently there are 72 member countries as full member and 18 associate members. WHL celebrated its 25th anniversary on October 29, 2009 in Beijing, China. The WHL is a division of the International Society of Hypertension (ISH), and is in official relations with the World Health Organization (WHO).

Zona Health
www.zona.com
The Journal of Hypertension reports that Zona Plus™ (a new, innovative, handheld device providing individualized guided isometric therapy), significantly lowers blood pressure and may reduce the risk of mortality due to stroke by more than 28% and coronary heart disease by over 18%. The Zona Plus™ improves sympathetic balance and endothelial function. In a dozen published articles, this innovative therapy has significantly reduced blood pressure for over 99% of the participants. The Zona Plus™ is now available to physicians and their patients through our company, Zona Health. Come to our booth (#600) at ISH to see it for yourself!
Hypertension Canada Awards

Hypertension Canada Awards Presentations
The awards presentations will be made at the Hypertension Canada Annual General Meeting.

Date: Tuesday, September 28
Time: 18:00 - 21:30
Location: Malaspina Room, Fairmont Waterfront

Hypertension Canada Awards Listing

The George Fodor Award recognizes a distinguished record of substantial contributions by individuals or organizations that have increased awareness and/or improved control of blood pressure in Canada. Contributions worthy of this prestigious award are expected to be broad in scope (i.e. national) and enduring over time.

Award recipient: Dr. Ross Feldman

The Distinguished Service Award is presented in recognition of career achievement in the areas of service and hypertension research. Individuals nominated for this recognition must be considered to have made a prolonged and significant contribution.

Award recipient: Dr. Rhian Touyz

The New Investigator Award is presented in recognition of excellence in the field of hypertension research by a new investigator. The recipient must not have exceeded a time period of 5 years from the first appointment as an independent investigator at a University/Research Institute and must be the principal investigator of the work submitted for consideration of the award.

Award recipient: Dr. Sébastien Bonnet
Certificates of Excellence are presented as annual recognition and acknowledgement of the contribution made by an individual, organization or program to high blood pressure prevention or control in Canada (local community, regional, provincial, or national initiatives).

Award recipients:
- Canadian Council of Cardiovascular Nurses
- Canadian Pharmacists Association / Canadian Pharmacists Journal
- College of Family Physicians of Canada
- Servier Canada
- Larry W. Chambers
- Sandra Matheson
- Donald W. McKay
- Dorothy Morris
- Debra Reid
- Ann Thompson
- Carly Weeks
- Eleanor Wilson

Education Awards are presented in nominal amounts to support the participation of trainee abstract and poster presenters at significant scientific meetings.

Research Awards are reviewed and considered on an annual basis. Research awards are funded through our research endowment fund as financially practical and negotiated in partnership with other funding bodies such as the Canadian Institutes of Health Research and industry partners. In the past, Hypertension Canada has funded trainee awards including summer studentships, doctoral awards, postdoctoral fellowships, travel awards and recognition awards at scientific meetings. Hypertension Canada is currently proud to be a funding partner in support of the Canadian Hypertension Research Chair.

CHS (Hypertension Canada)-Pfizer Award recipient: Dr. Jason Dyck
ISH Awards

ISH Awards Ceremony

Winners will be announced during the ISH Awards Ceremony, Presidential Lecture and Franz Volhard Lecture.

Date: Wednesday September 29
Time: 16:30-18:00
Location: Ballroom A, West Level 1

ISH Awards Listing

ISH, with the collaboration and generous support of corporate sponsors, is pleased to announce the availability of the following awards and prizes in 2010.

AstraZeneca Award: To be presented to a distinguished investigator responsible for outstanding work related to the clinical pharmacology and therapy of arterial hypertension.

Award recipient: Professor Peter Sever, UK

Boehringer Ingelheim Developing World Award: This award is for a researcher in the developing world who has done outstanding work in the region. The recipient will be expected to submit an abstract of his/her research to ISH 2010.

Award recipient: Professor Karen Sliwa, South Africa

Distinguished Membership Awards: Members who have given outstanding service to the Society and have made unusually distinguished contributions to experimental and clinical research in hypertension may be nominated to be Distinguished Members of the Society.

Award recipients: Professor Eoin O’Brien, Ireland and Professor Judith Whitworth, Australia
Franz Volhard Award and Lectureship: To be presented to a person or persons who shall have initiated in the field of hypertension or in a related discipline, a concept, which remains of current interest. (Supported by Bayer Schering Pharma AG)

Award recipient: Professor Graham MacGregor, UK

Professor MacGregor will give a lecture entitled 'Salt – A Pathophysiological Pursuit' during the ISH Awards Ceremony and Presidential Lecture.

The Jiří Widimský Sr. Awards: The Czech Foundation of Hypertension is pleased to announce that Jiří Widimský Sr. Awards will be presented at ISH 2010. Awards have been presented at ISH and ESH meetings since 2002 to young investigators from developing countries or countries with economic hardship. Recipients of the award receive a certificate and a cheque for $2,000 USD.

Three award recipients will be announced during the ISH Awards Ceremony.

ISH Research Scholar Fellowship Award: This new initiative, funded by the ISH, supports the training of postdoctoral scientists in the formative stages of their careers to conduct clinical, epidemiology/population science, or outcomes research. It provides the successful candidate with a period of mentored research as part of a collaboration between the Scholar and a Sponsor at an established research institution. It is expected that this experience will prepare the Scholar to pursue a productive research career involving on-going collaboration with scientists from established institutions.

Award recipient: Dr. Andre Pascal Kengne, Australia

The Robert Tigerstedt Award: To be presented to a person, persons or institution responsible for distinguished work relating to the aetiology, epidemiology, pathology or treatment of high blood pressure. (Supported by ISH)

Award recipient: Professor Jan Danser, Netherlands
**AWARDS**

**The Stevo Julius Award:** To be given to a person or persons demonstrating exceptional and continuous commitment to the dissemination of information, knowledge and skills in the field of hypertension to: (a) general public; (b) medical community; (c) specialists in the hypertension field; and (d) investigators involved in hypertension research.

(Supported by Novartis)

Award recipient: Professor Lawrie Beilin, Australia

**ISH Abstract Awards**

**ISH 2010 Award:** Presented by the ISH 2010 Executive Organizing Committee, this award has been created to assist Young Investigators from around the world in attending ISH 2010.

Award recipients will be announced during the ISH Awards Ceremony.

**ISH Austin Doyle Award:** Presented by the ISH, this award is available to a graduate who is within 5 years of post graduate qualification and who has submitted the best original presentation relevant to clinical medicine. The recipient must be willing to join the ISH as a member following receipt of the award.

(Supported by Servier Australia)

The award recipient will be announced during the ISH Awards Ceremony.

**ISH International Forum Poster Prizes:** Presented by the ISH, the best posters presented at ISH 2010 in Basic Science, Clinical Science and Public Health/Population Science will each be awarded $1,000 USD. Prizes in all three tracks will be awarded to each of the regions that comprise the ISH International Forum (Africa, Asia & Australia, Europe & Middle East, Latin America, and North America).

The fifteen award recipients will be announced during the ISH Awards Ceremony.

**Pfizer Award:** To be given to an investigator presenting a superior research project, at ISH 2010, in the study of basic mechanisms by which blood pressure and lipids interact in the development of cardiovascular disease.

The award recipient will be announced during the ISH Awards Ceremony.
Top quality systems for studies in Smooth & Striated Muscle

VISIT US AT BOOTH NO. 705

YOUR NEW SYSTEM FOR HYPERTENSION RESEARCH

Multi Wire Myograph System - 620M
- Multi Wire Myograph with four chambers allows studies of four vessels or tissue rings simultaneously
- Ideal for work requiring a higher throughput such as repetitive concentration-response curves
- Jaw and pin mounts facilitate the use of a mix of small or larger ring segments from 60 µm to 450 µm (up to 10 mm when using pins)
- The segments remain viable for >12 hours
- Built-in electrical heating

DMT VAS for Pressure Myograph Systems
- Multiple imaging windows to monitor up to 4 different sections of the same vessel
- New, calculated parameters such as shear stress, vascular resistance, and Reynolds number
- Trace recording data for ALL recorded and calculated parameters, including flow measurements
Other Awards

Asian-Pacific Society of Hypertension (APSH) Young Investigator Fellowships: The APSH is pleased to announce the establishment of the APSH Young Investigator Fellowships. The fellowships have been created to aid young investigators from APSH Member Societies in attending ISH 2010. The fellowship consists of $1,000 USD and complimentary registration for ISH 2010.

Award recipients:

- Song Vogue Ahn
- Karen Andrews
- Tatsuhiko Azegami
- Yap-Hang Chan
- Arata Hagikura
- Liping Hao
- Chin-Chou Huang
- Emma Jones
- Sacha Khong
- Ju-Hee Lee
- Yan Li
- Su May Liew
- Min Liu
- Jose Donato Magno
- Mariana Osako
- Yoichi Oshima
- Rizaldy Pinzon
- Sahoo Saddichha
- Prin Vathesatogkit
- Yan Yang
Vancouver Hypertension 2010 Award (Industry Roundtable)

The Executive Organizing Committee of ISH 2010 is pleased to announce the establishment of the Vancouver Hypertension 2010 Award. The award has been created to assist young investigators from around the world in attending ISH 2010. Recipients of an award received complimentary registration for ISH 2010.

Award recipients:

Adeseye Akintunde
Bader Almustafa
Danielle Arita
Eunhwi Bae
Marcus Baumann
Volodymyr Bezrodnyy
Dylan Burger
Elizabeth Callaly
Shorena Chumburidze
Dambadarjaa Davaalkham
Sofia Enhörning
Rosmar Fama
Sona Gahramanova
Svetlana Gusakova
Piotr Jankowski
Majid Khazaei
Rano Mal Kotak
Aksana Kotava

Praveen Kumar
Carlos Mavimbe
Morten Pedersen
Marta Pena Seijo
Maria Pinterova
Athanase Protogerou
Niwanthi Rajapakse
Anis Ramli
Freddy Romero
Moekanyi Sibiya
Marco Simonini
Maciej Tomaszewski
Bas van den Bogaard
Fen Wang
Jianzhong Xu
Jin Zhang
Yi Zhang
SERVIER Research Group

The leading French independent pharmaceutical company, committed to research

Worldwide workforce of over 20,000 employees, including nearly 3,000 in Research and Development

More than 25% of the turnover reinvested in R&D

30 new chemical entities in 30 years

Your Cardiovascular Partner

www.servier.ca

Proud member of (Close)
8th Asian-Pacific Congress of Hypertension 2011

in conjunction with
2011 Annual Meeting of Taiwan Society of Internal Medicine
3rd World Congress on Ningen Dock
2011 Cross-Strait Hypertension Symposium

Hypertension Prevention:
Metabolic Syndrome and Beyond

Date | November 24th - 27th (Thu. - Sun.), 2011
Venue | Taipei International Convention Center, Taipei, Taiwan

www.apch2011.tw
New Skills and New Solutions in Heart Disease Treatment
At Novartis, we are developing treatments to help people suffering from hypertension and to reduce the risk of heart attack. Thanks to a treatment from Novartis, elderly people can lead an active life knowing that their medication reduces the risks associated with heart disease.

Novartis. We’re with you... for life.